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General introduction

1.1
Management o�� patients with 
neuroendocrine tumours 

12
The	discovery	of	the	neuropeptide	somatostatin	(SS)	 in	1973	by	Guillemin	and	
co-workers	at	the	Salk	Institute	1	and	the	extensive	work	on	the	function	of	peptides,	
including	SS,	by	the	group	of	Schally	et al.2,	for	which	both	received	the	Nobel	prize	
in	1977,	was	an	important	step	towards	the	current	knowledge	of	neuroendocrine	
tumours.	Almost	two	decades	later,	its	counterpart,	the	somatostatin	receptor	(SSTR)	
was	characterized	by	Yamada	et al.3,	4.	Furthermore,	the	widespread	presence	and	
functions	within	the	body	of	both	the	hormone	and	its	ligand	has	been	intensively	
studied.	The	polypeptide	somatostatin	comprises	several	peptides	formed	after	
different	posttranslational	processing	of	the	pre-prosomatostatin	protein	encoded	by	
a	single	gene.	Only	two	of	these	small	peptides,	somatostatin-14	and	somatostatin-
28,	are	biologically	active	and	are	the	most	common	somatostatin	peptides	present	
in	 the	peripheral	and	central	nervous	system	(CNS).	The	somatostatin-14	and	
somatostatin-28	isoforms	consist	of	14	and	28	amino	acids,	respectively.	The	entire	
somatostatin-14	sequence	is	present	in	the	C-terminus	of	somatostatin-28.	The	
predominant	biologically	active	isoform	is	somatostatin-14.	The	relative	proportions	
of	somatostatin-14	and	somatostatin-28	differ	among	various	somatostatin-producing	
tissues.	However,	 somatostatin-14	 and	 somatostatin-28	display	overlapping	
physiological	functions.	Both	somatostatin-14	and	somatostatin-18	are	produced	
by	neuroendocrine,	inflammatory,	and	immune	cells	in	response	to	ions,	nutrients,	
neuropeptides,	neurotransmitters,	thyroid	and	steroid	hormones,	growth	factors,	
and	cytokines	5.	
The	somatostatin	peptides	exert	their	regulatory	biological	role	after	binding	to	
an	SSTR.	At	present,	five	different	human	SSTRs,	named	SSTR1,	SSTR2,	SSTR3,	
SSTR4	and	SSTR5	have	been	identified	and	cloned	3,	4.	All	five	SSTRs	belong	to	the	
superfamily	of	G-protein-coupled	receptors	with	seven	transmembrane	domains	
and	have	been	identified	throughout	the	CNS,	endocrine	and	exocrine	glands.	All	
five	subtypes	bind	somatostatin-14	and	somatostatin-28	with	high	affinity.	Although	
the	different	SSTR	subtypes	are	40%	to	60%	structurally	homologous,	each	subtype	
has	its	specific	role	in	signalling	between	cells	and	the	different	tissues.	The	most	
prominent	role,	however,	is	the	inhibitory	effect	of	somatostatin	on	the	secretion	
of	hormones	in	various	organs	such	as	the	inhibition	of	growth	hormone,	prolactin	
and	thyroid	stimulating	hormone	within	the	pituitary	or	inhibition	of	glucagon	and	
insulin	release	within	the	pancreas.	
Somatostatin	receptors	are	expressed	in	various	tissues	such	as	the	CNS,	anterior	
pituitary,	 the	endocrine	and	exocrine	pancreas,	 the	gastrointestinal	 tract	 and	
the	adrenals,	but	neuroendocrine	tumours	also	frequently	express	somatostatin	
receptors.	Table	1	summarizes	the	characteristics	of	somatostatin	receptor	expression	
in	neuroendocrine	tumours.
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Table 1.	Somatostatin	receptor	expression	in	neuroendocrine	tumours
Receptor	incidence
Pancreatic	and	gut	endocrine	tumours:	80-100%
Insulinomas:	50-70%
Receptor	density Commonly	high
Receptor	distribution Commonly	homogeneous
Receptor	expression Well-differentiated	tumour	>	undifferentiated	tumour
Receptor	subtype	expression	frequency SSTR2	>>	SSTR1=SSTR5>	SSTR3	>>SSTR4
Receptor	localisation Usually	cell	membrane	bound,	especially	SSTR2
Adapted from Reubi 7
The	receptor	density	is	high	in	the	majority	of	cases	but	may	vary	between	the	
tumours.	Undifferentiated	endocrine	tumours	express	less	often	SSTRs	and	if	so,	the	
density	is	reported	to	be	low	6,	7.	The	SSTR	most	commonly	expressed	in	endocrine	
tumours	is	the	SSTR2.
Incidence 
The	age-standardised	incidence	of	carcinoids,	the	most	common	gastroentero-
pancreatic 	 neuroendocr ine	 tumour	 (GEP-NET), 	 descr ibed	 as 	 the	 age-
standardised	 incidence	 per	 100,000	 inhabitants	 per	 year,	 is	 approximately	
1-2/100,000	8.	The	lowest	percentage	of	patients	is	reported	in	Italy,	whereas	the	
highest	number	has	been	reported	in	the	USA	9,	10.	A	slight	preponderance	in	women	
was	reported	in	Europe,	whereas	in	the	USA	a	higher	incidence	was	found	among	
black	people	8.	 Interestingly,	the	incidental	finding	of	carcinoid	tumours	during	
autopsies	is	much	higher	and	is	reported	to	be	about	1%	11.	In	a	recent	Dutch	study,	
the	primary	site	of	NETs	was	reported	to	be	within	the	gastrointestinal	tract	(62%),	
especially	the	appendix	(27%),	followed	by	the	small	bowel	(13%).	Thereafter,	the	
lungs	and	mediastinum	are	the	second	most	common	localisation	of	neuroendocrine	
tumours.	
Modlin	et al.	12,	who	used	the	Surveillance,	Epidemiology,	and	End	Results	database	
(SEER,	1973–1991)	registry,	reported	the	overall	incidence	of	nonlocalised	carcinoids	
at	the	time	of	diagnosis	as	45.3%	in	a	total	of	5468	carcinoid	patients.	The	frequently	
during	surgery	incidentally	encountered	appendiceal	carcinoid	was	demonstrated	
to	be	nonlocalised	in	35.4%.	Carcinoids	originating	from	different	anatomical	sites,	
like	the	pancreas,	small	intestine	or	colon,	were	encountered	more	frequently	with	
metastasis	at	diagnosis	(76.1%,	70.7%	and	71.2%,	respectively).	Pancreatic	NETs	
14
of	which	up	to	40%	are	non-functioning,	have	about	50%	hepatic	metastases	at	
diagnosis	13.	In	twelve	percent	of	patients	who	present	with	metastatic	disease,	the	
primary	site	remains	unknown	8.
Histology and classification
In	the	last	century	several	classifications	of	GEP-NETs	have	been	applied.	Obern-
dorfer,	who	was	the	first	to	characterize	these	tumours,	reported	the	existence	of	
rare	epithelial	tumours	in	the	gut	that	have	a	relatively	monotonous	structure	and	
exhibit	a	 less	aggressive	or	 indolent	nature	than	gut	derived	carcinomas	 14.	The	
latter	characteristic	feature	of	the	tumour	made	him	choose	the	name	‘carcinoid’.	
Until	1963,	all	GEP-NETs	tumours	were	referred	to	as	carcinoids.	At	that	time,	
Williams	and	Sandler	divided	the	carcinoids	into	fore-,	mid-	and	hindgut	carcinoids,	
according	to	their	embryologic	origin	15.	This	classification	was	never	fully	accepted	
by	clinicians	mainly	because	of	the	wide	range	of	differences	of	morphology,	function	
and	biology	that	could	be	found	within	one	single	class	of	tumours.	In	1980,	the	
first	World	Health	Organization	(WHO)	classification	of	endocrine	gastrointestinal	
tumours	was	introduced.	Endocrine	tumours	were	subdivided	based	on	cell	type	into	
enterochromaffin	cell,	gastrin	cell	and	unspecified	carcinoids	16.	This	classification	
caused	misunderstanding	between	pathologists	and	clinicians	because	for	the	latter	
group	the	term	carcinoid	was	mainly	reserved	for	patients	who	had	symptoms	
due	to	the	secretion	of	hormones	by	the	tumour.	Obviously,	the	WHO	definition	
did	not	cover	the	whole	morphological,	biological	and	clinical	spectrum	of	GEP-
NETs.	A	more	structured	WHO	classification	was	introduced	in	2000	17,	18.	The	new	
classification	is	based	on	a	combination	of	pathological	and	clinical	features	with	
parameters	specific	for	each	organ	from	which	the	endocrine	tumours	originate.	
All	GEP-NETs	are	grossly	divided	into	three	main	categories:	(1)	well-differentiated	
endocrine	tumours,	further	subdivided	into	tumours	with	benign	and	with	uncertain	
biological	behaviour;	(2)	well-differentiated	endocrine	carcinomas	or	low	grade;	and	
(3)	poorly	differentiated	endocrine	carcinomas	or	high	grade	(Table	2).	
Because	poorly	differentiated	 tumours	have	a	highly	aggressive	course,	 these	
neoplasms	are	profoundly	different	from	the	other	subgroups	and,	therefore,	require	
a	more	aggressive	therapeutic	approach	(see	further	 in	this	chapter).	A	further	
distinction	was	made	according	to	the	specific	organ	localisations.	The	stomach,	
duodenum	(and	proximal	jejunum),	ileum	(including	the	distal	jejunum),	appendix,	
colon-rectum,	and	pancreas	were	distinguished.	Besides	 the	histopathological	
characteristics	and	primary	site	of	origin,	the	endocrine	tumours	are	classified	into	
whether	biologically	active	substances/hormones	are	produced	and	secreted	and	
thereby	distinguished	into	functioning	or	non-functioning	endocrine	tumours.	
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Table 2.	WHO	classification	of	gastroenteropancreatic	endocrine	tumours	
Tumour Site
Well differentiated 
endocrine tumour 
(Benign behaviour)
Well differentiated 
endocrine tumour 
(Uncertain 
behaviour)
Well differentiated 
endocrine 
carcinoma 
(Low grade 
malignant)
Poorly differentiated 
endocrine 
carcinoma
 (High grade 
malignant)
Pancreas Confined	to	pancreas
<	2cm
Confined	to	pancreas
≥	2cm
Well	to	moderately	
differentiated	
Gross	local	invasion	
and/or	metastases
Small	cell	carcinoma
Necrosis	common
<	2	mitoses	per	10	HPF >	2	mitoses	per	10	HPF Mitotic	rate	often	
higher
(2-10	per	10	HPF)
>	10	mitosis	per	10	
HPF
<	2%	Ki-67	positive	
cells
No	vascular	invasion
>	2%	Ki-67	positive	
cells	or	vascular	
invasion
Ki-67	index	>	5% >	15%	Ki-67	positive	
cells
Prominent	vascular	
and/	or	perineural	
invasion
Stomach Confined	to	mucosa-
submucosa
≤	1	cm.	No	vascular	
invasion
Confined	to	mucosa-
submucosa
>1	cm	or	vascular	
invasion
Well	to	moderately	
differentiated	
Invasion	to	
muscularis	propria	or	
beyond	or	metastases
Small	cell	carcinoma
Duodenum, 
upper 
jejunum
Confined	to	mucosa-
submucosa
≤	1	cm.	No	vascular	
invasion
Confined	to	mucosa-
submucosa
>	1	cm	or	vascular	
invasion
Well	to	moderately	
differentiated	
Invasion	to	
muscularis	propria	or	
beyond	or	metastases
Small	cell	carcinoma
Ileum, 
colon, 
rectum
Confined	to	mucosa-
submucosa
≤	1	cm	(small	intestine)
Confined	to	mucosa-
submucosa
>	1	cm	(small	intestine)
Well	to	moderately	
differentiated	
Invasion	to	
muscularis	propria	or	
beyond	or	metastases
Small	cell	carcinoma
≤	2	cm	(large	intestine).	
No	vascular	invasion
>	2	cm	(large	intestine)	
or	vascular	invasion
Appendix Non-functioning
Confined	to	the	
appendiceal	wall
Enteroglucagon-
producing
Confined	to	subserosa
Well	to	moderately	
differentiated	
Invasion	to	
mesoappendix	or	
beyond	or	metastases
Small	cell	carcinoma
≤	2	cm.	No	vascular	
invasion
>	2	cm	or	vascular	
invasion
HPF, high power field. Adapted from Ramage et al. 2005 19
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Functioning	endocrine	tumours	or	carcinomas	are	still	traditionally	named	according	
to	the	hormone(s)	that	are	produced	such	as	gastrinomas,	insulinomas	and	vasoactive	
intestinal	peptide-omas	 (‘VIPomas’)	 20.	The	 term	carcinoid	 is	 reserved	 for	 the	
functioning	well-differentiated	endocrine	tumours,	which	produce	and	secrete	
serotonin	and	thereby	cause	the	so-called	carcinoid	syndrome.	The	term	malignant	
carcinoid	is	reserved	for	the	functioning	well-differentiated	endocrine	carcinomas.	
Poorly	differentiated	(usually	small	cell)	endocrine	carcinoma,	which	is	characterised	
by	high	grade	malignancy,	is	no	longer	associated	with	the	term	carcinoid.
With	the	use	of	the	new	WHO	classification	the	individual	tumour	within	the	
heterogeneous	group	of	endocrine	tumours	can	be	better	classified	according	to	
their	histology,	biological	behaviour	and	clinical	presentation.	Most	of	the	endocrine	
tumours,	 including	those	described	within	this	 thesis	are	well-differentiated,	
slow	growing	and	have	a	relative	good	prognosis.	With	respect	to	the	tumours	
described	in	this	thesis,	the	terms	‘endocrine’	and	‘neuroendocrine’	can	be	considered	
synonymous.	Since	the	results	described	within	the	present	thesis	are	compared	with	
studies	from	the	past,	the	tumour	nomenclature	may	differ	from	the	most	recent	
WHO	definitions.	Where	possible	the	new	WHO	classification	is	used.
TREATMENT
Evaluation of therapy outcome
The	treatment	of	GEP-NETs	is	extremely	variable	and	different	treatment	modalities	
are	currently	used	and	developed.	To	have	 insight	 in	and	for	comparison	with	
the	reported	outcomes	of	 the	different	treatment	options,	 it	 is	necessary	to	be	
familiar	with	the	methods,	which	are	used	to	measure	and	compare	the	outcomes	
of	treatment.	
The	most	obvious	treatment	outcome	or	endpoint	of	a	study,	especially	in	early	phase	
II	clinical	trials,	is	tumour	reduction.	However,	it	is	often	not	clear	which	tumour	
response	criteria	have	been	used	or	what	is	meant	with	partial	response	or	remission	
(PR),	stable	disease	(SD)	or	progressive	disease	(PD)	mentioned	in	the	those	studies.	
Most	studies	discussed	in	this	general	introduction	use	established	criteria,	such	as	
the	criteria	of	the	WHO,	Response	Evaluation	Criteria	in	Solid	Tumours	(RECIST)	
or	criteria	defined	by	the	Southwest	Oncology	Group	(SWOG).	Definitions	of	these	
different	criteria	are	shown	in	Table	3.	
The	use	of	this	type	of	criteria	allows	better	comparison	of	results	among	patients	
treated	differently.	However,	to	fully	understand	and	compare	clinical	trials	it	is	
important	to	realize	these	differences.	The	most	important	difference	between	
these	criteria	lies	within	the	method	of	measuring	the	tumours	(bidimensional	
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versus	unidimensional).	This	may	lead	to	different	response	outcome	in	the	same	
patient	when	other	criteria	are	used.	As	the	definition	of	progressive	disease	is	also	
different	in	all	criteria,	differences	can	be	expected	especially	when	establishing	
the	number	of	patients	with	PD	21.	Also,	although	outcome	of	therapy	based	on	
tumour	size	measurement	seems	to	be	straightforward,	it	has	the	disadvantage	that	
it	does	not	take	into	account	that	inhibition	of	tumour	growth,	resulting	in	SD,	can	
be	also	of	significant	clinical	benefit	and	vice	versa;	that	response	does	not	per	se	
imply	clinical	benefit	when	information	about	side-effects,	quality	of	life	and	time	
to	progression	(TTP)	is	lacking.	Furthermore,	only	morphological	information	on	
radiological	 imaging	is	currently	used	in	assessing	tumour	responses	following	
the	mentioned	criteria,	whereas	information	of	metabolic	response	assessed	by	
molecular	imaging	(e.g. Fluorodeoxyglucose-Positron	Emission	Tomography,	FDG-
PET)	is	not	taken	into	account,	but	may	be	possibly	at	least	as	important.	In	several	
studies,	it	is	reported	that	metabolic	response	had	additional	value	to	morphological	
response	data	 22,	23.	 In	the	management	of	GEP-NETs,	 for	example,	controversy	
exists	in	the	clinical	importance	of	the	occurrence	of	abdominal	fibrosis	commonly	
seen	in	carcinoid	patients.	This	evidence	of	disease	will	remain	stable	in	follow-up	
but	has	no	meaning	in	terms	of	disease	activity.	Nonetheless,	it	will	be	included	
in	the	assessment	of	morphological	response.	It	 is	therefore	not	unlikely	that	in	
the	future	the	current	criteria	for	response	evaluation	in	GEP-NETs	will	include	
response	criteria	based	on	both	morphological	response	and	assessment	of	metabolic	
response	by	molecular	imaging	or	even	that	results	of	molecular	imaging	can	serve	
as	a	surrogate	measure	of	therapeutic	efficacy.
In	most	phase	 III	 trials	and	some	phase	 II	 trials	more	stringent	endpoints	 like	
survival,	progression	free	survival	(PFS),	and	TTP	are	used.	These	endpoints	are	
more	logical	when	considering	tumour	response	in	terms	of	metabolic	activity,	
especially	since	more	and	more	cancer	therapeutics	are	based	on	the	inhibition	of	
tumour	cell	growth	rather	than	the	induction	of	tumour	cell	death	or	apoptosis	in	
conventional	cytotoxic	strategies.	Furthermore	these	endpoints	have	the	advantage	
of	assessing	the	therapeutic	efficacy	within	a	specific	patient	population	rather	than	
for	the	individual	patient.	Obviously	however,	these	trials	require	the	inclusion	of	
more	patients	and	longer,	carefully	monitored	follow-up.	Therefore,	data	on	PFS	
and	TTP	are	often	lacking	in	reports	on	anti-tumour	activity	of	recently	developed	
anti-cancer	agents.	The	different	and	most	commonly	used	definitions	of	survival	
and	corresponding	endpoints,	are	given	in	Table	4.
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Table 3.	Definition	of	response	according	to	WHO,	RECIST	and	SWOG	criteria.
Criteria
Tumour size 
measurement
CR PR SD PD
WHO 
a
Sum	of	products	
(bidimensional)
Disappearance	
of	all	known	
disease	
Confirmation	
≤	4	weeks
≥	50%	
decrease	of	
all	lesions;	no	
new	lesion,
no	
progression	of	
any	lesions
Confirmation	
≤	4	weeks
Neither	
PR	nor	PD	
criteria
are	met	
Confirmation	
≤	4	weeks
≥	25%	increase	of	
a	single	lesion;	
new	lesion(s);	
no	CR,	PR,	or	
SD	documented	
before	increased	
disease
RECIST 
b, c
Sum	of	
maximum	
diameters	of	
target	lesions
	
(unidimensional)	
Complete	
disappearance	
of	all	target	
and	non-target	
lesions
Confirmation	
≤	4	weeks
≥	30%	
decrease	of	all	
target	lesions;	
no	new
lesion(s);	no	
progression	of	
disease
Confirmation	
≤	4	weeks
Neither	
PR	nor	PD	
criteria
are	met
Confirmation	
≤	4	weeks
≥	20%	increase,	
new	lesion(s);	no	
CR,	PR,	or
SD	documented	
before
increased	disease
SWOG d Sum	of	
products	of	the	
perpendicular	
diameters	of	
all	measurable	
lesions
(bidimensional)
Complete	
disappearance	
all	measurable	
and	evaluable	
disease
Confirmation	
at	6	weeks
≥	50%	
decrease	of	
at	least	one	
measurable	
lesion;	no	
progression	
of	evaluable	
disease;	no	
new	lesions
Confirmation	
at	6	weeks
Neither	CR,	
PR	nor	PD	
criteria	are	
met
Confirmation	
at	6	weeks
≥	50%	or	increase	
of	10	cm2	increase,	
or	clear	worsening	
of	any	evaluable	
disease,	or	
reappearance	of	
any	lesion	which	
had	disappeared,	
or	appearance	of	
any	new	lesion/	
site,	or	failure	
to	return	for	
evaluation	due
to	death	or	
deteriorating	
condition
WHO, World Health Organization; SWOG, Southwest Oncology Group; RECIST, Response Evaluation 
Criteria in Solid Tumours; CR, complete response; PR, partial response; SD, stable disease; PD, progressive 
disease
(a) Cancer 1981; 47:207-214
(b) J Natl Cancer Inst 2000; 92:205-216
(c) target lesions, all measurable lesions up to a maximum of five lesions per organ and 10 lesions in total, 
representative of all involved organs
(d) Investigational New Drugs 1992; 10: 239-253
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1.1
The	most	important	treatment	outcome	is	whether	the	studied	therapy	can	alter	
the	natural	history	of	progression	of	the	patients’	disease	or	increase	of	survival.	
Methods	to	study	the	latter	endpoint	can	be	found	in	survival	analysis	studies.	
However,	the	slowly	progressive	or	indolent	nature	of	the	disease	present	in	most	
patients	makes	that	survival	analysis	of	GEP-NETs	requires	a	study	with	a	long	
follow-up	period.	Furthermore,	this	can	be	a	disadvantage	in	terms	of	determining	
the	effectiveness	of	therapy	within	a	limited	period	of	time.	Also,	careful	monitoring	
during	follow-up,	preferably	in	the	hospital	where	the	patient	was	treated,	is	not	
always	practically	feasible.	In	an	ideal	situation,	survival	analysis	contains	a	matched	
control	group,	which	in	some	studies	is,	for	practical	and	ethical	reasons,	not	available.	
An	alternative	option	is	to	look	at	historical	controls.	However,	this	method	does	not	
take	into	account	the	problem	of	a	different	patient	mix	and	historical	time-frame	
dependent	factors	such	as	differences	in	available	therapeutic	options	for	the	disease	
or	development	of	more	sensitive	diagnostic	modalities.	
Table 4.	Definition	of	survival	and	endpoints	for	clinical	trials
Survival Term Definition† Endpoint
Overall survival (OS) The	percentage	of	subjects	in	a	study	who	have	survived	
for	a	defined	period	of	time.	Usually	reported	as	time	since	
diagnosis	or	treatment.	
Death	from	any	cause
Disease-specific 
survival
The	percentage	of	subjects	in	a	study	who	have	survived	
a	particular	disease	for	a	defined	period	of	time.	Only	
deaths	from	the	disease	being	studied	are	counted.	Subjects	
who	died	from	some	other	cause	are	not	included	in	the	
calculation.	Usually	reported	as	time	since	diagnosis	or	
treatment.	
Death	from	the	disease	
studied
Time to progression 
(TTP)
A	measure	of	time	after	a	disease	is	diagnosed	(or	treated)	
until	the	progressive	disease	occurs.
Progressive	disease	
according	to	trial	
response	criteria
Progression-free 
survival (PFS)
One	type	of	measurement	that	can	be	used	in	a	clinical	
study	or	trial	to	help	determine	whether	a	new	treatment	
is	effective.	It	refers	to	the	probability	that	a	patient	will	
remain	alive,	without	the	disease	getting	worse.
Progressive	disease	or	
cancer-related	death	
Disease-free survival Length	of	time	after	treatment	during	which	no	cancer	is	
found.	Can	be	reported	for	an	individual	patient	or	for	a	
study	population.
Relapse
Survival rate The	percentage	of	people	in	a	study	or	treatment	group	who	
are	alive	for	a	given	period	of	time	after	diagnosis.	This	is	
commonly	expressed	as	5-year	survival.
NA
† these definitions were quoted from the National Cancer Institue (NCI) website: www.cancer.gov; NA, not 
applicable
20
Other	factors,	which	are	important	to	report,	include	changes	in	disease-related	
symptoms,	adverse	reactions/complications	and	side-effects.	In	most	cases,	except	
for	life-threatening	complications,	these	factors	are	not	influencing	the	primary	
endpoints	of	the	study,	such	as	response	to	treatment,	TTP	or	survival,	but	are	
important	in	judging	the	influence	of	the	therapy	on	normal	daily	life	and	non-
intended	effects	of	therapy.	Together,	these	effects	have	their	impact	on	the	so-called	
quality	of	life.
Quality	of	life	is	an	entity	that	is	difficult	to	define,	and	hence,	difficult	to	assess.	
Probably	one	of	the	main	reasons	for	this	is	that	it	differs	for	any	given	individual.	
Nonetheless,	standardised	methods	to	assess	quality	of	life	have	been	developed	
during	the	last	decades.	These	assessments	of	quality	of	life	have	become	a	commonly	
and	increasingly	used	endpoint	in	many	oncology	trials.	
One	of	 the	 currently	used	methods	 to	 assess	quality	of	 life	 is	 the	QLQ-C30	
questionnaire	developed	by	the	European	Organization	of	Research	and	Treatment	
of	Cancer	(EORTC)	and	can	be	used	for	evaluation	in	all	types	of	cancers.	For	specific	
cancers	add-on	modules	have	been	developed	including	a	separate	module	for	GEP-
NETs	 24.	Besides	the	EORTC	QLQ-C30	questionnaire	many	other	 instruments	
have	been	developed.	However,	despite	the	many	different	methods	available	to	
measure	quality	of	life,	reports	on	GEP-NETs	often	lack	the	assessment	of	quality	
of	life.	Comparison	of	changes	in	quality	of	life	between	treatments	is,	therefore,	
not	possible.
Surgery
Resection	of	the	primary	tumour	is	the	only	curative	treatment	option	and	remains	
the	cornerstone	in	the	treatment	of	patients	with	GEP-NETs.	Surgery	with	curative	
intent	can	be	successful,	especially	in	appendiceal	carcinoids.	The	appendix	is	one	of	
the	most	common	single	site	for	carcinoid	tumour	9.	Although	rare,	it	is	considered	
the	most	common	type	of	appendiceal	primary	malignant	lesion,	and	is	found	in	
0.3-0.9%	of	patients	undergoing	appendectomy	25.	Small	appendiceal	endocrine	
tumours	(<	1	cm)	have	an	excellent	prognosis	with	a	5-year	survival	rate	of	94%	after	
appendectomy.	Larger	tumours	(>	2	cm)	require	right	hemicolectomy.	Hemicolectomy	
should	also	be	considered	in	tumours	1–2	cm	in	size	if	(a)	the	mesoappendix	is	
involved;	(b)	angioinvasion	is	demonstrable;	and	(c)	a	high	proliferative	index	/	Ki-
67	level	is	apparent,	and	(d)	when	tumours	are	located	at	the	base	of	the	appendix	
with	positive	margins	26,	27.	The	5-year	survival	rate	for	patients	with	more	than	
local	disease	is	85%	27.	In	contrast,	surgery	with	curative	intent	is	often	not	possible	
in	patients	with	endocrine	tumours	in	adjacent	areas	such	as	the	ileum	and	distal	
jejunum.	At	the	time	of	diagnosis	the	tumours	are	commonly	larger	than	2	cm	and	
have	already	invaded	the	muscularis	propria.	Typical	findings	at	laparotomy	are	a	
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small	primary	tumour	with	large	mesenteric	metastases	with	marked	surrounding	
mesenteric	fibrosis	or	desmoplastic	reaction	due	to	local	effects	of	serotonin	and	
growth	factors	produced	by	the	tumour	28.	The	primary	tumour	and	mesenteric	
metastases	should	be	removed	by	wedge	resection	of	the	mesentery	and	limited	
intestinal	resection,	and	lymph	node	metastases	ought	to	be	cleared	as	efficiently	
as	possible	by	dissection	in	the	area	of	the	mesenteric	artery	and	its	branches.	This	
approach	has	been	recommended	since	without	this	management	patients	are	at	
risk	to	develop	abdominal	complications,	such	as	 intestinal	obstruction	due	to	
extensive	mesenteric	desmoplastic	reaction	or	encasement	of	mesenteric	vessels.	
The	 latter	may	cause	periodic	 intestinal	 ischemia	or	segmental	gangrene	with	
subsequent	risk	of	perforation.	If	the	primary	tumour	and	mesenteric	metastases	
appear	radically	removed,	the	patients	may	remain	symptom-free	for	a	long	period	
of	time.	However,	after	5-10	years	of	follow-up,	tumour	recurrences	occur	frequently	
with	liver	metastases	in	more	than	80%	of	patients	with	long	follow-up	29.	Besides	
frequent	recurrence	after	initial	resection	with	curative	intent,	cumulative	analysis	of	
all	types	of	endocrine	tumours	showed	that	in	45%	of	cases	metastases	were	already	
evident	at	the	time	of	diagnosis	12.
In	the	case	of	metastases,	of	which	liver	metastases	are	most	frequent,	surgery	with	
the	intention	to	cure	is	unlikely	to	succeed.	In	these	cases	surgery	of	the	primary	
tumour	in	a	palliative	setting	can	be	beneficial	to	the	patient	in	terms	of	improvement	
of	quality	of	life.	High	tumour	load	of	the	primary	may	cause	significant	morbidity,	
including	secretion	of	high	amounts	of	hormones	and	risk	of	mechanical	bowel	
obstruction,	and	decreased	survival.
The	spectrum	of	clinical	presentation	in	patients	with	liver	metastases	may	range	
from	patients	with	progressive	 liver	disease,	accompanied	by	extreme	clinical	
syndromes	secondary	to	increased	hormone	production,	to	cases	in	which	patients	
have	been	known	to	live	for	decades	with	remarkably	large	liver	metastases	without	
symptomatology.	Yao	et al.	30	indicated	that	surgery	in	patients	in	whom	the	tumour	
was	still	 in	situ	and	who	had	also	 liver	 involvement	with	a	 limited	number	of	
metastases,	might	be	rewarding	in	terms	of	extended	survival.	Sixteen	patients	
had	complete	surgical	resection	of	their	metastases	of	whom	ten	had	synchronous	
resection	of	their	primary	tumour.	The	total	group	had	a	5-year	survival	of	70%.	
Patients	with	a	limited	number	of	liver	metastases	(<	5)	had	a	favourable	disease-free	
survival	of	46	months	compared	to	20	months	in	patients	with	more	than	4	liver	
metastases.	It	was	concluded	that	even	in	patients	with	hepatic	metastases	surgery	
has	to	be	considered.	
Furthermore,	if	the	tumour	bulk	in	the	liver	is	too	extensive	for	complete	resection,	
surgery	might	also	have	a	place	in	palliation.	Several	studies	have	pointed	out	that	
22
for	patients	in	whom	cytoreductive	surgery	or	tumour	debulking	of	more	than	90%	
of	the	tumour	can	be	achieved,	surgery	should	be	offered	as	it	may	prolong	survival	
and	alter	the	natural	history	of	the	disease	process	31,	32.	Recently,	a	new	plea	for	this	
aggressive	surgical	approach	of	advanced-stage	carcinoid	tumours	was	published	
by	Boudreaux	et al.	 33.	This	approach	included	surgical	resection	of	the	primary	
tumour	when	possible	to	prevent	life	threatening	abdominal	complications	(such	as	
intestinal	obstruction,	ischaemia	or	perforation),	prophylactic	cholecystectomy	to	
negate	the	possibility	of	future	gall	stone	development	associated	with	long-term	
octreotide	therapy	and	staged	debulking	as	comorbidities	would	allow.	In	patients	
in	whom	such	an	approach	was	performed	major	complications	was	encountered	
in	17%,	minor	complications	in	39%.	Nonetheless,	according	to	the	authors,	these	
surgical	interventions	in	patients	with	advanced-stage	disease	provided	significant	
improvements	in	quality	of	life	and	patient	survival.	However,	despite	these	studies	
that	advocate	an	aggressive	approach,	such	an	approach	has	not	been	implemented	
in	all	specialised	centres.	In	the	Netherlands,	for	example,	major	surgery	in	GEP-
NETs	such	as	described	by	Boudreaux	is	not	widely	accepted.	Reason	for	a	 less	
aggressive	approach	is	probably	a	combination	of	factors	including	the	reported	
high	complication	rate,	the	lack	of	randomised	controlled	studies	and	lack	of	quality	
of	life	data.	Therefore,	although	the	results	of	abovementioned	aggressive	surgical	
approach	could	benefit	patients	with	GEP-NETs	in	terms	of	outcome,	survival	and	
quality	of	life,	randomised	controlled	studies	with	long	follow-up,	including	properly	
designed	quality	of	life	assessment	are	necessary.	
Liver transplantation
Orthotopic	 liver	 transplantation	 (OLT)	has	been	progressively	abandoned	 for	
the	management	of	hepatic	metastatic	disease	of	most	carcinomas	because	of	the	
unacceptable	high	recurrence	rate	which	does	not	justify	the	cost	of	the	procedure	
and	the	utilization	of	scarce	donor	organs.	However,	in	patients	with	GEP-NETs,	
the	tumours	are	usually	slow-growing	(with	the	exception	of	patients	with	poorly	
differentiated	endocrine	tumours).	Moreover,	metastases	are	often	only	confined	
to	the	liver	and,	therefore,	OLT	can	be	a	valuable	treatment	option.	Especially	since	
the	quality	of	life	of	these	patients	is	often	poor	due	to	pain	and	debility	related	
to	hepatomegaly	and/or	hormone	production,	endocrine	GEP	tumours	are	one	
of	the	few	malignancies	where	hepatic	metastases	are	not	a	contraindication	to	
liver	transplantation.	Obviously,	partial	hepatectomy,	followed	by	debulking	or	
cytoreductive	surgery	are	the	first	options	that	have	to	be	reviewed	in	any	patient.	In	
most	cases,	however,	partial	hepatectomy	is	not	possible	because	of	multifocal	and	
bilateral	localisation	of	disease	which	is	present	in	approximately	90%	of	patients	
who	present	with	liver	metastases	34.	When	medical	therapy	or	interventions	(local	
ablation/hepatic	arterial	embolisation)	also	fail	to	control	the	disease	in	terms	of	
progression	and/or	symptoms,	the	option	of	an	OLT	comes	in	view.
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Most	 reports	on	OLT	are	single	centre	studies	 that	describe	a	 limited	number	
(maximum	of	 19)	of	patients	with	 a	median	 follow-up	 ranging	 from	 11	 to	 54	
months	35.	Therefore,	the	outcome	of	OLT	in	terms	of	survival	rates	can	only	be	
based	on	the	three	large	multi-centre	studies	with	30	or	more	patients	included	36-38.	
Although	the	primary	goal	of	OLT	in	most	cases	is	cure,	documented	recurrence-
free	5-year	survival	rates	in	these	studies	were	relatively	low,	ranging	from	17	to	
24%	37,	38.	Reported	1-	and	5-year	true	survival	rates	after	transplantation	range	from	
58-68%	and	35-47%	39,	respectively	and	are	higher	than	historical	controls,	which	have	
documented	5-year	survival	rates	of	approximately	30%	40.	However,	randomised	
studies	are	lacking	and	since	the	publication	of	these	studies	several	new	therapeutic	
strategies	on	OLT	have	evolved,	which	increase	the	overall	survival,	especially	within	
the	group	of	patients	with	distant	metastases	9.	
Interesting	findings	were	reported	in	the	largest	retrospective	multi-centre	analysis	to	
date	38.	Four	factors	related	to	outcome	were	identified.	Subsequently,	a	proportional	
hazards	model	indicated	that	age	at	or	above	50	and	synchronous	upper	abdominal	
exenteration	or	Whipple’s	procedure	were	independent	factors	of	poor	outcome,	
whereas	location	of	the	primary	tumour	(lung	or	bowel)	and	pre-OLT	somatostatin	
analogue	treatment	were	favourable	prognostic	factors.	Patients	with	favourable	
prognostic	indicators	had	an	overall	5-years	survival	of	65%	and	median	survival	
of	more	 than	8	years.	 In	 contrast,	patients	who	had	extended	operation	with	
abdominal	exenteration	or	Whipple’s	operation	had	1-	and	5-year	survival	of	50%	
and	31%,	respectively.	The	role	of	tumour	biology	as	determined	by	three	different	
immunohistochemical	markers,	Ki-67,	E-cadherin	and	p53,	was	reported	in	the	
largest	single	centre	study	41.	Using	the	combination	of	Ki-67	and	E-cadherin	the	
authors	were	able	to	show	significant	differences	between	long-term	survivors	and	
patients	who	died	early	after	OLT.	
In	contrast	to	the	relatively	good	results	of	OLT,	the	postoperative	mortality	is	
high,	reported	to	be	10%	at	30	days	and	14%	at	60	days	38.	This	high	mortality	rate	is	
probably	one	of	the	reasons	why	OLT	has	not	been	implemented	in	the	management	
of	patients	with	GEP-NETs	in	most	transplantation	centres,	including	those	in	the	
Netherlands.	Furthermore,	surgeons	often	hesitate	to	perform	OLT	at	the	time	
metastatic	spread	is	evident,	because	of	the	risk	of	early	tumour	spread	secondary	
to	the	effects	of	immunosuppression	after	OLT.	
In	conclusion,	liver	transplantation	for	metastatic	GEP-NETs	is	controversial.	When	
considered,	the	overall	consensus	is	that	OLT	should	be	considered	only	in	carefully	
selected	individuals,	based	on	the	patients’	age	(<50	years),	extension	of	intended	
surgery	and	Ki-67/	E-cadherin	expression.	However,	the	exact	role,	including	finding	
optimal	histopathological	clinical	criteria	to	predict	clinical	outcome	and	the	exact	
24
timing	of	OLT,	need	to	be	defined	in	large	multi-centre	based	prospective	studies.	
Furthermore,	treating	physicians	should,	at	the	point	of	defining	the	best	treatment	
for	the	individual	patient,	always	realize	that	although	not	impossible,	cure	after	
OLT	is	improbable.	This	means	that	OLT	in	a	patient	with	extended	hepatic	disease	
will	usually	be	considered	as	the	last	possible	option	for	effective	palliation	and	
improvement	of	survival.	Furthermore,	it	may	be	questioned	whether	at	that	time	
of	disease	evolution,	the	patient	is	still	a	candidate	for	major	surgery.
LOCAL THERAPY
External Beam Radiation
External	 beam	 radiation	 therapy	 (EBRT)	never	had	 an	 important	 role	 in	 the	
management	of	patients	with	the	relatively	radioresistant	GEP-NETs.	Furthermore,	
the	location	of	liver	and	abdominal	metastases	limits	the	use	of	traditional	EBRT.	
Therefore,	reports	on	the	effectiveness	of	EBRT	in	patients	with	neuroendocrine	
tumours	are	 limited.	However,	occasionally,	EBRT	has	been	applied	for	 locally	
inoperable	 carcinoid	 and	pancreatic	 islet	 cell	 carcinomas	 42,	43.	 Small	 series	of	
patients	treated	with	EBRT	of	which	the	largest	included	a	total	of	sixty	patients	
indicated	that	only	in	selected	patients	substantial	symptomatic	improvement	can	be	
achieved	44,	45.	These	reports	should	be	regarded	separately	from	those	that	describe	
EBRT	in	patients	with	brain	and	bone	metastases	who	have	spinal	cord	compression	
or	bone	pain	due	to	 local	tumour	expansion.	 In	those	cases,	EBRT	remains	the	
standard	palliative	therapy	45.
Hepatic Artery (Chemo) Embolisation 
Hepatic	artery	embolisation	(HAE)	in	GEP-NETs	is	based	on	the	fact	that	metastases	
receive	most	of	their	blood	supply	from	the	hepatic	artery.	In	contrast,	the	normal	
hepatic	parenchyma	receives	20-25%	of	its	blood	supply	from	the	hepatic	artery	and	
75-80%	from	the	portal	vein.	HAE	will	induce	tumour	necrosis	by	selective	induction	
of	temporary	but	complete	ischaemia	in	hypervascular	liver	metastases	by	blocking	
branches	of	the	hepatic	artery	and	thus	the	oxygen	supply.	
The	 combination	of	 localised	delivery	of	 a	 cytotoxic	 compound	 followed	by	
embolisation	is	called	hepatic	artery	chemoembolisation	(HACE).	This	intravascular	
technique	makes	it	possible	to	deliver	a	cytotoxic	drug	in	very	close	proximity	to	
the	tumour	cells.	For	HACE,	the	cytotoxic	agent	most	often	used	is	doxorubicin	
(Adriamycin).	However,	other	cytotoxins	and/or	combinations	have	also	been	
used	46	,	47-49.
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Candidates	for	embolisation	are	patients	who	have	advanced	stage	disease	with	
multiple	 liver	metastases	 that	are	not	amenable	 to	surgical	 cure.	However,	 in	
HA(C)E,	despite	advances	in	interventional	techniques,	careful	patient	selection	is	
required,	as	disease-	and	also	treatment-related	adverse	effects	may	be	significant.	
Absolute	contraindications	include	portal	vein	thrombosis,	liver	failure	and	biliary	
reconstruction	(i.e.	after	a	Whipple	procedure).	Relative	contraindications	can	be	
tumour	load	exceeding	50%	of	the	liver,	contrast	allergy,	more	extrahepatic	than	
hepatic	disease,	and	poor	performance	status	of	the	patient	50,	51.
The	embolisation	procedure	is	in	most	patients	followed	by	a	complex	of	symptoms	
and	reactions	such	as	mild	and	transient	nausea	and	vomiting	(50–70%),	abdominal	
pain	(50–60%),	fever	up	to	38.5	°C	(30–60%)	and	raised	liver	transaminases	(100%)	
often	referred	to	as	the	post-embolisation	syndrome	52.	Such	symptoms	are	easily	
controlled,	but	patients	should	be	made	aware	that	such	symptoms	might	persist	
for	several	days.	Major	complications	are	rarely	seen,	but	renal	and	liver	failure	and	
bleeding	peptic	ulcers	have	been	observed.
Furthermore,	embolisation	may	lead	to	serious	complications	in	individual	patients	
(gallbladder	ischaemia,	pancreatitis,	liver	abscess,	vascular	damage	and	aneurysm	
formation,	hepatorenal	syndrome	and	hormonal	crisis).	The	mortality	rate	in	the	
major	series	is	less	than	5%	53.	Considering	the	risk	of	complications	and	relatively	
high	mortality	rate,	chemoembolisation	has	to	be	performed	in	experienced	hands	
and	specialised	centres,	which	are	not	widely	available.
Although	HACE	has	not	been	compared	in	a	randomised	manner	with	HAE	to	
date,	encouraging	results	suggest	that	embolisation	combined	with	intra-arterial	
chemotherapy	is	at	least	as	effective	as	without	chemotherapy.	Tumour	response	
rates	after	chemoembolisation	are	given	in	Table	5.	
Objective	 tumour	 response	 rates	 are	widely	 variable	 and	 range	 from	 33	 to	
79%46-49,	55-58.	Median	duration	of	response	varied	from	6–21	months.	Differences	
in	number	of	patients	and	tumour	type	studied,	protocol	and	tumour	response	
evaluation	criteria	used	and	choice	of	cytotoxic	compound	employed	varied	widely	
which	makes	interpretation	and	comparison	between	the	different	studies	very	
difficult.	Furthermore,	in	most	patients	chemoembolisation	was	not	performed	as	
first-line	therapy.	These	patients	had	additional	medical	therapy	(e.g.	octreotide	s.c.)	
before	or	during	treatment	which	can	be	a	confounding	factor	in	the	observed	results.	
Interestingly,	in	the	largest	study	to	date,	predictors	of	efficacy	were	identified57.	
Arterial	enhancement	on	abdominal	computed	tomography	and	body	mass	index	
(BMI)	were	factors	that	were	positively	correlated	with	TTP	in	multivariate	analysis,	
thus	suggesting	that	the	cytoreductive	effect	on	the	tumour	by	HACE	requires	
26
hypervascularity	of	the	tumour.	The	question	why	the	BMI	has	an	effect	on	tumour	
response	after	HACE	 is	more	complicated.	Several	hypotheses	are	mentioned	
including	(a)	an	inverse	correlation	of	BMI	with	tumour	aggressiveness	and	(b)	higher	
dosages	given	to	patients	with	elevated	BMI	as	the	injected	dose	of	chemotherapy	
was	based	on	the	body	surface	area.	Still,	no	clear	evidence	for	these	explanations	
is	present	and,	therefore,	the	results	are	still	under	debate.	Furthermore,	although	
it	was	not	a	randomised	study,	results	with	streptozotocin	suggested	an	at	least	
equal	therapeutic	efficacy	compared	to	doxorubicin.	Streptozotocin	was	therefore	
recommended	to	be	used	with	HACE,	thereby	saving	the	cardiotoxic	doxorubicin	
for	possible	necessary	subsequent	intravenous	chemotherapy.
Radioembolisation 
The	technique	of	radioembolisation	involves	the	administration	of	microspheres	
labelled	with	 radioactive	 isotopes	 to	 induce	 hepatic	 artery	 occlusion	 and	
simultaneously	deliver	local	irradiation.	This	technique,	developed	by	the	group	of	
Grady	59	in	the	sixties,	was	initially	introduced	as	a	safe	procedure	in	the	management	
of	liver	metastasis	of	carcinoid	tumours	in	1971	60.	The	method,	reintroduced	in	1994	by	
the	group	of	Shapiro	61,	was	performed	in	twenty-four	patients	with	liver	metastasis,	
including	six	patients	with	metastatic	GEP-NETs.	In	this	preliminary	phase	I	study	in	
1994,	glass	microspheres	loaded	with	90Y	were	used.	Although	encouraging	data	were	
presented,	it	was	until	recently	that	more	reports	on	radioembolisation	in	patients	
with	metastasized	GEP-NETs	treated	with	90Y-microspheres	were	published	62,	63.	In	
eight	patients	with	unresectable	neuroendocrine	hepatic	metastases	Murthy	et al.63	
reported	one	PR,	four	cases	of	SD,	and	three	cases	of	PD.	Median	survival	times	were	
14	months	(range,	3-15	months)	from	the	time	of	treatment	and	36.5	months	(range,	
16-105	months)	from	the	time	of	diagnosis	of	hepatic	metastases.	
In	another	report,	hundred	thirty-seven	patients,	including	19	patients	with	GEP-
NETs	underwent	225	administrations	of	90Y	microspheres	by	arterial	infusion	62.	
Based	on	WHO	criteria,	43%	of	all	lesions	demonstrated	PR,	47%	had	SD	and	10%	
had	PD.	Limitations	of	this	study	included	the	heterogeneous	group	studied,	without	
specified	tumour	responses	per	subgroup.	Furthermore,	the	reported	response	per	
lesion	was	studied	rather	than	the	clinically	more	relevant	response	per	patient.	
Unfortunately,	the	median	survival	rate	of	25.9	months	for	neuroendocrine	tumours	
in	a	subgroup	analysis	was	the	only	specific	data	given	on	GEP-NETs.	Future	research	
on	the	use	of	radiolabelled	microspheres	in	the	cohort	of	patients	with	GEP-NETs,	
as	was	mentioned,	will	be	important	to	delineate	its	role	in	the	management	of	
GEP-NET	patients.
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Also	recently,	90Y-lanreotide	has	been	used	intra-arteriously	within	the	liver	of	23	
patients	with	GEP-NETs,	with	encouraging	results.	It	was	reported	that	3	out	of	19	
(16%)	evaluable	patients	had	PR,	12	(63%)	had	SD	and	4	(21%)	had	continued	disease	
progression.	Four	patients	died	before	therapy	evaluation	could	be	performed.	
However,	since	these	patients	most	probably	died	because	of	the	treated	disease,	
they	should	have	been	included	in	the	reported	results.	The	corrected	outcome	
would	be	3	out	of	23	(13%)	patients	having	PR,	12	out	of	23	(52%)	SD,	and	4	out	of	
23	(17%)	PD	despite	treatment.	Symptomatic	control	was	observed	in	14	out	of	23	
(61%)	64.	 Intrahepatic-arterial	 injection	of	radiolabelled	substances	may	achieve	
higher	intratumoural	concentrations	and	may	be	of	value	in	treating	isolated	hepatic	
lesions.	However,	in	the	management	of	disseminated	GEP-NETs,	which	is	the	case	
in	most	patients,	radioembolisation	is	probably	less	helpful,	especially	in	the	long-
term	control	of	the	disease.
Local ablative therapy 
Local,	imaging-guided	ablation	techniques,	such	as	radiofrequency	ablation	(RFA),	
laser	 induced	thermotherapy	(LITT)	or	cryotherapy	are	widely	used	to	 induce	
tumour	reduction	in	inoperable	hepatocellular	carcinomas	and	liver	metastases	from	
colorectal	carcinomas	65,	66.	RFA	uses	radiofrequency	waves	that	are	converted	to	heat.	
It	is	applied	with	an	electrode	directly	in	the	centre	of	a	tumour	and	subsequently	
results	in	cellular	destruction	at	temperatures	above	60	°C.	LITT	is	based	on	almost	
the	same	principle	except	that	with	this	technique	the	heat	is	induced	by	a	laser	
beam.	Hepatic	cryotherapy	or	ablation	involves	freezing	and	thawing	of	liver	tumours	
by	means	of	a	cryoprobe	inserted	into	the	tumours.	All	these	techniques	have	the	
advantage	that	normal	liver	tissue	is	preserved.	
A	 few	small	 series	and	case	 reports	of	 these	different	 techniques	have	shown	
excellent	results	with	tumour	responses	in	up	to	97%	of	patients	with	neuroendocrine	
hepatic	metastases	67-70.	Furthermore,	the	largest	study	of	34	patients	treated	with	
RFA,	including	18	with	carcinoid,	9	with	islet	cell	tumours	and	7	with	medullary	
thyroid	carcinoma,	showed	symptom	relief	in	95%	of	patients	with	significant	or	
complete	symptom	control	 in	80%,	with	a	mean	duration	of	 10	months	(range	
6–24	months)	67.	Disadvantages	of	these	therapies,	however,	include	(a)	high	rate	
of	reported	complications,	such	as	abscess formation, haemorrhage and biloma, (b)	 	 	 	 	 	
liver	metastases	are	treated	only,	and	(c)	only	intrahepatic	tumours	with	relatively	
small	volume	are	treated.	In	large	clinical	trials	with	RFA,	it	was	demonstrated	that	
eradication	of	tumours	with	diameter	of	less	than	4	cm	is	more	likely	than	that	of	
larger	tumours	71.	However,	recently	Veenendaal	et al.	70	reported	that	with	the	use	
of	simultaneous	multiple	fibre	LITT	or	bipolar	RFA,	ablation	of	tumours	as	large	as	7	
cm	in	diameter	and	up	to	7	lesions	in	one	session	is	feasible.	Still,	numerous	lesions	
and	close	proximity	to	the	main	vessels	of	the	liver	remain	the	most	important	
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reasons	not	to	perform	LITT	or	RFA,	and	to	start	other	therapies.	Cryotherapy	
was	also	reported	successful	in	terms	of	symptom	control	and	objective	tumour	
responses	65,	72,	73.	This	type	of	therapy	can	therefore	be	regarded	as	an	important	
supplement	to	surgical	resection	and	allows	regional	destruction	of	 lesions	not	
amenable	to	resection.	
Unfortunately,	carefully	conducted	(large)	prospective	studies	for	these	different	local	
therapies	are	lacking.	Nonetheless,	with	an	overall	complication	rate	of	5-10%	and	a	
mortality	rate	of	0.5%	for	RFA	and	LITT	in	large	studies	with	non-neuroendocrine	
tumours	74-76,	local	therapeutic	modalities	such	as	these	can	be	considered	in	selected	
patients	with	a	 limited	number	of	 local	hepatic	recurrences	or	new	metastases	
developing	during	follow-up	if	other	inclusion	criteria	are	met	as	well.	
MEDICAL THERAPY
Somatostatin analogues
When	surgery	 is	no	 longer	 an	option	 in	patients	with	metastatic	disease	and	
symptoms	occur,	most	patients	are	 treated	with	somatostatin	analogues.	The	
octapeptide	analogues	of	somatostatin,	of	which	octreotide	and	lanreotide	are	the	
most	commonly	used,	are	cyclic	peptides	that	are	resistant	to	peptidase	degradation.	
Consequently,	a	prolonged	half	life	of	1.5-2	hours	is	achieved,	which	is	considerably	
longer	than	that	of	the	native	forms	of	somatostatin	(1-2	minutes).	Furthermore,	these	
somatostatin	analogues	differ	from	native	forms	of	somatostatin	in	their	affinity	to	
the	different	receptor	subtypes	as	these	analogues	exhibit	high	affinity	to	the	SSTR2	
and	5,	moderate	affinity	to	the	SSTR3	and	very	low	affinity	to	the	SSTR1	and	SSTR4,	
whereas	the	native	somatostatin	forms	have	high	affinity	to	all	somatostatin	receptor	
subtypes.	However,	since	SSTR2	is	expressed	in	more	than	80%	of	the	classical	
midgut	carcinoid	tumours	and	in	50-80%	of	the	endocrine	pancreatic	tumours,	these	
stable	somatostatin	analogues	are	suitable	for	therapy.	Besides	providing	symptomatic	
relief	by	suppression	of	hypersecretion	of	hormones	and	thereby	improvement	or	
maintenance	of	the	patients’	quality	of	life,	therapy	with	somatostatin	analogues	
can	 inhibit	 tumour	growth.	The	efficacy	of	somatostatin	analogue	therapy	can	
be	divided	into	subjective,	biochemical	and	objective	tumour	responses.	In	the	
first	trial	in	25	symptomatic	carcinoid	patients	who	were	treated	with	octreotide	
subcutaneously	(150	µg	three-times	daily),	symptomatic	improvement	(reduction	
of	flushing	and/or	diarrhoea)	was	observed	in	22/25	(88%)	patients.	Biochemical	
response,	which	was	defined	as	a	50%	or	more	decrease	of	5-hydroxyindoleacetic	
acid	(5-HIAA)	levels,	was	observed	in	17/25	(72%)	of	patients.	The	median	duration	
of	the	biochemical	response	was	12	months	(range	1	to	more	than	18	months)	 77.	
The	cause	of	diminished	effectiveness	of	octreotide	analogues	in	the	long-term,	a	
well-recognised	phenomenon,	has	not	been	not	fully	elucidated	yet	78.	However,	as	
30
somatostatin	receptor	scintigraphy	with	the	simultaneous	use	of	octreotide	analogs	
in	patients	is	relatively	unaffected	and	therefore	withdrawal	probably	not	mandatory	
79,	80,	it	is	likely	that	this	phenomenon	of	tachyphylaxis	or	therapy	resistance	is	based	
on	a	post-membrane	receptor	defect	rather	than	involving	the	somatostatin	receptor	
itself.	
In	a	meta-analysis,	which	compiled	the	studies	that	followed	the	first	trial,	Gorden	et 
al.	81	reported	symptomatic	improvement	in	92%	and	biochemical	responses	in	66%.	
Reduction	of	tumour	size	was	noted	in	only	8%	and	stable	disease	in	85%.	
Beside	administration	of	somatostatin	analogues	by	daily	injection,	slow-release	
formulations	became	available,	which	can	be	considered	an	important	improvement	
in	the	daily	management	of	patients.	Long-acting	release	Sandostatin	(Sandostatin-
LAR®;	once	every	2-4	weeks)	and	lanreotide	prolonged	release	(Lanreotide-PR®;	once	
every	two	weeks)	in	which	octreotide	or	lanreotide	have	been	incorporated	into	
microspheres	of	a	biodegradable	polymer,	are	able	to	control	the	symptoms	as	well	
as	the	short-acting	formulations,	however	without	the	burden	of	daily	subcutaneous	
injections	82.	
Common	early	side-effects,	especially	with	the	daily	formulation,	include	nausea,	
abdominal	cramps,	loose	stools,	mild	steatorrhoea	and	flatulence.	Most	side-effects	
start	quickly	after	administration	and	are	dose-dependent,	but	subside	spontaneously	
after	the	first	weeks	of	treatment	83.	Persistent	side-effects	of	somatostatin	analogues	
are	few.	However,	paradoxical	diarrhoea	can	occur.	Furthermore,	induction	of	gall-
stones	has	been	reported	in	up	to	13-60%	in	patients	with	acromegaly	on	long-term	
octreotide	treatment	84.	However	,	in	many	of	these	patients	bile	sludge	is	present	
instead	of	full	blown	stones.	Furthermore,	only	in	a	small	minority	of	patients	with	
real	stones,	these	become	symptomatic.	
Patients	with	functioning	tumours	often	use	the	long	acting	release	formulation	
(LAR)	of	octreotide,	like	Sandostatin-LAR,	with	doses	up	to	30	mg/month.	However,	
up	to	40%	of	the	patients	need	rescue	medication	several	times	a	week	for	the	acute	
control	of	symptoms	83.	Woltering	et al.	85	demonstrated	that	doses	of	30	mg/month	
lead	to	plasma	levels	of	5x	the	Kd	of	octreotide	for	the	SSTR2	(Kd	≈	1x10-9	mol/L),	but	
fail	to	achieve	the	plasma	concentrations	that	will	completely	saturate	the	SSTR2.	
It	was	concluded	that	this	could	explain	the	need	for	higher	doses	in	some	patients	
and	that	frequent	measurement	of	octreotide	blood	levels	could	guide	octreotide	
therapy.	Furthermore,	the	use	of	LAR,	at	doses	of	60	mg/month	was	advocated	
in	those	patients	with	poor	symptom	control	or	tumour	growth	despite	normally	
dosed	LAR	therapy.
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In	 summary,	 somatostatin	analogues	are	highly	effective	 in	 the	 symptomatic	
management	of	patients	with	overt	symptoms	of	GEP-NETs.	However,	it	is	still	
controversial	whether	treatment	with	somatostatin	analogues	must	be	started	in	
order	to	induce	inhibition	of	proliferation	of	the	tumour,	 if	progression	occurs	
in	patients	without	symptoms	or	with	non-functional	tumours.	The	dose	should	
then	preferably	be	within	the	high	range	of	the	normal	dosage	scheme.	However,	it	
must	be	stressed	that	because	of	the	small	chances	of	success	in	relation	to	the	high	
costs,	the	use	of	somatostatin	analogues	as	an	anti-neoplastic	therapy	is	questioned	
by	many	86.
Interferon
Interferon	(IFN)-alpha	was	introduced	in	the	early	1980s	as	a	treatment	option	in	
patients	with	GEP-NETs	by	the	group	of	Öberg	87.	In	a	recent	meta-analysis	they	
reported	the	results	of	treatment	with	recombinant	IFN-alpha	88.	The	median	dose	
used	was	5	million	units	of	IFN-alpha	every	other	day	subcutaneously.	The	median	
biochemical	response	rate	from	pooled	studies	was	44%	and	the	median	tumour	
response	rate	11%.	However,	no	survival	analysis	was	available,	as	most	published	
studies	were	not	randomised	controlled.	Furthermore,	frequent	adverse	reactions	to	
IFN-alpha	included	temporary	‘flu-like’	symptoms,	chronic	fatigue	syndrome	and	
mental	depression.	The	latter	two	can	develop	in	varying	severity	at	various	grades	
in	up	to	50%	of	patients.	Auto-immune	reactions	were	also	reported	and	occurred	in	
15-20%	of	patients.	Most	frequent	of	these	was	thyroid	dysfunction.	The	significantly	
higher	incidence	and	severity	of	adverse	effects,	and	lower	biochemical	response	
rate	compared	with	somatostatin	analogues	makes	IFN-alpha	not	the	first	choice	of	
medical	therapy	in	patients	with	GEP-NETs.	
Combined	therapy	with	IFN-alpha	and	somatostatin	analogues	was	proposed	to	
increase	the	antiproliferative	therapeutic	effect.	Several	studies	indeed	reported	
encouraging	results	of	the	addition	of	IFN-alpha	to	octreotide	89,	90.	However,	in	
contrast	 to	 these	studies,	 the	 first	prospective,	 randomized,	multi-centre	 trial	
that	studied	the	effect	of	somatostatin	analogue	(lanreotide),	IFN-alpha	and	their	
combination	for	therapy	of	metastatic	GEP-NETs	indicated	that	no	significantly	
higher	antiproliferative	effect	could	be	achieved	with	the	addition	of	IFN-alpha	to	
lanreotide	91.	When	both	therapies	were	compared	as	single	therapy,	no	differences	
were	evident.	However,	treatment	with	lanreotide	was	generally	well	tolerated	and	
only	a	few	minor	side-effects	occurred.	IFN-alpha	related	side-effects	were	more	
common	than	those	attributable	to	lanreotide	91.	
Systemic Chemotherapy
The	use	 of	 chemotherapy	 in	 patients	with	GEP-NETs	 is	 limited	 because	 of	
disappointing	results	and	high	 incidence	of	major	side-effects.	Most	objective	
32
responses	were	reported	in	well-differentiated	pancreatic	or	duodenal	tumours.	
Single-agent	chemotherapy	demonstrated	lack	of	objective	responses	and	high	
toxicity	and	was	therefore	replaced	by	combinational	chemotherapy	in	studies	that	
followed.	The	best	results	were	obtained	with	the	combination	of	streptozotocin	with	
either	doxorubicin	or	fluorouracil	(5-FU).	Objective	responses	for	the	combination	of	
streptozotocin	with	5-FU	in	GEP-NETs	as	published	by	Moertel	et al.	ranged	from	45	
to	63%	92,	93,	whereas	the	combination	of	streptozotocin	and	doxorubicin	had	similar	
objective	responses	in	up	to	69%	92,	94.	However,	these	impressive	results	were	never	
reproduced	in	later	studies.	Interestingly,	Cheng	et al.	95	who	reported	on	the	effect	
of	combination	therapy	with	streptozotocin	and	doxorubicin	had	only	1	out	of	16	
(6%)	patients	with	major	objective	response	by	standard	CT	criteria.	
The	difference	between	their	results	and	those	from	Moertel	et al.	92	was	explained	
by	the	differences	in	the	response	criteria	used,	which	included	clinical	measurement	
of	hepatomegaly	on	physical	examination,	or	measurement	on	radionuclide	liver-
spleen	scanning,	as	an	indicator	of	a	major	objective	response	in	the	early	studies	
by	Moertel	et al.	93,	96.	Nonetheless,	others	have	reported	relatively	higher	objective	
response	rates	of	36%-55%	94,	97,	98.	Mean	duration	of	responses	in	the	studies	that	
used	streptozotocin	and	doxorubicin	ranged	from	14-22	months.	At	this	moment,	
the	combination	of	doxorubicin	and	streptozotocin	is	regarded	as	the	standard	
chemotherapy	in	patients	with	progressive	well-differentiated	endocrine	pancreatic	
or	duodenal	carcinoma	98,	99.	In	patients	with	well-differentiated	carcinoid	of	midgut	
origin	the	best	results,	in	terms	of	the	highest	objective	response,	was	also	reported	
with	doxorubicin	and	streptozotocin	100.	Forty	percent	of	patients	had	an	objective	
response.	These	results,	however,	were	only	established	in	a	small	number	of	patients	
and	were	never	reproduced	since	then.	
With	the	use	of	streptozotocin	and	doxorubicin	major	side-effects	have	to	be	taken	
into	account.	Streptozotocin	can	induce	renal	impairment.	Renal	insufficiency	in	up	
to	30%	of	patients	treated	with	streptozotocin	was	reported.	Therefore,	the	kidneys	
are	dose	limiting	93.	Obviously,	careful	monitoring	of	renal	function	is	necessary	to	
prevent	renal	damage.	Cardiac	function	is	the	dose	limiting	factor	for	chemotherapy	
with	doxorubicin.	Development	of	doxorubicin-associated	cardiomyopathy	 is	
dose-dependent	and	congestive	heart	failure	was	reported	in	more	than	4	percent	
of	patients	who	had	received	a	cumulative	dose	of	500-550	mg	of	doxorubicin	per	
square	meter.	Incidence	rose	to	more	than	18	percent	at	doses	over	550	mg	m-2	101.	
Other	chemotherapeutic	agents,	 like	dimethyltriazenoimidazole	carboxamide	
(DTIC)	or	dacarbazine	proved	to	have	minimal	activity	in	patients	with	metastatic	
carcinoid	tumours	or	neuroendocrine	pancreatic	tumours	102-104.	An	overview	of	the	
most	studied	chemotherapy	modalities	is	given	in	Table	6.
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34
In	recent	years,	new	chemotherapeutic	agents	and	regimens	have	been	evaluated,	
including	high	dose	paclitaxel	administered	with	granulocyte-colony	stimulating	
factor,	 docetaxel,	 gemcitabin	 and	 irinotecan	 in	 combination	with	 5-FU	 and	
Leucovorin	107,	109-111.	However,	most	therapy	strategies	proved	to	be	disappointing	in	
GEP-NET	patients	and	some	of	them	had	considerably	toxicity	profiles.	Promising	is	
the	use	of	temozolomide,	a	cytotoxic	alkylating	agent	that	was	specifically	developed	
as	an	oral	and	less	toxic	alternative	to	DTIC,	in	combination	with	thalidomide.	
This	combinational	regimen	was	used	in	29	patients	with	metastatic	carcinoid	
(n=15),	pheochromocytoma	(n=3),	or	pancreatic	neuroendocrine	tumours	(n=11)	
112.	Radiologic	response	according	to	RECIST	criteria	was	documented	in	5	(45%)	
patients	with	pancreatic	NETs,	1	(33%)	patient	with	pheochromocytoma	and	1	(7%)	
patient	with	a	carcinoid	tumour.	Therefore,	this	study	suggests	more	efficacy	with	
this	regimen	in	patient	with	pancreatic	NETs	than	in	carcinoid	tumours.	
Poorly	differentiated	endocrine	carcinomas	(PDEC)	are	preferentially	treated	with	the	
combination	of	etoposide	and	cisplatin.	High	response	rates	with	objective	tumour	
response	in	up	to	65%	of	patients	were	reported	 113,	114.	However,	the	duration	of	
response	was	often	very	limited	and	rarely	exceeded	10	months.	In	addition,	reported	
percentages	of	nephrotoxicity	and	neutropenia	were	high.	In	the	most	recent	phase	
II	clinical	study	in	78	patients	with	PDEC,	patients	were	treated	with	a	three-drug	
regimen	of	paclitaxel,	carboplatin,	and	etoposide	115.	Forty-one	(56%)	patients	had	
major	responses	(of	whom	15%	complete	response).	Survival	data	showed	median,	
2-year,	and	3-year	survival	rates	of	14.5	months,	33%,	and	24%,	respectively.	
Clearly,	the	combination	of	cisplatin/carboplatin	and	etoposide	with	or	without	
an	additional	chemotherapeutic	agent	is	currently	the	most	effective	therapeutic	
regimen	of	systemic	chemotherapy	for	PDEC	provided	the	patient	has	adequate	
organ	function	and	performance	status.	
In	conclusion,	within	the	currently	published	European	guidelines	for	the	Management	
of	patients	with	GEP-NETs	as	proposed	by	the	European	Neuroendocrine	Tumour	
Society	(ENETS)	chemotherapy	using	combinations	of	streptozotocin,	doxorubicin	
and	5-FU	is	indicated	in	patients	with	progressive	advanced	metastatic	or	symptomatic	
diffuse	metastatic	foregut	NETs	with	liver	metastases,	not	in	NETs	from	midgut	
origin	 116.	 Also,	 in	 colorectal	NETs	with	moderately	 to	well-differentiated	
histopathology	chemotherapy	has	no	role	within	the	therapeutic	armamentarium	
117.	Cisplatin/carboplatin	plus	etoposide	is	recommended	in	patients	with	NETs	with	
poorly	differentiated	(i.e.	above	20%	Ki-67	positive	cells)	tumours	regardless	of	the	
origin	of	the	primary	118,	119.
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INTERNAL RADIOTHERAPY
Meta- [131I] Iodobenzylguanidine (MIBG) Therapy
Meta-iodobenzylguanidine	(MIBG)	is	an	arkyl-guanidine	derivative,	structurally	
similar	to	noradrenaline,	which	utilizes	the	vesicular	monoamine	transporters	and	is	
incorporated	into	vesicles	or	neurosecretory	granules	in	the	cytoplasm	120.	However,	
it	 is	not	significantly	metabolized.	MIBG	shows	little	binding	to	post-synaptic	
receptors	and	causes	little	or	no	pharmacological	response	121.	It	may	be	labelled	by	
123I	for	imaging	or	131I	for	both	imaging	and	therapy.	
MIBG	scintigraphy	has	been	used	for	many	years	to	visualize	carcinoid	tumours	as	
it	is	concentrated	in	endocrine	cells	122.	This	method	was	initially	developed	to	detect	
tumours	arising	from	chromaffin	cells	such	as	phaeochromocytomas,	paragangliomas	
and	neuroblastomas	with	overall	 reported	high	 sensitivity	of	 approximately	
90%	and	specificity	as	high	as	99%	122,	123.	Although	with	lower	sensitivity,	MIBG	
scintigraphy	was	thereafter	utilized	to	detect	neuroendocrine	tumours.	However,	
MIBG	scintigraphy	in	carcinoid	tumours,	including	the	initially	used	diagnostic	
131I-MIBG	scintigraphy,	has	shown	lower	sensitivity	than	111In-octreotide	scintigraphy.	
In	a	recent	review,	the	cumulutive	results	of	twenty	years	of	experience	with	MIBG,	
including	MIBG	scintigraphy,	median	detection	rate	and	sensitivity	of	50%	and	
76%,	respectively,	was	shown	 124.	 In	contrast,	 the	 largest	 review,	 that	 included	
pooled	imaging	data	from	35	centers	with	in	total	more	than	1200	patients	with	
carcinoid	tumours,	described	that	111In-octreotide	scintigraphy	has	a	median	detection	
rate	of	89%	(range	67%	to	100%)	and	a	median	sensitivity	of	84%	(57%	to	93%)	125.	
Furthermore,	 imaging	with	 123I-MIBG	has	a	poor	sensitivity	in	identifying	islet	
cell	tumours	126.	Interestingly,	within	the	few	studies	that	compared	123I-MIBG	and	
somatostatin	receptor	scintigraphy	in	carcinoid	tumours,	a	complementary	role	of	
123I-MIBG	scintigraphy	has	been	noted	either	as	a	different	intensity	or	as	a	different	
pattern	of	uptake	in	non-octreotide	avid	regions	126,	127.	In	one	report	in	which	a	direct	
comparison	between	these	two	imaging	modalities	was	performed,	comparable	
results	with	sensitivities	of	about	84%	were	demonstrated,	whereas	the	combination	
of	these	scans	increased	the	sensitivity	to	95%	127.	It	was	concluded	that	111In-octreotide	
scintigraphy	is	more	sensitive	in	detecting	metastatic	lesions	from	GEP-NETs	than	
123I-MIBG	scintigraphy,	with	the	latter	imaging	modality	useful	in	the	occasional	
patient	who	has	MIBG-avid	lesions,	but	did	not	show	any	uptake	with	the	initially	
performed	111In-octreotide	scintigraphy	128.
Besides	diagnostic	and	staging	purposes	of	MIBG	scintigraphy	in	GEP-NETs,	it	can	
also	be	used	to	identify	patients	for	 131I-MIBG	therapy.	 131I-MIBG	therapy	has	the	
advantage	that	the	treatment	targets	all	sites	of	disease,	including	distant	metastases,	
as	was	shown	on	 123I-MIBG	scintigraphy	performed	before	therapy.	Treatment	
36
protocols	vary	between	different	centres.	The	usually	prescribed	doses	of	131I-MIBG	
range	between	7.4	and	11.2	GBq	(200–300	mCi),	administered	at	3-6	months	interval.	
Occasionally,	doses	up	to	14.8	GBq	(400	mCi)	per	treatment	are	used.	To	minimize	
thyroidal	131I	uptake,	potassium	iodide	(120-150	mg/d)	is	given	before,	during,	and	
several	days	after	the	therapy.
Reported	tumour	responses	after	 131I-MIBG	therapy	in	patients	with	metastatic	
carcinoid	disease	range	from	13-35%	129-132,	with	objective	tumour	shrinkage	in	15%	and	
13%	of	patients	in	the	two	largest	studies	comprising	52	and	75	patients,	respectively,	
who	could	be	evaluated	with	CT/MRI	129,	132.	
In	general,	biochemical	response,	which	was	defined	as	significant	reduction	in	the	
tumour	marker	levels	such	as	chromogranin	A	or	5-HIAA,	did	not	follow	the	tumour	
response	and	was	demonstrated	in	37-46%	130,	132.
Symptomatic	control	was	demonstrated	in	even	a	higher	proportion	of	patients.	In	49	
to	87%	131I-MIBG	therapy	patients	had	a	decrease	of	symptoms	130,	132-134.	Furthermore,	
besides	this	obvious	palliative	effect,	 131I-MIBG	therapy	also	proved	to	be	cost-
effective.	Pathirana	et al.	133	evaluated	12	patients	with	carcinoid	syndrome	and	found	
a	significant	reduction	in	octreotide	dosages	in	8	patients	after	 131I-MIBG	therapy,	
which	resulted	in	decreased	use	of	octreotide	and	thereby	minimized	costs,	even	
including	the	costs	of	the	131I-MIBG	therapies.	
Although	symptom	alleviation	has	been	well	described	in	the	majority	of	patients,	
and	partial	tumour	responses	do	occur,	complete	radiographic	responses	have	not	
been	reported	with	131I-MIBG	treatment.
Reports	on	survival	in	patients	with	neuroendocrine	tumours	(including	carcinoids)	
treated	with	131I-MIBG	are	few.	Recently,	two	studies	reported	survival	benefit	when	
patients	with	carcinoid	tumour	were	treated	with	at	least	15	GBq	131I-MIBG	given	over	
6	months	132,	135.	Furthermore,	symptomatic	response	to	treatment	in	patients	who	had	
progressive	disease	was	associated	with	an	improvement	of	median	survival	of	44	
months	(5.76	versus	2.09	years)	compared	with	patients	who	had	no	symptomatic	
response	 132.	Interestingly,	objective	tumour	response	and	reduction	of	hormone	
levels	did	not	correlate	with	improved	survival	in	the	studied	patients.	Within	the	
same	study,	a	direct,	linear	dose	dependent	relation	was	found	between	initial	dose	
and	survival.	An	initial	dose	of	400	mCi	131I-MIBG	was	recommended	for	further	
studies.	
In	general,	131I-MIBG	treatment	is	well	tolerated	with	side-effects	limited	to	nausea	or	
vomiting	in	24-72	hr	after	administration,	mild	hepatic	dysfunction	with	spontaneous	
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recovery	and	temporary	myelosuppression	4-6	weeks	post-therapy.	Only	incidentally	
patients	may	develop	significant	side-effects	such	as	severe	myelosuppression,	
especially	when	extensive	metastatic	spread	within	the	bone	marrow	is	present,	
or	hepatic	failure	in	patients	with	widespread	liver	metastases	136.	Furthermore,	the	
frequency	and	severity	of	most	haematological	side-effects	are	clearly	(cumulative)	
dose	dependent	130,	132.
Methods	to	enhance	131I-MIBG	uptake	with	the	intent	to	increase	the	effectiveness	
of	therapy	were	explored	and	included	the	use	of	premedication,	such	as	nifedipine	
and	unlabelled	MIBG,	or	the	intra-arterial	delivery	of	the	dose.	Blake	et al.	137	found	
a	2-fold	increase	in	tumour	uptake	after	premedication	with	nifedipine	in	patients	
with	malignant	phaeochromocytoma.	Hoefnagel	et al.	 138	achieved	an	improved	
tumour	to	non-tumour	(T/NT)	ratio	increase	of	7.8–111.4%	at	24	hr	on	131I	labelled	
(‘hot’)	MIBG	scintigraphy	in	17	of	24	patients	with	carcinoid	tumours	by	pre-treating	
them	with	cold	MIBG.	The	authors	claim	that	this	could	be	an	advantage	considering	
131I-MIBG	therapy	in	carcinoid	patients	with	initial	low	uptake	on	MIBG	scintigraphy,	
facilitating	higher	 131I-MIBG	uptake	in	metastatic	lesions	after	pre-treating	with	
cold	MIBG.	However,	the	demonstrated	increase	was	based	on	an	increase	of	T/NT	
ratios	instead	of	absolute	uptake	values.	Therefore,	a	decrease	of	background	uptake,	
which	is	likely	after	cold	MIBG,	could	have	accounted	for	the	observed	increase	of	
T/NT	ratio	as	well.	
In	another	study,	intra-arterial	treatment	compared	to	intravenous	administration	of	
131I-MIBG	in	patients	with	mostly	carcinoids	resulted	in	up	to	4-fold	higher	tumour	
uptake	(mean	1.7-fold)	of	131I-MIBG	in	liver	metastases	139.	Again,	the	reported	higher	
tumour	uptake	was	in	fact	a	higher	tumour	to	whole-body	activity	ratio	instead	of	
absolute	tumour	uptake.	Intra-arterial	treatment	with	131I-MIBG	was	claimed	to	be	
a	safe	alternative	to	standard	intravenous	application.	
In	none	of	 the	abovementioned	studies	 the	potential	benefit	of	 the	enhanced	
131I-MIBG	uptake	in	terms	of	effectiveness	was	studied.	Randomised	studies	between	
unenhanced	versus	enhanced	131I-MIBG	delivery,	which	also	include	measurement	
of	absolute	uptake	values	are	warranted	to	asses	the	true	potential	benefit	of	these	
therapeutic	strategies.
In	conclusion,	internal	irradiation	therapy	with	131I-MIBG	is	generally	safe	and	well	
tolerated	with	only	a	few	acute	and	long-term	adverse	effects.	 131I-MIBG	therapy	
appears	to	offer	effective	palliation	with	symptomatic	control.	Despite	the	fact	that	
objective	tumour	responses	can	be	found	only	in	a	minority	of	patients,	studies	
suggest	that	there	may	be	a	survival	benefit.
38
Peptide Receptor Radionuclide Therapy
As	mentioned	earlier	somatostatin	receptors	are	present	on	the	majority	of	GEP-NETs.	
Besides	targeted	therapy	with	somatostatin	analogues	like	octreotide	or	lanreotide,	the	
tumours	can	be	visualised	in	patients	using	the	radiolabelled	somatostatin	analogue	
[111Indium-DTPA0]octreotide	(OctreoScan®).	The	next	logical	step	after	the	successful	
imaging	was	to	try	to	use	radiolabelled	somatostatin	analogues	as	a	treatment	in	
these	patients.	Peptide	receptor	radionuclide	therapy	(PRRT)	with	radiolabelled	
somatostatin	analogues	is	a	relatively	new	and	promising	treatment	modality	for	
patients	with	inoperable	or	metastasised	GEP-NETs.	Chapter	1.2	of	this	thesis	gives	
a	review	of	the	role	and	therapeutic	place	of	PRRT	in	the	whole	armamentarium	of	
treatment	modalities	in	the	management	of	patients	with	endocrine	tumours.
MOLECULAR THERAPY
Recently,	there	has	been	increasing	interest	in	the	use	of	molecularly	targeted	therapy	
for	patients	with	metastasised	endocrine	tumours.	Especially	molecular	targets	
within	the	tumour	cell	such	as	the	Bcl-2	and	Bax	gene,	which	are	both	involved	in	
the	cascade	of	apoptosis	and	vascular	endothelial	growth	factor	(VEGF)	which	is	
involved	in	angiogenesis,	but	also	platelet	derived	growth	factor	(PDGF),	epithelial	
growth	factor	receptor	(EGFR)	and	mammalian	target	of	rapamycin	(mTOR)	which	
are	factors	known	to	be	involved	in	control	of	growth,	have	become	molecular	targets	
for	therapy.	Targeted	therapies	with	inhibitors	and	antibodies	against	these	molecular	
targets	are	currently	clinically	tested.	A	summary	of	the	different	therapies	and	stage	
of	clinical	trials	is	given	in	Table	7.
Therapy	with	imatinib	(Glivec	®),	a	receptor	tyrosine	kinase	(TK)	inhibitor,	which	
targets	the activated portion of the BCR-ABL oncoprotein and the tyrosine kinases	 	 	 	 	 	 	 	 	 	 	
of	the	c-kit	receptor	and	PDGF	receptor,	has	been	successfully	applied	in	patients	
with	chronic	myeloid	leukaemia	140	and	in	gastrointestinal	stromal	tumours	141.	Both	
PDGF	and	PDGF	receptors	are	expressed	in	endocrine	tumours.	Therefore,	the	effect	
of	imatinib	was	evaluated	in	a	phase	II	trial	 in	patients	with	advanced	carcinoid	
tumours.	One	out	of	27	patients	had	an	objective	response,	17	had	stable	disease,	
and	9	had	progressive	disease	as	evaluated	by	the	RECIST	criteria	142.	
Therapy	which	targets	angiogenesis	 is	currently	clinically	evaluated	and	can	be	
grouped	by	mechanism	of	targeting:	(1)	by	counteracting	VEGF	with	monoclonal	
antibodies,	such	as	the	VEGF	blocking	humanized	monoclonal	antibody	bevacizumab	
(Avastin®);	(2)	small	molecules	that	inhibit	the	receptor	TK	domains	of	the	VEGF	
and	PDGF	receptor,	 such	as	 sunitinib	 (Sutent®),	 sorafenib	 (Nexavar®)	 and	 (3)	
other	compounds	with	different	antiangiogenic	mechanisms,	such	as	thalidomide	
(Thalomid®)	or	endostatin	143.	
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Although	not	yet	published	in	peer-reviewed	journals,	several	trials	are	planned	or	
already	ongoing.	The	preliminary	results	of	these	trials	are	in	general	promising	and	
have	been	presented	on	scientific	meetings.	
The	first	preliminary	reported	clinical	trial	on	bevacizumab	therapy	in	GEP-NETs	
was	performed	 in	44	patients	with	advanced	carcinoid	 tumours	who	were	on	
stable	doses	of	octreotide.	Patients	were	randomized	to	additionally	receive	either	
bevacizumab	15	mg/kg	on	an	every	3	weeks	basis	or	pegylated	interferon	alpha-2b	
weekly	(0.5	µg/kg)	during	18	weeks	 145.	Bevacizumab	was	superior	to	pegylated	
interferon	alpha-2b	both	in	terms	of	progression	free	survival	and	suppression	of	
tumour	blood	flow	measured	by	functional	computed	tomography	scan.	This	result	
led	to	the	planned	phase	III	trial	in	which	patients	with	advanced	poor-prognosis	
carcinoid	tumour	under	control	with	depot	octreotide	will	be	randomized	to	receive	
either	additionally	interferon	alpha-2b	subcutaneously	or	bevacizumab.
Small	multi-TK	inhibitors,	such	as	sunitinib,	sorafenib	and	valatanib,	are	currently	
investigated	for	their	effect	in	patients	with	GEP-NET.	Clinical	results	have	been	
only	published	for	sunitinib	which	has	been	approved	in	patients	with	metastatic	
renal	cell	carcinoma	146.	Preliminary	data	of	a	large	phase	II	trial	with	106	patients	
reported	a	15%	objective	response	in	patients	with	metastatic	islet	cell	carcinomas	
and	2%	objective	response	in	patients	with	carcinoid	tumours,	along	with	high	rates	
of	disease	stabilization	(75%	for	islet	cell	carcinomas	and	93%	for	carcinoids)147.	These	
studies	suggest	that	tyrosine	kinase	inhibition	may	be	a	useful	therapeutic	strategy	in	
this	disease.	However,	whether	these	patients	had	progressive	disease	at	study	entry,	
which	is	important	to	judge	the	outcome	of	stable	disease	in	relative	slow-growing	
tumours	was	not	indicated.	Furthermore,	unfortunately,	no	definitive	peer-reviewed	
publication	followed	this	preliminary	report	yet.	
Gefitinib,	a	small-molecule	inhibitor	of	the	EGFR	tyrosine	kinase	domain,	is	currently	
studied	in	patients	with	GEP-NET,	and	preliminary	data	showed	that	one	of	40	
patients	with	carcinoids	had	PR	148.	Within	the	group	of	islet	cell	carcinomas	(n=31),	
2	had	PR	and	1	MR.	In	patients	with	carcinoid	disease,	23	of	38	(61%)	and	in	patients	
with	islet	cell	carcinomas,	9	of	29	(31%)	were	progression-free	at	6	months,	which	was	
considered	promising.	In	addition,	32%	(12/38)	of	carcinoid	and	14%	(4/29)	of	islet	cell	
carcinoma	patients	had	a	longer	(at	least	4	months)	TTP	than	the	TTP	documented	
prior	to	study	entry.	Side-effects	with	high-grade	toxicity	were	infrequent.	Clearly,	
gefitinib	can	be	promising	in	the	treatment	of	GEP-NETs	in	the	future.	
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Table 7. Molecular	targeted	agents	in	gastroenteropancreatic	neuroendocrine	tumours
Agent Generic name (Trade Mark) Stage of development
VEGF	monoclonal	antibody
Bevacizumab	(Avastin®). In	phase-III	development	
Small	multi-tyrosine	kinase	inhibitor
Sunitinib	(Sutent®) Phase-II	completed
Vatalanib Phase-II	in	progress
Sorafenib	(Nexavar®) Phase-II	in	progress
Pazonpanib Phase-II	in	progress
PDGFR/	c-kit/	bcr-abl	inhibitor
Imatinib	(Glivec®) Phase-II	completed
EGFR	inhibitor
Gefitinib	(Iressa®) Phase-II	completed
mTOR	inhibitor
Everolimus	(RAD001;	Certican®) In	phase-III	development
Temsirolimus	(CCI-779)	 Phase-II	completed
Other
Bortezomib	(Velcade®) Phase-II	completed
VEGF,	vascular	endothelial	growth	factor;	PDGFR,	platelet-derived	growth	factor	receptor;	EGFR,	
epidermal	growth	factor	receptor;	mTOR,	mammalian	target	of	rapamycin
Adapted from Yao et al. 144
Mammalian	target	of	rapamycin	(mTOR)	is	a	serine/threonine	protein	kinase	that	is	
essential	in	the	control	of	cell	growth,	protein	synthesis,	and	autophagy.	Inhibition of	 	
mTOR	may	inhibit	abnormal	cell	proliferation,	tumour	angiogenesis,	and	abnormal	
cell	metabolism	and	thereby	potentially	be	effective	as	a	cancer	therapy	149.
Although	not	published	to	date,	the	first	phase	II	human	clinical	trials	with	mTOR	
inhibitors	in	low-grade	GEP-NETs	are	currently	underway.	Preliminary	data	on	the	
use	of	10	mg	of	oral	everolimus	daily	combined	with	30	mg	intramuscular	depot	of	
octreotide	every	4	weeks	showed	that	10	out	of	60	(17%)	patients	had	PR,	45	(75%)	
had	SD	and	5	(8%)	had	PD	150.	This	outcome	is	more	than	could	be	expected	from	
the	use	of	a	long-acting	octreotide	formula	alone.	However,	an	effect	of	octreotide	
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treatment,	whether	direct	or	synergistical	with	everolimus	cannot	be	excluded.	
Everolimus	was	well	tolerated	in	combination	with	octreotide.	To	evaluate	the	effect	
in	larger	patient	groups	further	research	in	clinical	trials	is	planned.	
In	the	first	published	study	with	temsirolimus,	two	out	of	36	(6%)	patients	(21	with	
carcinoid,	15	with	islet	cell	carcinoma)	who	received	intravenous	temsirolimus	on	
a	weakly	basis,	achieved	PR	by	RECIST	criteria.	Twenty-three	out	of	36	(64%)	of	
patients	had	PR	or	SD	151.	Surprisingly,	the	authors	concluded	that	temsirolimus	
appears	to	have	little	activity	and	does	not	warrant	further	single-agent	evaluation	
in	advanced	neuroendocrine	carcinomas.	However,	as	was	clearly	explained	by	
O’Donnell	and	Ratain	152,	64%	patients	with	tumour	control	after	therapy	and	a	1-year	
progression	free	rate	of	40%	in	a	group	of	treated	patients	that	had	progressive	disease	
at	entry	of	the	study	is	suggestive	of	drug	activity	beyond	the	natural	course	of	
disease	and	thus	an	effective	therapy.	Furthermore,	the	outcome	compares	favourably	
with	agents	like	somatostatin	analogues	and	interferon-alpha	that	were	previously	
studied	in	GEP-NETs.	Therefore,	 it	was	concluded	that	further	research	on	the	
effectiveness	of	temsirolimus	as	a	single-agent	therapy	in	GEP-NETs	should	not	
be	abandoned.	The	authors	made	clear	that	single-arm	studies	have	to	be	carefully	
analysed	or	even	abandoned	and	that	randomised	trials	are	superior	for	studying	
new	therapeutic	agents.	
In	conclusion,	the	recent	developments	in	molecularly	targeted	therapy	in	general	
oncology	have	renewed	the	interest	of	treatment	of	patients	with	GEP-NETs	with	
systemic	therapy.	Preliminary	results	 from	mostly	phase	 II	clinical	studies	are	
promising,	but	large	confirmatory	studies	are	warranted.	
CONCLUDING REMARKS
This	review	indicates	the	variety	of	therapeutic	approaches	and	the	multitude	of	
techniques	that	can	be	employed	in	the	treatment	of	patients	with	GEP-NETs,	
especially	when	metastatic	disease	is	evident.	At	that	moment	the	management	of	
GEP-NETs	patients	is	a	difficult,	but	challenging	task.	An	example	of	an	algorithm	
for	clinical	decision	making	is	given	in	Figures	1a	and	1b.	Figure	1a	displays	the	
management	of	patients	with	limited	(resectable)	disease,	whereas	in	Figure	1b	the	
therapeutical	strategies	are	pointed	out	with	the	intent	to	decrease	the	tumour	burden	
as	much	as	possible	to	establish	an	increase	of	patients’	well-being	and	survival.	
Nonetheless,	not	always	the	best	 therapeutical	option	is	chosen	as	therapeutic	
decisions	are	often	based	upon	the	technique	locally	available	and/	or	on	the	evidence	
level	of	expert	opinion.	Therefore,	therapeutic	management	decisions	for	this	group	
of	patients	has	to	be	placed	in	a	multidisciplinary	team-based	setting,	so	that	the	best	
therapeutical	option	for	each	individual	patient	can	be	chosen.	Specialists	within	such	
a	team	should	ideally	include	an	endocrinologist,	oncologist,	(endocrine	specialised)	
42
surgeon,	(intervention)	radiologist,	nuclear	medicine	physician	and	pathologist.	
Furthermore,	 in	patients	with	severe	pain,	a	radiotherapist	or	anaesthesiologist	
should	be	consulted	for	optimal	palliation.	Also,	since	the	patients	are	suffering	from	
a	rare	disease,	treatment	and	follow-up	should,	if	practically	feasible,	be	performed	
in	a	tertiary	(university)	referral	hospital	with	facilities	for	expert	treatment.	In	this	
way,	the	full	spectrum	of	treatment	modalities	can	be	offered	and	applied	so	that	
optimal	management	of	patients	with	these	tumours	is	guaranteed.
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Figure 1b.	Management	of	metastatic	gastroenteropancreatic	neuroendrocrine	tumours	
(GEP-NETs)
Abbreviations: IFN-α, interferon-α; RFA, radiofrequency ablation; LIT T, laser-induced Interstitial 
thermotherapy; PD, progressive disease; SD, stable disease; MR, minor response; PR, partial response
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Abstract
Peptide	receptor	radionuclide	therapy	is	a	new	treatment	modality	for	patients	with	
inoperable	or	metastasised	neuroendocrine	gastroenteropancreatic	tumours.	After	
the	successful	implementation	of	somatostatin	receptor	scintigraphy	in	daily	clinical	
practice,	the	next	logical	step	was	to	increase	the	radiation	dose	of	the	administered	
radiolabelled	somatostatin	analogue	in	an	attempt	to	induce	tumour	shrinkage.	
Since	then,	an	increasing	number	of	patients	has	been	successfully	treated	with	
this	approach,	resulting	in	a	substantial	numbers	of	patient	with	objective	tumour	
shrinkage.	Serious	side-effects	have	been	rare.	This	article	reviews	the	effectiveness	
of	the	different	radiolabelled	somatostatin	analogues	used,	the	currently	known	
side-effects	and	the	survival	data	available.	Furthermore,	clinical	issues,	including	
indication	and	timing	of	therapy,	are	discussed.	Finally,	important	directions	for	
future	research	are	briefly	mentioned	to	 illustrate	that,	although	the	currently	
available	results	already	suggest	a	favourable	outcome	compared	with	other	systemic	
therapies,	new	strategies	are	being	developed	to	increase	efficacy.	
Abstract INTRODUCTION
Somatostatin	 receptor	 (SSTR)	 scintigraphy,	which	was	developed	 in	 the	 late	
1980s,	has	become	an	important	image	modality	in	patients	with	SSTR-positive	
tumours	1,2.	This	is	not	only	because	of	its	high	sensitivity	for	visualising	somatostatin-
positive	tumours	and	thereby	its	ability	to	localise	otherwise	undetectable	disease,	
but	also	because	of	the	selection	of	known	metastatic	disease	for	peptide	receptor	
radionuclide	therapy	(PRRT)	with	radiolabelled	somatostatin	analogues.	This	new	
modality	of	targeted	therapy	is	very	promising,	especially	in	patients	with	inoperable	
or	metastatic	gastroenteropancreatic	(GEP)	tumours	(i.e.	gastrointestinal	carcinoids	
and	functioning	and	non-functioning	pancreatic	endocrine	tumours).	
RADIONUCLIDES AND SOMATOSTATIN ANALOGUES IN 
PEPTIDE RECEPTOR RADIONUCLIDE THERAPY 
Several	radiolabelled	somatostatin	analogues	are	currently	used	to	treat	patients	
with	SSTR-positive	metastasised	GEP	tumours.	These	conjugates	all	consist	of	a	
somatostatin	analogue,	such	as	octreotide	or	octreotate,	a	complexing	moiety	(or	
chelator)	and	a	radionuclide.	The	chelator,	which	is	attached	to	the	somatostatin	
analogue,	allows	a	stable	connection	between	the	analogue	and	the	radionuclide.	The	
basic	principle	of	tumour-targeting	after	systemic	administration	of	the	conjugate	
involves	binding	to	SSTRs,	which	are	expressed	on	the	cell	surface	of	the	tumour	
cell,	followed	by	effective	internalisation	of	the	radionuclide-peptide	complex	3–5.	
The	emitted	radiation	can	damage	the	DNA,	which	may	subsequently	lead	to	the	
induction	of	cell	death.	In	clinical	practice,	different	combinations	of	radionuclides	
and	somatostatin	analogues	are	used	to	target	the	SSTR-positive	tumour.	These	
analogues	differ	from	each	other	in	their	affinity	for	the	various	SSTR	subtypes.	
This	variable	affinity	is	important	because	it	can	have	great	influence	on	the	clinical	
effectiveness	of	the	radiolabelled	somatostatin	analogue.	The	available	radionuclides	
and	somatostatin	analogues	used	will	be	discussed.	
Radionuclides in peptide receptor radionuclide therapy
Indium	(111In),	yttrium	(90Y)	and	lutetium	(177Lu)	have	been	the	most	frequently	
used	radionuclides	for	targeted	radiotherapy	in	the	various	clinical	trials	over	the	
past	decade.	Differences	in	the	physical	properties	of	these	radionuclides,	which	
are	important	for	the	effectiveness	of	the	therapy,	relate	to,	for	example,	emitted	
particles,	particle	energy	and	tissue	penetration	range	(Table	1).	
111In,	coupled	via	the	chelator	DTPA	to	D-Phe1-octreotide	([111In-DTPA0]octreotide;	
111In-octreotide),	was	used	in	the	first	clinical	trials	in	which	patients	with	metastasised	
GEP	tumours	were	treated	with	radiolabelled	somatostatin	analogues	6–8.	
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Table 1.	Physical	characteristics	of	the	radionuclides	used	in	peptide	receptor	radionuclide	
therapy	
Radionuclides Emitted Particle
Particle energy
(mean keV)
Maximum Tissue 
Penetration Range
(~ number of cells *) 
Half-life 
(days)
Indium	(111In) Auger	electrons	
γ-	radiation	
3	and	19	keV	
171	and	245	keV
10	µm	(	<	1) 2.8
Yttrium	(90Y) β-radiation	 935	keV	 12	mm	(~	600) 2.7
Lutetium	(177Lu) β-radiation	
γ-	radiation
130	keV
113	and	208	keV
2	mm	(~	100) 6.7
* Number of cells based on an average tumour cell size of 20 μm; ~, approximately
Besides	γ-radiation,	which	makes	111In	a	suitable	radionuclide	for	imaging,	it	emits	
both	Auger	and	conversion	electrons	with	a	medium-to-short	tissue	penetration	
range	 (0.02–10	 and	 200–500	µm,	 respectively).	 In	 vitro	 PRRT	 studies	with	
[111In-DTPA0]octreotide	 showed	 that	 the	 therapeutic	effect	was	dependent	on	
internalisation,	which	enables	the	Auger	electrons	to	reach	the	nucleus	9.	These	
results	suggest	that	the	Auger	electrons	and	not	the	conversion	electrons	can	be	
held	responsible	for	the	reported	tumour	responses	with	111In-labelled	somatostatin	
analogues.	In	an	attempt	to	increase	the	efficacy	of	PRRT,	clinical	trials	that	followed	
used	β-emitting	radionuclides,	such	as	90Y	or	177Lu.	Radionuclides	emitting	β-radiation	
have	greater	therapeutic	potential	since	the	emitted	particle	range	exceeds	the	cell	
diameter	10–12.
Furthermore,	 the	ability	 to	 irradiate	neighbouring	cells	 is	 an	advantage	with	
tumours,	such	as	breast	carcinomas,	 that	are	characterised	by	a	heterogeneous	
SSTR	tissue	distribution,	with	regions	of	high	density	next	to	regions	that	lack	
receptor	expression13.	As	expected,	the	clinical	and	preclinical	studies	in	which	
90Y-	or	 17 7Lu-coupled	 somatostatin	 analogues	were	used	demonstrated	more	
effectiveness	in	terms	of	tumour	shrinkage	than	was	reported	with	somatostatin	
analogues	coupled	to	111In	14–17.	O’Donoghue	et al.	12,	who	used	a	mathematical	model	
to	examine	tumour	curability	and	its	relationship	to	tumour	size	for	22	β-emitting	
radionuclides,	calculated	an	optimal	tumour	diameter	for	cure	of	34	and	2	mm	for	
90Y	and	177Lu,	respectively.	With	respect	to	these	calculations,	the	preclinical	studies	
by	de	Jong	et al.	14,18,	in	which	Lewis	rats	bearing	SSTR-positive	pancreatic	CA20948	
tumours	of	different	sizes	(0.1–15	cm2)	were	treated	with	[177Lu-DOTA0,Tyr3]octreotate	
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(177Lu-DOTATATE)	and	[90Y-DOTA0,Tyr3]octreotide	(90Y-DOTATOC)	are	of	special	
interest.	After	treatment	with	177Lu-DOTATATE	(total	cumulative	dose	555	MBq,	
maximum	estimated	tumour	dose	60	Gy),	a	higher	cure	rate	was	observed	in	the	
group	of	rats	bearing	small	tumours	(<	1	cm2)	than	in	the	rats	bearing	larger	tumours	
(>	1	cm2,	mean	approximately	5	cm2).	In	contrast,	treatment	with	a	single	dose	of	
370	MBq	90Y-DOTATOC,	 leading	up	to	a	maximum	of	60	Gy	 in	 the	medium-
sized	(3–9	cm2)	tumours,	showed	less	cure	within	the	group	of	rats	bearing	small	
(<	1	cm2)	tumours	compared	with	the	rats	bearing	medium-sized	tumours	(Figure	
1)	 19.	These	results	suggested	that	treatment	with	a	combination	of	90Y-	and	177Lu-
labelled	somatostatin	analogues	can	be	more	effective	in	the	treatment	of	multiple	
tumours	that	differ	in	size	than	can	one	of	the	analogues	separately.	Recently,	de	
Jong	et al.	 20	 reported	the	results	of	such	a	combination	versus	single	analogue	
therapy.	 In	rats	bearing	both	a	small	 (<	0.5	cm2)	and	a	 large	tumour	(7–9	cm2),	
significantly	better	survival	was	observed	after	PRRT	with	the	combination	of	185	
MBq	(half-dose)	90Y-DOTATOC	and	278	MBq	(half-dose)	177Lu-DOTATATE	than	
after	a	single	full	dose	of	370	MBq	90Y-DOTATOC	or	555	MBq	177Lu-DOTATATE.	To	
translate	these	results	to	the	clinical	setting	with	patients	with	GEP	tumours,	90Y-
labelled	somatostatin	analogues	may	be	more	effective	in	larger	tumours,	whereas	
177Lu-labelled	somatostatin	analogues	may	be	more	effective	in	smaller	tumours,	with	
the	combination	of	both	radionuclides	as	the	most	suitable	therapy	for	the	clinical	
situation	in	which	most	patients	have	tumour	metastases	varying	in	size.
Unfortunately,	randomised	controlled	clinical	studies	comparing	the	therapeutic	
efficacy	of	90Y	and	177Lu	somatostatin	analogues	or	combination-based	regimens	are	
still	lacking.	
Somatostatin analogues in peptide receptor radionuclide 
therapy
The	various	111In-,	90Y-	or	177Lu-labelled	somatostatin	analogues	differ	in	their	affinity	
for	the	expressed	SSTRs.	Five	human	SSTR	subtypes	(SSTR1–SSTR5)	that	bind	
native	human	somatostatin	(SS14)	and	its	high-affinity	28	amino	acid	precursor	
(SS28)	have	been	cloned	21–23.	However,	their	affinities	for	synthetic	somatostatin	
analogues	differ	considerably.	The	‘cold’	analogue	octreotide,	which	is	frequently	
used	to	control	symptoms	related	to	hormone	overproduction	by	GEP	tumours,	
binds	with	high	affinity	to	SSTR2	and	with	 low	affinity	to	SSTR3	and	SSTR5,	
whereas	it	does	not	bind	to	SSTR1	and	SSTR4	24,25.	Furthermore,	autoradiography	
studies	by	Reubi et al.	 26	demonstrated	that,	after	labelling	octreotide,	via	DTPA,	
with	111In,	the	affinities	to	SSTR2	and	SSTR5	were	diminished	(Table	2).
1.2
60
Figure 1. Cure	rate	(expressed	as	percentage	of	cured	rats)	found	in	groups	of	rats	bearing	
CA20948	 tumours	 of	 different	 indicated	 sizes	 after	 treatment	with	 370	MBq	 [90Y-
DOTA0,Tyr3]octreotide	or	555	MBq	[177Lu-DOTA0,Tyr3]octreotate	 (maximum	estimated	
tumour	dose	of	60	Gy	for	both	treatments).	CR,	complete	response;	PR,	partial	response.	
(Modified	from	de	Jong	et al. 14).
However,	despite	the	change	in	affinities,	SSTR2	remains	the	receptor	subtype	for	
which	[111In-DTPA0]octreotide	has	the	highest	affinity.	Hofland	et al.	27	demonstrated	
that	the	uptake	of	[111In-DTPA0]octreotide	in	the	SSTR-positive	organs	of	mice	was	
predominantly	determined	by	SSTR2.	Moreover,	John	et al.	28	demonstrated	that	a	
positive	[111In-DTPA0]octreotide	scintigram	in	patients	with	neuroendocrine	tumours	
is	mainly	 the	result	of	SSTR2	expression,	whereas	SSTR1,	SSTR3,	SSTR4	and	
probably	SSTR5	are	less	important.	Radiolabelled	somatostatin	analogues	that	had	
a	higher	affinity	for	SSTR2	than	did	111In-octreotide,	and	were	therefore	potentially	
more	effective	for	therapy,	thus	became	available.	Small	structural	changes	in	the	
radioligand	molecule,	for	example	a	different	radionuclide,	chelator	or	peptide,	
revealed	distinct	differences	in	the	binding	properties	of	the	analogue	for	the	various	
SSTR	subtypes	(Table	2)	26.
In	animal	experiments,	several	111In-labelled	somatostatin	analogues	showed	a	higher	
specific	uptake	than	 111In-labelled	[DTPA0]octreotide	in	SSTR-positive	organs	5.	
Furthermore,	the	analogue	[DOTA0,	Tyr3]octreotate	has	a	ninefold	higher	affinity	
for	SSTR2	compared	with	[DOTA0,	Tyr3	]octreotide,	whereas	the	affinities	for	SSTR3	
and	SSTR5	were	found	to	be	lower	26.	In	line	with	the	higher	affinity	for	SSTR2,	
biodistribution	studies	on	 111In-octreotide	and	 177Lu-DOTATATE	scintigraphy	
showed	a	three-	to	fourfold	higher	tumour	uptake	in	four	out	of	five	patients	with	
Pe
pt
id
e 
re
ce
pt
or
 ra
di
on
uc
lid
e 
th
er
ap
y
somatostatin-positive	tumours,	of	whom	three	had	GEP	tumours	29.	As	most	GEP	
tumours	are	known	to	predominantly	express	SSTR2,	all	clinical	studies	selected	
a	radiolabelled	somatostatin	analogue	for	PRRT	with	at	 least	a	high	affinity	for	
SSTR2.
CLINICAL STUDIES 
The	outcome	of	several	phase	 I	and	phase	 II	PRRT	studies,	 in	which	different	
radiolabelled	somatostatin	analogues	were	used,	has	been	published.	In	addition,	
it	has	become	apparent	that	the	bone	marrow	and	kidneys	are	the	most	important	
dose-limiting	organs	in	this	type	of	therapy.	
Table 2. Affinity	profiles	 (IC50)	a	 for	human	SSTR1-SSTR5	(hSSTR1-5)	of	a	 series	of	
somatostatin	analogues
Peptides hSSTR1 hSSTR2 hSSTR3 hSSTR4 hSSTR5
SS-28 5.2	±	0.3	(19) 2.7	±	0.3	(19) 7.7	±	0.9	(19) 5.6	±	0.4	(19) 4.0	±	0.3	(19)
Octreotide >10,000	(5) 2.0	±	0.7	(5) 187	±	55	(3) >1,000	(5) 22	±	6	(5)
DTPA-
octreotide
>10,000	(6) 12	±	2	(5) 376	±	84	(5) >1,000	(5) 299	±	50	(6)
111In-octreotide >10,000	(5) 22	±	3.6	(5) 182	±	13	(5) >1,000	(5) 237	±	52	(5)
DOTATOC >10,000	(7) 14	±	2.6	(6) 880	±	324	(4) >1,000	(6) 393	±	84	(6)
90Y-
DOTATOC
>10,000	(4) 11	±	1.7	(6) 389	±	135	(5) >10,000	(5) 114	±	29	(5)
DOTALAN >10,000	(7) 26	±	3.4	(6) 771	±	229	(6) >10,000	(4) 73	±	12	(6)
90Y-DOTALAN >10,000	(3) 23	±	5	(4) 290	±	105	(4) >10,000	(4) 16	±	3.4	(4)
DOTA-OC >10,000	(3) 14	±	3	(4) 27	±	9	(4) >1,000	(4) 103	±	39	(3)
90Y-DOTA-OC >10,000	(5) 20	±	2	(5) 27	±	8	(4) >10,000	(4) 57	±	22	(4)
DTPA-Tyr3-
octreotate
>10,000	(4) 3.9	±	1	(4) >10,000	(4) >1,000	(4) >1,000	(4)
111In-DTPA-
Tyr3-octreotate
>10,000	(3) 1.3	±	0.2	(3) >10,000	(3) 433	±	16	(3) >1,000	(3)
DOTA-Tyr3-
octreotate
>10,000	(3) 1.5	±	0.4	(3) >1,000	(3) 453	±	176	(3) 547	±	160	(3)
90Y-DOTA-
Tyr3-octreotate
>10,000	(3) 1.6	±	0.4	(3) >1,000	(3) 523	±	239	(3) 187	±	50	(3)
Modified from Reubi et al. 26 
a All values are IC50 ± SEM in nM. The number of experiments is in parenthesis.
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[111In-DTPA0]octreotide 
The	 first	 radiolabelled	 somatostatin	 analogue	 therapy	 in	GEP	patients	with	
advanced-stage	disease	was	 based	on	 the	 administration	of	high	dosages	 of	
111In-octreotide,	which	 at	 that	 time	was	 available	 for	 diagnostic	 purposes	
(Table	3)	6,7,30,31.
The	total	cumulative	dose	varied	from	3.1	GBq	up	to	160.0	GBq.	In	a	report	by	
Valkema	et al. 6,	in	which	the	outcome	of	 111In-octreotide	treatment	in	50	patients	
with	SSTR-positive	tumours	was	reviewed,	15	out	of	the	26	(58%)	GEP	patients	had	
a	stabilisation	of	their	metastatic	disease,	and	two	out	of	26	(8%)	showed	minor	
remission,	defined	as	a	reduction	in	tumour	size	of	between	25%	and	50%.	Patients	
with	stable	disease	and	minor	remission	(17	out	of	26;	65%)	were	considered	to	have	
shown	a	beneficial	therapeutic	effect	as	all	patients	had	documented	progressive	
disease	at	study	entry.	In	another	report	by	Anthony	et al.	30,	2	out	of	26	(8%)	patients	
had	a	partial	remission,	whereas	21	out	of	26	(81%)	had	stable	disease.	Buscombe	et 
al.	31	reported	the	outcome	of	111In-octreotide	therapy	in	12	GEP	patients	treated	with	
cumulative	activities	as	high	as	36.6	GBq.	Seven	out	of	the	12	(58%)	patients	had	stable	
disease	6	months	after	the	last	therapy,	2	(17%)	demonstrated	partial	remission	and	
3	(25%)	had	progressive	disease	despite	treatment.	
Table 3.	Peptide	receptor	radionuclide	therapy	with	111In-octreotide	in	patients	with	
GEP	tumours	
Response a
Authors [Ref.] No. of 
patients
PD before therapy Cum dose 
(GBq) 
PR MR b SD PD
Valkema	et al.	[6] 26
24/26	(92%)	
(clinical	and/or
imaging	based)
4.7-160.0 0
2	
(8%)
15	
(58%)
9	
(35%)
Anthony	et al.	[30] 26
100%
(clinical	and/or	
imaging	based)
6.7-46.6
2	
(8%)
N/I
20	
(77%)
4	
(15%)
Buscombe	et al.	[31] 12
100%
(biochemical	or	
imaging	based)
3.1-36.6
2
(17%)
N/I
7	
(58%)
3	
(25%)
Cum dose, cumulatieve dose of 111In-octreotide; N/I, not indicated
a Criteria of Tumour Response: PR (partial remission), > 50%reduction of tumour size; SD (stable disease), 
< 25% reduction or increase of tumour size; PD (progressive disease), > 25% increase of tumour size. 
b Modification of SWOG criteria including MR (minor remission), between 25 and 50% reduction in 
tumour size.
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All	the	clinical	PRRT	studies	reported	encouraging	and	promising	results,	especially	
in	terms	of	clinical	benefit	and	biochemical	responses.	Reported	cases	of	objective	
tumour	shrinkage	were,	however,	few.	These	outcomes	suggested	that	the	anti-
tumour	effect	of	111In-octreotide	is	not	ideal	for	PRRT,	at	least	for	visible	GEP	tumours.	
However,	experimental	data	in	rats	have	shown	that	high	doses	of	111In-octreotide	
can	inhibit	the	growth	of	liver	metastases	after	injecting	SSTR2	receptor-positive	
tumour	cells	into	the	portal	vein	32.	These	results	suggest	that	PRRT	with	111In-labelled	
analogues	might	be	effective	in	the	treatment	of	micro-metastases	or	metastatic	
spread	during	initial	surgery.	Clinical	studies	that	could	confirm	these	observations	
are,	however,	lacking.	
[90Y-DOTA0,Tyr3]octreotide, [90Y-DOTA]lanreotide 
and [90Y-DOTA0,Tyr3]-octreotate 
In	the	clinical	trials	that	followed	the	PRRT	with	111In-labelled	analogues,	90Y-labelled	
analogues	were	used.	A	summary	of	these	studies	is	shown	in	Table	4.
In	1998,	Otte	et al.	33	reported	the	first	results	of	10	patients	with	SSTR-positive	tumours	
treated	with	90Y-DOTATOC.	Two	out	of	10	patients	had	partial	remission	and	six	
stable	disease;	in	two	patients,	18F-deoxyglucose	positron	emission	tomography,	after	
a	single	dose	of	90Y-DOTATOC,	showed	a	substantial	reduction	of	18F-deoxyglucose	
uptake	in	the	tumour.	In	the	studies	that	followed,	the	response	rates	(complete	and	
partial	remission)	in	patients	with	GEP	tumours,	who	were	treated	with	either	6.0	
GBq/m2	or	7.4	GBq/m2,	were	10	out	37	(27%)	and	8	out	of	37	(22%),	respectively	
16,34.	To	determine	whether	a	decrease	in	the	number	of	treatments,	but	at	the	same	
time	maintaining	the	maximum	cumulative	dose	of	7.4	GBq/m2	due	to	an	increase	
of	dosage	per	treatment,	could	increase	the	objective	response	another	study	was	
performed	35.	Twelve	out	of	35	patients	(34%)	had	complete	or	partial	remission,	
which	indicated	a	higher	percentage	of	tumour	regression.	No	increase	in	the	number	
of	side-effects	was	reported.	Although	these	results	suggested	that	an	increase	of	
dose,	and	as	a	consequence	a	decrease	in	the	number	of	therapeutic	injections,	could	
be	more	beneficial,	it	must	be	stressed	that	this	was	not	a	randomised	controlled	trial	
and	the	number	of	treated	patients	was	low.	Nonetheless,	the	variation	of	protocol	
characteristics,	such	as	the	number	of	treatments,	the	doses	per	treatment	or	the	
length	of	treatment	interval,	are	of	great	interest	and	may	play	an	important	role	
in	the	reported	outcome	of	PRRT	studies.	Randomised	controlled	studies	on	the	
effects	of	these	variables	are	therefore	needed.	
Clinical	studies	performed	 in	Milan	also	used	90Y-DOTATOC	to	treat	various	
SSTR	positive	tumours	 36–40.	Recently,	Bodei	et al.	 40	 reported	their	experience	
with	90Y-DOTATOC,	in	which	a	total	of	141	patients	with	various,	SSTR	positive	
tumours	were	treated.	An	objective	response	(complete	or	partial	remission)	of	26%	
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was	observed.	More	precisely,	23%	of	patients	who	had	progressive	disease	before	
therapy	(113	out	of	141;	80%)	had	complete	or	partial	remission,	whereas	in	the	group	
with	stable	disease	(28	out	of	141;	20%),	32%	had	complete	or	partial	remission.	
Unfortunately,	the	specified	treatment	outcome	according	to	tumour	type	was	not	
given.	It	was,	however,	reported	that	most	of	the	patients	who	had	a	favourable	
outcome	had	neuroendocrine	GEP	tumours.	In	a	more	detailed	study	from	Milan,	
the	outcome	of	therapy	in	40	patients	with	SSTR-positive	tumours	was	reported	
39.	The	cumulative	dose	of	90Y-DOTATOC,	which	was	given	in	two	cycles,	ranged	
from	5.9	to	11.1	GBq.	In	the	group	with	GEP	tumours,	this	therapy	regimen	resulted	
in	partial	remission	in	6	out	of	21	patients	(29%),	whereas	11	out	of	21	(52%)	had	
stable	disease	and	4/21	(19%)	had	progressive	disease.	Valkema	et al.	41	reported	the	
preliminary	results	of	a	multicentre	phase	I	study	performed	in	Rotterdam,	Brussels	
and	Tampa.	The	objective	was	to	define	the	maximum	tolerated	single	and	four-cycle	
doses	of	90Y-DOTATOC	6,11,14.	Escalating	doses	up	to	14.8	GBq/m2	in	four	doses	or	
up	to	9.3	GBq/m2	in	a	single	dose	were	administered	to	a	total	of	60	patients.	Four	
of	the	54	(7%)	patients	who	were	treated	with	their	maximum	allowed	dose	had	
partial	remission,	7	out	of	54	(13%)	had	minor	remission,	and	33	out	of	54	(61%)	
showed	stabilisation	of	their	disease.	Anti-tumour	effect	in	terms	of	improvement	
of	response,	according	to	the	SWOG	(Southwest	Oncology	Group)	tumour	response	
criteria,	including	stable	disease	and	minor	remission	in	patients	with	progressive	
disease	at	the	start	of	therapy,	was	reported	as	65%	41.	The	median	time	to	progression	
of	that	same	group	had	not	been	reached	at	26	months	42.	
In	a	European	multicentre	study	(MAURITIUS),	another	90Y-labelled	somatostatin	
analogue,	 90Y-DOTA-lanreotide,	was	used	 to	 treat	39	GEP	patients.	The	 total	
cumulative	dose	ranged	from	1.9	GBq	to	8.6	GBq	(50–232	mCi)	of	 90Y-DOTA-
lanreotide	15.	Eight	out	of	39	(20%)	patients	showed	minor	remission,	and	17	out	of	39	
(44%)	had	stable	disease.	The	first	results	of	the	therapeutic	efficacy	in	patients	with	
SSTR-positive	tumours	with	the	somatostatin	analogue	[90Y-DOTA0,Tyr3]octreotate	
(90Y-DOTATATE)	were	recently	reported	by	Baum	et al.	 43,44.	Twenty-eight	out	
of	75	(37%)	patients	had	partial	remission,	and	39	out	of	75	(52%)	demonstrated	
stable	disease	after	therapy.	Therefore,	90Y-DOTATATE	might	also	be	a	promising	
90Y-labelled	somatostatin	analogue.	Despite	the	differences	in	somatostatin	analogues	
and	protocols	used	in	the	various	90Y-based	PRRT	studies,	the	reported	results	of	
therapy	in	terms	of	complete	and	partial	remission	percentages,	ranging	up	to	37%	
(Table	4),	indicated	an	improvement	in	therapeutic	effectiveness	compared	with	the	
studies	with	111In-labelled	octreotide.	
Pe
pt
id
e 
re
ce
pt
or
 ra
di
on
uc
lid
e 
th
er
ap
y
Table 4.	Peptide	receptor	radionuclide	therapy	with	90Y-	and	 177Lu-labeled	somatostatin	
analogues	in	patients	with	GEP	tumours	
Response *
Authors [Ref.]
No.
of 
Patients
PD at 
baseline
CR PR MR ‡ SD PD CR + PR
[90Y-DOTA0, Tyr3]octreotide
Otte	et al.	1999	[48]	} 16 N/I 0
1
(6%)
N/I
14
(88%)
1
(6%)
1/16
(6%)
Waldherr	et al.	2001	[34] 37
34/37	
(84%)
1
(3%)
9
(24%)
N/I
23
(62%)
4
(11%)
10/37
(27%)
Waldherr	et al.	2002	[16] 37
37/37	
(100%)
1
(3%)
7
(19%)
N/I
26
(70%)
3
(8%)
8/37
(22%)
Waldherr	et al.	2002	[35] 35
35/35	
(100%)
2
(6%)
10
(29%)
N/I
19
(54%)
4
(11%)
12/35
(34%)
Bodei	et al.	2003	[39] 21 N/I 0
6
(29%)
N/I
11
(52%)
4
(19%)
6/21
(29%)
Valkema et al.	2003	[41] 54
41/54	§	
(76%)
0
4
(7%)
7
(13%)
33
(61%)
10
(19%)
4/54
(7%)
[90Y-DOTA]lanreotide
Virgolini	et al.	2002	[15] 39
39/39	
(100%)
0 0
8
(20%)
17	
(44%)
14	
(36%)
0/39
(0%)
[90Y-DOTA0,Tyr3]octreotate
Baum et al.	2004	[43,44] 75
67/75	
(89%)
0
28
(37%)
N/I
39
(52%)
8	
(11%)
28/75	
(37%)
[177Lu-DOTA0,Tyr3]octreotate
Kwekkeboom	et al.	2003	[45] 76
29/76	
(38%)
1	
(1%)
22	
(29%)
9	
(12%)
30	
(39%)
14	
(18%)
23/76	
(30%)
* Criteria of Tumour Response (SWOG); CR (complete remission), no evidence of disease; PR (partial 
remission), > 50% reduction of tumour size; SD (stable disease), < 25% reduction or increase of tumour 
size; PD (progressive disease), > 25% increase of tumour size; ‡, modification of SWOG criteria including 
MR (minor remission), between 25 and 50% reduction of tumour size; N/I, not indicated; §, Valkema, 
personal communication
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[177Lu-DOTA0,Tyr3]octreotate 
The	first	results	of	[177Lu-DOTA0,Tyr3]octreotate	(177Lu-DOTATATE)	therapy	were	
described	in	a	study	of	35	patients	with	neuroendocrine	GEP	tumours,	who	had	
a	follow-up	of	3–6	months	after	receiving	their	final	dose	17.	Patients	were	treated	
with	escalating	dosages	from	100	to	150,	and	a	maximum	of	200	mCi	(3.7,	5.6	and	
7.4	GBq,	respectively)	177Lu-DOTATATE,	up	to	a	final	cumulative	dose	of	600–800	
mCi	(22.2–29.6	GBq),	with	treatment	intervals	of	6–9	weeks.	The	effects	of	the	
therapy	on	tumour	size	were	evaluable	 in	34	patients.	Three	months	after	 the	
final	administration,	a	complete	remission	was	found	in	one	patient	(3%),	a	partial	
remission	in	12	(35%),	stable	disease	in	14	(41%)	and	progressive	disease	in	seven	
(21%),	including	three	patients	who	died	during	the	treatment	period.	
In	an	update	on	this	treatment	in	76	patients	with	GEP	tumours	45,	complete	remission	
was	found	in	one	patient	(1%),	partial	remission	in	22	(29%),	minor	remission	in	
9	(12%),	stable	disease	in	30	(40%),	and	progressive	disease	in	14	patients	(18%).	
The	effect	of	 177Lu-DOTATATE	therapy	on	tumour	size,	uptake	on	post-therapy	
scintigraphy,	liver	enzymes	and	the	tumour	marker	chromogranin	A	in	a	patient	who	
showed	partial	remission	is	shown	in	Figure	2.	Six	out	of	32	patients	who	had	induced	
stable	disease	or	tumour	regression	after	the	therapy	and	were	also	evaluated	after	
12	months	(mean	18	months	from	therapy	start)	developed	progressive	disease;	in	
the	other	26,	the	tumour	response	was	unchanged.	Median	time	to	progression	was	
not	reached	at	25	months	from	the	beginning	of	therapy.	In	a	more	recent	evaluation	
of	response	in	a	total	of	131	GEP	tumour	patients,	these	outcomes	were	confirmed,	
with	a	median	time	to	progression	of	more	than	36	months	46.	
Comparison of the different treatments 
Treatment	with	90Y-	and	177Lu-labelled	somatostatin	analogues	is	very	encouraging	
in	terms	of	tumour	shrinkage.	However,	direct	comparison	to	evaluate	the	optimal	
treatment	remains	difficult.	Differences	in	treatment	protocol,	such	as	administered	
doses,	dosing	schemes	and	the	tumour	response	criteria	used,	can	be	responsible	for	
the	observed	differences	in	treatment	outcome.	Therefore,	randomised	controlled	
trials	are	necessary	to	define	the	optimal	PRRT	and	treatment	scheme.	
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Figure 2. Baseline	and	follow-up	data	of	a	patient	with	carcinoid	with	liver	metastases.	(A)	
Post-therapy	scintigraphy	after	each	cycle	is	shown	(top	row).	Note	the	decrease	of	uptake	
of	[177Lu-DOTA0,Tyr3]octreotate	on	the	last	scintigraphy	scan	in	comparison	with	the	first	
(black	arrows	indicating	the	index	lesion).	At	3	and	6	months	after	four	cycles	of	therapy,	the	
patient	had	a	partial	remission	(>	50%	decrease	in	tumour	volume	on	computed	tomography;	
white	arrows	indicate	the	index	lesion)	(bottom	row).	(B)	Regression	of	the	tumour	mass	was	
accompanied	by	a	decrease	in	serum	concentration	of	alkaline	phosphatase	(reference	range	
0–119	U/l),	gamma-glutamyl	transpeptidase	(gamma-GT;	reference	range	0–49	U/l)	and	the	
tumour	marker	chromogranin	A	(reference	range	10–100	ng/ml).	
A
B
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SIDE-EFFECTS AND RADIATION TOXICITY 
Adverse	reactions	observed	after	PRRT	can	be	divided	into	direct	side-effects	and	
the	more	delayed	effects	of	 radiotoxicity.	Direct	effects	commonly	mentioned	
during	and	after	therapy	are	nausea,	vomiting	and	abdominal	pain	17,30,34.	In	general,	
these	side-effects	occur	in	a	minority	of	patients	and	are	easily	treated	with	anti-
emetics	or	pain	medication.	Mild	hair	loss	was	observed	in	patients	treated	with	
177Lu-DOTATATE,	but	hair	growth	had	normalised	at	follow-up	3–6	months	after	
the	last	administration	17.	Beside	these	mild	side-effects,	more	serious	toxicity	may	
occur,	especially	to	the	bone	marrow,	kidneys	and	liver.	The	reported	percentages	
of	these	side-effects	or	toxicities	are	shown	in	Table	5.	
Table 5.	Side-effects	in	patients	with	somatostatin	receptor-positive	(GEP	and	non	
GEP)	tumours	treated	with	different	radiolabelled	somatostatin	analogues
Grade 3-4 Haematologic 
Toxicity § 
Other 
Toxicities
Author [Ref.] Radioligand Number 
of 
Patients
Platelets Haemo-
globulin
White 
blood 
cells
Valkema	et al.	[6]		 [111In-DTPA0]octreotide 50 10% 15% 2% 3	AML/MDS
Anthony	et al.	[30] [111In-DTPA0]octreotide 27 7% 11% 7%
3	Liver,	
1	Renal
	
Bodei	et al.	[39] [90Y-DOTA0,Tyr3]octreotide 40 7% 3% 7%
Otte	et al.	[48] [90Y-DOTA0,Tyr3]octreotide 29 3% 7% 0% 4	Renal	*
Waldherr	et al.	[16] [90Y-DOTA0,Tyr3]octreotide 39 0 3% 0% 1	Renal	
Valkema	et al.	[41] [90Y-DOTA0,Tyr3]octreotide 60 12% 1% 2%
1	MDS,	
1	Liver,	
1	Renal	
Kwekkeboom	et al.	
																											[45]
[177Lu-DOTA0,Tyr3]octreotate 200 3% 8% 13%
1	MDS,	
2	Liver	‡,	
1	Renal
Percentages are based on patient numbers. AML: acute myeloid leukaemia; MDS: myelodysplastic 
syndrome 
§, Most of the mentioned haematologic toxicities were transient. See reference for more detailed 
information;
*, No amino-acid infusion in half of the patients; 
‡ personal communication, Kwekkeboom et al. 
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Haematological toxicity 
Haematological	 toxicities	of	grade	3–4	for	haemoglobin,	white	blood	cells	and	
platelets	were	reported	up	to	a	maximum	of	15%	16,30,39,45,47,48.	In	general,	the	decrease	
in	blood	cell	count	was	transient,	and	transfusion	was	only	occasionally	needed.	
More	serious	side-effecs	were	reported	from	a	clinical	trial	in	which	50	patients	
were	treated	with	111In-octreotide	6.	Leukaemia	and	myelodysplastic	syndrome	were	
reported	in	three	patients	who	had	been	treated	with	total	cumulative	doses	of	over	
2.7	Ci	(100	GBq),	with	an	estimated	cumulative	bone	marrow	radiation	dose	of	about	
3	Gy.	One	patient,	who	developed	acute	myeloid	leukaemia	17	months	after	the	first	
dose	of	111In-octreotide,	had	had	chemotherapy	and	treatment	with	interferon	before	
PRRT.	The	other	two	patients,	who	had	had	no	previous	cytotoxic	therapy,	developed	
myelodysplastic	syndrome	after	more	than	3	years.	None	of	the	44	patients	who	
were	treated	with	a	cumulative	dose	lower	than	100	GBq	developed	myelodysplastic	
syndrome	or	leukaemia.	In	a	phase	I	trial	with	90Y-DOTATOC	in	which	the	objective	
was	to	define	the	maximal	tolerated	single	and	four-cycle	doses,	one	patient	had	
myelodysplastic	syndrome	2	years	after	the	start	of	PRRT;	this	patient	had	also	had	
previous	chemotherapy	41.	In	the	report	by	Kwekkeboom et al.	45,	who	studied	the	
patients	treated	with	177Lu-DOTATATE	as	PRRT,	one	patient	in	the	whole	group	of	
patients	who	had	been	treated	or	were	being	treated	up	to	that	time	(201	patients,	
637	administrations)	developed	myelodysplastic	syndrome.	This	patient	had	also	
previously	received	chemotherapy.	In	summary,	haematological	toxicity	in	PRRT	is	
in	general	mild	and	reversible,	and	the	risk	of	developing	myelodysplastic	syndrome	
or	leukaemia	is	low	if	certain	dosing	limits	are	respected.	
Renal toxicity 
Chelated	somatostatin	analogues	are	cleared	predominantly	by	the	kidneys.	An	
accumulation	and	retention	of	these	analogues	within	the	kidney	occurs	but	 is	
not	SSTR	mediated	49.	Because	of	the	rapid	clearance,	[111In-DTPA0]octreotide	can	
be	safely	applied	for	diagnostic	use	without	any	damage	to	the	kidneys	 1,50.	For	
therapeutic	use,	however,	 the	renal	accumulation	and	the	relatively	 long	renal	
effective	half-life	of	 the	radiopharmaceutical	can	be	dose-limiting.	 In	external	
beam	radiation	therapy,	renal	absorbed	doses	of	23	Gy	(fractions	of	2	Gy)	may	cause	
nephropathy	in	5%	of	patients	in	5	years,	whereas	28	Gy	leads	to	a	50%	risk	over	the	
same	period	51.	However,	since	PRRT	is	applied	as	continuous	low-dose	radiation	
with	intracellular	accumulation,	a	maximum	cumulative	dose	limit	of	23	Gy	may	
not	be	applicable.	The	first	reports	on	acute	(6–12	months	after	radiation	exposure)	
and	 late	 (1–5	years	after	exposure)	 renal	 side-effects	appeared	after	 the	use	of	
90Y-DOTATOC	in	various	clinical	trials	33,52–54.	The	results	suggested	that	a	cumulative	
dose	of	90Y-DOTATOC	of	more	than	7.4	GBq/m2	might	be	a	risk	factor	for	renal	
insufficiency	33.	However,	some	years	later,	a	case	report	of	a	patient	who	developed	
late-onset	renal	insufficiency	with	a	total	cumulative	dose	of	less	than	7.4	GBq/m2	
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indicated	that	even	less	radiation	can	cause	renal	damage	at	a	later	time	point	53.	In	
contrast,	no	renal	toxicity	was	found	in	patients	treated	with	[111In-DTPA0]octreotide6.	
The	difference	between	 111In	and	 90Y	with	regard	 to	 the	 induction	of	 radiation	
nephropathy	may	be	explained	by	the	difference	in	the	particle	range	emitted	(10	
µm	versus	approximately	12	mm,	respectively).	The	Auger	electrons	emitted	by	111In	
within	the	tubular	cells	do	not	reach	the	radiosensitive	glomeruli.	This	particle	range	
advantage	might	also	be	the	reason	why	only	one	patient	of	a	group	of	201	patients	
treated	with	177Lu-DOTATATE	developed	renal	failure	45.	Although	the	number	of	
patients	reported	with	radiation	nephropathy	was	relatively	low,	and	the	potential	
benefit	for	the	patients	outweighed	the	risk	of	occurrence	of	this	severe	complication,	
it	became	clear	that	PRRT-induced	radiation	nephropathy	was	difficult	to	predict	
with	the	currently	applied	maximum	cumulative	dose	limits.	Two	recent	studies	
in	which	patients	were	treated	with	90Y-DOTATOC	provided	more	insight	into	
individual	kidney	dosimetry	and	its	importance	in	PRRT	55,56.	These	studies	indicated	
that,	apart	from	the	total	renal	radiation	dose,	the	dose	volume,	fractionation	rate	
and	clinical	parameters	of	hypertension,	diabetes	and	age	are	relevant	risk	factors	
for	 the	development	of	a	 loss	of	renal	 function.	Kidney	protection	methods	to	
prevent	damage	to	the	kidney	from	high	absorbed	doses	with	each	administration	
are	obviously	of	importance.	The	most	important	method	currently	used	to	reduce	
the	renal	uptake	of	radioactivity	in	PRRT	is	the	use	of	amino	acid	solutions,	which	
can	be	easily	co-administered	during	therapy.	Preclinical	studies	have	shown	that	
the	infusion	of	positively	charged	amino	acids,	mainly	L-lysine	and	L-arginine,	are	
able	to	reduce	the	tubular	reabsorption	of	radiolabelled	somatostatin	analogues	
in	rats	57.	Clinical	studies	have	proved	that	co-infusion	with	a	combination	of	the	
L-lysine	and	L-arginine	or	a	mixed	amino	acid	solution	on	the	day	of	therapy	led	to	
a	reduction	in	renal	uptake	of	between	20	and	47%	29,39,58,59.	Higher	doses	of	amino	
acids	are	more	effective	but	have	the	disadvantage	of	inducing	a	higher	incidence	of	
side-effects,	such	as	nausea,	vomiting	and,	especially	with	higher	doses	of	L-lysine,	
hyperkalaemia	59,60.	
Liver toxicity 
Most	patients	treated	with	PRRT	in	the	clinical	trials	studied	had	liver	metastases.	The	
extent	of	liver	involvement	ranged	from	a	single	lesion	to	diffuse	liver	involvement	
with	pronounced	hepatomegaly.	It	is	therefore	not	unlikely	that	PRRT	can	induce	
hepatocellular	radiation	injury.	In	clinical	practice,	however,	it	may	be	difficult	to	
distinguish	an	increase	of	liver	function	parameters	induced	by	radiation	from	a	
subtle	progression	of	 liver	metastases.	Anthony	et al.	 30	reported	three	patients	
(from	a	total	of	27),	treated	with	 111In-octreotide,	in	whom	a	temporary	increase	
in	liver	function	parameters	(grade	3	liver	toxicity	on	World	Health	Organization	
toxicity	grading)	was	observed.	All	three	patients	had	a	tumour	replacement	of	
more	than	75%	of	 their	hepatic	parenchyma	and	treatment-associated	necrosis	
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on	the	computed	tomography	scans.	In	patients	with	less	extensive	liver	disease,	
changes	in	liver	function	parameters	did	not	occur.	A	significant	increase	in	liver	
function	parameters	after	the	administration	of	90Y-DOTATOC	was	reported	in	
two	studies	41,61.	Valkema	et al.	41	reported	one	transient	grade	3	toxicity	in	a	group	
of	60	patients	treated	with	90Y-DOTATOC	(phase	I	study).	In	another	study,	15	
patients	with	proven	liver	metastases	(of	whom	12	had	extensive	liver	involvement,	
defined	as	25%	or	more)	from	neuroendocrine	tumours	were	treated	with	three	
cycles	of	120	mCi	(4.4	GBq)	each	61.	In	only	four	of	these	15	patients,	one	or	more	
of	the	three	liver	enzymes	that	were	measured	-	serum	aspartate	aminotransferase,	
alanine	aminotransferase	and	alkaline	phosphatase	-	increased	at	least	one	grade,	
according	to	the	World	Health	Organization	common	toxicity	criteria,	from	baseline	
to	final	follow-up	measurement	(4–6	weeks	post	cycle	3).	It	was	concluded	that	
patients	with	diffuse	SSTR-positive	hepatic	metastases	could	be	treated	with	a	
cumulative	administered	activity	of	360	mCi	(13.2	GBq)	of	90Y-DOTATOC	with	
only	a	small	chance	of	developing	mild	acute	or	subacute	hepatic	injury.	In	the	group	
of	patients	treated	with	 177Lu-DOTATATE,	significantly	increased	liver	function	
parameters	(grade	4	liver	toxicity)	was	evident	in	two	patients	after	the	first	cycle	
of	treatment	(D.J.	Kwekkeboom,	personal	communication,	2004).	One	patient,	
who	suffered	from	a	rapidly	growing	neuroendocrine	tumour	with	extensive	liver	
involvement,	clinically	progressed	to	liver	failure	within	3	weeks	and	died	shortly	
thereafter.	Whether	the	aggressive	nature	of	the	tumour	or	the	PRRT-induced	
toxicity	led	to	this	fatal	condition	remains	unclear.	The	other	patient,	who	after	
the	first	therapy	developed	dyspnoea,	acute	abdominal	pain	and	increased	liver	
function	parameters,	was	hospitalised	for	several	weeks.	Gradually,	the	liver	function	
parameters	and	hyperbilirubinaemia	returned	to	pre-therapy	levels.	Treatment	with	
177Lu-DOTATATE	was	continued	for	6	months	after	the	first	therapy	with	a	reduced	
dose	of	1.9	GBq	followed	by	a	third	administration	of	4.1	GBq	without	any	acute	
side-effects.	
CLINICAL PRACTICE 
In	patients	with	metastasised	GEP	tumours,	for	whom	surgery	is	no	longer	an	option,	
PRRT	can	be	an	effective	alternative	therapeutic	modality	with	limited	side-effects.	
The	results	in	terms	of	tumour	volume	reduction,	as	shown	in	the	different	clinical	
trials,	are	very	encouraging	and	seem	to	compare	favourably	with	chemotherapy.	
No	randomised	controlled	study	has,	however,	been	performed	to	confirm	this.	
Although	proven	effective	in	a	substantial	percentage	of	patients,	PRRT	has	not	
been	widely	recognised	as	alternative	systemic	therapy.	Instead,	the	 ‘wait-and-
see’	approach	often	remains	the	mainstay	of	initial	management	in	patients	with	
unresectable	disease.	The	rationale	for	this	approach	is	found	in	the	natural	history	
of	well-differentiated	GEP	tumours	not	receiving	treatment,	in	which	tumours	can	
be	indolent	for	many	years	and	the	well-being	of	patients,	even	with	metastasised	
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tumours,	can	be	unchanged	for	many	years.	However,	the	reported	studies	on	PRRT	
clearly	indicate	that	patients	with	documented	progressive	disease	or	a	substantial	
increase	in	symptoms	can	benefit	from	this	therapy.	The	recognition	of	the	possible	
benefit	of	PRRT	for	patients	with	GEP	tumours	is	increasing,	but	its	implementation	
within	the	whole	therapeutic	array	is	rather	poor.	Factors	that	contribute	to	this	
include	the	fact	that	PRRT	is	a	relatively	new	therapeutic	modality,	 the	lack	of	
approved	radiopharmaceuticals,	which	is	in	part	related	to	increased	governmental	
demands,	and	therapy-related	costs.
Indications for peptide receptor radionuclide therapy
Candidates	for	PRRT	are	those	patients	with	inoperable	GEP	tumours	who	have	
progressive	disease	or	symptomatology	that	is	difficult	to	manage	with	medication.	
If	it	is	agreed	that	the	malignancy	is	inoperable,	the	tumour	has	to	be	SSTR-positive,	
based	on	tumour	uptake	on	111In-octreotide	scintigraphy.	Furthermore,	the	amount	of	
tumour	uptake	has	to	be	equal	to	or	higher	than	that	of	normal	liver	tissue	(according	
to	criteria	previously	described	by	Krenning et al.	10).
High	uptake	during	111In-octreotide	scintigraphy	has	been	shown	to	be	correlated	
with	tumour	regression	after	PRRT	17.	Additionally,	because	of	the	radiation	to	the	
bone	marrow	and	the	risk	of	temporary	bone	marrow	suppression,	patients	need	to	
fulfil	certain	minimal	haematological	criteria.	Kidney	function	has	to	be	determined	
before	therapy	to	exclude	patients	with	signs	of	impending	renal	failure	(glomerular	
filtration	rate	<	40	ml/minute).	The	presence	of	bone	metastases,	which	occur	in	a	
minority	of	patients,	is	no	exclusion	criterion.	As	a	rule,	if	a	tumour	response	occurs,	
all	tumour	sites	decrease	in	size.	However,	cystic	and	bone	lesions	seem	to	respond	
in	a	more	protracted	way	than	the	more	common,	solid	liver	metastases.	Up	until	
now,	no	systematic	study	has	been	performed	to	address	the	issue	of	a	possible	
differential	response	of	metastases	based	on	their	location.	The	full	patient	selection	
criteria	are	summarised	in	Table	6.	
Timing of therapy
There	is	currently	no	consensus	about	when	to	start	PRRT	in	patients	with	GEP	
tumours.	The	stage	of	disease	at	which	the	diagnosis	is	made	is	highly	variable	
and	ranges	from	a	localised,	non-metastatic	primary	tumour	to	more	advanced	
or	end-stage	disease	with	hepatomegaly	and	ascites.	In	a	recent	report	in	which	
the	relationship	between	delay	of	diagnosis,	extent	of	disease	and	survival	in	115	
patients	with	carcinoid	was	studied,	a	mean	delay	in	the	diagnosis	of	66	months	was	
found62.	It	was	concluded	that	the	diagnosis	of	carcinoid	is	difficult,	and	therefore	
a	delay	of	diagnosis	by	physicians	is	common.	Strikingly,	the	delay	of	the	diagnosis	
did	not	correlate	with	the	extent	of	the	disease.	However,	the	extent	of	the	disease	
did	correlate	with	survival.	
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Table 6. Criteria	for	peptide	receptor	radionuclide	therapy	in	patients	with	GEP	tumours
Inclusion
Sufficient	tumour	uptake	on	111In-octreotide	scintigrams
Haematology
Platelet	count	≥	75-100	x	109/L
White	blood	cell	count	≥	2-3.5	x	109/L	
Haemoglobin	≥	5.0	mmol/L
Kidney	function
Creatinin	(serum)	≤	150	µmol/L	or	creatinine	clearance	≥	40	ml/min
Karnofsky	Performance	Status	≥	50
Life	expectancy	>	6	months
Exclusion
Chemotherapy	within	6	weeks	prior	to	treatment	start
Pregnancy/	lactation
Patients	with	primary	tumours	and	lymph	node	metastases	were	less	likely	to	die	
of	carcinoid	disease	than	patients	with	hepatic	metastases,	carcinomatosis	or	extra-
abdominal	metastases.	Unfortunately,	reports	on	PRRT	with	explicit	survival	data	
are	few.	In	the	multicentre	trial	with	111In-octreotide	6,	it	was	reported	that	PRRT	for	
end-stage	patients	with	a	higher	tumour	burden	was	less	likely	to	have	a	favourable	
outcome	than	for	patients	with	lower	tumour	burden	or	in	a	better	general	condition.	
Survival	data	in	a	group	of	27	patients	treated	with	 111In-octreotide	presented	by	
Anthony	et al.	30	suggested	a	survival	benefit	in	patients	treated	with	111In-octreotide.	
The	number	of	patients	studied	was,	however,	 low,	and	the	survival	data	of	the	
treated	group	were	compared	with	data	from	a	historical	control	group.	In	the	studies	
with	177Lu-DOTATATE,	it	was	suggested	that,	because	of	the	high	success	rate	of	the	
therapy,	the	low	incidence	of	side-effecs	and	the	high	median	time	to	progression	
(>	36	months),	its	use	can	be	advocated	in	patients	with	metastasised,	unresectable	
GEP	tumours	without	waiting	for	tumour	progression	17,63.	
Another	argument	in	favour	of	early	treatment	is	that	neuroendocrine	tumours	can	
dedifferentiate	in	the	course	of	the	disease	and	thereby	lose	the	expression	of	SSTRs.	
Treatment	with	radiolabelled	somatostatin	analogues	will	then	be	impossible17.	
However,	whether	early	 treatment	would	benefit	patients	with	metastasised,	
unresectable	GEP	tumours	in	terms	of	longer	survival	remains	to	be	studied	and	
should	imply	randomisation	into	groups	with	and	without	PRRT.	At	this	moment,	
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when	there	seems	to	be	proof	that	PRRT	is	an	effective	therapy,	such	a	survival	
study	seems	unethical.	
Another	issue,	regarding	the	question	whether	we	should	treat	patients	with	PRRT	
or	not	at	an	early	stage	of	the	disease,	is	the	benefit	in	terms	of	clinical	response	
and	quality	of	life.	Not	all	studies	address	this	issue.	There	is,	however,	a	growing	
awareness	of	its	importance	in	clinical	oncology	trials,	especially	in	therapies	for	
which	cure	is	not	the	primary	goal	and	survival	gains	are	low	or	unknown	64.	As	
a	consequence,	the	more	recent	PRRT	reports	have	included	data	on	the	clinical	
effectiveness	of	therapy.	Two	studies	with	90Y-DOTATOC	provided	evidence	for	a	
favourable	clinical	response	in	60–70%	of	the	patients	47,65.	In	patients	treated	with	
177Lu-DOTATATE,	quality	of	life	assessment	showed	a	significant	improvement	
in	the	global	health/quality	of	life	score	(Δ	score	+9.2,	scale	range	0–100,	P<0.01),	
especially	in	those	patients	with	proven	tumour	regression	(Δ	score	+10.5,	P<0.05)	
(Figure	3)	66.	Although	the	assessment	methods	for	identifying	clinical	changes	differ	
in	these	studies,	the	combined	results	suggest	that	patients	may	experience	a	clinical	
benefit	from	PRRT.	
FUTURE DEVELOPMENTS 
A	direction	of	future	research	to	improve	current	PRRT	for	GEP	tumours	includes	
the	development	of	new	stable	somatostatin	analogues	with	a	high	affinity	for	
the	different	SSTR	subtypes.	The	new	analogue	[DOTA0-1-naphthyl3]octreotide	
(DOTANOC),	for	example,	is	an	analogue	that	has	a	high	affinity	for	SSTR2,	SSTR3	
and	SSTR5	67.	It	might	therefore	be	a	promising	analogue	to	be	used	for	treatment	
of	patients	with	tumours	that	not	bear	only	SSTR2,	but	also	express	SSTR3	and/or	
SSTR5.	Furthermore,	combined	treatment	with	different	radiolabelled	somatostatin	
analogues,	analogous	to	the	favourable	response	with	combinational	chemotherapy	in	
solid	tumours	compared	with	single-agent	therapy,	is	of	great	interest.	This	approach	
will	of	course	be	limited	by	the	combined	toxicity	of	the	radiolabelled	peptides.	
Preclinical	PRRT	studies	with	90Y-DOTATOC	and	177Lu-DOTATATE	indicate	that	
there	is	an	optimal	tumour	size	in	terms	of	the	efficacy	of	tumour	reduction	for	each	
radionuclide.	As	most	patients	have	metastatic	disease	with	tumours	of	different	
sizes,	combination	PRRT	could	achieve	higher	cure	rates	compared	with	single-
agent	therapy.	Higher	cure	rates	are	possible	when	the	density	of	expressed	SSTRs	
is	enhanced.	In	vitro	and	in	vivo	studies	show	that	the	irradiation	of	neuroendocrine	
AR42J	(rat	pancreatic	tumour)	cells	can	upregulate	the	expression	of	SSTR2	and	gastrin	
receptors	68.	PRRT	after	the	upregulated	expression	of	SSTR2	may	lead	to	a	higher	
uptake	of	the	radiolabelled	peptide	and	consequently	a	higher	therapeutic	efficacy.	
Most	research	in	PRRT	is	focused	on	the	different	SSTR	subtypes.	Neuroendocrine	
tumours	may,	however,	coexpress	other	tumour-specific	peptides,	such	as	vasoactive	
intestinal	peptide,	cholecystokin,	bombesin	and	GLP-1	receptors	69.	
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Figure 3. Global	health/quality	of	life	scale	scores	of	all	the	patients	(n=50)	and	the	different	
outcome	groups	according	to	tumour	evaluation	before	(hatched	bars)	and	3	months	after	(grey	
bars)	 177Lu-octreotate	therapy.	REGR,	regression	(complete,	partial	and	minor	remission);	
SD,	stable	disease;	PD,	progressive	disease.	Standard	errors	of	the	mean	are	shown;	*P<0.05;	
**P<0.01;	NS,	not	 significant	 (two-sided	analysis	of	variance;	P<0.05	was	 considered	
significant).	(Modified	from	Teunissen	et al.66).
The	concomitant	expression	of	these	receptors	could	be	used	in	the	future	in	a	
multireceptor	PRRT	 to	 target	more	 efficiently	GEP	 tumours	 in	 each	patient	
individually.	This	approach	could,	especially	in	tumours	with	a	heterogeneous	or	even	
a	reciprocal	receptor	distribution,	be	very	favourable	in	terms	of	achieving	a	more	
homogenous	distribution	of	the	absorbed	radiation	dose	within	the	tumour	mass.	
The	combination	of	PRRT	with	surgery	and/or	chemotherapy	as	a	multimodality	
treatment	strategy	is	of	interest	and	requires	the	start	of	randomised	trials	to	prove	
whether	current	results	can	be	improved.	Studies	that	can	also	be	considered	are	
the	use	of	PRRT	combined	with	surgery	in	an	adjuvant	setting	to	irradiate	occult	
metastases,	or	PRRT	as	debulking	therapy	followed	by	surgery	in	patients	with	
inoperable	but	limited	local	disease.	External	beam	radiotherapy	in	combination	with	
chemotherapy	such	as	gemcitabine,	which	is	a	known	potent	radiation	sensitiser,	has	
been	shown	to	have	favourable	effects	in	patients	with	non-small-cell	lung	cancer	70.	
Although	the	patients	were	treated	with	external	radiotherapy,	gemcitabine	and	other	
radiosensitising	agents	with	concurrent	PRRT	might	prove	effective	in	the	future.	
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SUMMARY 
PRRT	holds	great	promise	for	the	future	regarding	the	treatment	of	various	cancers.	
Using	radiolabelled	peptides,	which	bind	with	high	affinity	to	specific	receptors	on	
cancer	cells,	it	is	possible	to	target	the	cancer	efficiently.	In	GEP	tumours,	radiolabelled	
somatostatin	analogue	therapy	has	been	proven	to	be	effective.	Dose-limiting	organs	
are	the	bone	marrow	and	the	kidneys.	With	the	currently	used	maximum	allowed	
dose,	PRRT	is	relatively	safe,	and	serious	side-effects	are	rare.	It	is	impossible	to	
conclude	from	the	available	literature	which	radiolabelled	somatostatin	analogue	can	
be	regarded	as	the	most	effective	therapy.	Also,	the	development	of	therapy	strategies	
with	combinations	of	different	radionuclides,	which	is	underway,	is	of	interest	as	
these	strategies	may	in	future	provide	an	increase	in	therapeutic	efficacy.	
Practice points
•	 PRRT	with	β-emitting	agents	such	as	90Y	and	177Lu	can	induce	tumour	shrinkage	in	patients	with	
somatostatin-positive	GEP	tumours
•	 octreotide	scintigraphy	is	used	to	select	candidates	for	PRRT
•	 a	high	uptake	during	octreotide	scintigraphy	is	correlated	with	a	favourable	outcome	of	therapy
•	 the	co-administration	of	amino	acids	during	PRRT	is	essential	to	minimise	the	risk	of	renal	toxicity
•	 blood	examination	before	each	cycle	of	PRRT	is	necessary	as	bone	marrow	suppression	is	a	known	risk	
of	PRRT
Research Agenda
The	following	areas	are	of	interest	in	optimising	PRRT:
•	 the	development	of	new	somatostatin	analogues	with	a	high	affinity	for	different	SSTR	subtypes
•	 randomised	controlled	(multicentre)	trials	to	compare	the	therapeutic	efficacy	of	90Y-	and	177Lu-labelled	
somatostatin	analogues,	and	their	use	in	combination
•	 the	development	of	different	peptide	analogues	with	a	high	affinity
•	 the	implementation	of	multimodality	treatment	strategies:
–	 surgery	with	adjuvant	PRRT
–	 PRRT	for	debulking	before	surgery
–	 chemotherapy	as	a	radiosensitiser	for	PRRT
•	 methods	to	upregulate	the	expression	of	SSTRs	in	vivo
•	 the	reduction	of	kidney	and	bone	marrow	uptake	
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The overall aims of the work presented in this thesis are:
-	to	evaluate	the	effect	of	treatment	with	[177Lu-DOTA0,Tyr3]octreotate	in	the	
treatment	of	patients	with	inoperable,	metastasised	somatostatin	receptor
positive	endocrine	gastroenteropancreatic	tumours	in	terms	of:
	 	 i.	 Toxicity
	 	 ii.	 Effects	on	tumour	size
	 	 iii.	 Side-effects
	 	 iv.	 Quality	of	life
-	to	investigate	the	feasibility	of	peptide	receptor	radionuclide	therapy	in	patients	
with	non-radioiodine	avid	differentiated	thyroid	carcinoma.
In chapter 2.1 the	first	results	of	[177Lu-DOTA0,Tyr3]octreotate	therapy	as	a	novel	
peptide	receptor	radionuclide	therapy	(PRRT)	in	a	small	series	of	patients	with	inop-
erable	endocrine	gastroenteropancreatic	(GEP)	tumours	are	presented	with	emphasis	
on	the	feasibility	of	therapy	regarding	toxicity	and	side-effects.	Additionally,	the	first	
results	of	therapy	outcome	in	terms	of	objective	tumour	responses	were	reported.	
Besides	the	results	of	therapy	outcome	in	a	larger	group	of	patients	(n=131),	chapter 
2.2 is	focused	on	predictive	factors	for	a	favourable	tumour	response	or	tumour	
progression.	Furthermore,	the	first	results	on	the	long-term	outcome	of	 [177Lu-
DOTA0,Tyr3]octreotate	therapy	are	presented	and	a	comparison	with	chemotherapy	
is	made.	Chapter 3 is	focused	on	the	quality	of	life	in	patients	with	endocrine	GEP	
tumours	treated	with	[177Lu-	DOTA0,Tyr3]octreotate,	whereas chapter 4 describes	
long-term	changes	in	hormonal	status	after	therapy.	The	differential	uptake	of	[177Lu-
DOTA0,Tyr3]octreotate	versus	[177Lu-	DOTA0,Tyr3]octreotide	is	evaluated	in	chapter 
5. 	In	chapter 6.1 the	feasibility	of	therapy	with	[177Lu-	DOTA0,Tyr3]octreotate	in	
patients	with	non-radioiodine-avid	differentiated	thyroid	carcinoma	is	evaluated.	
Chapter 6.2 reviews	both	the	diagnostic	and	therapeutic	use	of	radiolabelled	so-
matostatin	analogues	in	the	management	of	patients	with	non-radioiodine-avid	
differentiated	thyroid	carcinoma.	A	summary	and	general	discussion,	including	
recommendations	for	future	research	completes	this	thesis	(chapter 7).
1.3
2
Outcome o�� PRRT with 
[177Lu-DOTA0,Tyr3]octreotate

Treatment o�� patients with 
gastroenteropancreatic (GEP)�� 
tumours with the novel 
radiolabelled somatostatin analogue 
[177Lu-DOTA0,Tyr3]octreotate
2.1
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Ananth Srinivasan, Jack L. Erion and Eric P. Krenning 
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Abstract
Medical	treatment	and	chemotherapy	are	seldom	successful	in	achieving	objective	
tumour	reduction	in	patients	with	metastatic	neuroendocrine	tumours.	Treatment	
with	the	radiolabelled	somatostatin	analogue	[90Y-DOTA0,Tyr3]octreotide	may	result	in	
partial	remissions	in	10–25%	of	patients.	The	newer	analogue	[DOTA0,Tyr3]octreotate	
(octreotate)	has	a	ninefold	higher	affinity	for	the	somatostatin	receptor	subtype	2	as	
compared	with	[DOTA0,Tyr3]octreotide.	Also,	labelled	with	the	beta-	and	gamma-
emitting	radionuclide	 177Lu,	 it	has	proved	very	successful	 in	achieving	tumour	
regression	in	animal	models.	The	effects	of	 177Lu-octreotate	therapy	were	studied	
in	35	patients	with	neuroendocrine	gastro-entero-pancreatic	(GEP)	tumours	who	
underwent	follow-up	for	3–6	months	after	receiving	their	final	dose.	Patients	were	
treated	with	doses	of	100,	150	or	200	mCi	177Lu-octreotate,	to	a	final	cumulative	dose	
of	600–	800	mCi,	with	treatment	intervals	of	6–9	weeks.	Nausea	and	vomiting	
within	 the	 first	24	h	after	administration	were	present	 in	30%	and	14%	of	 the	
administrations,	respectively.	WHO	toxicity	grade	3	anaemia,	leucocytopenia	and	
thrombocytopenia	occurred	after	0%,	1%	and	1%	of	the	administrations,	respectively.	
Serum	creatinine	and	creatinine	clearance	did	not	change	significantly.	The	effects	of	
the	therapy	on	tumour	size	were	evaluable	in	34	patients.	Three	months	after	the	final	
administration,	complete	remission	was	found	in	one	patient	(3%),	partial	remission	
in	12	(35%),	stable	disease	in	14	(41%)	and	progressive	disease	in	seven	(21%),	including	
three	patients	who	died	during	the	treatment	period.	Tumour	response	was	positively	
correlated	with	a	high	uptake	on	the	OctreoScan,	limited	hepatic	tumour	mass	and	
a	high	Karnofsky	Performance	Score.	Because	of	the	limited	efficacy	of	alternative	
therapies,	many	physicians	currently	adopt	an	expectant	attitude	when	dealing	with	
patients	with	metastatic	GEP	tumours.	However,	in	view	of	the	high	success	rate	of	
therapy	with	177Lu-octreotate	and	the	absence	of	serious	side-effects,	we	advocate	its	
use	in	patients	with	GEP	tumours	without	waiting	for	tumour	progression.
Abstract INTRODUCTION
Neuroendocrine	 gastro-entero-pancreatic	 (GEP)	 tumours,	which	 comprise	
pancreatic	islet	cell	tumours,	non-functioning	neuroendocrine	pancreatic	tumours	
and	carcinoids,	are	usually	slow	growing.	If	the	tumour	is	localized,	the	therapy	
of	choice	is	surgery.	When	a	metastatic	tumour	causes	a	syndrome	by	hormonal	
overproduction	(i.e.	carcinoid	syndrome,	hypergastrinaemia),	treatment	with	
somatostatin	analogues	results	in	symptomatic	relief	in	most	cases.	In	terms	of	
objective	tumour	reduction	(complete	and	partial	remission),	however,	treatment	
with	somatostatin	analogues	is	seldom	successful,	whether	or	not	it	is	given	in	
combination	with	interferon-α	1-3.	
A	new	development	 in	cyto-reductive	therapy	for	GEP	tumours	 is	 the	use	of	
radiolabelled	somatostatin	analogues.	 Initial	studies	with	high	doses	of	 [111In-
DTPA0]octreotide	 (111In-octreotide;	OctreoScan)	 in	patients	with	metastatic	
neuroendocrine	tumours	were	encouraging,	although	partial	remissions	were	
exceptional	4,	5.	However,	111	In-coupled	peptides	are	not	ideal	for	peptide	receptor	
radionuclide	radiotherapy	(PRRT)	because	of	the	small	particle	range	and	therefore	
short	tissue	penetration.	Therefore,	another	radiolabelled	somatostatin	analogue,	
[90Y-DOTA0,Tyr3]octreotide,	was	developed.	Using	 this	 compound,	partial	
remissions	have	been	reported	in	10–25%	of	patients	with	neuroendocrine	tu-
mours	6-8.
Recently,	it	was	reported	that	the	somatostatin	analogue	[DOTA0,Tyr3]octreotate	
has	a	ninefold	higher	affinity	for	the	somatostatin	receptor	subtype	2	as	compared	
with	[DOTA0,Tyr3]octreotide	9.	Also,	labelled	with	the	beta-	and	gamma-emitting	
radionuclide	177Lu,	this	compound	was	shown	to	be	very	successful	in	achieving	
tumour	regression	and	animal	survival	in	a	rat	model	10.	In	a	comparison	in	patients,	
we	found	that	the	uptake	of	radioactivity,	expressed	as	a	percentage	of	the	injected	
dose	of	[177Lu-DOTA0,Tyr3]octreotate	(177Lu-octreotate),	was	comparable	to	that	after	
111In-octreotide	for	kidneys,	spleen	and	liver,	but	was	three-	to	fourfold	higher	for	
four	of	five	tumours	11.	We	concluded	that	177Lu-octreotate	potentially	represents	
an	important	improvement	because	of	(a)	the	higher	absorbed	doses	that	can	be	
delivered	to	most	tumours	with	about	equal	doses	to	potentially	dose-limiting	
organs	and	(b)	the	lower	tissue	penetration	range	of	 177Lu	as	compared	with	90Y,	
which	may	be	especially	important	for	small	tumours.	
In	this	study	we	present	the	first	data	on	the	side	effects	as	well	as	the	antitumoral	
effects	of	 177Lu-octreotate	therapy	in	35	patients	with	GEP	tumours,	who	had	a	
follow-up	of	3–6	months	after	receiving	their	final	dose.
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MATERIALS AND METHODS
Patients
Thirty-five	patients	with	GEP	tumours	were	studied.	All	patients	had	tumour	uptake	
on	the	OctreoScan	preceding	the	therapy	that	was	at	least	as	high	as	the	uptake	
in	the	normal	liver	tissue.	None	of	the	patients	had	received	prior	treatment	with	
other	radiolabelled	somatostatin	analogues.	Eight	patients	used	Sandostatin	s.c.;	
this	medication	was	discontinued	from	1	day	before	to	1	day	after	the	treatment.	
Prerequisites	for	treatment	were:	Hb	≥6	mmol/l,	WBC	≥2×109/l,	platelets	≥80×109/l,	
creatinine	≤150	µmol/l	and	Karnofsky	Performance	Score	≥50.	
All	patients	gave	written	informed	consent	to	participate	in	the	study,	which	was	
approved	by	the	medical	ethical	committee	of	the	hospital.
Methods 
[DOTA0,Tyr3]octreotate	was	obtained	from	Mallinckrodt,	St	Louis,	Mo.,	USA.	177LuCl3	
was	obtained	from	NRG,	Petten,	the	Netherlands	and	Missouri	University	Research	
Reactor	(MURR),	Missouri,	Mo.,	USA,	and	was	distributed	by	IDB,	Baarle-Nassau,	
the	Netherlands.	177Lu-octreotate	was	prepared	as	described	previously	11.
Granisetron	3	mg	was	injected	i.v.	and	an	infusion	of	amino	acids	(lysine	2.5%,	arginine	
2.5%	in	1	l	0.9%	NaCl;	250	ml/h)	was	started	30	min	before	the	administration	of	
the	radiopharmaceutical	and	lasted	up	to	3.5	h	afterwards.	The	radiopharmaceutical	
was	co-administered	via	a	second	pump	system.	The	treatment	doses	of	100	mCi	
were	injected	in	20	min	and	those	of	150	and	200	mCi	were	injected	in	30	min.	The	
interval	between	treatments	was	6–9	weeks.	Patients	were	treated	up	to	a	cumulative	
dose	of	750–800	mCi	(27.8–29.6	GBq)	(corresponding	to	a	radiation	dose	to	the	
bone	marrow	of	2	Gy)	11,	unless	dosimetric	calculations	indicated	that	the	radiation	
dose	to	the	kidneys	would	then	exceed	23	Gy;	in	these	cases	the	cumulative	dose	
was	reduced	to	600–700	mCi.
Routine	haematology,	liver	and	kidney	function	tests,	hormone	measurements	and	
serum	tumour	markers	were	measured	1	week	prior	to	each	therapy,	as	well	as	at	
follow-up	visits.	EORTC	quality	of	life	forms	(QLQ-C30)	12	were	filled	out	by	the	
patients	at	each	visit.	
CT	or	MRI	scanning	was	done	within	3	months	before	the	first	therapy,	and	6–8	
weeks,	3	months	and	6	months	after	the	last	treatment.
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In vivo measurements
The	tumours	on	the	CT	or	MRI	scans	were	measured	and	scored	according	to	the	
WHO	solid	tumour	response	criteria.	The	uptake	on	the	pretreatment	OctreoScans	
was	scored	visually	on	planar	images	on	a	4-point	scale:	grade	1,	lower	than	normal	
liver	tissue	uptake;	grade	2,	equal	to	normal	liver	tissue	uptake;	grade	3,	greater	than	
normal	liver	tissue	uptake;	grade	4,	higher	than	normal	spleen/kidney	uptake.
Statistics
Analysis	of	variance	(ANOVA),	paired t tests	and	chi-square	tests	were	used.	P	values	
<0.05	were	considered	significant.
RESULTS
The	study	population	comprised	14	men	and	21	women	with	a	mean	age	of	54	years	
(range	19–78	years).	Twelve	had	carcinoid	tumour,	12	neuroendocrine	pancreatic	
tumour,	8	neuroendocrine	tumour	of	unknown	origin	and	3	gastrinoma.	
Figure 1A–C. Planar	scans	of	 the	abdomen,	3	days	after	 the	 injection	of	200	mCi	 177Lu-
octreotate	in	a	patient	with	liver	metastases	of	an	operated	neuroendocrine	pancreatic	tumour.	
A After	the	first	treatment;	B after	the	second	treatment;	C after	the	fourth	treatment.	Note	
the	loss	of	intensity	of	uptake	in	the	liver	lesions	(arrows in	A).	This	sign	virtually	always	
indicates	a	tumour	volume	response.	D, E CT	scans	of	the	same	patient:	before	treatment	(D)	
and	3	months	after	the	last	treatment	(E).	Tumour	(arrows in	D)	is	not	demonstrated	on	E.	
Neither	MRI	nor	OctreoScan	could	demonstrate	definite	tumour	deposits	at	that	time.	
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Twelve	patients	had	been	operated	in	the	past,	1	had	had	radiotherapy,	3	had	had	
chemotherapy	and	14	had	been	treated	with	octreotide	(Sandostatin).	
Sixteen	of	the	35	(46%)	patients	had	documented	progressive	disease	within	1	year	
before	the	start	of	the	therapy.	Cycle	doses	were	100	mCi	in	seven	patients,150	mCi	
in	14	and	200	mCi	in	the	remaining	14.	Higher	dosages	were	not	administered,	since	
200	mCi	 177LuCl3	 is	typically	bound	to	180–300	µg	[DOTA0,Tyr3]octreotate,	and	
higher	doses	would	result	in	a	lower	percentage	tumour	uptake	owing	to	receptor	
saturation.	In	30	patients,	the	final	intended	cumulative	dose	of	600-800	mCi	was	
administered.	Three	of	the	five	remaining	patients	had	progressive	disease	and	died	
before	completing	their	treatment;	the	other	two	patients,	who	were	both	elderly,	
stopped	their	treatment	after	reaching	a	cumulative	dose	of	600	mCi	because	of	the	
burden	they	felt	the	treatment	to	be.
Table 1. Tumour	responses	in	34	patients,	3	months	after	the	final	administration	of	 177Lu-
octreotate.	Three	patients	with	PD	died	before	reaching	their	final	dose.
RESPONSE Total
Tumour	type CR PR SD PD
Carcinoid 4	(33%) 6	(50%) 2	(17%) 12
NE	Pancreas 1	(8%) 1	(8%) 7	(58%) 3	(25%) 12
NE	unknown	origin 4	(57%) 1	(14%) 2	(29%) 7
Gastrinoma 3	(100%) 3
Total	 1	(3%) 12	(35%) 14	(41%) 7	(21%) 34
WHO	toxicity	grade	2	or	3	anaemia	(Hb	4.95–6.2	or	4.0–4.9	mmol/l,	respectively),	
leucocytopenia	(WBC	2.0–2.9	or	1.0–1.9×109/l,	respectively)	and	thrombocytopenia	
(platelets	50–74.9	or	25.0–49.9×109/l,	respectively)	occurred	after	8%	and	0%,	5%	
and	1%,	and	3%	and	1%	of	the	administrations,	respectively.	Toxicity	grade	2	or	3	
leucocytopenia	or	thrombocytopenia	occurred	in	two	out	of	three	(67%)	patients	
who	had	had	previous	chemotherapy,	as	against	seven	out	of	32	(22%)	patients	who	
had	not.	Mean	haematological	parameters	rose	again	during	the	follow-up	after	the	
final	administration.	Serum	creatinine,	creatinine	clearance	and	serum	HbA1c	did	
not	change	significantly	(data	not	shown).	In	patients	without	thyroid	hormone	
medication,	serum	TSH	and	fT4	levels	did	not	change.	In	women,	serum	LH	and	FSH	
concentrations	did	not	change	significantly;	in	men,	serum	testosterone	decreased	
and	serum	LH	concentrations	increased	significantly.	Also	inhibin-B	concentrations	
decreased	and	serum	FSH	levels	increased	significantly.	
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Figure 2. A, B	MRI	scans	 in	a	woman	with	hepatic	metastases	of	a	gastrinoma.	Before	
treatment	(A)	she	was	inoperable	because	of	the	size	and	localization	of	the	metastases.	Three	
months	after	completion	of	her	treatment	with	800	mCi	177Lu-octreotate	she	had	a	PR	(B).	Note	
also	that	the	hypertrophy	of	the	gastric	wall	(arrow in	A)	had	diminished.	Concomitantly,	
serum	concentrations	of	gastrin	(closed dots)	and	chromogranin-A	(open dots)	had	decreased	
markedly	(C).	At	6	months	the	MRI	showed	no	further	regression.	The	patient	underwent	left	
partial	hepatectomy	and	the	two	right-sided	lesions	were	drained	and	injected	with	alcohol.	
MRI	3	months	after	surgery	showed	further	regression	of	the	right-sided	lesions.
The	effects	of	the	therapy	on	tumour	size	were	evaluable	 in	34	patients.	Three	
months	after	the	final	administration	(on	average	9	months	from	the	start	of	the	
treatment),	a	complete	remission	(CR),	evaluated	with	CT	scanning,	MRI	and	
somatostatin	receptor	imaging,	was	found	in	one	patient	(3%),	partial	remission	(PR)	
in	12	(35%),	stable	disease	(SD)	in	14	(41%)	and	progressive	disease	(PD)	in	7	(21%),	
including	the	three	patients	who	died	during	the	treatment	period	(Table	1)	(Figs.	
1,	2).	Follow-up	evaluation	6	months	after	the	final	therapy	was	available	for	19	of	
the	34	patients.	All	seven	patients	who	had	PR	after	3	months	still	had	PR	after	6	
months;	in	10	of	the	12	patients	with	SD,	the	evaluation	was	unchanged,	whereas	
one	had	a	minimal	response	(MR)	and	one	had	PD.
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Tumour	response	(CR	or	PR)	was	significantly	more	frequent	in	patients	whose	
tumours	had	a	high	uptake	on	the	OctreoScan	[6/7	(86%)	with	grade	4	uptake	vs.	7/27	
(26%)	with	grade	2	or	3	uptake;	chi-square	test:	P<0.05].	Five	out	of	the	seven	patients	
(71%)	with	PD	had	hepatomegaly	and	diffuse	liver	metastases	vs	6	out	of	27	(22%)	
with	CR,	PR	or	SD	(chi-square	test:	P<0.05).	Tumour	response	was	more	frequent	
in	patients	with	documented	PD	within	1	year	before	the	start	of	the	treatment	
(8/15;	53%)	than	in	those	without	(5/19;	26%),	although	this	difference	was	not	
statistically	significant	(P=0.11;	chi-square	test).	Of	the	15	patients	with	documented	
PD	before	the	start	of	the	treatment,	3	(20%)	had	SD	at	follow-up.	Patients	who	had	
a	Karnofsky	Performance	Score	of	less	than	80	before	the	treatment	more	frequently	
had	PD	(5/8;	63%)	than	those	who	had	higher	scores	(2/26;	8%)	(P<0.01;	chi-square	
test).
The	serum	tumour	marker	chromogranin-A	was	elevated	in	29	patients.	During	
the	treatment	and	follow-up,	there	was	a	clear	decrease	in	serum	chromogranin-
A	concentrations	in	patients	with	PR	or	CR,	whereas	these	concentrations	were	
virtually	unchanged	in	patients	with	SD,	and	initially	showed	an	increase	in	patients	
with	PD	(Fig.	3).	
The	patient-assessed	quality	of	life,	according	to	the	EORTC-QLQ30	questionnaire,	
was	evaluated	in	25	patients.	Ten	patients	were	excluded	because	of	progressive	
disease/death	(n=5)	or	missing	forms	during	the	follow-up	period	(n=5,	foreign	
patients).	Scores	before	the	start	of	the	treatment,	after	receiving	400–600	mCi	
177Lu-octreotate	and	at	follow-up	3	months	after	the	final	treatment	were	evaluated.	
There	were	no	significant	differences	for	functional	scales	or	single	symptom	scales.	
The	global	health	scale,	on	which	patients	were	asked	to	assign	marks	regarding	both	
their	general	health	and	their	quality	of	life,	and	which	ranged	from	0	to	100,	was	
judged	as	higher	than	70	by	nine	patients	(36%)	before	the	start	of	the	treatment,	by	
17	(68%)	patients	during	the	treatment	and	by	16	(64%)	patients	after	the	treatment	
(P<0.05;	chi-square	test).
DISCUSSION
There	are	few	treatment	options	for	metastatic	GEP	tumours.	The	use	of	radiolabelled	
somatostatin	analogues	for	tumour	regression	is	a	promising	new	development.	
With	 [90Y-DOTA0,Tyr3]octreotide,	PR	(or	CR)	has	been	reported	 in	 10–25%	of	
patients	with	neuroendocrine	tumours	6-8.	In	the	present	study	we	found	objective	
tumour	shrinkage	in	38%	of	the	patients,	but	PD	before	the	start	of	the	treatment	
was	documented	in	only	46%	of	the	patients.	This	last	fact	is	important,	because	
documented	PD	was	present	in	more	than	80%	of	patients	in	two	of	the	reported	
series	 treated	with	 [90Y-DOTA0,	Tyr3]octreotide	 6,	8.	As	with	chemotherapy,	an	
objective	tumour	response	after	PRRT	is	more	likely	in	patients	with	(fast)	growing	
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tumours.	Indeed,	in	our	series	we	also	found	a	trend	towards	a	more	favourable	
treatment	outcome	in	patients	with	documented	PD	before	the	start	of	the	treatment.	
It	may	therefore	be	concluded	that	the	percentage	of	patients	with	significant	tumour	
shrinkage	in	our	study	might	have	been	even	higher	had	the	percentage	of	patients	
with	PD	prior	to	treatment	been	comparable	to	that	in	studies	with	[90Y-DOTA0,	
Tyr3]octreotide.	The	side-effects	of	treatment	with	 177Lu-octreotate	are	few	and	
mostly	transient,	with	mild	bone	marrow	depression	as	the	most	common	finding.	
Neither	renal	nor	pituitary	function	deteriorated	in	any	of	our	patients.	Other	side-
effects	can	be	ascribed	to	the	radiation	dose	to	the	testes	in	men.	This	dose	leads	to	
significantly	lower	serum	testosterone	and	inhibin-B	levels	which	in	turn	give	rise	to	
higher	serum	LH	and	FSH	concentrations,	thereby	substantiating	that	the	pituitary	
function	is	unimpaired.	
The	patient-assessed	global	health	score	improved	in	30%	of	patients	during	the	
treatment	and	the	follow-up	period.	This	is	an	important	finding	which	reflects	
the	improvement	in	patient	well-being	and	stresses	the	scarcity	of	side-effects	as	
perceived	by	patients.	The	fact	that	other	scores	mainly	addressing	symptoms	did	
not	change	significantly	is	likely	due	to	the	diversity	of	symptoms	between	patients,	
the	use	of	Sandostatin	by	symptomatic	patients	and	the	small	size	of	the	patient	
group.	
Figure 3. Serum	chromogranin-A	concentrations	during	and	after	therapy	in	patients	with	
PR,	SD	or	PD.	The	reduction	in	the	number	of	patients	during	the	course	of	the	follow-up	
was	due	to	death	or	missing	values.	Note	the	logarithmic	y-axis.
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Many	physicians	adopt	an	expectant	attitude	when	dealing	with	patients	with	
metastatic	GEP	tumours	owing	to	the	low	success	rates	of	chemotherapy	protocols.	
However,	given	that	treatment	with	177Lu-octreotate	resulted	in	PR	(or	CR)	in	38%	
of	our	patients,	this	attitude	may	be	questioned.	Although	there	was	a	(statistically	
non-significant)	tendency	towards	more	frequent	tumour	regression	in	patients	
who	had	documented	PD	before	the	start	of	the	treatment,	those	of	our	patients	
who	had	an	objective	tumour	response	more	frequently	had	a	limited	tumour	load.	
This	implies	that	waiting	for	tumour	progression	might	place	patients	in	a	worse	
position,	as	PD	during	or	after	treatment	was	more	frequent	in	patients	with	an	
extensive	tumour	load,	especially	in	the	liver.	We	therefore	advocate	treatment	with	
177Lu-octreotate	at	an	earlier	stage	of	metastatic	disease,	when	even	CR	may	be	
possible.	Another	argument	in	favour	of	early	treatment	is	that	neuroendocrine	
tumours	can	dedifferentiate	in	the	course	of	the	disease,	and	lose	their	somatostatin	
receptors,	making	treatment	with	radiolabelled	somatostatin	analogues	impossible.	
If	serious	side-effects	of	treatment	with	177Lu-octreotate	remain	absent	during	longer	
patient	follow-up,	such	treatment	could	also	be	considered	in	an	adjuvant	setting	in	
patients	with	neuroendocrine	tumours	who	are	operated	on	with	curative	intent.	
Lastly,	as	it	has	been	shown	in	animal	experiments	that	90Y-labelled	somatostatin	
analogues	are	more	effective	for	 larger	tumours	and	 177Lu-labelled	somatostatin	
analogues	are	more	effective	for	smaller	tumours	 13,	14,	combination	therapy	with	
90Y-labelled	and	177Lu-labelled	octreotate	may	be	tried	in	the	near	future.	Such	therapy	
might	yield	even	better	results	than	treatment	with	either	of	the	radionuclides	
alone	15.
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Abstract
Purpose
There	are	 few	treatment	options	 for	patients	with	metastasized	or	 inoperable	
endocrine	gastroenteropancreatic	(GEP)	tumors.	Chemotherapy	can	be	effective,	but	
the	response	is	usually	less	than	1	year.	Here,	we	present	the	results	of	treatment	with	a	
radiolabeled	somatostatin	analog,	[177Lu-DOTA0,Tyr3]octreotate	(177Lu-octreotate).	
Patients and methods
One	hundred	thirty-one	patients	with	somatostatin	receptor-positive	 tumors	
were	treated	with	up	to	a	cumulative	dose	of	600	to	800	mCi	(22.2	to	29.6	GBq)	of	
177Lu-octreotate.
Results
One	patient	developed	renal	insufficiency,	and	another	patient	developed	hepatorenal	
syndrome.	Creatinine	clearance	did	not	change	significantly	in	the	other	patients.	
WHO	hematologic	 toxicity	 grade	 3	 or	 4	 occurred	 after	 less	 than	 2%	 of	 the	
administrations.	We	observed	complete	remission	in	three	patients	(2%),	partial	
remission	in	32	patients	(26%),	minor	response	(tumor	diameter	decrease	of	25%	to	
50%)	in	24	patients	(19%),	stable	disease	(SD)	in	44	patients	(35%),	and	progressive	
disease	(PD)	in	22	patients	(18%).	Higher	remission	rates	were	positively	correlated	
with	high	uptake	on	pretherapy	somatostatin	receptor	imaging	and	a	limited	number	
of	liver	metastases,	whereas	PD	was	significantly	more	frequent	in	patients	with	a	
low	performance	score	and	extensive	disease.	Median	time	to	progression	in	103	
patients	who	either	had	SD	or	tumor	regression	was	more	than	36	months.	
Conclusion
Treatment	with	 177Lu-octreotate	results	in	tumor	remission	in	a	high	percentage	
of	patients	with	GEP	tumors.	Serious	side	effects	are	rare.	The	median	time	to	
progression	compares	favorably	with	chemotherapy.	Results	are	better	in	patients	
with	a	limited	tumor	load.	Therefore,	early	treatment,	even	in	patients	who	have	no	
PD,	may	be	better.	
Abstract INTRODUCTION
Endocrine	gastroenteropancreatic	(GEP)	tumors,	which	comprise	pancreatic	islet-cell	
tumors,	nonfunctioning	endocrine	pancreatic	tumors,	and	carcinoids,	are	usually	
slow	growing.	When	metastasized,	treatment	with	somatostatin	analogs	results	in	
reduced	hormonal	overproduction	and	symptomatic	relief	in	most	cases.	However,	
treatment	with	somatostatin	analogs	is	seldom	successful	in	terms	of	tumor	size	
reduction	1-3.	
A	new	treatment	modality	for	inoperable	or	metastasized	endocrine	GEP	tumors	
is	the	use	of	radiolabeled	somatostatin	analogs.	The	majority	of	endocrine	GEP	
tumors	possess	somatostatin	receptors	and	can,	therefore,	be	visualized	using	the	
radiolabeled	somatostatin	analog	[111In-DTPA0]octreotide	(OctreoScan;	Mallinckrodt,	
St	Louis,	MO).	Therefore,	a	logical	sequence	to	this	tumor	visualization	in	patients	
was	to	also	try	to	treat	these	patients	with	radiolabeled	somatostatin	analogs.	Initial	
studies	with	high	dosages	of	[111In-DTPA0]octreotide	in	patients	with	metastasized	
neuroendocrine	tumors	were	encouraging,	although	partial	remissions	(PRs)	were	
exceptional	4,5.	This	is	not	surprising	because	111In-coupled	peptides	are	not	ideal	for	
peptide	receptor	radionuclide	radiotherapy	(PRRT)	because	of	the	small	particle	
range	and,	therefore,	short	tissue	penetration	of	the	Auger	electrons.	
Another 	 r ad iolabeled 	 somatost at in 	 analog 	 that 	 i s 	 u sed 	 for 	 PRRT 	 i s	
[90Y-DOTA0,Tyr3]octreotide.	Several	phase	I	and	II	PRRT	trials	have	been	performed	
using	this	compound.	Complete	remissions	(CRs)	and	PRs	have	been	reported	in	7%	
to	33%	of	patients	with	neuroendocrine	tumors	6-11.
The	somatostatin	analog	[DOTA0,Tyr3]octreotate	has	a	nine-fold	higher	affinity	for	
the	somatostatin	receptor	subtype	2	compared	with	[DOTA0,Tyr3]octreotide	in	vitro12.	
Also,	labeled	with	the	beta-	and	gamma-emitting	radionuclide	177Lu,	this	compound	
was	shown	to	be	successful	in	terms	of	tumor	regression	and	animal	survival	in	a	
rat	model	13.	In	a	comparison	in	patients,	we	found	that	the	uptake	of	radioactivity,	
expressed	 as	percentage	of	the	 injected	dose	of	 [177Lu-DOTA0,Tyr3]octreotate	
(177Lu-octreotate),	was	comparable	to	that	after	[111In-DTPA0]octreotide	for	kidneys,	
spleen,	and	liver	but	was	three-	to	four-fold	higher	for	four	of	five	tumors	 14.	 In	
a	preliminary	report	on	the	results	of	this	treatment	in	the	first	35	patients	with	
endocrine	GEP	tumors	15,	we	found	CRs	and	PRs	in	38%	of	the	patients.	No	serious	side	
effects	were	observed.	Here,	we	present	the	results	of	treatment	with	177Lu-octreotate	
in	a	large	series	of	patients	with	endocrine	GEP	tumors.	Also,	we	analyzed	whether	
certain	patient	or	tumor-related	factors	predict	a	favorable	treatment	response	or	
predict	the	duration	of	such	a	response.	
2.2
106
PATIENTS AND METHODS
Patients
One	hundred	thirty-one	patients	with	endocrine	GEP	tumors	were	studied.	All	
patients	had	 tumor	 tissue	uptake	during	 [111In-DTPA0]octreotide	scintigraphy	
preceding	the	therapy	that	was	at	least	as	high	as	the	uptake	in	the	normal	liver	
tissue.	None	of	the	patients	had	received	prior	treatment	with	other	radiolabeled	
somatostatin	analogs.	Four	patients	had	previously	been	treated	with	embolization,	
and	one	patient	was	treated	with	chemoembolization	for	liver	metastases.	Prerequisites	
for	treatment	were	hemoglobin	(Hb)	≥	6	mmol/L,	WBC	≥	2	x	109/L,	platelets	≥	
80	x	109/L,	creatinine	≤	150	µmol/L	or	creatinine	clearance	≥	40	mL/min,	and	
Karnofsky	performance	score	(KPS)	≥	50.	The	preliminary	results	in	35	patients	were	
also	reported	previously	elsewhere	15.	All	patients	gave	written	informed	consent	to	
participate	in	the	study,	which	was	approved	by	the	medical	ethical	committee	of	
the	hospital.	
Methods
[DOTA0,Tyr3]octreotate	was	obtained	from	Mallinckrodt	(St	Louis,	MO).	 177LuCl3	
was	obtained	 from	NRG	 (Petten,	 the	Netherlands)	and	Missouri	University	
Research	Reactor	(Columbia,	MO)	and	was	distributed	by	IDB	(Baarle-Nassau,	the	
Netherlands).	177Lu-octreotate	was	locally	prepared	as	described	previously	14.
Granisetron	3	mg	was	injected	intravenously,	and	an	infusion	of	amino	acids	(lysine	
2.5%	and	arginine	2.5%	in	1	L	0.9%	NaCl;	250	mL/h)	was	started	30	minutes	before	
the	administration	of	the	radiopharmaceutical	and	lasted	4	hours.	Via	a	second	pump	
system,	the	radiopharmaceutical	was	coadministered.	Cycle	dosages	were	100	mCi	
(3.7	GBq)	in	seven	patients,	150	mCi	(5.6	GBq)	in	16	patients,	and	200	mCi	(7.4	GBq)	
in	the	remaining	108	patients.	The	treatment	doses	of	100	mCi	were	injected	in	20	
minutes,	and	the	doses	of	150	and	200	mCi	were	injected	in	30	minutes.	The	interval	
between	treatments	was	6	to	10	weeks.	Patients	were	treated	up	to	a	cumulative	dose	
of	750	to	800	mCi	(27.8	to	29.6	GBq;	corresponding	with	a	radiation	dose	to	the	
bone	marrow	of	2	Gy)	14,	unless	dosimetric	calculations	indicated	that	the	radiation	
dose	to	the	kidneys	would	then	exceed	23	Gy;	in	these	cases,	the	cumulative	dose	
was	reduced	to	600	to	700	mCi.	
Routine	hematology,	liver	and	kidney	function	tests,	and	hormone	measurements	
were	performed	before	each	 therapy,	as	well	as	at	 follow-up	visits.	Computed	
tomography	(CT)	or	magnetic	resonance	imaging	was	performed	within	3	months	
before	the	first	therapy,	and	6	to	8	weeks,	3	months,	and	6	months	after	the	last	
treatment,	and	thereafter	every	6	months.	
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In Vivo Measurements
The	 tumors	on	CT	or	magnetic	 resonance	 imaging	were	measured	and	scored	
according	to	the	Southwest	Oncology	Group	solid	tumor	response	criteria	 16.	The	
uptake	during	pretreatment	[111In-DTPA0]octreotide	scintigraphy	was	scored	visually	
on	planar	images	using	the	following	4-point	scale:	lower	than	(grade	1),	equal	to	
(grade	2),	or	greater	than	(grade	3)	normal	liver	tissue;	or	higher	than	normal	spleen	
or	kidney	uptake	(grade	4).
Statistics
Analysis	of	variance,	paired	t	tests,	χ2	tests	(or,	if	applicable,	Fisher’s	exact	tests),	
Pearson’s	correlation	tests,	and	logistic	regression	were	used.	For	survival	analysis,	
log-rank	tests	and	Cox	regression	models	were	used.	
RESULTS
One	hundred	thirty-one	patients	with	metastasized	or	inoperable	endocrine	GEP	
tumors	were	treated	between	January	2000	and	September	2003.	Two	patients	
were	lost	to	follow-up;	in	all	of	the	other	129	patients,	follow-up	data	for	at	least	
3	months	after	the	last	therapy	were	available.	There	were	66	women	and	65	men;	
the	mean	age	was	56	years	(range,	19	to	83	years).	Eight	patients	had	gastrinoma,	
two	had	insulinoma,	33	had	nonfunctioning	endocrine	pancreatic	tumors,	18	had	
endocrine	tumors	of	unknown	origin,	and	70	had	carcinoid	tumors	(one	thymic,	
one	gastric,	four	bronchial,	and	64	small	bowel	carcinoids).	In	18	patients,	the	liver	
was	the	only	known	site	of	tumor	spread;	in	two	patients,	this	was	the	skeleton;	
and	in	11	other	patients,	sites	such	as	lymph	nodes	or	pancreas	were	the	sole	known	
tumor	sites.	In	the	remaining	100	patients,	combinations	of	these	tumor	sites	were	
present	(Figure	1).
Sixty-three	patients	had	previously	been	operated	on,	seven	had	had	external-beam	
radiation,	20	had	been	treated	with	chemotherapy,	and	66	had	used	somatostatin	
analogs	(usually	Sandostatin;	Novartis,	Basel,	Switzerland).	Fifty-two	patients	used	
somatostatin	analogs	in	between	treatments.	In	all	but	three	patients,	short-acting	
somatostatin	analogs	were	stopped	at	least	1	day	before	the	treatment,	and	long-
acting	somatostatin	analogs	were	stopped	at	least	6	weeks	before	the	treatment.	In	
three	patients	with	severe	symptoms	of	carcinoid	syndrome,	the	administration	
of	somatostatin	analogs	was	not	stopped;	in	these	three	patients,	a	pretreatment	
OctreoScan	during	continued	somatostatin	analog	treatment	had	shown	sufficient	
uptake	of	the	radiolabeled	analog	in	the	tumor	sites.	Fifty-five	(42%)	of	the	131	patients	
had	documented	progressive	disease	(PD)	within	1	year	before	the	start	of	the	therapy,	
37	patients	(28%)	had	stable	disease	(SD),	and	in	39	patients	(30%),	information	on	
disease	progression	was	absent.
2.2
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Figure 1. The	distribution	of	known	tumor	sites	in	131	patients.	Venn	diagram	is	shown	in	
which	circle	diameters	are	proportional	to	total	numbers	of	patients	with	certain	localizations.	
Overlapping	areas	represent	patients	with	lesions	in	both	categories.
Treatment	intervals	were	6	to	10	weeks,	except	in	four	patients	who	had	persistent	
thrombocytopenia	and	in	13	other	patients	because	of	reasons	unrelated	to	the	
treatment.	In	116	patients,	the	final	intended	cumulative	dose	of	600	to	800	mCi	was	
administered.	Ten	of	the	15	remaining	patients	died	of	PD	before	completing	their	
treatment;	two	elderly	patients	stopped	treatment	after	having	received	600	mCi	
because	they	felt	the	treatment	was	too	tiring;	one	patient	stopped	early	because	of	
developing	kidney	failure;	one	patient	stopped	early	because	a	colorectal	carcinoma	
was	diagnosed;	and	one	patient	stopped	early	because	of	social	reasons.
Nausea	and	vomiting	(WHO	toxicity	grade	1	to	2)	within	the	first	24	hours	after	the	
administration	were	present	in	31%	and	14%	of	the	administrations,	respectively.	
Mild	abdominal	pain	was	noticed	by	12%	of	the	patients,	especially	those	with	liver	
enlargement.	Increased	hair	loss	(WHO	toxicity	grade	1)	was	noticed	by	64%	of	the	
patients;	hair	regrowth	occurred	within	3	months	after	the	last	administration.	
Serious	side	effects	occurred	in	two	patients.	One	patient	in	whom,	in	the	year	
preceding	the	therapy,	serum	creatinine	concentrations	had	risen	from	60	to	70	
µmol/L	to	90	to	 100	µmol/L	and	who	had	a	urinary	creatinine	clearance	of	41	
mL/min	when	entering	the	study	eventually	developed	renal	insufficiency	1.5	years	
after	receiving	her	last	treatment	(cumulative	dose,	600	mCi).	A	kidney	biopsy	
demonstrated	tubular	depositions	and	microangiopathy.	Eventually,	the	patient	
refrained	from	hemodialysis	and	died	shortly	thereafter.	In	another	patient	who	
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2.2
had	diffuse	liver	metastases	from	an	endocrine	pancreatic	tumor	that	had	grown	
rapidly	in	the	months	preceding	the	therapy,	an	increase	in	upper	abdominal	pain	
and	a	deterioration	of	liver	functions	occurred	in	the	days	and	weeks	after	the	first	
administration.	The	patient	developed	hepatorenal	 syndrome	and	died	after	5	
weeks.	
WHO	toxicity	grade	3	or	4	anemia	(Hb,	4.0	to	4.9	or	<	4.0	mmol/L,	respectively),	
leukocytopenia	(WBC,	1.0	to	1.9	or	<	1.0	x	109/L,	respectively),	and	thrombocytopenia	
(platelets,	25.0	to	49.9	or	<	25	x	109/L,	respectively)	occurred	after	0.4%	and	0.0%,	1.3%	
and	0.0%,	and	1.5%	and	0.2%	of	the	administrations,	respectively.	Patients	who	had	
been	treated	with	chemotherapy	had	significantly	more	frequent	thrombocytopenia	
toxicity	grade	2,	whereas	patients	older	than	70	years	had	a	significantly	higher	
frequency	of	WHO	toxicity	grade	2	leukocytopenia,	especially	neutropenia	(Fisher’s	
exact	test,	P	<	.01).	Mean	Hb,	leukocytes,	and	platelets	decreased	significantly	during	
treatment	but	were	not	significantly	different	from	pretreatment	values	18	to	24	
months	after	the	last	therapy	(Figure	2).
	
Figure 2.	Mean	(±	SEM)	serum	hemoglobin	(Hb;	closed	circles,	solid	line),	WBC	(closed	
squares,	solid	line),	and	platelets	(open	circles,	dotted	line)	during	and	after	therapy	with	
[177Lu-DOTA0,Tyr3]octreotate.
Serum	creatinine,	creatinine	clearance,	and	serum	HbA1c	did	not	change	significantly.	
Excluding	five	patients	who	were	hypothyroid	before	the	treatment	and	in	whom,	
subsequently,	replacement	therapy	was	started	and	also	excluding	another	six	patients	
who	already	used	thyroid	medication,	serum	thyrotropin	levels	did	not	change	
significantly	during	or	after	treatment,	whereas	free	thyroxine	concentrations	were	
significantly	lower	(mean,	18.3	pmol/L	before	therapy;	and	15.5	to	17.5	pmol/L	3	to	
24	months	after	therapy).	
110
In	women,	serum	luteinizing	hormone	(LH),	follicle-stimulating	hormone	(FSH),	
estradiol,	 and	 inhibin-B	concentrations	did	not	change	 significantly.	 In	men,	
serum	testosterone	concentrations	decreased	significantly	in	the	follow-up	period	
(from	a	mean	of	14.4	nmol/L	before	treatment	to	10.4	nmol/L	24	months	after	
the	last	treatment;	P	<	 .01,	analysis	of	variance,	Bonferroni	tests),	whereas	serum	
LH	concentrations	did	not	change	significantly.	Serum	inhibin-B	concentrations	
decreased	significantly	(from	a	mean	of	179	ng/L	before	treatment	to	a	nadir	of	23	ng/L	
3	months	after	the	last	treatment)	accompanied	by	a	rise	in	serum	FSH	concentrations,	
but	both	returned	to	values	not	significantly	different	from	pretreatment	levels	18	
to	24	months	after	the	last	treatment	(Figure	3).	
Figure 3.	Mean	(±	SEM)	serum	inhibin-B	(squares,	dotted	line)	and	follicle-stimulating	
hormone	(FSH;	circles,	solid	line)	concentrations	in	men	during	and	after	therapy	with	[177Lu-
DOTA0,Tyr3]octreotate.
Tumor	size	could	be	evaluated	in	125	patients	(two	patients	were	lost	to	follow-up,	
and	in	four	patients,	no	measurable	disease	was	documented).	A	CR	was	found	in	
three	patients	(2%),	PR	was	found	in	32	patients	(26%),	minor	response	(MR)	was	
found	in	24	patients	(19%),	SD	was	found	in	44	patients	(35%),	and	PD	was	found	in	
22	patients	(18%),	including	the	10	patients	who	died	before	the	intended	cumulative	
dose	was	reached	(Table	1;	Figure	4).
Higher	remission	rates	were	positively	correlated	with	high	uptake	during	pretherapy	
[111In-DTPA0]octreotide	scintigraphy	and	a	 limited	number	of	 liver	metastases,	
whereas	PD	was	significantly	more	frequent	in	patients	with	a	low	KPS	and	extensive	
disease	(logistic	regression,	Table	2,	Figures	5	and	6).	A	high	tumor	uptake	during	
[111In-DTPA0]octreotide	scintigraphy	and	gastrinoma	tumor	type	were	significantly	
correlated;	also,	a	low	KPS	and	weight	loss	and	extensive	liver	involvement	were	
also	significantly	correlated	(Pearson’s	correlation	test,	P	<	.05).	
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Table 1. Tumor	 responses	 in	 125	 patients	 3	months	 after	 the	 last	 administration	 of	
177Lu-octreotate
CR PR MR SD PD
Tumor Type
No. of 
patients
%
No. of 
patients
%
No. of 
patients
%
No. of 
patients
%
No. Of 
patients
%
Total 
patients 
(No.)
Carcinoid - - 13 20 13 20 28 42 12 18 66
NE	pancreas 3 9 7 22 7 22 11 34 4 13 32
NE	unknown	
origin
- - 6 35 2 12 4 24 5 29 17
Gastrinoma - - 5 63 2 25 1 12 - - 8
Insulinoma - - 1 50 - - - - 1 50 2
Total 3 2 32 26 24 19 44 35 22 18 125
NOTE. Ten patients with PD died before reaching their final dose.
Abbreviations: CR, complete remission; PR, partial remission; MR, minor response; SD, stable disease; PD, 
progressive disease; NE, neuroendocrine; 177Lu-octreotate, [177Lu-DOTA0,Tyr3]octreotate.
	
Figure 4. Computed	tomography	scans	in	a	patient	with	a	metastasized	nonfunctioning	
endocrine	pancreatic	tumor	before	treatment	(left)	and	3	months	after	the	last	treatment	
(right).	Notice	the	decrease	in	number	of	cystic	liver	lesions	and	the	decrease	in	total	liver	
size.	The	patient	had	a	minor	response.
On	the	posttherapy	scans	after	the	third	or	fourth	treatment,	if	compared	with	the	
scan	after	the	first	treatment,	a	reduced	tumor	uptake	was	frequently	seen	in	patients	
who	eventually	experienced	a	tumor	regression	(Figures	7	and	8).
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Table 2.	Results	of	the	analysis	of	factors	that	may	predict	the	chances	of	tumor	regression	
or	progression,	tested	with	χ2	tests	and	logistic	regression	for	multivariate	analysis	
Remission PD
Factor No. Patients No. % P (χ2) P (logistic) No. % P (χ2) P (logistic)
[111In-DTPA0]octreotide scintigraphy uptake
				≈	Liver 4 1 25 .008 .002 0 0 NS NS
				>	Liver 97 40 41 21 22
				>>	Liver 24 18 75 1 4
Tumor type
				Gastrinoma 8 7 88 .018 NS 0 0 NS NS
				Other 117 52 44 22 19
Tumor mass
				Limited 21 14 67 NS NS 0 0 .045 .028
				Moderate 78 35 45 15 19
				Extensive 26 10 38 7 27
Liver metastases
				None/moderate 91 48 53 .042 .017 11 12 .008 NS
				Extensive 34 11 32 11 32
Bone metastases
				Absent 94 48 51 NS NS 15 16 NS NS
				Present 31 11 36 7 23
Weight loss
				Absent 103 50 49 NS NS 12 12 .000 NS
				Present 22 9 41 10 46
KPS
				>	70 104 53 51 NS NS 10 10 .000 .000
				≤	70 21 6 29 12 57
Progressive at baseline
				No 34 16 47 NS NS 4 12 NS NS
				Yes 53 26 49 13 25
NOTE: Remission includes CR, PR, and MR. All tumor characteristics listed in the first column pertain to 
baseline observations. Tumor mass was judged on [111In-DTPA0]octreotide scintigrams, and liver involvement 
was judged on CT/MRI. Weight loss was scored positive if it at least amounted to 1 kg per month, existing 
for at least 3 months. 
Abbreviations: PD, progressive disease; ≈, Liver, approximately equal to liver uptake; > Liver, more than liver 
uptake; >> Liver, very high uptake; KPS, Karnofsky performance score; NS, not significant; CR, complete 
remission; PR, partial remission; MR, minor response; CT, computed tomography; MRI, magnetic resonance 
imaging. 
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Figure 5. Analysis	of	factors	that	may	predict	tumor	remission	(minor	response,	partial	
remission,	or	complete	remission).	(*)	P <	.05;	(**)	P <	.01,	logistic	regression.	KPS,	
Karnofsky	performance	score.
Median	follow-up	time	in	the	103	patients	who	had	either	SD	or	tumor	regression	
was	16	months	(range,	7	to	44	months).	Median	time	to	progression	was	more	than	
36	months;	in	the	eight	patients	who	had	gastrinoma,	median	time	to	progression	
was	20	months	(P <	.01,	log-rank	test;	Fig	9).	Also,	in	patients	with	extensive	liver	
involvement,	the	median	time	to	progression	was	significantly	shorter	at	26	months	
(P <	 .05,	log-rank	test).	Neither	initial	tumor	response	nor	any	other	of	the	factors	
listed	in	Table	2	were	significant	in	predicting	the	time	to	progression	when	tested	
separately.
Figure 6. Analysis	of	factors	that	may	predict	tumor	progression	(progressive	disease).	(*)	
P <	.05;	(**)	P <	.01,	logistic	regression.	KPS,	Karnofsky	performance	score.
2.2
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Figure 7. Posttherapy	scans	after	200	mCi	of	[177Lu-DOTA0,Tyr3]octreotate	(first	to	last	therapy,	
left	to	right)	in	a	patient	with	gastrinoma	who	eventually	had	partial	remission.	Notice	the	
decreasing	uptake	in	the	liver	metastases.
In	a	multivariate	model,	however,	gastrinoma	tumor	type	and	the	presence	of	bone	
metastases	were	the	factors	that	indicated	a	significantly	shorter	time	to	progression	
(Cox	regression,	P <	.004	and	P <	.037,	respectively).	
Figure 8. The	uptake	in	tumor	sites	after	the	last	(third	or	fourth)	therapy,	expressed	as	
percentage	of	the	uptake	after	the	first	treatment,	according	to	treatment	outcome	(x-axis).	
Boxes	show	medians	and	25th	to	75th	percentiles;	whiskers	indicate	ranges.	PD,	progressive	
disease;	SD,	stable	disease;	MR,	minor	response;	PR,	partial	response.
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DISCUSSION 
In	this	study	in	a	large	number	of	patients	with	endocrine	GEP	tumors	who	were	
treated	with	177Lu-octreotate,	we	found	a	favorable	effect	on	tumor	size	(MR,	PR,	
or	CR)	 in	47%	of	patients.	Serious	side	effects	 that	were	potentially	 treatment	
related	were	found	in	only	two	patients.	Renal	insufficiency	occurred	in	one	of	our	
patients.	
It	has	also	been	reported	in	patients	who	were	treated	with	[90Y-DOTA0,	Tyr3]oct-
reotide,	especially	 if	no	amino	acids	were	coadministered	to	reduce	the	kidney	
radiation	dose	 7,10,17.	Therefore,	our	protocol,	which	used	amino	acid	coinfusion	
and	limited	the	estimated	cumulative	dose	to	the	kidneys	to	23	Gy	or	less,	seems	
adequate	in	reducing	the	chances	of	therapy-related	kidney	failure.	One	patient	who	
had	extensive	and	diffuse	liver	metastases	developed	lethal	hepatic	failure.	This	
grave	complication,	which	was	probably	a	result	of	a	much	higher	radiation	dose	to	
the	relatively	limited	number	of	viable	hepatocytes	than	in	patients	with	a	limited	
tumor	burden	in	the	liver,	has	also	been	reported	in	three	patients	who	were	treated	
with	[111In-DTPA0]octreotide	5	and	one	patient	who	was	treated	with	[90Y-DOTA0,	
Tyr3]octreotide	10,	all	of	whom	also	had	extensive	liver	disease.	Therefore,	in	such	
patients,	extra	caution,	in	terms	of	additional	testing	for	liver-synthesizing	capacity	
and,	if	necessary,	lowering	the	cycle	dose,	seems	well	advised.	
Figure 9. Progression-free	period	in	patients	with	gastrinoma	(dotted	line)	and	patients	
with	other	tumors	(solid	line).	The	time	to	progression	was	significantly	shorter	in	the	eight	
patients	with	gastrinomas.
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In	previous	studies	with	111In-	and	90Y-labeled	somatostatin	analogs,	myelodysplastic	
syndrome	and	leukemia	have	been	reported	as	infrequent	side	effects,	especially	in	
patients	treated	with	high	cumulative	doses	4,10.	In	the	present	study,	none	of	the	
patients	had	this	grave	complication,	and	this	is	probably	because	of	the	fact	that	
we	limited	our	maximum	cumulative	dose	to	a	relatively	safe	upper	value,	which	
corresponds	to	a	bone	marrow	radiation	absorbed	dose	of	2	Gy.	
Transient	and	relatively	mild	bone	marrow	suppression	was	found	in	a	minority	
of	patients	and	in	a	lower	percentage	than	reported	in	most	studies	with	111In-	and	
90Y-labeled	somatostatin	analogs	4,5,9,10,17.	Transient	hair	loss,	but	no	turning	bold,	
was	present	in	two	thirds	of	the	patients;	this	is	probably	a	result	of	the	fact	that	
177Lu-octreotate	has	a	slower	urinary	excretion	rate	than	[111In-DTPA0]octreotide	14,	
thus	causing	a	longer	retention	of	radioactivity	in	the	whole	body.	To	date,	there	are	
no	reports	on	the	presence	of	somatostatin	receptors	in,	for	instance,	hair	follicles.	
The	pituitary	gland	possesses	somatostatin	receptors.	Therefore,	 theoretically,	
treatment	with	177Lu-octreotate	could	impair	pituitary	function.	In	our	patients,	we	
saw	no	decrease	in	serum	gonadotroph	or	thyrotroph	hormone	concentrations,	so	
obviously	the	absorbed	radiation	dose	to	the	pituitary	was	low.	In	men,	a	transient	
significant	decrease	in	serum	inhibin-B	concentrations	and	a	concomitant	increase	
in	serum	FSH	levels	were	found	during	and	after	therapy.	This	radiation	effect	on	
the	testicular	Sertoli	cells	has	also	been	described	after	therapy	with	131I	in	patients	
with	thyroid	cancer	18.	Longer	lasting,	significant	decreases	of	testosterone	in	men	
and	of	 free	 thyroxine	 in	 the	whole	patient	group	were	also	 found.	These	were	
not	accompanied	by	significant	 increases	 in	serum	LH	or	TSH	concentrations,	
and	therefore,	although	statistically	significant,	the	decreases	were	clinically	not	
significantly	relevant.	It	can	also	be	hypothesized	that	these	minor	decreases	in	
testosterone	and	thyroid	hormone	concentrations	were	caused	by	chronic	illness	
as	well.	
We	found	antitumor	effects	(CR,	PR,	or	MR)	in	47%	of	our	patients.	The	reasons	
to	categorize	tumor	size	reductions	of	25%	to	50%	as	MRs	and	to	regard	these	as	
favorable	therapeutic	effects	are	that	endocrine	GEP	tumors	usually	grow	slowly	
and	also	because	many	of	these	tumors	are	cystic,	which	makes	it	unlikely	that	their	
response	to	therapy	is	comparable	to	that	of	fast-growing	solid	tumors.	CR	and	PR	
occurred	in	28%	of	the	patients.	With	[90Y-DOTA0,Tyr3]octreotide,	remission	rates	
of	7%	to	33%	in	GEP	tumor	patients	have	been	reported	6,7,9-11.	The	differences	in	
remission	rates	may,	in	part,	be	a	result	of	differences	in	study	design	and	dosages	
used,	but	the	differences	may	also	be	a	result	of	patient	selection.	In	our	patients,	we	
found	that	a	high	uptake	during	[111In-DTPA0]octreotide	scintigraphy	and	limited	liver	
involvement	were	predictive	factors	for	a	favorable	tumor	response,	whereas	a	low	
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2.2
KPS	and,	to	a	lesser	extent,	a	high	tumor	load	were	significant	factors	in	predicting	
tumor	progression.	In	the	studies	using	[90Y-DOTA0,Tyr3]octreotide,	which	were	
performed	in	relatively	small	patient	groups,	insufficient	data	on	these	important	
factors	are	available.	This	lack	of	comparable	data	underscores	the	need	for	randomized	
trials	comparing	[90Y-DOTA0,Tyr3]octreotide	and	177Lu-octreotate.	Indeed,	we	plan	to	
perform	such	a	study	comparing	90Y-	and	177Lu-labeled	somatostatin	analogs.	
We	treated	both	patients	who	had	PD	at	baseline	and	those	who	were	stable	or	in	
whom	disease	progression	was	not	documented.	The	reason	for	this	was	that,	in	
many	of	these	patients,	waiting	for	disease	progression	would	have	implied	a	serious	
deterioration	of	their	clinical	condition.	As	the	present	analysis	shows,	this	would	
also	have	implied	diminished	chances	of	a	successful	therapy.	Unfortunately,	we	
did	not	have	a	control	group	of	untreated	patients.	However,	Faiss	et al.	 19	recently	
reported	tumor	remissions	in	four	(5%)	of	80	GEP	tumor	patients	who	had	PD	at	
study	entry	and	were	treated	with	somatostatin	analogs	and/or	interferon	alfa.	By	
contrast,	we	found	tumor	remissions	in	47%	of	our	patients,	whether	or	not	they	
had	PD	at	study	entry.	It	seems	highly	unlikely	that	such	a	difference	could	have	
been	caused	by	patient	selection.	
Apart	from	the	proportion	of	patients	with	a	tumor	remission,	the	duration	of	such	
a	response	is	another	important	treatment	outcome	parameter.	Reported	response	
rates	for	single-agent	and	combination	chemotherapy	in	patients	with	endocrine	
GEP	tumors	are	as	high	as	40%	to	60%	for	well-differentiated	pancreatic	tumors	and	
poorly	differentiated	tumors	of	any	origin,	whereas	success	rates	for	midgut	tumors	
rarely	exceed	20%	in	recent	studies	(Table	3,	20-29	see	review	in	30).	High	response	rates	
have	been	reported	in	older	series	20-22	(Table	3),	but	in	these	studies,	the	response	
evaluation	also	included	biochemical	responses	(changes	in	serum	tumor	marker	
levels)	as	well	as	physical	examination	for	the	evaluation	of	hepatomegaly.	Indeed,	
much	of	the	discrepancy	between	older	and	more	recent	studies	can	be	ascribed	to	
differences	in	response	criteria,	as	is	illustrated	in	a	more	recent	study	by	Cheng	and	
Saltz	23	who	maintained	that	their	percentage	of	patients	with	an	objective	response	
would	have	increased	from	6%	to	25%	if	they	had	accepted	not	only	measured	CT	
scan	changes	as	response	criteria,	but	also	decreases	of	hepatomegaly	assessed	with	
physical	examination.	Despite	the	varying	percentages	of	objective	responses	that	
have	been	reported	for	chemotherapy,	the	median	time	to	progression	in	most	of	the	
studies	is	less	than	18	months.	In	this	respect,	our	treatment	with	177Lu-octreotate	
performed	considerably	better,	with	a	median	time	to	progression	of	more	than	36	
months.	However,	some	caution	in	the	interpretation	of	these	data	is	warranted	
because	the	median	follow-up	in	this	ongoing	study	is	16	months.	Also,	cardiac	and	
renal	toxicity,	as	well	as	vomiting	and	hematologic	toxicity,	are	much	more	frequent	
with	chemotherapy	than	with	treatment	with	177Lu-octreotate	(Table	3).	
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Unexpectedly,	we	 found	that	patients	with	gastrinomas	had	a	shorter	 time	to	
progression	than	other	patients	who	had,	for	instance,	carcinoids	or	nonfunctioning	
endocrine	pancreatic	tumors.	In	theory,	this	could	be	caused	by	a	faster	growth	
pattern	of	gastrinomas.	There	are	only	a	few	reports	in	relatively	small	numbers	of	
neuroendocrine	tumor	specimens	on	proliferative	markers	like	Ki-67.	To	date,	there	
are	reports	that	evidence	that	a	high	Ki-67	proliferative	index	correlates	with	a	fast	
tumor	growth	and	short	survival	in	vivo	for	both	functioning	and	nonfunctioning	
endocrine	GEP	tumors	31-33,	but	as	far	as	the	authors	are	aware,	there	is	no	direct	
evidence	that	proliferative	indices	differ	between	metastasized	gastrinomas	and	other	
endocrine	GEP	tumors.	However,	an	interesting	difference	is	that,	on	immunostains,	
gastrinomas,	in	contrast	to	other	endocrine	pancreatic	tumors,	frequently	coexpress	
neuroendocrine	and	exocrine	markers,	such	as	carcinoembryonic	antigen,	cytokeratin	
19,	and	epithelial	membrane	antigen	34.	This	could	imply	the	different	origins	of	
gastrinomas	and,	it	can	be	speculated	that	gastrinomas	also	have	different	behavior	
in	vivo.	
Tumor	remission	was	positively	correlated	with	a	high	uptake	during	[111In-DTPA0]oct-
reotide	scintigraphy	and	a	 limited	number	of	 liver	metastases,	whereas	disease	
progression	was	significantly	more	frequent	in	patients	with	a	low	performance	
status	and	a	high	tumor	load.	This	implies	that	the	chances	of	a	successful	treatment	
are	greater	if	patients	are	treated	in	an	early	stage	of	their	disease.	In	contrast	to	
what	we	reported	earlier	in	a	much	smaller	group	of	patients	 15,	the	percentage	of	
patients	with	a	remission	does	not	differ	significantly	between	those	patients	who	
have	disease	progression	at	baseline	and	those	who	do	not;	therefore,	to	wait	for	
disease	progression	has	no	advantage	in	terms	of	chances	of	success.	However,	firm	
conclusions	on	the	effect	of	our	therapy	on	overall	survival	cannot	be	drawn	from	
this	or	any	other	study	with	radiolabeled	somatostatin	analogs	because	randomized	
trials	comparing	treatment	with	radiolabeled	analogs	with	no	additional	treatment	
have	not	been	performed.	
Treatment	with	the	radiolabeled	somatostatin	analog	177Lu-octreotate	results	in	tumor	
remission	in	a	high	percentage	of	patients	with	endocrine	GEP	tumors.	Serious	side	
effects	are	rare.	The	median	time	to	progression	is	more	than	36	months,	which	
compares	favorably	with	chemotherapy.	Results	are	better	in	patients	with	a	limited	
tumor	load.	Therefore,	early	treatment,	even	in	patients	who	have	no	PD,	may	be	
better.
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Abstract
Purpose  
To	evaluate	the	quality	of	life	(QoL)	in	patients	with	metastatic	somatostatin	receptor	
positive	gastroenteropancreatic	tumors	treated	with	[177Lu-DOTA0,Tyr3]octreotate	
(177Lu-octreotate)	therapy.	
Patients and Methods 
Fifty	patients	who	had	been	treated	with	600	to	800	mCi	of	177Lu-octreotate	and	had	
a	follow-up	of	at	least	3	months	were	studied.	The	patients	completed	the	European	
Organization	for	the	Research	and	Treatment	of	Cancer	Quality	of	Life	Questionnaire	
C30	before	therapy	and	at	follow-up	visit	6	weeks	after	the	last	cycle.	Overall	QoL	
and	specific	QoL	domains	of	both	the	total	group	of	patients	and	subgroups	according	
to	treatment	outcome	were	analyzed.	Twenty-four	patients	had	regression,	19	had	
stable	disease,	six	had	progressive	disease,	and	one	had	nonassessable	disease	status.	
Analysis	of	variance	was	used	for	statistical	comparison.	
Results 
A	significant	improvement	in	the	global	health	status/QoL	scale	was	observed	
after	 therapy	with	 177Lu-octreotate	 (P <	 .01).	The	score	 increased	significantly	
six	weeks	after	therapy	to	a	mean	of	78.2,	up	from	69.0	(scale	range,	0	to	100).	
Furthermore,	significant	improvement	was	observed	in	the	role,	emotional,	and	
social	function	scales.	The	symptom	scores	for	fatigue,	insomnia,	and	pain	were	
significantly	decreased.	Patients	with	proven	tumor	regression	most	frequently	had	
an	improvement	of	QoL	domains.	Unexpectedly,	patients	with	progressive	disease	
also	indicated	an	improvement	in	their	global	health/QoL	score.	
Conclusion 
177Lu-octreotate	therapy	significantly	improved	the	global	health/QoL	and	several	
function	and	symptom	scales	in	patients	with	metastasized	gastroenteropancreatic	
tumors,	but	especially	in	those	patients	with	proven	tumor	regression.
Abstract
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INTRODUCTION
Neuroendocrine	gastroenteropancreatic	(GEP)	tumors,	including	pancreatic	islet-
cell	tumors,	nonfunctioning	neuroendocrine	pancreatic	tumors,	and	carcinoids,	
are	relatively	rare	neoplasms.	In	comparison	with	other	malignancies,	these	tumors	
usually	grow	slowly	 1.	Manifestations	of	disease	in	patients	are	mainly	based	on	
symptoms	or	syndromes	caused	by	the	overproduction	of	bioactive	substances	
or	hormones	by	the	tumor,	like	in	carcinoids,	gastrinomas,	and	insulinomas.	In	
nonfunctioning	tumors,	diagnosis	occurs	at	a	relatively	late	stage	of	the	disease	and	
therefore,	widespread	metastatic	disease	is	often	present.	In	symptomatic	patients,	
treatment	with	somatostatin	analogs	is	the	therapy	of	choice	and	highly	effective	
in	these	symptoms	reduction	2,3.	However,	somatostatin	analog	treatment	results	
in	tumor	regression	in	only	4%	to	10%	of	the	patients	4-6.	
Peptide	receptor	radionuclide	therapy	is	a	promising	treatment	modality	in	patients	
with	metastasized	GEP	tumors	7-9.	Treatment	with	[177Lu-DOTA0,Tyr3]octreotate	
(177Lu-octreotate)	resulted	in	a	complete	remission	(CR)	in	3%,	partial	remission	
(PR)	in	35%,	stable	disease	(SD)	in	41%,	and	progressive	disease	(PD)	in	21%	of	the	
patients.	Also,	reported	side	effects	were	few	9.	The	therapeutic	effect	on	tumor	
volume	is	most	frequently	used	as	the	primary	end	point	in	clinical	oncologic	trials.	
However,	over	the	last	decades,	the	effect	of	therapy	on	the	self-reported	quality	of	
life	(QoL)	has	also	become	an	important	(secondary)	end	point.	To	detect	subjective	
differences	in	aspects	of	QoL,	many	assessment	instruments	have	been	developed.	
Most	widely	used	is	the	European	Organization	of	Research	and	Therapy	in	Cancer	
Quality	of	Life	Questionnaire	C30	(EORTC	QLQ-C30),	which	is	especially	designed	
to	assess	QoL	in	clinical	cancer	trials.	This	questionnaire	has	been	validated	and	is	
accepted	as	a	reliable	method	for	the	assessment	of	QoL	10.	Therefore,	we	chose	this	
questionnaire	to	evaluate	the	impact	of	treatment	with	177Lu-octreotate	on	QoL	in	
patients	with	metastasized	GEP	tumors.
PATIENTS AND METHODS
Study Design
Patients	were	referred	from	both	tertiary	care	referral	centers	and	community	
hospitals	throughout	the	country.	During	the	treatment	and	thereafter,	the	patients	
came	for	follow-up	in	our	hospital.	The	most	important	criteria	for	inclusion	were	
histologically	proven	metastatic	GEP	tumor(s)	and	good	tumor	uptake	on	somatostatin	
receptor	scintigraphy.	Also,	patients	had	to	have	a	Karnofsky	performance	status	score	
(KPS)	≥	50	9,11.	Exclusion	criteria	were:	creatinin	clearance	>	40	mL/min,	platelets	
>	80	x	109/L,	hemoglobin	>	9.7	g/dL,	and	WBC	count	>	2.0	x	109/L.	A	total	of	66	
patients	with	metastatic	somatostatin	receptor	positive	GEP	tumors	treated	with	
600	to	800	mCi	177Lu-octreotate	(three	to	four	cycles,	6-	to	9-week	interval)	could	
126
be	analyzed.	Eight	patients	were	excluded	because	of	missing	forms	at	the	6-week	
follow-up	visit.	In	these	cases,	the	forms	were	missing	because	of	administrative	
reasons.	Seven	patients	were	excluded	because	of	follow-up	outside	the	Netherlands,	
and	one	because	of	progressive	disease.	A	total	of	50	patients	were	analyzed.
Outcome Measures
QoL	was	 assessed	with	 the	EORTC	QLQ-C30	 (version	 3.0),	 a	patient-based	
questionnaire	which	includes	a	total	of	30	items	and	is	composed	of	scales	that	
evaluate	physical	(five	items),	emotional	(four	items),	role	(two	items),	cognitive	
(two	items),	and	social	(two	items)	functioning,	as	well	as	global	health	status	(two	
items).	Higher	mean	scores	on	these	scales	represent	better	functioning.	There	are	
also	three	symptom	scales	measuring	nausea	and	vomiting	(two	items),	fatigue	
(three	items),	and	pain	(two	items),	and	six	single	items	assessing	financial	impact	
and	various	physical	symptoms.	A	higher	mean	value	on	the	symptom	scales/single	
items	means	more	symptomatology.	Following	the	scoring	instructions	given	by	
the	EORTC	Quality	of	Life	Study	group,	the	raw	EORTC	QLQ-C30	scores	were	
linearly	transformed	to	0-100	scales	before	statistical	analyses	were	performed	12.	
A	mean	change	in	score	between	0	and	5	was	regarded	as	not	clinically	important.	
A	change	in	scores	between	5	and	10	was	regarded	as	a	“little”	subjective	change,	
whereas	a	change	between	10	and	20	was	regarded	as	a	“moderate”	change,	and	
more	than	20	was	regarded	as	an	“important”	change,	as	previously	described	13.	
The	different	outcome	groups	were	defined	as	regression	(including	CR,	PR,	and	
minimal	regression	[MR];	25%	to	50%	reduction	in	tumor	size),	SD,	and	PD,	and	
were	determined	by	means	of	computed	tomography	(CT)	and	magnetic	resonance	
imaging	(MRI)	measurements	following	the	WHO	solid	tumor	response	criteria.	
MR	was	included	in	the	regression	group	because	of	the	usually	slow	growth	rate	
of	neuroendocrine	tumors,	if	compared	with	other	carcinomas,	and	because	of	the	
cystic	lesions	that	these	tumors	often	cause.
Timing and Data Collection
In	accordance	with	the	requirements	from	the	hospital’s	Ethics	Committee,	informed	
consent	was	obtained	from	all	the	patients.	Questionnaires	were	filled	out	at	fixed	
points	in	the	treatment	scheme	in	the	week	before	the	first	treatment	and	at	the	
first	follow-up	visit	6	weeks	after	the	last	treatment.	The	treating	physician	scored	
their	KPS.	The	patients	were	carefully	instructed	how	to	fill	out	the	questionnaire,	
but	were	not	assisted	in	answering	the	questions.	At	the	6-week	follow-up	visit,	
the	patients	were	unaware	of	the	response	as	the	questionnaires	were	filled	out	
on	the	same	day	the	first	follow-up	CT	or	MRI	was	performed.	Patients	were	only	
informed	about	outcome	of	therapy	at	the	next	follow-up	visit	when	tumor	imaging	
was	evaluated.	The	first	questionnaire	was	used	as	baseline.	
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Missing Data
The	questionnaires	were	collected	carefully,	but	some	were	not	filled	out	adequately	
and	contained	missing	values	at	the	time	of	analysis.	The	missing	items	were	handled	
with	the	method	of	simple	mean	imputation	as	described	in	the	Guidelines	for	
assessing	QoL	in	clinical	trials	provided	by	the	EORTC	12.
	
Data Analysis
Analysis	of	variance	(two-sided)	was	used	to	compare	the	patients’	ratings	before	and	
after	treatment.	P	<.05	was	considered	significant.	The	linear	associations	between	
changes	in	KPS	scores	and	patients’	global	health/QoL	scores	were	investigated	using	
Spearman’s	rank	correlation	(two-tailed).
RESULTS
Baseline	patients’	characteristics	are	 listed	in	Table	1.	The	questionnaires	of	50	
patients	(mean	age,	58	years;	range,	30	to	78	years),	before	and	after	treatment,	were	
available	for	analysis.	
Of	the	50	patients,	26	patients	(52%)	had	carcinoid	tumor,	13	(26%)	neuroendocrine	
(NE)	pancreatic	tumor,	seven	(14%)	had	NE	tumor	of	unknown	origin,	three	(6%)	
had	gastrinoma,	and	one	(2%)	had	insulinoma.	Twenty-two	patients	(44%)	had	
been	operated	in	the	past,	five	patients	(10%)	had	received	chemotherapy,	and	24	
patients	(48%)	had	been	treated	with	somatostatin	analogs	before	the	177Lu-octreotate	
therapy.	Seventeen	of	the	included	50	patients	(34%)	had	documented	progressive	
disease	within	1	year	before	the	start	of	therapy.	In	the	other	patients,	disease	was	
stable	for	more	than	1	year,	or	progression	had	not	been	documented	with	CT	or	MRI	
within	the	preceding	year.	Treatment	with	177Lu-octreotate	resulted	in	the	following	
responses	3	months	after	therapy:	24	patients	(48%)	had	tumor	regression	(CR,	PR,	
and	MR),	19	patients	(38%)	had	SD,	and	six	patients	(12%)	had	PD.	In	one	patient,	it	
was	not	possible	to	measure	tumor	response	because	evidence	of	disease	before	and	
after	therapy	could	only	be	visualized	with	somatostatin	scintigraphy.
Eight	patients	were	excluded	from	the	analysis	because	of	missing	forms.	Two	of	these	
had	tumor	regression,	three	had	SD,	two	had	PD,	and	in	one	patient	no	treatment	
outcome	could	be	established.	These	treatment	outcomes	were	not	significantly	
different	from	the	whole	patient	group	(Fisher’s	exact	test	[two-sided];	P <	.05).	The	
total	amount	of	missing	items	of	all	the	EORTC	QLQ-C30	questionnaires	was	14	
of	3,000,	yielding	a	completion	rate	of	99.5%.	These	missing	items	were	randomly	
distributed	and	therefore,	simple	mean	imputation	was	considered	appropriate	to	
handle	the	data	without	the	introduction	of	significant	bias	14.	
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 Table 1. Baseline	characteristics	at	study	entry
seline	characteristics	at	Study	Entry No.	of	patients %
Total 50
Sex
Male 22 44
Female 28 56
Age,	years
Mean 58.3
Range 30-78
Karnofsky	Performance	Score
Mean 87.2
Median 90
Range 50-100
Type	of	tumor
Carcinoid 26 52
NE	tumor	unknown	origin 7 14
NE	tumor	pancreas 13 26
Gastrinoma 3 6
Insulinoma 1 2
Metastases
Liver 45 90
Bone 10 20
Prior	Therapy
Surgery 22 44
Chemotherapy 5 10
Somatostatin	analogs 24 48
Abbreviation: NE, neuroendocrine.
The	mean	interval	between	baseline	and	first	follow-up	visit	(6	weeks	after	the	last	
therapy)	was	approximately	7	months	(range,	5	to	12	months).	This	interval	varied	
because	in	some	patients,	treatments	had	to	be	postponed	as	a	result	of	sustained	
bone	marrow	suppression,	and	because	the	number	of	treatments	varied	due	to	
patients	reaching	their	cumulative	maximum	kidney	radiation	dose.	The	latter	was	
calculated	for	each	indiviual	patient	separately,	and	varied	considerably.	All	patients	
received	between	600	and	800	mCi	of	177Lu-octreotate.	
The	EORTC	QLQ-C30	data	 indicated	that	patients	assigned	high	scores	to	the	
functional	scales	at	baseline	(Table	2).
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Table 2. Patients	(n=50)	mean	scores	on	EORTC	QLQ-C30	scales	and	single	items
	
At baseline Follow-up (6 weeks)
Mean SD Mean SD Change P*
Global quality of life †
Global	health-status/quality	of	life 69.0 20.8 78.2 16.9 9.2 <	0.01
Functional scales †
Physical 80.8 19.3 84.6 20.4 3.8 0.07
Role 67.0 31.7 82.0 25.2 15.0 <	0.01
Emotional 77.7 15.7 85.8 15.5 8.1 <	0.001
Cognitive 88.7 16.0 88.3 17.3 -0.4 0.89
Social 80.7 22.7 90.3 21.3 9.6 <	0.01
Symptom scales ‡
Fatigue 31.9 24.4 22.8 22.5 -9.1 <	0.01
Nausea/Vomiting 6.7 16.5 5.0 11.3 -1.7 0.46
Pain 23.3 28.8 15.0 20.0 -8.3 <	0.05
Single items ‡
Dyspnea 16.3 23.7 17.3 27.1 1.0 0.71
Insomnia 26.0 30.3 14.3 21.5 -11.7 <	0.01
Appetite	loss 10.2 19.5 8.7 21.1 -1.5 0.70
Constipation 8.8 20.2 6.1 16.2 -2.7 0.32
Diarrhea 16.7 26.3 12.2 18.9 -4.5 0.26
Economical	impact 5.3 14.1 5.3 15.6 0.0 1.00
Body Weight 71.3 14.5 74.0 15.5 2.7 0.01
Karnofsky Performance Status 
Scale
87.2 12.3 87.9 12.0 0.7 0.52
NOTE Mean scores and ± SD of the EORTC QLQ-C30 questionnaire before and after (6 weeks follow-up 
visit) 177Lutetium-octreotate therapy. Body weight and KPS are also shown.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality 
of Life Questionnaire C30; SD, standard deviation.
*: P < .05 was regarded as statistical significant.
†: Scores ranges from 0 to 100, with a higher score representing a higher level of function. 
‡: Scores ranges from 0 to 100, with a higher score representing a higher level of symptoms. 
The	role	and	cognitive	function	scales	were	given	respectively	the	lowest	(67.0)	and	
the	highest	(88.7)	scores.	The	score	for	the	global	health	status/QoL	scale	(69.0)	was	
slightly	lower	than	most	of	the	functional	scales.	The	highest	scores	of	the	symptoms	
scales	and	single	items	were	assigned	to	fatigue	(31.9),	insomnia	(26.0),	and	pain	
(23.3),	as	well	as	diarrhea	(16.7)	and	dyspnea	(16.3).	
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The	global	health/QoL	scale	score	changed	significantly	from	69.0	to	78.2	(P <	.01).	
Moreover,	significant	improvements	were	demonstrated	in	the	emotional	function	
scale	(77.7	to	85.8;	P <	.001),	the	role	function	scale	(67.0	to	82.0;	P < .01)	and	in	the	
social	function	scale	(80.7	to	90.3;	P < .01).	In	the	symptoms	scale	scores,	fatigue	
and	pain	decreased	from	31.9	to	22.8	(P <	.01)	and	23.3	to	15.0	(P <	.05),	respectively.	
Only	insomnia,	as	one	of	the	six	single	items,	decreased	11.7	points	in	score	(P <	.01).	
At	baseline,	17	(34%)	of	50	patients	had	diarrhea	as	part	of	a	secretory	syndrome,	
versus	16	(32%)	of	50	at	the	first	follow-up	visit	(P <.05).	However,	patients	who	
initially	had	diarrhea	had	a	significant	decrease	in	diarrhea	score	from	49.0	to	15.7	
(P <	.0001)	after	therapy.	Only	one	patient	in	this	group	switched	to	morphine,	which	
probably	accounted	for	the	observed	decrease	of	diarrhea	in	this	patient.	Mean	body	
weight	increase	during	the	average	period	of	7	months	changed	significantly	from	
71.3	to	74.0	kg	(P <	.01).	
In	the	group	with	tumor	regression,	the	global	health/	QoL	scale	score	increased	
significantly	from	70.1	to	80.6	(P <	 .05).	The	physical,	role,	emotional,	and	social	
scale	improved	with	an	increase	in	score	of	6.0,	22.2,	10.0,	and	11.1,	respectively	
(P<.05).	The	score	of	the	symptom	scale	fatigue	decreased	from	30.3	to	19.2	(P<.01)	
and	the	single	item	insomnia	decreased	from	23.6	to	8.7	(P <	.01)	after	therapy.	Body	
weight	increased	significantly	from	72.4	to	77.2	kg	(P <.01).	The	KPS	did	not	change	
significantly	(Figure	1).	
In	the	group	with	stable	disease,	no	significant	changes	were	found	in	the	functional	
scales.	In	patients	with	pain	at	baseline	(13	of	19	patients;	68%),	a	significant	decrease	
in	score	was	found	from	41.0	(baseline)	to	17.9	(6	weeks	after	therapy;	P <	 .01).	In	
patients	with	stable	disease	(n	=	19),	no	further	significant	change	of	any	other	score	
was	found.	In	patients	with	progressive	disease	(n	=	6),	only	the	global	health/QoL	
score	increased	from	48.6	to	72.2	(P <.01;	Fig	2).
The	change	in	score	of	the	self-reported	global	health/	QoL	scale	between	before	
and	after	therapy	was	positively	correlated	with	the	change	in	KPS	(Pearson’s	rank	
correlation;	ρ	=	0.39;	P <	 .01).	Twenty	(60%)	out	of	33	patients	who	had	a	lower	
or	equal	KPS	after	therapy	reported	an	increase	in	global	health/QoL	scale,	and	12	
(80%)	of	15	patients	who	had	a	higher	KPS	after	the	therapy	also	had	a	higher	global	
health/QoL	scale	score	compared	to	baseline	(Fig	3).
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Figure 1. Changes	in	the	European	Organization	for	the	Research	and	Treatment	of	Cancer	
Quality	of	Life	Questionnaire	C30	scales	and	Karnofsky	performance	score	(KPS)	in	patients	
with	tumor	regression	before	(baseline)	and	at	6	weeks	follow-up.	Only	scales	that	changed	
significantly	are	shown.	SE	to	the	mean	are	shown	above	each	bar.	Gray	bars:before	[177Lu-
DOTA0,Tyr3]octreotate	therapy;	black	bars:	after	therapy.*P <	.05	;	**P <	.01.
Figure 2. Global	health/quality	of	life	(QoL)	scale	scores	of	all	the	patients	(N	=	50)	and	the	
different	outcome	groups	according	to	tumor	evaluation	before	(gray	bars)	and	after	(black	
bars)	[177Lu-DOTA0,Tyr3]octreotate	therapy.	SE	to	the	mean	are	shown	above	each	bar.	REGR,	
regression;	SD,	stable	disease;	PD,	progressive	disease;	NS,	not	significant.
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Figure 3.	Changes	in	global	health/quality	of	life	(QoL)	scores	per	patient	versus	changes	
in	Karnofsky	performance	score	(KPS).	Values	are	scores	at	6	weeks	follow-up	minus	scores	
at	baseline.	The	line	(y	=	x)	represents	equal	changes.	Note	that	positive	changes	in	global	
health/QoL	scale	are	more	frequent	than	positive	changes	in	KPS.
DISCUSSION
Treatment	with	radiolabeled	somatostatin	analogs,	like	177Lu-octreotate,	in	patients	
with	metastasized	neuroendocrine	GEP	tumors	may	be	very	rewarding	in	terms	of	
tumor	volume	reduction	7-9.	Here,	we	report	the	outcome	of	health	related	quality-
of-life	(HRQoL)	assessment	before	and	after	treatment	with	177Lu-octreotate.	The	
EORTC	QLQ-C30	scores	of	patients	with	metastasized	GEP	tumors	at	baseline	
indicated	that	the	patients	maintain	a	relatively	good	HRQoL.	This	is	in	line	with	a	
previous	study	by	Larsson	et al.15	in	which	the	questionnaire	was	used	to	study	the	
general	HRQoL	in	patients	with	GEP	tumors.	Assessment	of	HRQoL	data	results	in	
detailed	information	about	many	aspects	of	the	patients’	QoL,	including	symptoms,	
specific	functional	scales,	and	the	overall	health/QoL	scale.	The	combined	global	
health/QoL	scale	is	regarded	as	the	most	important	scale	to	score,	as	it	gives	an	
overall	impression	of	the	experienced	HRQoL.	Furthermore,	it	has	been	shown	to	
be	a	good	predictor	of	survival	16,17.	
To	identify	aspects	of	HRQOL	in	which	the	patients	clearly	had	gained	meaningful	
improvement,	a	significant	change	of	more	than	five	points	was	considered	to	be	
clinically	important,	according	to	the	method	described	by	Osoba	et al.	13.	The	patients	
in	our	study	experienced	such	an	improvement	of	their	global	health/QoL	after	
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therapy	with	177Lu-octreotate.	In	addition,	the	role,	emotional,	and	social	function	
scale	score	showed	a	clinically	important	improvement.	The	symptom	scales	fatigue	
and	pain	and	the	single	item	insomnia	were	the	only	scores	that	were	high	at	baseline	
and	decreased	significantly.	Fatigue	is	the	most	frequently	reported	symptom	in	
cancer	patients,	and	its	reason	is	often	obscure	18-20.	Also,	insomnia	is	reported	in	
30%	to	50%	of	patients	with	cancer	21.	Profound	diarrhea	is	a	common	symptom	in	
patients	with	GEP	tumors.	However,	we	found	no	significant	change	in	diarrhea,	
most	probably	because	most	patients	with	severe	diarrhea	used	somatostatin	analogs	
that	resulted	in	an	adequate	symptom	control.	However,	patients	who	still	suffered	
from	diarrhea	before	the	start	of	177Lu-octreotate	therapy	did	notice	an	improvement	
of	this	symptom.	
The	change	in	self-reported	global	health/QoL	was	positively	correlated	with	the	
change	in	KPS	as	judged	by	the	physician.	Correlation	between	KPS	scores	and	the	
different	domains	of	QoL	have	been	reported	in	other	studies	22,23.	In	these	studies,	
however,	it	was	concluded	that,	although	associated,	both	measures	are	not	assessing	
the	same	construct.	Schaafsma	et al.	 22	stated	that	the	EORTC	QLQ-C30	is	a	more	
comprehensive	measure	of	QoL	than	the	KPS.	This	is	in	line	with	the	greater	number	
of	positive	changes	we	found	in	the	global	health/QoL	scale	as	reported	by	the	
patient,	as	compared	with	the	changes	in	the	physician-based	KPS.	Larsson	et al.	24	
stated	that	patients	with	GEP	tumors	rated	the	physical	aspects	of	life	as	the	most	
important	aspect	for	experiencing	a	good	HRQoL.	In	contrast,	we	found	no	evidence	
of	significant	change	in	the	physical	function	scale,	whereas	other	scales,	including	
the	global	health/QoL,	did	increase	significantly.	Thus,	although	reported	as	the	
most	important	aspect	of	QoL,	it	appears	that,	when	the	level	of	physical	functioning	
is	relatively	high	as	in	our	patients,	aspects	of	QoL	other	than	physical	functioning	
become	important	to	determine	the	patients’	overall	QoL.	
In	the	group	with	SD,	no	worsening	of	symptoms	or	decrease	in	functioning	scales	
was	found.	However,	considering	the	five	(26%)	of	19	patients	who	had	documented	
PD	in	the	year	before	therapy,	a	stabilization	of	any	aspect	of	QoL	suggests	a	positive	
effect	of	177Lu-octreotate	therapy.	Furthermore,	patients	with	pain	at	baseline	had	a	
significant	decrease	in	score	with	more	than	20	points.	Waldherr	et al.	 25	reported	
similar	findings	of	clinical	benefit	in	a	group	of	21	patients	with	NE	tumors	treated	
with	the	radiolabeled	somatostatin	analog	90Y-DOTATOC.	However,	they	used	
a	physician-based	method,	whereas	we	preferred	 to	use	a	more	patient-based	
method	with	the	EORTC	QLQ-C30.	In	contrast	to	the	group	of	patients	with	SD,	a	
significant	improvement	of	the	global	health/QoL	scale	was	found	in	patients	with	
PD.	The	difference	between	the	low	score	at	baseline	in	the	latter	group,	compared	
with	the	relatively	high	score	in	patients	with	SD,	could	explain	this	contradicting	
observation.	In	combination	with	the	absence	of	any	significant	change	in	any	other	
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scale,	it	suggests	that,	in	patients	with	PD,	even	a	small	change	in	any	other	scale	
could	have	had	a	large	impact	on	their	overall	health/QoL.	Because	our	group	with	
PD	represented	a	small	number	of	patients	and,	moreover,	one	patient	was	lost	to	
follow-up,	the	accuracy	of	these	observations	remains	questionable.	Also,	a	placebo	
effect	cannot	be	ruled	out	completely.	
In	conclusion,	we	found	that	177Lu-octreotate	therapy	improved	the	QoL	in	patients	
with	metastasized	GEP	tumors,	especially	in	the	patients	with	proven	regression.
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Abstract
Purpose 	
Peptide	receptor	radionuclide	therapy	(PRRT)	with	radiolabelled	somatostatin	
analogues	 is	 a	novel	 therapy	 for	patients	with	somatostatin	 receptor-positive	
tumours.	We	determined	the	effects	of	PRRT	with	[177Lu-DOTA0,Tyr3]octreotate	
(177Lu–octreotate)	on	glucose-homeostasis	and	the	pituitary-gonadal,	-thyroidal	and	
-adrenal	axes.
Methods 	
Hormone	levels	were	measured	and	adrenal	function	assessed	at	baseline	and	up	to	
24	months	of	follow-up.	
Results  
In	35	men,	mean	serum	inhibin	B	levels	were	decreased	at	3	months	posttherapy	
(205±16	to	25±4	pg/ml; P<0.05)	and	FSH	levels	increased	(5.9±0.5	to	22.7±1.4IU/L; 
P<0.05).	These	levels	returned	to	near	baseline	levels.	Total	testosteron	and	SHBG	
levels	decreased	(15.0±0.9	to	10.6±1.0	nmol/L	and	61.8±8.7	to	33.2±3.7	nmol/L; 
P<0.05),	respectively,	whereas	non-SHBG-bound-T	did	not	change.	An	increase	
(5.2±0.6	to	7.7±0.7I	IU/L; P<0.05)	of	LH	levels	was	found	3	months	of	follow-up	
returning	to	baseline	levels	thereafter.	In	21	postmenopausal	women,	decrease	in	
FSH	(74.4±5.6	to	62.4±7.7	IU/L; P<0.05)	and	LH	levels	(26.8±2.1	to	21.1±3.0	IU/L; 
P<0.05)	were	found.	
Two	out	of	66	patients	developed	persistent	primary	hypothyroidism.	FT4	levels	
decreased	(17.7±0.4	to	15.6±0.6pmol/L; P<0.05),	whereas	TSH	and	T3	levels	did	not	
change.	rT3	levels	decreased	(0.38±0.03	to	0.30±0.01	nmol/L; P<0.05).	Before	and	
after	therapy	ACTH-stimulation	tests	showed	an	adequate	response	(>550	nmol/L;	
n=18).	Five	patients	developed	elevated	HbA1c	levels	(>6.5%).
Conclusion  
In	 men	 17 7Lu–octreotate	 therapy	 induced	 transient	 inhibitory	 effects	 on	
spermatogenesis,	but,	non-SHBG-bound-T	levels	remained	unaffected.	In	the	long-
term,	gonadotropin	levels	decreased	significantly	in	postmenopausal	women.	Only	
few	patients	developed	hypothyroidism	or	elevated	levels	of	HbA1c.	Therefore,	PRRT	
with	177Lu–octreotate	can	be	regarded	as	a	safe	treatment	modality	with	respect	to	
short-and	long-term	endocrine	function.
Abstract
4
INTRODUCTION
Treatment	with	 radiolabelled	 somatostatin	 analogues,	 or	 peptide	 receptor	
radionuclide	 therapy	 (PRRT),	 is	 a	 new	 treatment	modality	 in	patients	with	
metastasised	or	inoperable	somatostatin	receptor-positive	tumours.	Recent	reports	
on	the	effectiveness	of	PRRT	with	the	radioligands	[90Y-DOTA0,Tyr3]octreotide	
(90Y-octreotide)	or	[177Lu-DOTA0,Tyr3]octreotate	(177Lu–octreotate)	in	patients	with	
neuroendocrine	tumours,	report	20-30%	partial	remissions1-3.	Short-term	side-
effects	included	mild	nausea,	vomiting	and	abdominal	pain	4,5.	Serious	side-effects	
are	related	to	tissue	specific	radiation	exposure	and	radiation	sensitivity.	Radiation	
absorbed	doses	to	bone	marrow	and	kidneys	are	dose	limiting.	So	far,	reported	
serious	complications	include	2	cases	of	myelodysplastic	syndrome	5	and	several	
cases	of	radiation-induced	renal	failure	6-8,	especially	in	patients	who	did	not	receive	
amino-acid	co-infusion,	which	is	currently	used	to	reduce	renal	absorbed	radiation	
dose	9.
Additional	non-intended	targets	of	PRRT	are	endocrine	organs.	Many	of	these,	such	
as	the	anterior	pituitary	gland,	endocrine	pancreas,	adrenal	medulla	and	thyroid	
are	known	to	express	somatostain	receptors	(SSTRs),	especifically	SSTR	subtype	
210-13.	The	radiopharmaceuticals	currently	used	in	PRRT	target	especially	this	SSTR	
subtype,	followed	by	subtype	5	and	3	14.
Until	recently,	limited	data	regarding	the	effect	of	PRRT	on	endocrine	function	was	
available.	In	a	previous	report	on	the	therapeutic	effect	of	177Lu-octreotate	in	a	large	
group	of	patients	with	gastroenteropancreatic	neuroendocrine	tumours,	we	briefly	
reported	on	the	short-term	effects	of	PRRT	on	endocrine	function	5.	In	the	present	
study,	we	focused	on	both	the	short-	and	long-term	effects	of	PRRT	on	the	anterior	
pituitary,	gonadal,	thyroid,	endocrine	pancreas	and	adrenal	function.	
SUBjECTS AND METHODS
Patients and study design
Seventy-nine	patients	who	were	treated	with	600-800	mCi	177Lu-octreotate	(three	
to	four	cycles	with	6	to	9-week	interval)	between	January	2000	and	December	2004	
and	with	a	follow-up	period	of	12-24	months,	were	selected	for	analysis.	Only	local	
(Dutch)	residents	were	analysed,	because	these	had	their	follow-up	at	our	institution.	
All	patients	had	tumour	uptake	on	SSTR	scintigraphy	that	was	at	least	as	high	as	
the	physiological	uptake	in	normal	liver	tissue	on	planar	imaging	preceding	therapy.	
Hormone	measurements,	routine	haematology,	liver	and	kidney	function	tests	were	
performed	before	each	administration	of	177Lu-octreotate	and	at	each	follow-up	visit.	
Outcome	of	therapy	was	assessed	by	computed	tomography	or	magnetic	resonance	
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imaging	and	performed	within	3	months	before	the	first	therapy,	at	6	to	8	weeks,	at	
3	and	6	months	after	the	last	treatment,	and	thereafter	every	6	months.	
Inclusion	criteria	were:	Karnofsky	performance	score	≥	50,	creatinin	clearance	≥	40	
ml/min,	haemoglobin	>	9.7	g/dL,	platelet	count	>	75x109/L	and	WBC	>	2.0x109/L.	
All	patients	gave	written	informed	consent	before	inclusion	in	the	study,	which	
was	approved	by	the	medical	ethics	committee	of	the	hospital.	 177Lu-octreotate	
preparation	and	administration	of	therapy	were	performed	as	described	earlier	5.
Hormone measurements
Blood	samples	were	processed	within	2	hours	after	withdrawal.	Serum	was	stored	
at	–20	°C	until	assayed.
Gonadotropins, gonadal hormones and cortisol
Serum	levels	of	LH,	FSH,	SHBG	and	cortisol	were	measured	using	luminescence-
based	immunometric	assays	(Immulite	2000,	Diagnostic	Products	Corp.,	Los	Angeles,	
CA,	USA)	Serum	estradiol	(E2),	and	total	testosterone	(TT)	levels	were	measured	
using	nonextraction	coated-tube	radioimmunassay	(Coat-a-Count,	Diagnostic	
Products	Corp.,	Los	Angeles,	CA,	USA).	Sensitivities	of	the	assays	were	0.1	IU/L	
for	FSH	and	LH,	10	pmol/L	for	E2	and	0.1	nmol/L	for	TT.	Interassay	coefficients	of	
variation	for	LH	and	FSH,	were	<7%,	<5%	for	SHBG,	5%	for	cortisol,	<10%	for	E2	and	
<9%	for	TT.	Non-SHBG-bound-T	levels	were	calculated	by	using	the	mass	action	
equation	as	described	by	Södergard	15	using	a	variable	albumin	concentration.	The	
affinity	constants	used	for	the	binding	of	testosterone	to	SHBG	or	albumin	were	
5.97x108	L/mol	and	4.06x104	L/mol,	respectively.	Dimeric	inhibin	B	levels	were	
assessed	using	an	immunoenzymometric	assay	Oxford	BioInnovation,	(Oxford,	UK),	
The	detection	limit	of	the	assay	was	10	ng/L.	Interassay	coefficients	of	variation	were	
<15%	and	21%	at	concentrations	of	215	and	19	ng/L,	respectively.	
Thyroid hormones
Serum	FT4	and	T3	were	measured	by	chemoluminescence	assays	 (Vitros	ECi	
Immunodiagnostic	System;	Ortho-Clinical-Diagnostics	Inc.,	Rochester,	NY,	USA).	
Serum	levels	of	TSH	were	measured	using	the	Immulite	2000	system.	Reverse	
T3	(rT3)	was	measured	by	RIA	as	previously	described	16.	Interassay	coefficients	of	
variation	amounted	to	4%	for	TSH,	5%	for	FT4,	3.3%	for	T3,	and	10%	for	rT3.
HbA1c
Percentage	 of	 glycolysated	 hemoglobin	 (HbA1c)	was	 determined	 by	HPLC	
measurement.	
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4Hypothalamo-pituitary-adrenal (HPA)-axis assessment
The	1	µg	(low-dose)	ACTH	stimulation	test	(LDST)	was	used	to	test	the	integrity	of	the	
HPA	axis.	The	LDST	was	performed	in	thirty-nine	patients	before	therapy.	Eighteen	
patients	also	had	an	LDST	12-18	months	after	therapy.	Cortisol	was	measured	0,	20,	30	
and	60	minutes	after	the	injection	of	1	µg	tetracosactrin	(Synacthen,	Novartis	Pharma)	
intravenously.	The	solution	of	1	µg	ACTH/ml	was	used	immediately	after	preparation.	
The	intravenous	line	used	was	flushed	with	saline	after	the	administration	and	after	
each	time	a	blood	sample	was	taken.	A	stimulated	peak	cortisol	concentration	of	at	
least	550	nmol/L	was	considered	to	be	an	adequate	response.	
Statistical Analyses  
All	 results	are	expressed	as	mean	concentrations	±	standard	error	of	 the	mean	
(SEM).	Hormones	were	analysed	using	repeated-measures	analysis	of	variance	
(ANOVA)	with	Bonferroni’s	correction	for	multiple	comparisons.	For	the	HPA-axis	
analysis	paired	student	t-tests	was	used.	P-values	<0.05	(2-tailed)	were	considered	
significant.
RESULTS
Patients’	characteristics	are	listed	in	Table	1.	Data	from	thirty-five	men	were	available	
for	analysis.	Three	were	excluded	at	baseline:	one	had	severe	chemotherapy-induced	
hypogonadism,	one	had	testicular	atrophy	and	one	had	high	levels	of	FSH	and	LH	
suggestive	of	a	co-existing	gonadotropin-secreting	pituitary	adenoma,	which	was	
not	further	analysed.	
At	baseline,	one	patient	had	combined	low	TT	(<8.1	nmol/L)	and	inhibin	B	(<150	
pg/ml)	levels,	2	patients	had	isolated	low	TT	levels,	2	other	patients	had	low	non-
SHBG-bound-T	(<5.9	nmol/L)	and	another	10	patients	had	isolated	low	inhibin	B	
levels.	
Mean	inhibin	B	level	decreased	significantly	from	205±16	pg/ml	to	a	nadir	level	of	
25±4	pg/ml	at	3	months	after	177Lu-octreotate	therapy	(P<0.05)	and	returned	to	near	
pre-treatment	levels	in	the	follow-up	period	thereafter.	At	24	months	posttherapy,	
although	marginal,	the	inhibine	B	level	was	significantly	decreased	(Figure	1a).	Mean	
FSH	levels	had	a	mirrored	course	with	a	transient	increase	from	5.9±0.5	IU/L	to	a	
maximum	of	22.7±1.4	IU/L	3	months	after	the	last	therapy.	Twenty-four	months	after	
the	last	therapy,	the	mean	FSH	level	was	not	significantly	different	from	baseline.	
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Table 1. Baseline	patient	characteristics
No. of Patients Mean (range) %
Total 79
Gender	
Male 38 48
Age 58.4	(30-83)
Female 41 52
Age 54.8	(20-74)
Age	at	diagnosis	(yr) 56.7	(20	–	83)
Weight	(kg) 74.3	(43	–	142)
BMI	(kg/m2) 25.0	(15.6	-	45.1)
Height	(cm) 172	(152-196)
Karnofsky	Performance	Score 89.4	(50-100)
Diagnosis
Carcinoid 49 62
NE	of	unknown	origin 8 10
NE	pancreas 15 20
Gastrinoma 1 1
Insulinoma 1 1
Hürthle	cell	Thyroid	Carcinoma 3 4
Medullary	Thyroid	Carcinoma 1 1
Paraganglioma 1 1
Metastases
	Liver 66 84
	Bone 18 23
Prior	therapy
Surgery 36 46
Chemotherapy 6 8
External	Radiotherapy 3 4
Somatostatin	analog	therapy 36 46
Abbreviations: BMI, body mass index; NE, neuroendocrine
Mean	TT	level	decreased	significantly	from	15.0±0.9	nmol/L	at	baseline	to	12.3±0.7	
nmol/L	at	3	months	(P<0.05)	with	a	further	decline	to	10.6±1.0	nmol/L	at	24	months	
after	therapy	(Figure	1b).	Mean	LH	level	from	5.2±0.6	IU/L	to	7.7±0.7	IU/L	at	3	
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4months	of	follow-up	and	returned	to	levels	not	significantly	different	from	baseline	
at	6	months.	
Concomitant	with	the	decrease	of	TT,	the	mean	SHBG	level	decreased	significantly	
from	baseline	level	of	61.8±8.7	nmol/L	to	a	nadir	of	33.2±3.7	nmol/L	at	24	months	
after	the	last	therapy	(P<0.05).	The	calculated	levels	of	non-SHBG-T	did	not	change	
significantly	(Figure	1c).	
Based	on	the	levels	of	FSH,	LH,	inhibin	B	and	E2,	and	age	before	therapy,	three	groups	
of	women	(41	patients	in	total)	could	be	distinguished.	Eight	women	had	hormonal	
changes	during	follow-up	which	were	suggestive	for	menopausal	transition	and	were	
therefore	excluded.	Since	no	menstrual	data	was	available	from	six	premenopausal	
women,	these	women	were	also	excluded	from	analysis.
Gonadotropin	analysis	was	performed	in	21	postmenopausal	women.	Five	women	
were	excluded	because	of	hormonal	changes	due	to	concomitant	disease	(n=3),	
previous	cranial	external	beam	radiation	because	of	meningeoma	(n=1)	and	temporary	
use	of	high	dose	opioid	medication	(n=1).	One	39-year-old	woman	was	excluded	
because	of	bilateral	oophorectomy,	followed	by	hormone	replacement	therapy.	
In	the	postmenopausal	women,	both	mean	inhibin	B	and	E2	were	at	low	levels,	
<10	ng/L	and	<50	pmol/L,	respectively,	at	baseline	and	did	not	change	significantly	
thereafter.	Before	therapy,	the	mean	FSH	concentration	was	74.4±5.6	IU/L.	During	
follow-up	it	decreased	significantly	to	62.4±7.7	IU/L,	at	24	months	of	follow-up.	
The	mean	LH	concentration,	which	was	26.8±2.1	IU/L	before	therapy,	decreased	
significantly	to	21.1±3.0	IU/L	at	24	months	(P<0.05).	(Figure	2).	
Sixty-six	patients	were	included	for	analysis	of	thyroid	hormone	status.	Excluded	
were	ten	patients	with	thyroid	associated	conditions	before	therapy	including	primary	
hypothyroidism	(n=4),	TSH	suppressive	therapy	for	 thyroid	carcinoma	(n=4),	
hyperthyroidism	(n=1)	and	combined	neck	surgery	and	external	beam	radiotherapy	
(n=1).	Furthermore,	3	patients	were	excluded	because	they	had	either	undetected	
hypothyroidism	(n=1)	or	subclinical	hypothyroidism	(n=2)	before	177Lu-octreotate	
therapy	and	were	subsequently	started	on	thyroxine	therapy.	After	the	third	cycle	
of	therapy	one	patient	developed	anti-TPO	antibody-positive	hypothyroidism.	
Another	patient	gradually	developed	primary	hypothyroidism	after	therapy	and	was	
eventually	started	on	substitution	therapy	3.5	years	after	177Lu-octreotate	therapy.	
Thyroid	hormone	levels	from	these	patients	were	included	in	the	analyses	until	
hypothyroidism	was	evident.
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Figure 1. Longitudinal	analyses	of	mean	(±	SEM)	serum	levels	of	(A)	FSH	(dotted	line	with	
open	squares),	Inhibin	B	(black	line	with	open	circles),	(B,C)	LH	(dotted	line	with	filled	
squares)	total	testosterone	(TT;	black	line	with	filled	circles),	sex	hormone	binding	globuline	
(SHBG;	dotted	line	with	filled	triangles),	and	non-SHBG-bound	testosterone	(n-SHBG-bound	
T;	black	line	with	filled	diamonds)	in	35	men	with	SSTR	positive	tumors	before,	during	and	
up	to	24	months	after	600-800	mCi	177Lu-octreotate	therapy.	Bars	along	both	y-axes	represent	
the	reference	range	(4	SD)	values;	*, P	<0.05.
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4The	course	of	the	mean	thyroid	hormone	levels	of	the	included	patients	is	shown	
in	Figure	3. Mean	FT4	decreased	significantly	 from	17.7±0.4	 to	 15.6±0.6	 IU/L	
pmol/L	(reference	range	11-25	pmol/L; P<0.05);	TSH	and	T3	levels	did	not	change	
significantly.	Mean	rT3	concentration	of	0.38±0.03	nmol/L	was	above	the	reference	
range	(0.14-0.34	nmol/L)	before	therapy.	During	therapy	a	significant	18%	decrease	
of	mean	rT3	level	with	a	nadir	of	0.30±0.01	nmol/L	after	a	cumulative	dose	of	400	
mCi	was	found	(P<0.05).	Thereafter	the	mean	rT3	level	increased	slowly	to	0.32±0.03	
nmol/L,	24	months	after	therapy.	The	ratio	of	T3	over	rT3	(T3/rT3),	with	a	T3/rT3	
of	6.24±0.03	at	baseline	was	significantly	elevated	with	a	maximum	of	7.54±0.33	
after	a	cumulative	dose	of	400	mCi	(P<0.05)	after	which	it	returned	to	levels	not	
significantly	different	from	baseline.	
Figure 2.	Longitudinal	analysis	of	mean	(±	SEM)	serum	levels	of	FSH	(dotted	line	with	open	
squares)	and	LH	(dotted	line	with	filled	squares)	in	21	postmenopausal	women	with	SSTR	
positive	tumors	before,	during	and	up	to	24	months	after	600-800	mCi	 177Lu-octreotate	
therapy.	Mean	inhibin	B	and	E2	level	not	shown	as	these	were	at	normal	low	postmenopausal	
levels(<10	ng/L	and	<50	pmol/L,	respectively).	Bars	along	both	y-axes	represent	the	reference	
range	(4	SD)	values;	*, P	<	0.05
In	a	subanalysis,	 in	which	3	groups	of	patients	were	analysed	according	to	their	
outcome	of	tumour	assessment	at	3	months	of	follow-up	(progressive	disease,	PD;	
stable	disease,	SD;.	minor	or	partial	remission,	MR	or	PR)	a	significant	decrease	of	
mean	rT3	(P<0.05)	level	during	therapy	was	demonstrated	in	the	groups	with	SD	and	
MR	or	PR	whereas	in	the	PD	group	no	significant	change	was	observed	(Figure	4).	
An	LDST	was	performed	before	therapy	in	39	patients,	which	showed	stimulated	
cortisol	values	higher	than	the	cut-off	value	of	550	nmol/L	in	all	patients.	The	mean	
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peak	level	after	LDST	was	822±28	nmol/L.	The	LDST	was	repeated	12-18	months	after	
the	last	therapy	in	18	patients	(8	men,	10	women).	All	patients	again	had	stimulated	
cortisol	values	higher	than	550	nmol/L	after	177Lu-octreotate	therapy.	The	mean	peak	
cortisol	response	before	therapy	was	significant	higher	than	after	therapy	(909±57	
nmol/L	vs.	822±35	nmol/L; P<0.001,	n=18)	(Figure	5).	
Figure 3a-c. Longitudinal	analysis	of	mean	(±	SEM)	serum	levels	of	TSH	(dotted	line	with	
filled	triangles),	FT4	(black	line	with	filled	cirlces),	T3	(black	line	with	filled	diamonds),	rT3	
(dotted	line	with	open	triangles),	and	T3/	rT3	ratio	(line	with	open	circles),	of	66	patients	with	
SSTR	positive	tumors	before,	during	and	up	to	24	months	after	600-800	mCi	177Lu-octreotate	
therapy.	Bars	along	y-axes	represent	the	reference	range	(4	SD)	values;	*, P <0.05.
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4Nine	out	of	79	patients	had	diabetes	mellitus	diagnosed	before	treatment	and	were	
either	on	subcutanous	 insulin	 therapy	(n=4)	or	oral	antihyperglycemic	agents	
(n=5).	Furthermore,	one	patient	had	an	insulinoma	and	another	patient	had	an	
abnormal	hemoglobin	pattern	and	therefore	serum	unfit	for	HbA1c	measurement.	
Five	patients	had	elevated	HbA1c	(>6.5%)	before	177Lu-octreotate	therapy	of	whom	3	
were	started	on	oral	antihyperglycemic	drugs	during	or	after	177Lu-octreotate	therapy.	
Six	patients	developed	high	levels	of	HbA1c	after	PRRT.	In	one	patient	this	occurred	
after	pancreatic	surgery.	In	the	other	5	patients,	elevated	HbA1c	levels	occurred	after	
2-30	months	from	study	inclusion	(Table	2).	Analysis	in	69	patients	demonstrated	a	
decrease	of	HbA1c	from	5.7±0.1	to	5.5±0.1%	(P<0.05)	during	therapy,	but	an	increase	
to	6.0±0.1%	(P<0.05)	thereafter.
Figure 4.	Longitudinal	analysis	of	mean	(±	SEM)	serum	levels	of	rT3	in	patients	with	SSTR	
positive	 tumors	before,	during	and	at	3	months	of	 follow-up	after	600-800	mCi	 177Lu-
octreotate	therapy	grouped	according	to	their	therapy	outcome	(partial	remission	and	minor	
remission,	PR/MR;	filled	circles;	stable	disease,	SD,	filled	diamonds;	progressive	disease,	PD,	
filled	triangles)	at	3	months	of	follow-up.	Bar	along	the	y-axis	represent	the	reference	range	
values.	*, P	<	0.05.
150
Figure 5. Mean	peak	cortisol	response	with	the	low	dose	(1	µg)	ACTH	stimulation	test	in	18	
patients	before	and	12-18	months	after	177Lu-octreotate	therapy	are	shown.	Each	dotted	line	
connects	one	individual	patient.
Table 2.	Number	of	patients(n)	who	were	evaluable	for	HbA1c	percentages	based	on	
their	HbA1c	percentage	at	baseline	and	after	177Lu-octreotate	therapy.	Patients	excluded	
at	baseline	were	medically	treated	patients	with	diabetes	(n=9),	one	patient	who	had	
an	insulinoma	and	one	patient	had	with	an	abnormal	hemoglobin	pattern.
Posttherapy
HbA1c	(in	%) n	≤	6.5 n	>	6.5 Total
B
as
el
in
e
n	>	6.5 0	(0%) 5	(100%) 5
n	≤	6.5 57	(90%) 6*	(10%) 63
Total 57 11 68
*, one patient developed elevated levels of HbA1c after Whipple surgery
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4DISCUSSION
Besides	the	currently	known	complications	and	adverse	effects	due	to	the	non-specific	
radiation	absorbed	doses	to	the	bone	marrow	and	kidneys,	specific	receptor-related	
effects	on	non-tumourous	tissue	by	PRRT	have	not	been	studied	in	detail.	SSTRs	
are	expressed	in	most	hormone	secreting	organs,	such	as	pituitary	gland,	pancreas,	
thyroid	and	adrenals,	as	evidenced	by	in vitro	studies	as	well	as	by	the	physiological	
uptake	in vivo	during	somatostatin	receptor	scintigraphy10,	17-20.	Although	the	receptor	
density	of	SSTRs	in	normal,	non-pathologic	hormone	secreting	organs	is	not	as	
high	as	observed	in	neuroendocrine	tumours,	the	presence	of	SSTRs	implicates	the	
possibility	of	specific	receptor-mediated	targeting	by	radiolabelled	somatostatin	
analogues.	Furthermore,	as	the	radiopharmaceuticals	used	in	PRRT	are	systemically	
administered,	all	organs	will	receive	an	additional	non-specific	dose,	including	those	
organs	that	are	known	to	be	radiosensitive	(e.g.	the	gonads).	
Fifteen	out	of	35	(43%)	of	our	male	patients	had	evidence	of	hypogonadism	prior	
to	PRRT.	Gonadal	dysfunction	 in	patients	with	disseminated	cancer	prior	 to	
chemotherapeutic	treatment	has	been	reported	by	Chlebowski	et al.	21.	A	relationship	
between	markedly	decreased	gonadal	function	and	weight	loss	was	also	observed.	
Furthermore,	other	factors,	including	age,	history	of	alcohol	intake,	and	liver	disease	
have	been	reported	to	have	effects	on	the	TT	levels	in	male	patients	22.	As	there	are	
many	factors	that	may	cause	decreased	TT	levels,	a	specific	or	common	cause	of	
the	high	percentage	of	hypogonadism	within	our	group	of	patients	before	PRRT	
is	difficult	to	point	out.	Because	of	the	very	similar	patterns	of	hormonal	changes	
observed	after	PRRT	in	men	with	normal	or	low	levels	of	TT	before	therapy	(data	not	
shown),	it	is	likely	that	these	additional	factors	did	not	contribute	to	the	observed	
change	in	hormone	levels	in	our	study.	
Decrease	of	mean	TT	level	coincided	with	a	decrease	of	SHBG	level,	whereas	the	mean	
non-SHBG-bound-T	remained	stable	after	PRRT.	These	observations	are	in	line	with	
findings	of	de	Ronde	et al.	23	who	demonstrated	a	strong	positive	relationship	between	
SHBG	and	TT	levels	and	no	or	only	a	weak	positive	association	between	SHBG	and	
circulating	non-SHBG-bound-T	levels.	Because	SHBG	correlates	negatively	with	
BMI	24,	a	possible	explanation	for	the	decrease	of	SHBG	is	the	significant	increase	
of	body	mass	index	(BMI)	in	our	patients	from	24.0±0.7	kg.m-2	to	a	maximum	of	
25.3±0.8	kg.m-2	at	12	months	of	follow-up.	Furthermore,	we	found	a	weak	positive,	
but	significant	correlation	(Spearman’s	rho	=	0.29,	p=0.01)	between	FT4	and	SHBG	
(data	not	shown).	Correlation	between	FT4	and	SHBG	was	demonstrated	during	
thyroid	hormone	replacement	therapy	in	hypothyroid	men	by	Cavaliere	et al.	 25.	
However,	whether	the	relatively	small	increase	of	mean	BMI	or	the	limited	decline	
in	mean	FT4	level	observed	in	our	study	is	responsible	for	the	marked	decline	of	
SHBG	is	questionable.	In	theory,	impaired	liver	function	after	therapy	can	also	cause	
152
decreased	SHBG	levels.	This	is	unlikely,	however,	because	of	unchanged	albumin	
levels	and	stable	or	decreased	serum	levels	of	gamma-GT,	alkaline	fosfatase,	ASAT	
and	ALAT	throughout	the	whole	study	period	(data	not	shown).	
Our	data	indicate	that	transient	impairment	of	spermatogenesis	occurs	following	
PRRT.	A	significant	decrease	of	mean	serum	inhibin	B	levels	with	a	concomitant	
increase	in	FSH	levels	was	observed,	with	recovery	to	almost	pretreatment	levels	
after	24	months.	This	is	in	line	with	several	studies	in	patients	with	differentiated	
thyroid	carcinoma	who	received	radioiodine	therapy	26-29.	 Inhibin	B	is	produced	
in	the	Sertoli	cells	of	the	testis	and	is	the	major	feedback	regulator	of	FSH	30,	31.	It	
has	been	demonstrated	that	serum	inhibin	B	levels	are	positively	correlated	with	
spermatogenic	status	and	sperm	count	32,	33.	Therefore,	although	we	did	not	perform	
semen	analyses,	our	results	likely	indicate	temporarily	impaired	spermatogenesis.	
Both	the	gonadal	and	pituitary	gland	function	are	potentially	at	risk	after	PRRT.	
Effects	on	gonadotroph	levels	after	 177Lu-octreotate	therapy	was	demonstrated	in	
postmenopausal	women.	A	significant	decrease	in	both	FSH	and	LH	was	found.	The	
observed	decrease	in	mean	FSH	and	LH	level	of	approximately	12.5%	and	8.2%	per	
year,	respectively,	was	higher	than	could	be	expected	because	of	ageing	as	such.	In	
a	study	of	680	postmenopausal	women,	the	decrease	of	gonadtropin	levels	between	
the	ages	of	55	and	75	years	was	less	than	1%	per	year	34.
Two	out	of	66	(3%)	patients	developed	primary	hypothyroidism	after	treatment.	One	
patient	had	hypothyroidism	with	the	development	of	anti-TPO	antibodies	suggesting	
autoimmune	induced	hypothyroidism.	The	other	patient	had	slowly	progressive	
primary	hypothyroidism	and	was	put	on	 substitution	 therapy	3.5	years	 after	
177Lu-octreotate	therapy.	Thyroid	hormone	analyses	of	the	total	group	demonstrated	
a	significant	decrease	of	FT4	at	the	end	of	the	study	period.	This	is	 in	line	with	
a	significant	decrease	of	FT4	levels	we	reported	earlier	5.	The	decline	of	FT4	was	
not	accompanied	by	a	significant	increase	of	TSH	or	T3,	though	trends	towards	an	
increase	and	decrease,	respectively,	were	noticed.	Of	interest,	analysis	excluding	the	
two	hypothyroid	patients	revealed	no	significant	change	in	FT4,	TSH	or	T3.	Since	
chronicity	and	severity	of	disease	might	have	an	impact	on	the	thyroid	hormone	
status	and	even	can	induce	non-thyroidal	illness	(NTI),	the	observed	changes	of	
thyroid	hormones	in	the	long-term	could	reflect	the	development	of	NTI	rather	
than	the	effect	of	PRRT.	Signs	of	NTI	were	observed	at	baseline	with	an	increased	
mean	level	of	rT3.	Specific	changes	in	thyroid	hormone	levels	were	reported	to	
correlate	with	the	severity	of	illness	or	even	to	be	prognostic	for	survival	in	critically	
ill	patients	35.	Directly	after	the	first	cycle	of	PRRT,	rT3	returned	to	reference	range	
values.	Thereafter,	rT3	slowly	increased	but	remained	within	the	normal	reference	
range.	The	active	over	inactive	thyroid	hormone	(T3/rT3)	ratio	had	a	similar,	but	
inverse	pattern.	These	changes	suggest	a	rapid	change	to	a	more	favorable	disease	
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4state	directly	after	initiation	of	PRRT	and	which	persists	during	follow-up.	A	sub-
analysis	of	patients	according	to	therapy	outcome	indicated	that	patients	who	had	PD	
had	a	no	significant	change	in	rT3	level,	whereas	the	other	patients	had	a	significant	
decrease,	returning	to	the	normal	range	during	therapy.	Therefore,	in	our	group	
of	patients,	the	change	in	rT3	and	T3/rT3	ratio	probably	reflected	changes	in	the	
disease	status.	
The	hypothalamo-pituitary-adrenal	(HPA)	axis	is	not	affected	by	PRRT	in	terms	
of	 intact	 adrenal	 reserve.	All	patients	had	adequate	 responses	with	 the	LDST	
before	therapy.	Additionally,	adequate	responses	in	eighteen	patients	after	therapy	
indicated	no	apparent	primary	or	secondary	adrenal	 insufficiency.	The	LDST	is	
a	valid	replacement	for	the	commonly	used	short	synacthen	test	and	the	insulin	
tolerance	test	(ITT),	of	which	the	latter	is	widely	regarded	as	the	gold	standard	test	
for	the	integrity	of	the	HPA	axis	36.	Unfortunately,	the	ITT	is	not	completely	safe,	
costly	and	difficult	to	perform	in	an	outpatient	setting,	thus	hampering	its	clinical	
use.	An	LDST	peak	cortisol	response	higher	than	550	nmol/L	was	observed	in	all	
patients	and	was	regarded	as	a	sufficient	response	indicating	sustained	integrity	of	
the	HPA-axis.	In	a	recent	meta-analysis	on	the	diagnosis	of	adrenal	insufficiency,	it	
was	concluded	that	a	cut-off	value	between	500	and	600	nmol/L	cortisol	is	necessary	
to	achieve	reasonable	sensitivity	for	the	detection	of	both	primary	and	secondary	
adrenal	insufficiency	37.
Interestingly,	mean	peak	cortisol	level	after	PRRT	was	significantly	lower	than	before	
therapy.	Whether	this	subtle	difference	in	LDST	response	after	therapy	reflects	
radiation-induced	mild	partial	adrenal	insufficiency	or	simply	a	less	stressful	state	
of	the	patients	is	not	clear.	However,	Schmiegelow	et al.,	reported	similar	findings	
in	73	patients	treated	with	radiotherapy	and	chemotherapy	for	childhood	brain	
tumours	with	a	mean	follow-up	of	15	years	38.	Nineteen	percent	of	the	patients	had	
insufficiency	of	the	HPA	axis,	whereas	the	remainder	of	patients,	even	though	an	
adequate	response	to	an	ACTH	test	or	ITT,	had	lower	peak	cortisol	levels	compared	
with	controls.	The	external	beam	radiotherapy,	not	chemotherapy,	was	regarded	as	
the	main	factor	that	had	contributed	to	the	observed	adrenal	insufficiency.	It	was	
concluded	that	this	latter	group	might	be	potentially	at	risk	of	becoming	HPA	axis	
insufficient	in	the	future.	Life-long	follow-up	was	recommended	in	these	patients.	
Although	it	 is	difficult	to	compare	 177Lu-octreotate	therapy	with	external	beam	
radiation	therapy	in	terms	of	dose-tempo,	exposure	area	and	period	of	follow-
up,	these	studies	indicate	that	despite	the	adequate	LDST	responses	found	in	our	
patients,	awareness	of	a	radiation-induced	disturbance	of	the	HPA-axis	is	important	
in	the	long-term	follow-up.	
154
Five	patients	out	of	62	(8%)	developed	increased	levels	of	HbA1c	after	177Lu-octreotate	
therapy	without	any	obvious	cause,	such	as	subsequent	pancreatic	surgery.	Pancreatic	
islets	express	somatostatin	receptors,	especially	the	subtype	SSTR2a	39.	However,	
46%	of	our	patients	used	somatostatin	analogues,	such	as	octreotide,	during	and/or	
after	therapy.	Therefore,	besides	the	possibility	of	a	direct	radiation	effect	as	the	cause	
of	the	observed	subtle,	but	significant	increase	of	mean	HbA1c	after	therapy,	long-term	
treatment	with	somatostatin	analogues,	could	have	contributed	as	well.
In	conclusion,	in	men	177Lu–octreotate	therapy	induced	transient	inhibitory	effects	on	
spermatogenesis,	but,	non-SHBG-bound-T	levels	remained	unaffected.	In	the	long-
term,	gonadotropin	levels	decreased	significantly	in	postmenopausal	women.	Only	
few	patients	developed	hypothyroidism	or	elevated	levels	of	HbA1c.	No	clinically	
apparent	relevant	effects	was	observed	on	pituitary-adrenal	 function.	Despite	
temporary	and	minor	hormonal	changes,	PRRT	with	177Lu–octreotate	can	be	regarded	
as	a	safe	treatment	modality	with	respect	to	the	short	and	long-term	endocrine	
function.
We	conclude	that	patients	who	are	treated	with	177Lu-octreotate	therapy	may	develop	
radiation-induced	hormone	disturbances,	some	of	which	have	been	proven	to	
be	temporary,	and	which	are	in	general	mild.	No	severe	hormone	inbalance	was	
observed	and,	therefore,	177Lu-octreotate	therapy,	in	terms	of	endocrine	sequelae,	can	
be	regarded	as	safe.	However,	awareness	of	the	possibility	of	changes	in,	and	thereby	
surveillance	of,	the	endocrine	status,	is	important	and	implicates	the	necessity	of	
future	studies.	
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Abstract
Purpose 	
Patients	with	somatostatin	receptor	subtype	2-positive	metastasised	neuroendocrine	
tumours	can	be	treated	with	[177Lu-DOTA0,Tyr3]octreotate.	Some	use	octreotide	
as	the	peptide	for	peptide	receptor	radionuclide	therapy	(PRRT).	We	compared	
in	 seven	 patients 	 [ 17 7Lu-DOTA0,Tyr3]octreotide	 ( 17 7Lu-DOTATOC)	 and	
[177Lu-DOTA0,Tyr3]octreotate	(177Lu-DOTATATE),	to	see	which	peptide	should	be	
preferred	for	PRRT	with	177Lu.	
Methods 	
In	the	same	patients,	3,700	MBq	177Lu-DOTATOC	and	3,700	MBq	177Lu-DOTATATE	
was	administered	in	separate	therapy	sessions.	Amino	acids	were	co-administered.	
Whole-body	scanning	was	performed	on	days	1,	4	and	7	posttherapy.	Blood	and	
urine	samples	were	collected.	We	calculated	residence	times	for	tumours,	spleen	
and	kidneys.	
Results	
	All	patients	had	longer	residence	times	in	spleen,	kidneys	and	tumours	after	use	
of	 177Lu-DOTATATE	(p=0.016	in	each	case).	Comparing	 177Lu-DOTATATE	with	
177Lu-DOTATOC,	the	mean	residence	time	ratio	was	2.1	for	tumour,	1.5	for	spleen	and	
1.4	for	kidneys.	Dose	limiting	factors	for	PRRT	are	bone	marrow	and/or	kidney	dose.	
Although	the	residence	time	for	kidneys	was	longer	when	using	177Lu-DOTATATE,	
the	mean	administered	dose	to	tumours	would	still	be	advantageous	by	a	factor	of	
1.5,	assuming	a	fixed	maximum	kidney	dose	is	reached.	Plasma	radioactivity	after	
177Lu-DOTATATE	was	comparable	to	that	after	177Lu-DOTATOC.	Urinary	excretion	
of	radioactivity	was	comparable	during	the	first	6	h;	thereafter	there	was	a	significant	
advantage	for	177Lu-DOTATOC.	
Conclusion  
177Lu-DOTATATE	had	a	longer	tumour	residence	time	than	177Lu-DOTATOC.	Despite	
a	longer	residence	time	in	kidneys	after	177Lu-DOTATATE,	tumour	dose	will	always	
be	higher.	Therefore,	we	conclude	that	the	better	peptide	for	PRRT	is	octreotate.
Abstract
5
INTRODUCTION
One	of	the	new	treatment	modalities	for	metastasised	neuroendocrine	gastro-entero-
pancreatic	(GEP)	tumours—	taking	its	place	alongside	surgery,	(chemo)embolisation,	
chemotherapy	and	treatment	with	somatostatin	analogues	—is	peptide	receptor	
radionuclide	therapy	(PRRT).	Since	2000	we	have	treated	patients	with	somatostatin	
receptorpositive	pathology	with	[177Lu-DOTA0,Tyr3]octreotate;	in	most	cases	these	
patients	have	had	metastasised	neuroendocrine	tumours	(NETs).	An	analysis	of	131	of	
the	more	than	400	treated	patients	with	so-called	GEP	tumours	was	performed	after	
obtaining	all	results	following	completion	of	treatment.	A	decrease	in	tumour	size	
was	found	in	47%,	stable	disease	in	35%	and	tumour	progression	despite	treatment	
in	18%	1.	A	significant	improvement	in	quality	of	life	in	those	patients	with	tumour	
regression	was	also	noted	2.	The	average	duration	of	the	effect	of	therapy	was	more	
than	36	months,	calculated	from	the	start	of	therapy.	From	these	figures	it	seems	
that	PRRT	is	a	promising	choice	of	treatment	for	metastasised	neuroendocrine	GEP	
tumours.	Some	research	groups	use	radiolabelled	octreotide	for	PRRT	3,	4	whereas	we	
use	radiolabelled	octreotate	as	the	peptide,	this	approach	being	supported	by	evidence	
from	different	sources.	Reubi	et al.	reported	that	octreotate	has	a	higher	affinity	than	
octreotide	for	somatostatin	receptor	subtype	sst2	5.	De	Jong	et al.	compared	in	vitro	and	
in	vivo	111In-labelled	somatostatin	analogues	for	tumour	scintigraphy	and	radionuclide	
therapy	in	the	same	somatostatin	receptor-positive	rat	CA20948	pancreatic	tumour.	
DTPA-chelated	octreotate	had	the	highest	uptake	in	the	target	organs	6.	Further,	
the	same	authors	investigated	[177Lu-DOTA0,Tyr3]octreotate	in	biodistribution	and	
radionuclide	therapy	experiments	using	Lewis	rats	bearing	the	CA20948	tumour	
and	reported	excellent	results	of	radionuclide	therapy,	especially	in	animals	bearing	
smaller	tumours	 7.	Capello	and	co-workers	evaluated	the	therapeutic	effects	of	
somatostatin	analogues	chelated	with	DOTA	and	labelled	with	90Y	or	177Lu	in	an	in	
vitro	colony-forming	assay	using	the	rat	pancreatic	tumour	cell	line	CA20948.	They	
concluded	that	[DOTA0,Tyr3]octreotate	labelled	with	177Lu	or	90Y	is	the	most	promising	
analogue	for	PRRT	8.	Nilsson	et al.	studied	the	biokinetics	and	therapeutic	effect	of	
radiolabelled	somatostatin	analogues	on	a	midgut	carcinoid	(GOT1)	grafted	to	nude	
mice.	They	tested	[111In-DTPA-D-Phe1]octreotide	and	[177Lu-DOTA0,Tyr3]octreotate,	
and	concluded	that	octreotate	is	the	most	promising	peptide	for	use	in	treatment	
9.	Schmitt	et al.	 compared	the	biodistribution	of	 [177Lu-DOTA0,Tyr3]octreotate,	
[111In-DTPA]octreotide	and	99mTc-depreotide	in	nude	mice	bearing	tumours	from	
the	human	SCLC	cell	line	NCI-H69.	[177Lu-DOTA0,Tyr3]octreotate	gave	the	highest	
tumour	activity	concentration	10.	Kwekkeboom	et al.	found	in	a	comparison	with	
[111In-DTPA0]octreotide	in	patients	a	three-	to	fourfold	higher	tumour	uptake	with	
[177Lu-DOTA0,Tyr3]octreotate	11.	In	summary,	all	these	studies	showed	that	octreotate	
might	be	the	better	candidate	for	PRRT.	However,	recently	Forrer	et al.	could	not	
find	a	significant	difference	when	comparing	111In-DOTATOC	and	111In-DOTATATE	
in	five	patients	with	metastasised	NETs	12.	So	far,	however,	no	comparison	between	
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[177Lu-DOTA0,Tyr3]octreotide	(177Lu-DOTATOC)	and	[177Lu-	DOTA0,Tyr3]octreotate	
(177Lu-DOTATATE)	has	been	published.	Therefore	we	decided	to	compare	octreotide	
with	octreotate	in	therapeutic	doses	in	the	same	patients	to	investigate	which	is	the	
preferable	peptide	for	PRRT.	Randomly,	we	selected	patients	who	came	for	PRRT	and	
divided	the	usual	first	therapeutic	dose	of	7,400	MBq	(200	mCi)	into	two	separate	
doses/treatments,	each	of	3,700	MBq	(100	mCi)	177Lu.	In	order	to	exclude	possible	
therapeutic	effects,	one	group	started	with	octreotide	as	the	peptide	and	one	group	
with	octreotate,	then	switching	to	the	other	peptide	for	the	second	therapy.
MATERIAL AND METHODS
Patients
Four	male	patients	(age	44–64,	mean	59	years)	and	three	female	patients	(age	43–67,	
mean	56	years)	with	known	NETs	were	injected	with	3,700	MBq	177Lu-DOTATATE	
or	177Lu-DOTATOC.	Four	patients	received	177Lu-DOTATOC	for	the	first	treatment	
and	three,	177Lu-DOTATATE;	as	already	mentioned,	the	second	treatment	was	with	
the	other	peptide.	Three	patients	had	NETs	of	the	pancreas,	two	a	midgut	carcinoid,	
one	a	carcinoid	of	unknown	primary	and	one	a	carcinoid	of	the	lung.	All	except	
one	patient	with	a	NET	of	the	pancreas	had	metastases.	The	interval	between	the	
two	therapies	was	8	weeks.	Long-acting	somatostatin	analogues	were	stopped	at	
least	6	weeks	before	treatment	and	short-acting	analogues	were	stopped	at	least	24	
hours	before	treatment.	All	patients	had	a	histologically	proven	NET	and	had	never	
previously	had	PRRT.	Tumour	sites	were	confirmed	by	CT	or	MRI	together	with	
a	positive	OctreoScan.	All	patients	gave	informed	consent	to	participation	in	the	
study,	which	was	approved	by	the	hospital’s	ethics	committee.	
Radiopharmaceuticals
Both	 somatostatin	 analogues,	 [DOTA0,Tyr3]octreotide	 (DOTATOC)	 and	
[DOTA0,Tyr3]octreotate	(DOTATATE),	were	synthesised	according	to	previously	
published	procedures	 11	and	labelled	with	 177Lu	(obtained	from	NRG,	Petten,	the	
Netherlands	and	distributed	by	IDB-Holland,	Baarle	Nassau,	the	Netherlands).	
Infusion
To	prevent	nausea,	first	granisetron	3	mg	was	injected	i.v.;	thereafter	an	infusion	
of	amino	acids	(lysine	2.5%,	arginine	2.5%	in	1	l	0.9%	NaCl:	250	ml/h)	was	started	
30	min	before	the	administration	of	the	radiopharmaceutical	and	lasted	in	total	for	
4	h.	The	radiopharmaceutical	was	co-administered	in	30	min	via	a	second	pump	
system.
C
om
pa
ri
so
n 
o��
 [1
77
Lu
-D
O
TA
0
,T
yr
3 ]
oc
tr
eo
ta
te
 a
nd
 [1
77
Lu
-D
O
TA
0
,T
yr
3 ]
oc
tr
eo
ti
de
: w
hi
ch
 p
ep
ti
de
 is
 p
re
��e
ra
bl
e 
��o
r P
R
R
T?
5Imaging 
All	imaging	was	done	on	a	Picker	Prism	2000	XP	dual-head	gamma	camera.	Counts	
from	both	gamma	peaks	of	177Lu	(208	and	113	keV)	were	collected	in	separate	windows	
(width	20%).	Parallel-hole,	medium-energy	general-purpose	collimators	were	used.	
Whole-body	scans	of	40	min	were	obtained	24	h	and	4	and	7	days	post	therapy.	A	
known	aliquot	of	radioactivity	was	placed	between	the	patients’	knees	to	enable	
calculation	of	the	uptake	in	spleen,	kidneys	and	tumours.	
Measurement of radioactivity in blood and urine
Blood	samples	were	taken	10	min	after	the	infusion	of	the	radiopharmaceutical	
had	been	completed	and	30	min,	60	min,	4	h,	24	h,	4	days	and	7	days	thereafter.	
Urine	was	collected	in	four	intervals:	0–3,	3–6,	6–12	and	12–24	h	after	infusion.	
Radioactivity	in	these	samples	was	measured	with	a	gamma	counter	(LKB-Wallac	
1282	Compugamma,	Turku,	Finland)	and	a	dose	calibrator	(VDC-202,	Veenstra	
instrumenten	B.V.,	Joure,	the	Netherlands).	
Methods
Regions	of	interest	(ROIs)	were	drawn	manually	on	the	whole-body	scans	over	
kidneys,	spleen	and	tumours.	Regions	were	placed	close	to	the	ROIs	for	background	
correction.	Organs	showing	superimposition	of	tumour	were	excluded	for	evaluation	
of	organ	residence	time.	No	attenuation	correction	was	performed	because	every	
patient	was	his/her	own	control.	Instead,	the	ratio	of	residence	time	in	the	organs	
and	tumours	between	the	two	therapies	was	considered	most	important.	The	dose	
measured	before	infusion	minus	the	residual	radioactivity	in	the	infusion	system	
after	administration	was	defined	as	100%.	All	data	were	expressed	as	percentage	of	
this	100%.
Statistics
Analysis	of	variance	(ANOVA)	and	Sign	tests	were	used	for	statistical	analysis.	
P values	<0.05	were	considered	significant.
RESULTS
As	can	be	seen	in	Figure	1,	for	both	peptides	there	was	fast	clearance	from	the	blood	
expressed	as	percentage	of	injected	activity	(%IA),	resulting	in	a	decrease	to	less	than	
10%	within	the	first	3	h.	During	the	first	day	the	blood	clearance	of	177Lu-DOTATOC	
was	slightly	faster	than	that	of	177Lu-DOTATATE,	but	the	difference	did	not	reach	
significance	(ANOVA	test	P>0.05).	Thereafter	the	blood	clearance	for	both	peptides	
was	nearly	the	same.	
164
Figure 1.	Serum	radioactivity	expressed	as	mean	percentage	injected	activity	(%IA)
The	cumulative	excreted	activity	in	the	urine	was	higher	for	177Lu-DOTATOC	than	
for	177Lu-DOTATATE,	at	81%	versus	71%	(Figure	2).	This	was	significant	for	the	time	
periods	0–12	h	(ANOVA	P=0.045)	and	0–24	h	(ANOVA	P=0.026).	
The	biodistribution	pattern	for	the	two	peptides	was	nearly	the	same.	However,	the	
residence	time	of	radioactivity	in	the	tumours	was	significantly	longer	in	all	patients	
after	177Lu-DOTATATE	(Table	1;	Sign	test,	P=0.016).	Comparing	177Lu-DOTATATE	
with	177Lu-DOTATOC,	the	mean	ratio	of	the	tumour	residence	time	was	2.1	(Figure	3).	
Similarly,	the	residence	times	in	the	spleen	and	the	kidneys	were	significantly	longer	
after	177Lu-DOTATATE	(Sign	test,	P=0.016	for	both	spleen	and	kidneys).	Comparing	
177Lu-DOTATATE	with	177Lu-DOTATOC,	the	mean	ratio	of	the	residence	time	was	
1.5	for	spleen	and	1.4	for	kidneys.	
DISCUSSION
Treatment	options	for	inoperable,	metastasised	NETs	are	limited.	Usually,	treatment	
with	somatostatin	analogues	is	started	if	patients	suffer	from	syndromes	caused	by	
hormonal	overproduction	by	the	tumours.	Although	usually	very	rewarding	in	terms	
of	symptom	control,	such	treatment	seldom	results	in	tumour	growth	remission.	If	
the	tumour	is	progressive,	chemo-embolisation	or	embolisation	of	liver	metastases	
may	be	effective	if	the	bulk	of	the	tumour	is	situated	within	the	liver	13,	14.	Radiological	
expertise	in	this	procedure	has	to	be	available,	however.	
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5	
Figure 2. Cumulative	radioactivity	excreted	in	urine,	expressed	as	mean	(±SEM)	percentage	
injected	activity	(%IA)
Another	option	is	chemotherapy.	O’Toole	et al.	reviewed	the	use	of	chemotherapy	
for	GEP	tumours	and	found	that	the	published	series	evaluating	chemotherapy	for	
midgut	endocrine	tumours	were	outdated	and	had	yielded	disappointing	results.	
Thus	the	objective	response	rates	with	combination	chemotherapy	(including	
5-fluorouracil	and/or	streptozotocin)	rarely	exceeded	20%.	These	authors	reported	
that	only	for	the	relatively	rare	poorly	differentiated	GEP	tumours	is	chemotherapy,	
using	cisplatin	and	etoposide,	the	reference	treatment:	objective	response	rates	of	
>50%	were	achieved	in	such	patients,	but	despite	the	chemosensitivity	of	these	
tumours,	disease	control	was	limited	(8–10	months)	15.	Öberg	also	reviewed	chemo-
therapy	and	biotherapy	in	the	treatment	of	NETs.	He	reported	that	streptozotocin-
based	combinations	including	5-fluorouracil	and	doxorubicin	resulted	in	partial	
remissions	in	40–60%	of	the	patients,	with	a	median	survival	of	about	2	years	in	
patients	with	advanced	disease.	Cisplatin	plus	etoposide	demonstrated	significant	
anti-tumour	effects	in	anaplastic	endocrine	pancreatic	tumours	and	lung	carcinoids.	
However,	for	classical	midgut	carcinoids,	the	same	combination	of	cytotoxic	agents	
resulted	in	short-lasting	responses	in	only	10%	of	patients	 16.	Summarising,	the	
results	of	chemotherapy	are	disappointing	in	the	most	common	NETs,	the	midgut	
carcinoids.	Although	results	are	somewhat	better	for	pancreatic	NETs,	the	reported	
time	to	progression	and	the	duration	of	survival	are	relatively	short.	Therefore,	
chemotherapy	is	best	reserved	for	patients	with	relatively	rare	undifferentiated	or	
anaplastic	NETs.	
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A	relatively	new	treatment	modality	is	radiolabelled	somatostatin	analogues.	Various	
peptides	and	radionuclides	have	been	used.	The	most	commonly	used	peptides	are	
[DOTA0,Tyr3]octreotide	(DOTATOC)	and	[DOTA0,	Tyr3]octreotate	(DOTATATE),	
labelled	with	either	90Y	or	177Lu.	We	compared	177Lu-DOTATOC	and	177Lu-DOTATATE	
in	a	therapeutic	setting	and	within	the	same	patients.	
Our	assumption	that	octreotate	is	the	preferable	peptide	when	labelling	it	with	
177Lu	was	confirmed.	We	found	a	longer	residence	time	in	the	tumours	in	all	our	
patients	after	177Lu-DOTATATE	treatment	compared	with	177Lu-DOTATOC,	leading	
to	a	higher	absorbed	tumour	dose.	The	mean	difference	was	statistically	significant	
(P=0.016).	A	longer	residence	time	is	especially	of	interest	when	using	radionuclides	
with	a	longer	half-life	(6.7	days	for	177Lu	compared	with	2.7	days	for	90Y).	
Reubi	et al.	evaluated	the	in	vitro	binding	characteristics	of	different	somatostatin	
radiotracers,	among	which	were	labelled	and	unlabelled	DOTATOC	and	DOTATATE.	
They	showed	a	higher	binding	affinity	to	somatostatin	receptor	subtype	2	(sst2)	for	
90Y-DOTATATE	than	for	90Y-DOTATOC	5.	Our	findings	are	in	concordance	with	
those	of	Reubi	et al.:	we	found	a	significantly	longer	residence	time	in	the	tumours	
and	in	the	spleen	using	DOTATATE.	We	also	found	that	177Lu-DOTATATE	shows	
higher	affinity	for	sst2	compared	with	177Lu-	DOTATOC.	
Forrer	et al.	 12	compared	111In-DOTATOC	and	111In-	DOTATATE.	They	used	111In	as	
a	surrogate	for	90Y	and	found	comparable	data	for	the	two	peptides	with	regard	to	
tumour-to-kidney	ratios.	Therefore	they	concluded	that	they	would	continue	with	
therapy	using	90Y-DOTATOC.	
The	assumption	that	 111In	 is	comparable	 to	 90Y	 is	disputable.	 In	2000,	Reubi	et 
al.	tested	the	affinity	of	different	somatostatin	radiotracers.	There	was	a	marked	
difference	in	affinity	after	small	structural	changes	in	the	radioligand	molecule,	the	
introduction	of	a	metal,	the	replacement	of	one	metal	by	another	or	the	replacement	
of	one	chelator	by	another	5.	
Forrer	et al.	also	assumed	that	a	diagnostic	investigation	with	222	MBq	111In	could	
be	translated	to	a	therapeutic	session	12.	They	used	only	10	µg	peptide	to	predict	the	
outcome	of	a	therapeutic	dose	with	a	significantly	higher	peptide	concentration.	For	
our	evaluation	we	used	200	µg	of	peptide	with	3,700	MBq	of	activity.	The	amount	
of	peptide	that	we	typically	use	when	administering	177Lu-DOTATATE	is	130–210	
µg,	depending	on	the	specific	activity	of	the	radionuclide;	therefore,	we	think	that	
our	setup	is	far	more	comparable	to	the	usual	therapeutic	conditions.	
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Figure 3.	Planar	anterior	whole-body	scans	1	day	post	therapy,	after	177Lu-DOTATOC	(left)	
and	after	177Lu-DOTATATE	(right).	Patient	numbers	correspond	to	those	in	Table	1.
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5The	pharmacokinetics	of	177Lu-DOTATOC	and	177Lu-DOTATATE	in	our	study,	such	
as	urinary	excretion	and	blood	clearance,	were	nearly	the	same	compared	to	the	
results	of	Forrer	et al.	One	of	the	dose-limiting	factors	for	PRRT	can	be	the	total	
kidney	dose.	Comparing	177Lu-DOTATATE	with	177Lu-DOTATOC,	we	found	a	2.1	
times	longer	tumour	residence	time	of	the	radioactivity	after	 177Lu-DOTATATE,	
leading	to	a	higher	absorbed	tumour	dose.	The	residence	time	ratio	for	the	kidneys	
(1.4)	was	lower	than	that	for	tumours.	Consequently,	in	general	one	can	say	that	
tumours	treated	with	177Lu-DOTATATE	will	always	receive	a	higher	total	dose	of	
radioactivity	than	those	treated	with	177Lu-DOTATOC.	Even	if	one	assumes	that	
a	certain	maximum	total	dose	can	be	given	that	is	determined	by	the	maximum	
radiation	absorbed	dose	to	the	kidneys,	there	will	still	be	a	higher	radiation	absorbed	
dose	to	the	tumour	after	177Lu-DOTATATE,	given	that	division	of	the	mean	tumour	
residence	time	ratio	(2.1)	by	the	mean	kidney	residence	time	ratio	(1.4)	yields	a	
factor	of	1.5	in	favour	of	 177Lu-DOTATATE.	Furthermore,	we	know	from	our	own	
unpublished	data,	obtained	in	more	than	400	patients,	that	in	70%	of	patients	treated	
with	177Lu-DOTATATE,	the	maximum	dose	allowed	for	a	presumed	bone	marrow	
absorbed	dose	of	2	Gy,	i.e.	29,600	MBq	or	800	mCi,	determines	treatment	cessation,	
and	not	the	maximum	allowed	kidney	dose	of	23	Gy.	Therefore,	in	most	patients,	the	
mean	tumour	residence	time	ratio	of	2.1	in	favour	of	177Lu-DOTATATE	will	apply.	
In	conclusion,	[177Lu-DOTA0,Tyr3]octreotate	demonstrated	a	significantly	longer	
tumour	residence	time	than[177Lu-DOTA0,Tyr3]octreotide	 in	patients	with	sst2	
receptor-positive	metastasised	NETs.	Therefore,	when	labelled	with	177Lu,	octreotate	
is	the	preferred	peptide	for	PRRT.
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Radiolabelled somatostatin analogues 
and di����erentiated thyroid carcinoma

6.1
Peptide receptor radionuclide 
therapy ��or non–radioiodine-avid 
di����erentiated thyroid carcinoma 
Jaap J.M. Teunissen, Dik J. Kwekkeboom, Peter P.M. Kooij, Willem H. Bakker 
and Eric P. Krenning
Journal of Nuclear Medicine 2006; 46:107S–114S 
Abstract
In	patients	with	progressive	metastatic	 (or	 recurrent)	differentiated	 thyroid	
carcinoma	(DTC)	who	do	not	respond	to	radioiodine	therapy	or	do	not	show	uptake	
on	radioiodine	scintigraphy,	treatment	options	are	few.	Because	these	tumors	may	
express	somatostatin	receptors,	peptide	receptor	radionuclide	therapy	might	be	
effective.	We	evaluated	the	therapeutic	efficacy	of	the	radiolabeled	somatostatin	
analog	177Lu-1,4,7,10-tetraazacyclododecane-N,N ‘,N”,N’’’-tetraacetic	acid0	(DOTA),	
Tyr3-octreotate	(177Lu-DOTATATE)	in	patients	with	DTC.	The	uptake	of	radioactivity	
in	tumors	was	also	studied	in	relation	to	treatment	outcome.	
Methods  
Five	patients	with	DTC	(3	with	Hürthle	cell	thyroid	carcinoma	[HCTC],	1	with	
papillary	thyroid	carcinoma	[PTC],	and	1	with	follicular	thyroid	carcinoma	[FTC])	
were	treated	with	22.4–30.1	GBq	of	 177Lu-DOTATATE.	Response	to	therapy	was	
evaluated	with	CT.	Uptake	on	177Lu-DOTATATE	scintigraphy	(24	h	after	treatment),	
expressed	as	percentage	of	injected	dose,	was	compared	with	uptake	on	pretherapy	
111In-octreotide	scintigraphy	(24	h	after	injection).
Results  
After	the	last	treatment	with	177Lu-DOTATATE,	1	patient	with	HCTC	had	stable	
disease	 as	 a	maximum	 response,	 1	 patient	with	HCTC	had	minor	 remission	
(tumor	shrinkage	between	25%	and	50%),	and	1	patient	with	HCTC	had	partial	
remission	(shrinkage	>	50%).	The	responses	in	PTC	and	FTC	were	stable	disease	
and	progressive	disease,	respectively.	A	decrease	in	serum	thyroglobulin	level	was	
found	in	patients	with	HCTC.	Patients	with	minor	and	partial	remissions	had	the	
highest	177Lu-DOTATATE–to–111In-diethylenetriamine	pentaacetic	acid0-octreotide	
(111In-octreotide)	uptake	ratios	(3.2	and	2.4,	respectively)	whereas	the	other	patients	
had	uptake	ratios	smaller	than	1.5.
Conclusion  
177Lu-DOTATATE	therapy	can	be	effective	in	patients	with	progressive	DTC	who	
have	no	therapeutic	options	and	sufficient	uptake	of	111In-octreotide	in	tumor	lesions	
as	shown	on	111In-octreotide	scintigraphy.	This	finding	is	especially	important	in	
patients	with	HCTC,	because	they	cannot	benefit	from	radioiodine	therapy	because	
of	non–iodine-avid	lesions	at	diagnosis.
Abstract
6.1
INTRODUCTION
Standard	therapy	in	patients	with	differentiated	(follicular	and	papillary)	thyroid	
carcinoma	(DTC)	involves	total	or	near-total	thyroidectomy,	followed	by	ablation	of	
the	thyroid	remnant	with	131I.	Although	long-term	prognosis	with	this	combination	
of	surgery	and	radioiodine	therapy	is	generally	quite	good,	tumor	recurrences	occur	
in	about	20%	of	patients,	sometimes	decades	after	initial	therapy	1,2.	Follow-up	in	
these	patients	is	based	on	a	combination	of	serum	thyroglobulin	(Tg)	monitoring	
and	radioiodine	whole-body	scans	(WBSs).	Whenever	recurrence	or	metastatic	
disease	is	evident	on	the	WBS,	patients	are	retreated	with	radioiodine.	However,	
in	20%–30%	of	these	patients,	additional	131I	therapy	is	not	effective	because	of	the	
lack	of	radioiodine	uptake	in	tumors	3,	4.	In	addition,	Hürthle	cell	thyroid	carcinomas	
(HCTCs),	which	are	assigned	to	the	group	of	follicular	thyroid	carcinoma	(FTC),	are	
known	to	rarely	take	up	iodine,	even	at	the	time	of	diagnosis	5.	
Alternative	 treatments	 in	 patients	with	 no	 uptake	 of	 radioiodine	 are	 few.	
Dedifferentiation	is	associated	with	a	worse	prognosis,	which	is	largely	because	these	
patients	cannot	be	treated	with	radioiodine	6.	Patients	with	iodine-concentrating	
pulmonary	metastases	have	a	5-yr	survival	rate	of	60%	compared	with	30%	for	patients	
with	tumors	that	do	not	concentrate	radioiodine	4,7.	Therefore,	any	effective	therapy	
would	be	welcome.	As	most	of	these	patients	have	widespread	metastatic	disease,	
surgery	is	not	an	option.	External	beam	radiotherapy	can	provide	only	regional	
control	of	localized	recurrences.	Studies	on	the	effectiveness	of	chemotherapy	have	
been	disappointing	8,	9.	
In	 patients	with	 elevated	 serum	 thyroglobulin	 levels	with	 no	 evidence	 of	
disease	on	radioiodine	scintigraphy,	scintigraphy	with	the	somatostatin	analog	
111In-diethylenetriaminepentaacetic	acid0	 (DTPA0)-octreotide	 (111In-octreotide,	
OctreoScan;	Mallinckrodt)	can	be	an	alternative	imaging	modality.	Several	reports	
have	demonstrated	uptake	of	111In-octreotide	in	metastatic	or	recurrent	disease	in	the	
majority	of	these	patients	10–13.	As	a	consequence,	the	use	of	high	doses	of	radiolabeled	
somatostatin	analogs	as	targeted	therapy	in	peptide	receptor	radionuclide	therapy	
(PRRT)	has	become	the	focus	of	major	interest	as	an	alternative	therapy.	Patients	
with	progressive	DTC	and	tumor	uptake	on	111In-octreotide	scintigraphy	have	been	
treated	with	various	radiolabeled	somatostatin	analogs,	including	111In-octreotide,	
90Y-1,4,7,10-tetraazacyclododecane-N,N’,N”,N’’’-tetraacetic	 acid0	 (DOTA)-D-
Phe1,Tyr3-octreotide	(90Y-DOTATOC),	and	90Y-DOTA-lanreotide	14–17.	In	this	study,	
we	report	the	results	of	treatment	with	the	novel	radiolabeled	somatostatin	analog	
177Lu-DOTA0,Tyr3-octreotate	(177Lu-DOTATATE)	in	5	patients	with	DTC.
178
MATERIALS AND METHODS
Patients
Five	patients	with	recurrent	or	metastatic	differentiated	thyroid	carcinoma	were	
treated	with	177Lu-DOTATATE.	Patient	characteristics	are	summarized	in	Table	1.	
All	patients	had	visible	tumor	uptake	on	111In-octreotide	scintigraphy	before	therapy.	
None	of	the	patients	had	been	treated	with	other	radiolabeled	somatostatin	analogs	
in	the	past.	All	patients	were	on	thyroid-stimulating	hormone	(TSH)	suppressive	
thyroxin	therapy.	Prerequisites	for	treatment	were:	hemoglobin	>	5.5	mmol/L;	white	
blood	cell	count	>2	x	109/L;	platelets	>	75	x	109/L;	creatinine	<150	µmol/L;	Karnofsky	
performance	status	>	50.	All	patients	gave	written	informed	consent	to	participate	in	
the	study,	which	was	approved	by	the	medical	ethical	committee	of	the	hospital.
Imaging
111In-octreotide. Planar	spot	imaging	was	performed	with	a	double-head	γ-camera	
(Prism	2000XP;	Philips	Medical	Systems).	Windows	with	a	20%	width	were	centered	
over	each	of	the	2	111In	photon	peaks	(245	and	172	keV).	Fifteen-minute	spot	images	
were	obtained	24	h	after	injection	of	222	MBq	of	111In-octreotide.	A	standard	with	a	
known	aliquot	of	the	injected	dose	was	measured	for	dosimetry.	
177Lu-DOTATATE. Planar	spot	images	of	the	chest,	neck,	and	upper	abdomen	were	
obtained	24	h	after	injection	of	the	therapeutic	dose	of	177Lu-DOTATATE.	Upper	
abdomen	images	were	also	obtained	on	2	occasions	in	the	following	days	for	kidney	
dosimetry.	Counts	(20%	window	width)	from	the	208	keV	γ-peak	were	collected.	
The	acquisition	time	was	15	or	7.5	min/view.	For	dosimetry,	a	standard	with	a	known	
aliquot	of	the	injected	dose	was	also	measured.
Therapy
DOTATATE	was	obtained	from	Mallinckrodt.	177LuCl3	was	obtained	from	NRG	and	
the	Missouri	University	Research	Reactor,	distributed	by	IDB.	177Lu-DOTATATE	was	
prepared	as	described	in	a	previous	publication	18.	Three	milligrams	of	granisetron	
were	injected	intravenously	and	an	infusion	of	amino	acids	(2.5%	lysine	and	2.5%	
arginine	in	1	L	0.9%	NaCl	at	250	mL/h)	was	started	30	min	before	administration	of	
the	radiopharmaceutical	and	lasting	up	to	3.5	h	afterwards.	The	radiopharmaceutical	
was	coadministered	through	a	second	pump	system.	Treatment	doses	of	1.9	and	3.7	
GBq	were	injected	over	20	min	and	those	of	5.6	GBq	and	7.4	GBq	were	injected	
over	30	min.	The	interval	between	treatments	varied	from	6	to	15	wk.	The	number	
of	treatments	varied	from	3	to	8.	Some	patients	were	included	in	the	early	phase	of	
therapy	with	177Lu-DOTATATE,	when	dose	escalation	was	among	the	objectives.	
Pe
pt
id
e 
re
ce
pt
or
 ra
di
on
uc
lid
e 
th
er
ap
y 
��o
r n
on
–r
ad
io
io
di
ne
-a
vi
d 
di
����
er
en
ti
at
ed
 th
yr
oi
d 
ca
rc
in
om
a
6.1
T
ab
le
 1
. P
at
ie
n
t	
ch
ar
ac
te
ri
st
ic
s
P
re
 17
7 L
u
-o
ct
re
o
ta
te
 T
h
er
ap
y
17
7 L
u
-o
ct
re
o
ta
te
 T
h
er
ap
y
P
at
ie
n
t
G
en
d
er
A
ge
(y
rs
)
T
u
m
o
r 
C
la
ss
ifi
ca
ti
o
n
 *
P
ri
o
r 
T
h
er
ap
y 
†
T
g 
(µ
g/
m
l)
‡
T
S
H
 
(m
U
/
l)
 §
13
1 I
 /
12
3 I
 s
ca
n
 |
|
11
1 I
n
-o
ct
re
o
ti
d
e 
**
P
D
”
C
u
m
u
la
ti
ve
 d
o
se
 (
G
B
q
)
N
o
. o
f 
T
re
at
m
en
ts
1
M
52
PT
C
T
T
,	N
D
,	R
IT
	(
16
.7
	G
B
q)
	¶
,	R
4
9
.1
0
.1
6
8
-
2
Y
es
25
.7
8
2
F
73
F
T
C
T
T
,	R
IT
	(
10
.6
	G
B
q)
,	R
,	C
56
6
5
<	
0
.0
1
-
2
Y
es
22
.4
3
3
F
52
H
C
T
C
T
T
,	N
D
,	R
IT
	(
1.
9
	G
B
q)
11
10
0
.0
2
-
3
Y
es
27
.4
8
4
F
74
H
C
T
C
T
T
,	R
IT
	(
12
.9
	G
B
q)
12
6
N
/
A
+
2
N
o
30
.1
4
5
F
52
H
C
T
C
T
T
,	R
IT
	(
13
,0
	G
B
q)
,	R
	
23
7
0
.2
4
+/
-
1
N
o
22
.7
3
* 
P
T
C
, p
ap
ill
ar
y 
th
yr
oi
d 
ca
rc
in
om
a;
 F
T
C
, f
ol
lic
ul
ar
 th
yr
oi
d 
ca
rc
in
om
a;
 H
C
T
C
, H
ür
th
le
 c
el
l t
hy
ro
id
 c
ar
ci
no
m
a;
 †
 T
T,
 to
ta
l t
hy
ro
id
ec
to
m
y;
 N
D
, n
ec
k 
di
ss
ec
ti
on
; ¶
 R
IT
, 1
31
I 
th
er
ap
y 
(c
um
ul
at
iv
e 
do
se
);
 C
, c
he
m
ot
he
ra
py
; R
, e
x
te
rn
al
 r
ad
ia
ti
on
; ‡
 s
er
um
 th
yr
og
lo
bu
lin
e 
(T
g)
 le
ve
l d
ur
in
g 
le
vo
th
yr
ox
in
e 
tr
ea
tm
en
t p
ri
or
 to
 17
7 L
u
-o
ct
re
ot
at
e 
th
er
ap
y;
 
§
 T
SH
, t
hy
ro
id
 s
ti
m
u
la
ti
n
g 
ho
rm
on
e 
du
ri
n
g 
le
vo
th
yr
ox
in
e 
tr
ea
tm
en
t;
 ||
 o
ut
co
m
e 
of
 r
ad
io
io
di
n
e 
sc
an
; +
/-
, m
ix
ed
 13
1 I 
po
si
ti
ve
 a
n
d 
n
eg
at
iv
e 
le
si
on
s;
 N
/A
, n
ot
 a
va
ila
bl
e,
 
**
 t
um
or
 u
pt
ak
e 
sc
or
e 
on
 11
1 In
-o
ct
re
ot
id
e 
sc
in
ti
gr
ap
hy
: 1
; u
pt
ak
e 
in
 le
si
on
 le
ss
 t
ha
n 
th
e 
liv
er
, 2
; e
qu
al
 t
o 
th
e 
liv
er
, 3
; h
ig
he
r 
th
an
 t
he
 li
ve
r 
as
 d
es
cr
ib
ed
 p
re
vi
ou
sl
y 
19
; ”
 P
D
, 
do
cu
m
en
te
d 
pr
og
re
ss
iv
e 
di
se
as
e 
w
it
hi
n 
on
e 
ye
ar
 b
ef
or
e 
th
er
ap
y
180
As	a	result	of	the	time	schedule,	completion	of	all	treatments	varied	from	3	to	12	
months	for	any	individual.	All	patients	were	allowed	to	receive	up	to	a	cumulative	
dose	of	30	GBq,	which	corresponded	to	a	calculated	bone	marrow	dose	of	2	Gy,	
except	in	those	individual	cases	in	which	kidney	dosimetry	indicated	less	(maximum	
allowed	kidney	dose	was	23	Gy).	Routine	hematology,	liver	and	kidney	function	tests,	
hormone	measurements,	and	serum	tumor	markers	were	measured	1	wk	before	each	
therapy,	as	well	as	at	follow-up	visits.	CT	or	MR	imaging	was	performed	within	3	
months	before	the	first	therapy,	and	6–8	weeks,	3	months,	and	6	months	after	the	
last	treatment.	Thereafter	follow-up	continued	every	6	months.
In Vivo Measurements
CT-	or	MRI-assessed	tumor	measurements	were	scored	according	to	the	following	
criteria:	progressive	disease	(PD),	increase	in	measurable	tumor	mass	volume	≥25%;	
stable	disease	(SD),	tumor	mass	volume	increase	or	decrease	≤25%;	minor	remission	
(MR),	decrease	of	tumor	mass	volume	between	25%	and	50%;	and	partial	remission	
(PR),	decrease	of	tumor	mass	volume	≥50%.	Time	to	progression	(TTP)	was	defined	
as	the	time	interval	between	the	first	treatment	and	the	earliest	date	of	disease	
progression	based	on	CT	or	MR	imaging	measurements.	The	amount	of	uptake	
on	pretherapy	111In-octreotide	and	posttherapy	177Lu-DOTATATE	scintigraphy	was	
scored	visually	on	planar	images	on	a	4-point	scale	according	to	criteria	previously	
described	by	Krenning	et al.	 19:	 lower	than	(grade	1),	equal	to	(grade	2),	or	greater	
than	(grade	3)	normal	liver	tissue;	and	grade	4,	higher	than	normal	spleen/kidney	
uptake.
RESULTS
Five	patients	with	metastatic	DTC	(3	with	HCTC,	1	with	papillary	thyroid	carcinoma	
[PTC],	and	1	with	FTC)	were	treated	with	22.4–30.1	GBq	of	177Lu-DOTATATE.	The	
patients	were	either	negative	on	131I	scintigraphy	after	therapy	or	proven	unresponsive	
to	131I	therapy.	Metastatic	disease	was	present	in	all	patients	based	on	conventional	
imaging	(CT/MR	imaging	or	sonography),	pathologic	uptake	of	111In-octreotide,	and	
elevated	serum	Tg	levels.	Tumor	response	after	therapy	was	monitored	by	CT/MR	
imaging	and	serum	Tg	levels	(Table	2).	
Patient	1	was	diagnosed	in	1995	with	PTC	with	supraclavicular	metastases.	Initial	
treatment	consisted	of	total	thyroidectomy	followed	by	radioiodine	ablation.	In	April	
1996,	the	patient	was	treated	with	radioiodine	for	recurrent	disease.	Because	of	a	
newly	developed	sarcomatoid	carcinoma	of	the	vocal	chord,	a	total	laryngectomy	
and	bilateral	nodal	neck	dissection	was	performed	later	that	year.	Lymph	nodes	were	
positive	for	DTC,	and	a	third	dose	of	131I	was	given.	In	1998,	a	fourth	treatment	of	131I	
was	given	because	of	a	third	recurrence.	However,	no	uptake	of	 131I	was	visible	on	
posttherapy	scintigraphy.	In	contrast,	 111In-octreotide	scintigraphy	showed	uptake	
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in	the	mediastinum.	Subsequently,	 177Lu-DOTATATE	therapy	was	initiated.	Eight	
treatments	were	given	with	a	cumulative	treatment	dose	of	25.7	GBq,	which	resulted	
in	SD.	TTP	was	documented	18	months	after	the	first	treatment,	with	gradually	
increasing	serum	Tg	levels.	Thereafter,	CT	measurements	showed	PD.	Four	years	
after	the	first	treatment,	the	patient	died	of	the	disease.	
Patient	2	was	diagnosed	in	1990	with	FTC.	Within	1	yr	after	total	thyroidectomy	
and	ablation,	CT	assessment	showed	lung	metastases,	which	were	treated	with	a	
therapeutic	dose	of	131I.	However,	posttherapy	131I	scintigraphy	did	not	reveal	any	uptake	
in	tumor.	Therefore,	additional	treatment	consisted	of	local	external	radiotherapy	
and	chemotherapy	with	adriamycine.	However,	the	patient	had	PD,	and	her	clinical	
condition	worsened.	In	2000,	tumor	progression	led	to	airway	obstruction,	which	
was	complicated	with	pneumonia	and	severe	stridor,	necessitating	emergency	
tracheostomy.	At	that	time,	111In-octreotide	scintigraphy	revealed	numerous	lesions	in	
the	chest,	and,	subsequently,	177Lu-DOTATATE	therapy	was	started.	Three	treatments	
of	177Lu-DOTATATE	with	a	total	dose	of	22.4	GBq	could	not	stop	tumor	progression,	
which	was	obvious	from	both	symptomatology	and	increased	serum	Tg	levels.	Two	
weeks	after	the	last	therapy,	the	patient	died	of	tumor	progression.	
Patient	3	was	diagnosed	with	HCTC	and	had	undergone	 total	 thyroidectomy	
combined	with	a	neck	dissection.	However,	complete	removal	of	the	tumor	mass	
was	not	possible	because	of	intraoperative	identification	of	tumor	growth	into	the	
trachea.	Surgery	was	followed	by	radioiodine	therapy.	Eighteen	months	later,	an	
ultrasound	of	the	neck	revealed	continued	growth	of	the	(para)tracheal	mass,	which	
did	not	accumulate	any	123I.	 111In-octreotide	scintigraphy,	however,	showed	uptake	
in	the	lower	neck	region.	177Lu-DOTATATE	therapy	was	initiated,	and	the	patient	
received	8	treatments	with	a	cumulative	dose	of	27.4	GBq.	Six	months	after	the	
last	therapy,	the	patient	was	found	to	be	in	MR.	Two	years	later	progression	was	
demonstrated.	After	an	initial	rise	in	serum	Tg	level	after	treatment,	this	decreased	to	
a	nadir	of	46.6	µg/L,	which	reflected	decrease	of	tumor	mass	volume	(Figure	1a).	
Patient	4	initially	had	a	left-sided	hemithyroidectomy	for	HCTC.	Sixteen	years	later,	
3	 lung	metastases	were	detected,	and	she	had	a	right-sided	hemithyroidectomy	
followed	by	 131I	therapy	with	3.7	GBq,	after	which	the	serum	Tg	levels	decreased	
from	150	to	18	µg/L.	However,	no	change	in	tumor	size	was	found.	One	year	later	no	
accumulation	during	123I	scintigraphy	was	found.	Despite	the	absence	of	radioiodine	
uptake,	she	was	retreated	with	3.7	GBq	of	131I,	with	no	effect	on	tumor	mass	or	serum	
Tg	levels.	In	1999,	the	serum	Tg	level	increased	to	507	µg/L	and	5.5	GBq	of	131I	was	
administered.	Despite	a	positive	lesion	in	the	right	upper	lobe	of	the	lung	on	131I	
scintigraphy	after	therapy,	again	no	effect	was	found.	
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Because	of	positive	lesions	detected	on	 111In-octreotide	scintigraphy,	the	patient	
received	4	treatments	with	a	total	dose	of	30.1	GBq	177Lu-DOTATATE.	The	serum	
Tg	levels,	which	were	measured	before	each	treatment,	increased	up	to	a	maximum	
of	1,730	µg/L.	After	the	last	treatment,	the	serum	Tg	levels	decreased,	with	a	nadir	
of	746	µg/L	14	months	later	(Figure	1b).	On	CT,	no	difference	in	tumor	size	was	
found.	However,	the	radiology	report	mentioned	an	inhomogeneous	aspect	that	
suggested	tumor	necrosis.	
Figure 1a-c. Time	course	of	serum	Tg	and	TSH	levels	in	patient	3,	4,	and	5	treated	with	
177Lu-DOTATATE.	Broken	lines	represent	pretherapy	levels.
184
Patient	5	with	an	HCTC	was	diagnosed	in	1997	and	subsequently	underwent	a	total	
thyroidectomy	followed	by	radioiodine	ablation	therapy.	Because	of	local	recurrences	
in	the	surgical	bed	and	low	cervical	region,	she	was	retreated	with	radioiodine	in	
2000	and	2001.	Persistent	uptake	near	the	jugulum	was	seen	on	131I	scintigraphy	after	
therapy.	In	2001,	additional	imaging	was	performed	because	of	persistent	elevated	
serum	Tg	levels	and	progressive	pain	in	the	left	leg.	In	addition	to	the	neck	lesion	
seen	on	131I	scintigraphy,	both	18F-FDG-PET	and	MRI	showed	lesions	in	the	spine	
(L3	and	L5-S1).	Lack	of	radioiodine	accumulation	in	the	latter	 lesions	suggested	
dedifferentiation,	and,	therefore,	external	radiation	was	given.	Because	of	the	growth	
of	the	neck	lesion,	which	compressed	the	trachea,	the	patient	developed	a	stridor.	
111In-octreotide	scintigraphy	showed	uptake	in	all	tumor	lesions	as	previously	seen	on	
18F-FDG-PET	and	MRI.	The	patient	received	3	treatments	with	a	cumulative	dose	of	
22.7	GBq	of	177Lu-DOTATATE.	After	the	second	treatment,	serum	Tg	levels	began	to	
decrease	(Figure	1c).	At	the	same	time,	the	CT	scan	showed	regression	of	the	tracheal	
lesion	with	a	shrinkage	of	50%	12	months	after	the	last	therapy.	
A	comparison	between	pretherapy	111In-octreotide	and	posttherapy	177Lu-DOTATATE	
scintigraphy	in	patients	1	and	3	is	shown	in	Figure	2.	
Figure 2. Images	comparing	pretherapy	111In-octreotide	scintigraphy	(A)	and	posttherapy	
177Lu-DOTATATE	scintigraphy	at	24	h	(B).	Top	row	shows	corresponding	images	of	tumor	
sites	in	patient	1	with	metastatic	PTC.	Bottom	row	shows	corresponding	images	of	patient	
3	with	HCTC.	
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In	patient	1,	the	uptake	of	both	somatostatin	analogs	was	about	the	same.	In	contrast,	
more	uptake	was	shown	in	the	tracheal	lesion	of	patient	3	on	 177Lu-DOTATATE	
scintigraphy	than	on	111In-octreotide	scintigraphy.	Calculated	177Lu-DOTATATE/	
111In-octreotide	tumor	uptake	ratios	in	the	tumor	lesions	of	all	patients	varied	from	
1.1	to	3.2.	Two	patients	with	HCTC,	in	whom	tumor	shrinkage	was	demonstrated,	
had	the	highest	ratios	(Figure	3).
Figure 3. Ratios	of	177Lu-DOTATATE	and	111In-octreotide	uptake	in	tumor	sites.	Uptake	was	
expressed	as	percentage	of	administered	dose.	Note	differences	in	uptake	between	patients	
with	HCTC	who	responded	with	MR	and	PR	and	those	who	did	not	respond	with	tumor	
shrinkage.
DISCUSSION
Therapeutic	options	 in	patients	with	recurrent	or	metastatic	DTC	that	cannot	
concentrate	radioiodine	are	limited.	Also,	the	loss	of	iodine-trapping	ability,	or	
dedifferentiation,	is	associated	with	a	more	aggressive	behavior	6.	
In	this	paper	we	describe	the	results	of	therapy	with	177Lu-DOTATATE	in	5	patients	
with	DTC,	who	had	no	other	treatment	available.	CT-assessed	tumor	shrinkage	
was	found	in	2	patients	with	HCTC.	Concomitantly,	a	decrease	in	serum	Tg	levels	
was	observed	in	both	patients.	In	the	other	patient	with	HCTC	the	serum	Tg	levels	
decreased	significantly,	whereas	CT-assessed	tumor	volume	did	not	change.	However,	
the	aspect	of	the	lesions	changed,	which	suggested	necrosis.	Disease	stabilization	
was	achieved	in	one	patient	with	clearly	progressive	PTC	before	therapy,	whereas	
the	patient	with	FTC	progressed	despite	treatment.	These	results	suggest	that	in	
some	patients	with	DTC,	who	have	no	treatment	options	left,	 177Lu-DOTATATE	
therapy	can	be	effective.	
186
The	reason	to	treat	these	patients	with	177Lu-	DOTATATE,	was	found	in	the	successful	
treatment	with	this	compound	in	patients	with	somatostatin	receptor–positive	
gastroenteropancreatic	(GEP)	tumors.	Objective	tumor	shrinkage	was	demonstrated	
in	up	to	38%	of	patients	20.	In	addition,	reports	in	which	other	somatostatin	analogs	
were	 labeled	with	different	 radionuclides,	 such	as	 111In	or	 90Y,	 showed	similar	
therapeutic	benefit	in	patients	with	GEP	tumors	16,17,21,22.	Apart	from	GEP	tumors,	other	
results	of	therapy	in	patients	with	DTC	were	reported	(Table	3).	Patients	with	DTC	
were	treated	because	they	had	progressive	disease,	somatostatin	receptor–positive	
lesions	on	111In-octreotide	scintigraphy,	and	no	other	treatment	option	available.
Krenning	et al.	 19	 reported	 the	 first	 2	DTC	patients	 treated	with	 radiolabeled	
somatostatin	analogs.	Both	had	PTC	and	were	treated	with	111In-octreotide,	which	
was	available	for	therapy.	One	patient,	who	had	a	total	cumulative	dose	of	at	least	20	
GBq,	showed	disease	stabilization,	whereas	the	other	patient,	who	had	received	<20	
GBq,	was	lost	to	follow-up.	In	a	review	that	summarized	the	use	of	111In-octreotide	
therapy	in	a	total	of	50	patients	in	a	single	institution,	40	patients	were	evaluated	
after	cumulative	doses	of	at	 least	20	GBq	up	to	160	GBq.	Within	this	group,	5	
patients	had	DTC,	including	4	patients	with	PTC	and	1	with	FTC	17.	Four	patients	
were	progressive	despite	treatment,	whereas	1	patient,	who	was	reported	earlier	
to	have	SD	for	some	time,	ultimately	progressed.	In	a	recent	report,	11	patients	
with	progressive	iodine	nonresponsive	thyroid	carcinoma	were	treated	with	high,	
fixed	doses	of	 111In-octreotide	23.	Nine	patients	were	evaluable,	because	2	patients	
died	during	follow-up	of	causes	unrelated	to	their	disease.	Six	months	after	the	
last	therapy,	4	patients	had	SD	and	5	patients	had	PD.	Stablilization	of	disease	was	
accompanied	with	a	stable	Tg	level,	whereas	3	out	of	a	group	of	5	patients	with	
radiologic	progression	had	increasing	levels	of	Tg.	Interestingly,	the	mean	Tg	value	
in	the	latter	group	was	higher	than	in	the	group	with	stabilization	of	disease	(mean	
Tg	value	180,432	vs.	275	µg/L).	It	was	suggested	that	low	Tg	values	could	be	used	as	
selection	criteria	for	111In-octreotide	therapy.
Waldherr	et al.	 15	treated	8	DTC	patients	(3	FTC,	4	PTC,	and	1	anaplastic	thyroid	
carcinoma)	with	90Y-DOTATOC.	Two	patients,	who	were	treated	with	9.1	and	14.8	
GBq,	had	SD	and	documented	TTP	of	8	months,	whereas	the	other	patients	had	PD.	
Chinol	et al.	21	also	used	90Y-DOTATOC	to	treat	2	patients	with	PTC.	Unfortunately,	
the	efficacy	of	therapy	in	these	2	patients	was	difficult	to	determine	from	this	study,	
because	results	were	presented	as	the	effect	of	treatment	in	the	whole	group	of	
somatostatin	receptor	(SSTR)	positive	tumors.	Three	patients	had	regressive	disease	
(>25%	reduction	of	tumor	size),	11	had	SD,	and	11	had	PD.	In	a	very	recent	report,	5	
patients	with	DTC	were	treated	with	90Y-DOTATOC	with	a	dose	range	of	5.6	GBq	
to	7.4	GBq	24.
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The	authors	reported	that	patients	who	responded	under	this	therapy	regimen	had	
SD	for	at	least	5	months.	Especially	interesting	in	comparison	with	our	results	is	the	
report	by	Gorges	et al.	14,	who	described	the	courses	of	disease	of	the	first	3	patients	
with	HCTC	treated	with	90Y-DOTATOC	(total	dose,	1.7–9.6	GBq).	The	patient	with	
the	highest	dose	responded	with	a	period	of	SD	of	9	months,	whereas	the	other	2	
patients	had	progressive	disease	despite	treatment.	They	concluded	that	the	protocol	
was	not	ideal,	because	tumor	radiation	dose	was	suboptimal.	
To	draw	conclusions	from	all	the	studies	concerning	the	therapeutic	efficacy	of	PRRT	
in	patients	with	non–radioiodine-avid	or	unresponsive	thyroid	cancer	is	difficult.	
The	number	of	 treated	patients	 in	the	reported	studies	was	 low.	Furthermore,	
different	radiolabeled	somatostatin	analogs	were	used	with	individually	variable	
administered	doses.	Clearly,	PRRT	in	DTC	seems	to	be	less	effective	than	in	GEP	
neuroendocrine	tumors.	
One	reason	for	this	difference	in	efficacy	might	be	the	expression	profile	of	SSTR	
subtypes	by	tumors.	Reubi	et al.	 25,	who	intensively	studied	the	SSTR	subtype	
profile	of	numerous	human	tumors,	reported	a	predominance	of	SSTR2	or	SSTR1	
in	GEP	tumors.	In	contrast,	in	vitro	studies	with	thyroid	cancer	cell	line	monolayers	
and	xenografts	showed	a	predominant	expression	of	SSTR3	and	SSTR5,	whereas	
SSTR2	mRNA	was	only	faintly	detectable	26.	In	another	report,	in	which	the	receptor	
subtype	expression	in	biopsied	DTC	tumor	tissue	was	investigated	by	Northern	
Blot	analyses,	SSTR1,	SSTR3,	SSTR4,	and	SSTR5	were	expressed	in	all	tumors,	
whereas	SSTR2	was	not	detected	in	any	FTC	or	PTC	tumors.	In	line	with	these	
observations,	Forssell-Aronsson	et al.	27	also	demonstrated	that	the	highest	tumor-
to-background	ratio	and	expression	of	high-affinity	SSTR2,	was	found	in	medullary	
thyroid	carcinoma	and	Hürthle	cell	neoplasia.	In	the	latter,	the	expression	of	SSTR2	
was	irregular.	These	findings	suggest	that	the	SSTR	subtype	expression	profile	found	
in	DTC	cells	is	different	and	more	variable	than	that	in	GEP	tumors.	
Most	radiolabeled	somatostatin	analogs	available	for	therapy	share	the	high	binding	
affinity	for	the	SSTR2	receptor.	It	was	reported	that,	in	comparison	with	DTPA0,	
Tyr3-octreotide,	DTPA0,Tyr3-octreotate	showed	improved	binding	to	SSTR	positive	
tissues	in	animal	experiments	28.	Furthermore,	the	somatostatin	analog	DOTATATE	
has	a	9-fold	higher	affinity	for	the	SSTR2	than	does	DOTATOC,	whereas	the	affinity	
to	SSTR3	and	SSTR5	were	found	to	be	lower	29.	In	line	with	the	higher	affinity	for	
the	SSTR2,	our	biodistribution	studies	on	111In-octreotide	and	177Lu-DOTATATE	
scintigraphy,	reported	previously,	showed	a	3-	to	4-fold	higher	tumor	uptake	in	4	
out	of	5	patients	18.	The	presence	of	SSTR	subtypes	other	than	SSTR2	was	suggested	
as	an	explanation	for	equivalent	tumor	uptake	of	both	somatostatin	analogs	in	1	
patient	with	PTC,	who	is	also	described	in	this	article	(patient	1).	Interestingly,	the	
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17 7Lu-DOTATATE/111In-octreotide	 uptake	 ratios	 calculated	 in	 the	 5	 patients	
demonstrated	that	the	2	HCTC	patients	with	the	highest	uptake	ratios	responded	
with	tumor	shrinkage,	whereas	the	others	had	ratios	<1.5.	Thus,	in	patients	with	PTC	
or	FTC	with	tumors	that	probably	exhibit	a	different	and	variable	SSTR	expression	
profile	with	predominantly	SSTR5	and	SSTR3	instead	of	SSTR2,	there	is	no	clear	
advantage	of	Tyr3-octreotate	over	Tyr3-octreotide.	
For	the	better	tumor	targeting	and	increase	in	uptake	required	for	better	therapeutic	
efficacy	of	PRRT	in	DTC,	SSTR	subtype-specific	analogs	with	higher	affinity	for	
SSTR3	and	SSTR5	are	necessary.	Most	promising	 is	 the	 recent	study	by	Wild	
et al.	 30,	who	reported	the	first	preclinical	data	on	111In-	and	90Y-labeled	DOTA-1-
Nal3-	octreotide	(DOTA-NOC),	which	has,	apart	from	high	affinity	to	SSTR2,	a	
favorable	affinity	for	SSTR3	and	SSTR5.	In	addition,	they	briefly	mentioned	excellent	
images	of	thyroid	cancer	patients	in	clinical	studies	with	[111In]DOTA-NOC.	It	was	
assumed	that	DOTA-NOC	labeled	with	either	90Y	or	177Lu	will	have	similar	favorable	
properties,	so	that	it	might	become	available	for	therapy	in	patients	with	DTC	in	
the	near	future.	
In	our	opinion,	the	best	candidates	for	PRRT	with	177Lu-DOTATATE	in	non–iodine-
avid	metastatic	and	radioiodine	unresponsive	DTC	are	patients	with	HCTC.	The	
combination	of	 a	 large	percentage	of	HCTC	patients	with	positive	 lesions	on	
111In-octreotide	scintigraphy,	relatively	high	tumor	uptake	of	 177Lu-DOTATATE	
compared	with	PTC	or	FTC,	and	the	favorable	outcomes	observed	in	our	patients	
suggest	 that	especially	 in	 these	patients	 177Lu-DOTATATE	may	 induce	 tumor	
shrinkage	or	prolonged	disease	stabilization.
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Abstract
In	patients	with	progressive	metastatic	 (or	 recurrent)	differentiated	 thyroid	
carcinoma	that	either	do	not	take	up	radioioidine	or	are	unresponsive	to	continued	
radioiodine	therapy,	staging	is	difficult	and	treatment	options	are	few.	However,	
in	most	of	these	patients	uptake	of	radiolabeled	somatostatin	analogs	is	evident	
on	somatostatin-receptor	scintigraphy	(SRS).	Using	SRS,	patients	with	sufficient	
uptake	of	radiolabeled	somatostatin	analogs	can	be	selected	for	high-dose	peptide	
receptor	radionuclide	therapy	(PRRT)	as	an	alternative	targeted-treatment	option.	
PRRT	with	the	β-particle-emitting	radionuclides	90Yttrium	(90Y)	and	177Lutetium	
(177Lu)	gives	the	best	results	in	terms	of	objective	tumor	response.	Promising,	novel,	
radiolabeled	somatostatin	analogs	that	have	a	broader	receptor	affinity	profile	and,	
thus,	a	potentially	wider	therapeutic	range	are	being	tested	clinically.	
Abstract
6.2
INTRODUCTION
Standard	therapy	in	most	patients	with	non-medullary	differentiated	(papillary,	
follicular	and	Hürthle	cell)	thyroid	carcinoma	(DTC)	involves	either	total	or	near-
total	thyroidectomy	followed	by	ablation	of	the	thyroid	remnant	with	radioiodine.	
With	a	reported	overall	 10-	year-survival	rate	of	75–95%,	DTC	is	regarded	as	a	
malignancy	with	a	relatively	good	prognosis	 1-3.	However,	tumors	recur	in	~20%	
of	patients	2,	3.	Long-term	follow-up	after	initial	therapy,	which	is	based	primarily	
on	measurements	of	serum	thyroglobulin	(Tg)	in	combination	with	radioiodine	
whole-body	scans	(WBSs),	 is,	 therefore,	obligatory.	Additional	treatment	with	
radioiodine	can	be	initiated	when	recurrence	and/or	metastases	are	evident	and	
imaged	by	radioiodine	WBS.	However,	radioiodine	therapy	is	no	longer	an	option	
in	the	20–30%	of	patients	who	have	recurrences	and/or	persistent	metastases	caused	
by	dedifferentiation	with	a	lack	of	radioiodine	uptake	(non-radioiodine-avid)	within	
the	tumors	(4–6%	of	patients	diagnosed	with	DTC)	4,	5.	
Patients	with	dedifferentiated	DTC	have	a	worse	prognosis,	largely	because	they	
cannot	be	treated	with	radioiodine	2,	5,	6.	Therefore,	alternative,	accurate	imaging	
methods	for	diagnosis,	and	therapeutic	modalities	are	of	interest.	Hürthle	cell	thyroid	
carcinoma	(HCTC),	an	uncommon	form	of	thyroid	cancer	that	is	usually	classified	
as	a	variant	of	follicular	thyroid	carcinoma	(FTC),	 is	of	special	 interest	because	
these	carcinomas	rarely	take	up	radioiodine,	even	at	the	time	of	diagnosis	7.	In	this	
review,	we	focus	on	both	the	staging	and	the	therapeutic	potential	of	radiolabeled	
somatostatin	analogs	in	patients	with	non-radioiodine-avid	DTC.	
	
SOMATOSTATIN RECEPTOR SCINTIGRAPHY 
Over	ten	years	ago,	we	published	the	first	results	of	patients	with	DTC	who	were	
imaged	by	somatostatin	receptor	scintigraphy	(SRS)	8,	9.	The	potential	value	of	SRS	
in	patients	with	non-radioiodine-avid	DTC	was	clear	because,	in	some	patients,	
either	new	or	more	tumor	localizations	were	detected	compared	with	radioiodine	
WBS.	Furthermore,	in	some	patients	with	a	negative	radioiodine	WBS,	SRS	showed	
tumor	uptake	of	the	radiolabeled	somatostatin	analog	111Indium-diethylene	triamine	
pentaacetic	acid	(DTPA)	octreotide	(111In-octreotide).	The	finding	that	SRS	visualizes	
tumors	in	patients	with	DTC	whose	tumors	do	not	take	up	radioiodine	has	great	
potential	for	staging	the	disease	and	treating	it	with	somatostatin	analogs.	
The value of SRS in clinical practice 
Most	reported	studies	on	SRS	focus	on	the	clinical	value	of	this	image	modality	in	
patients	with	non-radioiodine-avid	DTC	with	progressive	disease.	Tenenbaum	et al.	
10	studied	four	patients	with	DTC	of	whom	three	showed	no	uptake	on	radioiodine	
WBS.	Two	patients,	one	with	papillary	thyroid	carcinoma	(PTC)	and	one	with	
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poorly	differentiated	thyroid	carcinoma	(insular;	PDTC),	showed	111In-octreotide	
uptake	on	SRS.	In	a	larger	study	of	25	DTC	patients	(16	with	radioiodine-negative	
tumors	and	nine	with	radioiodine-positive	tumors),	20	out	of	25	(80%)	showed	
uptake	during	SRS	with	111In-octreotide	11.	In	the	patients	with	radioiodine-negative	
tumors,	12	out	of	16	(75%)	showed	uptake	on	SRS.	All	patients	had	elevated	serum	
levels	of	Tg,	which	reflected	the	presence	of	disease.	It	was	concluded	that	SRS	
is	a	useful,	additional	image	and	staging	modality	for	follow-up	in	patients	with	
elevated	serum	Tg	 levels	and	negative	 radioiodine	WBS.	Several	 studies	have	
confirmed	these	findings	and	reported	uptake	of	 111In-octreotide	in	either	non-
radioiodine-avid	metastatic	or	recurrent	disease	in	74–100%	of	patients	(Table	1)	
12-15.	By	contrast,	Garin	et al.	16	reported	a	positive	111In-octreotide	scan	in	only	three	
out	of	16	patients	(19%)	in	whom	no	radioiodine	uptake	could	be	demonstrated.	
Valli	et al.	17	reported	similar	results	and	concluded	that	octreotide	scintigraphy	has	
a	lower	diagnostic	accuracy	than	conventional	imaging	modalities,	including	chest	
x-ray,	ultrasound	(US)	of	the	neck,	spiral	computed	tomography	(CT),	magnetic	
resonance	imaging	(MRI)	and	bone	scintigraphy.	However,	the	administration	of	
a	low	dose	of	111In-octreotide	and	a	short	acquisition	time	compared	with	the	other	
studies	might	account	for	the	discrepancy	in	sensitivity	observed.	Giammarile	
et al.	18,	who	performed	111In-octreotide	scintigraphy	with	the	largest	group	of	patients	
with	no	detectable	radioiodine	uptake	and	elevated	serum	Tg	levels,	reported	an	
overall	sensitivity	of	51%	which	was	clearly	lower	than	that	of	both	conventional	
imaging,	such	as	US	of	the	neck	and	abdomen,	CT	and/or	MRI,	and	bone	scintigraphy,	
and	the	relatively	new	technique	of	positron	emission	tomography	(PET)	using	
18F-fluorodeoxyglucose	(18F-FDG).	With	the	large	number	of	patients	studied,	factors	
that	might	influence	diagnostic	accuracy	of	SRS,	were	discussed.	The	first	of	these	
is	the	anatomical	localization	of	the	tumors.	The	sensitivity	of	SRS	was	high	for	the	
detection	of	mediastinal	lesions	(93%),	whereas	most	false-negative	results	were	
observed	in	patients	who,	at	follow-up,	were	proved	to	have	had	undetectable,	small,	
neck	and	lung	metastases	at	the	time	of	SRS.	
In	addition	to	anatomical	location,	a	high	serum	Tg	level	(>50	ng	ml-1)	in	patients	
who	had	thyroxine	substitution	therapy	(Tg-on)	was	associated	with	significantly	
increased	sensitivity.	Furthermore,	Görges	et al.	19	reported	a	clear	distinction	between	
the	detected	lesions	within	the	group	of	patients	with	low	serum	Tg-on	levels	
(<10	ng	ml-1,	n=11)	 and	 those	 from	 the	 group	with	high	 serum	Tg-on	 levels	
(>10	ng	ml-1,	n=39).	In	the	latter	group,	85%	of	patients	had	a	positive	SRS	whereas	
in	the	group	with	low	serum	Tg-on	levels	only	27%	of	patients	had	a	positive	SRS.	
Garin	et al.	 16	 reported	that	all	 their	studied	patients	with	a	positive	SRS	had	a	
serum	Tg-on	level	>5	ng	ml-1.	Patients	without	uptake	had	low	serum	Tg-on	levels	
(<5	ng	ml-1).	These	results	indicate	a	positive	correlation	between	the	serum	Tg	level	
and/or	thyroid-stimulating	hormone	(TSH)	and	visualization	on	SRS.
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Table 1.	111In-octreotide	scintigraphy	in	non-radioiodine-avid	differentiated	thyroid	
carcinoma	a
Study 
year
Number 
of 
patients
Tumor classification Serum Tg level range (ng ml-1) Imaging Refs
Tg-on	b
(number	of	
patients)
Tg-off	b
(number	of	
patients)
Number	of	patients	
with	radioiodine	
negative	but	SRS	
positive	scans	
1995 3 2	PTC;	1	insular	TC 120-60	000	(3) 2	out	of	3	(67%) [10]
1996 16 11	FTC;	5	PDTC 2-42	500	(16) 12	out	of	15	(75%) [11]
1996 6 5	FTC;	1	PTC 	NA NA 6	out	of	6	(100%) [12]
1998 16 15	PTC;	1	vesicular	TC	 <	0.2-1440	(11) 3	out	of	16	(19%) [16]
1999 15 14	PTC;	1	HCTC 10-65	000	(15) 1670/	2030	(2) 7	out	of	15	(49%) [17]
2001 29
3	FTC;	4	PTC;	21	HCTC;	
1	insular	TC
0.48-48	300	(27) 19	out	of	29	(66%) [19]
2001 25 9	FTC;	16	PTC <	1.5-14	910	(25) 6	out	of	8	(75%) [13]
2003 17 1	FTC;	4	PTC;	12	HCTC NA NA 14	out	of	17	(82%) [14]
2004 23 8	FTC;	13	PTC;	2	HCTC 16.6-586	000	(22)	c 17	out	of	23	(74%) [15]
2004 43
9	FTC;	20	PTC;	8	HCTC;	
	6	insular	TC	
0.7-5250	(40) 171-5850	(3) 22	out	of	43	(51%) [18]
a Abbreviations: FTC, follicular thyroid carcinoma; HCTC, Hürthle cell thyroid carcinoma; NA, not available; 
PTC, papillary thyroid carcinoma; SRS, somatostatin receptor scintigraphy; TC, thyroid carcinoma; Tg, 
thyroglobulin
b Tg-off, thyroglobulin levels without TSH suppressive treatment (L-thyroxine); Tg-on, thyroglobulin levels 
under TSH suppressive treatment
c excluding one patient with serum Tg of 0.8 ng ml-1 who was Tg antibody positive
To	test	this	hypothesis	Haslinghuis	et al.	13	studied	whether	withdrawal	of	thyroxine	
therapy	and	the	subsequent	increase	in	TSH	and	serum	Tg	levels	might	optimize	
the	information	obtained	with	SRS.	Direct	comparison	of	SRS	before	and	after	
withdrawal	of	thyroxine	therapy	was	performed	in	six	patients.	Essentially,	the	same	
clinical	information	was	obtained	after	withdrawal	of	thyroxine,	and	it	was	concluded	
that	there	is	no	need	to	withdraw	patients	from	thyroxine	to	perform	SRS.	In	the	
case	of	SRS	for	purely	diagnostic	purposes,	this	conclusion	is	fair	and	the	benefit	for	
patients	is	that	they	do	not	have	to	suffer	the	burden	of	thyroxine	withdrawal	before	
SRS.	However,	although	the	same	information	was	obtained,	higher	pathological	
uptake	was	observed	in	at	least	two	patients	in	whom	thyroxin-substitution	therapy	
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was	withdrawn	temporarily	13.	In	view	of	therapy	with	radiolabeled	somatostatin	
analogs	(see	later),	increased	uptake	in	the	tumors	after	thyroxine	withdrawal	might	
be	beneficial	in	terms	of	tumor	shrinkage.	Such	a	correlation	between	uptake	on	
pretherapy	SRS	and	favorable	outcome	of	therapy	with	radiolabeled	somatostatin	
analogs	was	reported	in	patients	with	neuroendocrine	gastroenteropancreatic	(GEP)	
tumors	20.	Further	quantitive	imaging	studies	into	the	effect	of	thyroxine	withdrawal	
on	tumor	uptake	of	radiolabeled	somatosatin	analogs	are	warranted	to	address	this	
issue.	In	view	of	a	possible	correlation	of	elevated	serum	Tg	level,	tumor	size	and	SRS	
sensitivity,	the	report	by	Bachelot	et al.	21	is	of	interest.	This	study	demonstrated	a	
close	relationship	between	the	serum	Tg	level	after	withdrawal	of	thyroid-hormone	
treatment	and	tumor	mass/extent	of	disease.	Thus,	the	reported	increased	SRS	
sensitivity	in	patients	with	elevated	serum	Tg	levels	16,	18,	19	might	reflect	an	increase	
in	SRS	sensitivity	in	larger	tumors,	rather	than	the	elevated	serum	Tg	level.	
In	 summary,	 these	 studies	 indicate	 that	 anatomical	 localization	 and	 tumor	
size/extent	of	disease	are	important	in	determining	the	outcome	of	SRS	in	patients	
with	non-radioiodine-avid	DTC.	
Somatostatin receptor subtypes 
Another	important	factor	in	the	observed	differences	in	uptake	during	SRS	might	
be	the	relative	expression	of	somatostatin	receptor	subtypes	(sstr1–sstr5)	and	their	
density	on	the	tumor	cell	surface.	John	et al.	demonstrated	that	positive	111In-octreotide	
scintigraphy	is	caused	mainly	by	sstr2,	whereas	sstr1,	sstr3,	sstr4	and	sstr5	are	less	
important.	Therefore,	the	presence	of	sstr2	is	essential	for	imaging	tumors	with	SRS	
22.	Reubi	et al.	 23,	who	used	autoradiography	to	study	the	sstr	profile	of	numerous	
human	tumors,	reported	a	predominance	of	sstr2	and/or	sstr1	in	neuroendocrine	
GEP	tumors.	No	DTC	tissue	was	studied.	In	contrast	to	the	high	concentration	of	
sstr1	and	sstr2	in	GEP	tumors,	in	vitro	studies	with	monolayers	of	thyroid	cancer	cell	
lines	and	xenografts	showed	predominant	expression	of	sstr3	and	sstr5,	with	sstr2	
mRNA	detected	only	faintly	24.	In	another	report,	which	investigated	sstr	expression	
in	biopsies	of	DTC	tumor	tissue	by	northern-blot	analyses,	sstr1,	sstr3,	sstr4	and	
sstr5	were	expressed	in	all	tumors,	but	sstr2	was	not	detected	in	either	FTC	or	PTC	
tumors	25.	The	same	report	demonstrated	the	highest	tumor:background	ratio	and	
expression	of	high-affinity	sstr2	in	medullary	thyroid	carcinoma	and	Hürthle	cell	
neoplasia,	 including	Hürthle	cell	adenenoma,	rather	than	in	the	clinically	more	
common,	in	vitro	studied	PTC	and	FTC.	In	Hürthle	cell	neoplasia,	the	expression	
of	sstr2	is	irregular,	and	tumors	with	high,	intermediate	and	low	expression	of	sstr2	
were	demonstrated.	These	findings	indicate	that	the	sstr	expression	profile	in	DTC	
cells	is	different	and	more	variable	than	in	neuroendocrine	GEP	tumors,	which	might	
explain	the	variation	of	uptake	observed	during	SRS	(Figure	1).	
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Figure 1. Somatostatin	analog	scintigraphy	images	from	three	patients	that	illustrate	the	
variable	uptake	of	somatostatin	analogs	in	DTC.	15-min	planar	spot	images	were	obtained	
24	h	after	injection	of	222	MBq	111In-octreotide.	Chest	and	upper	abdomen	are	shown.	All	
patients	had	pathological	uptake	of	111In-octreotide	in	the	chest	(dark	gray–black	areas).	Normal,	
physiological	uptake	of	111In-octreotide	by	the	liver	(apparent	as	the	gray	organ	in	the	left	corner	
of	each	image)	is	used	as	reference	to	semi-quantify	uptake	by	chest	tumors.	(a)	Patient	has	
PTC	metastatic	to	the	lungs	(black	arrow)	with	uptake	of	111In-octreotide	lower	than	normal	
liver	uptake.	(b)	Patient	has	FTC	with	widespread	metastatic	disease	in	the	lungs	(black	
arrows)	with	uptake	of	111In-octreotide	similar	to	liver	uptake.	(c)	Patient	has	recurrence	of	
HCTC	(black	arrow)	and	metastatic	lesions	in	bone	(not	shown)	with	uptake	of	111In-octreotide	
higher	than	liver	uptake.
Differences in SRS protocols 
In	addition	to	these	clinical	factors,	differences	in	SRS	imaging	protocols	must	also	
be	taken	into	account.	Differences	in	the	amount	of	injected	dose	and/or	imaging	
acquisition	characteristics	can	have	a	significant	impact	on	the	interpretation	of	
scintigraphy.	The	methodology	used	is,	therefore,	important	because	this	might	
lead	to	differences	in	the	sensitivity	of	SRS.	For	optimal	and	standardized	imaging,	
guidelines	for	SRS	with	111In-octreotide	were	published	in	2001	26,	but	only	three	of	the	
10	studies	in	Table	2	have	been	performed	in	accordance	with	these.	In	some	clinical	
centers,	only	half	of	the	recommended	dose	of	222	MBq	was	used.	Furthermore,	high-
speed	whole-body	scanning	(>3	cm	min-1)	was	performed	frequently,	rather	than	the	
recommended	≥10	min	planar-spot	imaging,	which	indicates	suboptimal	imaging.	
However,	adding	single-photon	emission	computed	tomography	(SPECT)	imaging,	
which	allows	a	more	precise	anatomic	delineation	than	planar	imaging,	resulted	in	
similar	sensitivity	to	the	SRS	studies	that	followed	the	guidelines.	This	underlines	
the	importance	of	SPECT	and	the	injection	of	sufficient	radioactive	dose	in	SRS	to	
obtain	the	best	possible	imaging	with	the	lowest	number	of	false-negative	cases.	
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Table 2. Differences	in	the	used	111In-octreotide	scintigraphy	protocols	a
Study 
year
Diagnostic 111In-octreotide scintigraphy protocol Guidelines b Refs
Dose
(MBq)
Images Acquisition (Y/N)
Scan	duration Time	after	injection	c
1995 110 	WBS 	NA	 4h,	24h	and	48h N [10]
1996 120-200 	WBS;	SPECT 	10	cm/min 4h,	24h	and	48h N [11]
1996 220 	Planar	spot	images 	15	min 24h	and	48h Y [12]
1998 137-200 	Planar	spot	images 	5	min	and	10	min	 1h,	4h	and	24h Y [16]
1999 111 	WBS;	SPECT 	8	cm/min 24h	and	48h N [17]
2001 110-170 	WBS;	SPECT 	10	cm/min 4h	and	24h N [19]
2001 222 	Planar	spot	images;	SPECT 	15	min 24h	and	48h Y [13]
2003 111 	WBS;	SPECT 	NA 24h	and	48h N [14]
2004 200 	WBS;	SPECT 	10	cm/min 4h	and	24h N [15]
2004 110
	WBS;	Planar	spot	Images;	
	SPECT
	10	cm/min	(WBS);	
10	min	(planar	spot	
images)
4h,	24h	and	48h N [18]
a Abbreviations: MBq, megabecquerel; NA, not available; SPEC T, single-photon emission computed 
tomography; WBS, whole-body scan;
 b Y = 111In-octreotide scintigraphy following the procedure guidelines for somatostatin receptor scintigraphy 
as described before [26]; N = different protocol 
c the 48h post injection scan was only performed when high background uptake was present on the 24h post 
injection scan to increase the sensitivity
NOVEL RADIOLABELED SOMATOSTATIN ANALOGS IN 
DTC 
Alternative	 radiolabeled	 somatostatin	 analogs	 are	 under	 investigation	 for	
SRS	27,	28.	Gabriel	et	al.29	studied	the	use	of	a	new	radiolabeled	somatostatin	analog	
99mTc-EDDA/HYNIC-TOC	 [99mTc-	 labeled	hydrazinonicotinyl	 (HYNIC)-Tyr3-
octreotide	(TOC)	coupled	with	ethylene	diamine	diacetic	acid	(EDDA)	as	a	co-
ligand]	 in	 54	patients	with	 thyroid	 cancer	 and	no	 radioiodine	uptake	during	
WBS.	The	rationale	for	conducting	this	study	were	the	favorable	characteristics	of	
99mTc-EDDA/HYNIC-TOC	scintigraphy	compared	with	111In-octreotide	scintigraphy,	
such	as	wider	availability	of	the	radionuclide,	shorter	acquisition	time	and	higher	
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spatial	resolution	30.	A	sensitivity	of	66%	for	99mTc-EDDA/HYNIC-TOC	scintigraphy	
in	patients	with	DTC	was	 reported.	Furthermore,	 it	demonstrated	a	positive	
correlation	between	true-positive	findings	and	elevated	serum	Tg	levels.	In	addition,	
direct	comparison	of	both	SRS	modalities	was	performed	in	eight	patients.	One	
discordant	finding	in	favor	of	99mTc-EDDA/	HYNIC-TOC	scintigraphy	was	reported.	
Although	these	results	indicate	that	both	radiopharmaceuticals	have	a	similar	affinity	
profile	for	the	different	somatostatin	receptor	subtypes,	this	remains	to	be	proven.	
Further	studies	are	necessary	to	assess	the	affinity	profile	of	99mTc-EDDA/HYNIC-
TOC	and	the	value	of	99mTc-EDDA/	HYNIC-TOC	scintigraphy	in	clinical	practice.	
Recently,	Rodrigues	 et al.	 31	 reported	 results	 of	 in	 vitro	binding	 studies	 and	
SRS	of	 two	other	 radiolabeled	somatostatin	analogs;	 111In-coupled	 to	 1,4,7,10-
tetraazacyclododecane	(DOTA)-lanreotide	(111In-DOTA-LAN)	and	DOTA-D-Phe1-
Tyr3-octreotide	 (111In-DOTA-TOC).	SRS	with	both	radioligands	demonstrated	
tumor-related	uptake	in	17	out	of	18	patients	(94%).	Each	radioligand	demonstrated	
an	equal	number	of	lesions	in	radioiodine-negative	and	in	radioiodine-positive	
patients.	 18F-FDG	PET	imaging	in	the	same	patients	detected	fewer	tumor	lesions	
in	15	out	of	18	(83%)	patients.	
In	addition,	the	novel	radiolabeled	somatostatin	analog,	[111In]DOTA-1-Nal3-octreotide	
(111In-DOTANOC),	which	besides	high	affinity	for	sstr2,	also	has	high	affinity	for	
sstr3	and	sstr5,	is	of	interest	28.	Because	of	this	affinity	profile,	which	clearly	differs	
from	that	of	111In-octreotide,	this	analog	holds	promise	for	better	tumor	imaging	in	
patients	with	non-radioiodine-avid	DTC.	
THERAPY WITH  RADIOLABELED  SOMATOSTATIN 
ANALOGS 
Despite	the	differences	in	sensitivity,	and	variations	in	the	expression	of	somatostatin	
receptor	subtypes	and	uptake	during	111In-octreotide	scintigraphy,	SRS	has	additional	
diagnostic	value	in	determining	either	the	extent	of	metastatic	disease	or	recurrences	
in	DTC.	Furthermore,	 the	uptake	of	 111In-octreotide	 in	 tumor	sites,	 imaged	by	
SRS,	indicates	somatostatin	receptors	on	the	tumor-cell	surface,	which	might	be	a	
potential	therapeutic	target	for	somatostatin	analogs	such	as	octreotide	in	patients	
with	DTC	for	whom	there	is	no	alternative	treatment.	However,	reports	on	the	use	
of	these	non-radioactive	somatostatin	analogs	to	treat	patients	with	non-radioiodine-
avid	DTC	tumors	are	scarce	and	evidence	of	therapeutic	benefit	is	limited	(Box	1).
	
Another	therapeutic	approach	in	patients	with	uptake	on	SRS	is	tumor-targeted	
therapy	with	radiolabeled	analogs	of	somatostatin.	This	approach,	called	peptide	
receptor	radionuclide	therapy	(PRRT),	is	known	to	be	effective	in	neuroendocrine	
GEP	tumors	with	several	radiolabeled	somatostatin	analogs	(Reviewed	in	20).	
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In	the	first	clinical	PRRT	study,	patients	with	SRS	positive	tumors,	five	of	whom	
had	DTC,	were	treated	with	high	doses	of	111In-octreotide	35.	PRRT	resulted	in	stable	
disease	in	one	patient	whereas	the	other	four	had	progressive	disease.	In	patients	
with	neuroendocrine	GEP	tumors,	2–17%	had	a	partial	remission	determined	by	
clinical	 imaging	and/or	biochemical	parameters	 35-37.	Although	the	results	were	
promising,	most	PRRT	studies	that	followed	used	β-particle-emitting	radionuclides	
such	as	90Y	and	177Lu	instead	of	the	Auger	electron	emitting	111In.	β-particle-emitting	
radionuclides	have	greater	therapeutic	potential	because	the	emitted	particle	range	
exceeds	the	cell	diameter	 38-40.	Furthermore,	the	ability	to	irradiate	neighboring	
cells	is	an	advantage	in	tumors,	which	are	characterized	by	a	heterogeneous	tissue	
distribution	of	somatostatin	receptors,	with	regions	of	high	density	next	to	regions	
that	do	not	express	the	receptor	41.	
In	addition	to	the	introduction	of	β-particle-emitting	radionuclides,	structural	
changes	in	the	analog,	such	as	insertion	of	tyrosine	(Tyr3-OC	or	TOC)	and	replacement	
of	the	C-terminal	threoninol	with	threonine	(TATE),	 increased	the	affinity	for	
the	sstr2	42.	As	expected,	clinical	and	pre-clinical	studies	in	which	somatostatin	
analogs	were	coupled	to	either	90Y	or	177Lu	were	more	successful	in	terms	of	tumor	
shrinkage	than	somatostatin	analogs	coupled	to	111In	43-46.	The	results	of	treatment	
with	the	β-particle-emitting	radiolabeled	somatostatin	analogs	90Y-DOTA-TOC	and	
Box 1.	Treatment	of	DTC	with	non-radioactive	somatostatin	analogs	
Zlock	et	al.	32	treated	four	patients	with	DTC	with	relatively	high	doses	(4	mg	daily)	of	non-radioactive	
octreotide	subcutaneously	for	up	to	12	months:	each	showed	progressive	disease	under	therapy.	
However,	 the	expression	of	 the	somatostatin	receptor	 in	biopsied	 tumor	 tissue	and	uptake	of	
	111In-octreotide	during	SRS	was	not	evaluated,	which	makes	it	difficult	to	evaluate	the	effect	of	
octreotide	treatment	in	this	study.	In	a	more	recent	report,	Robbins	et	al.	described	two	patients	
with	widely	metastatic	PTC	who,	because	of	failure	of	conventional	treatment,	were	treated	with	
monthly	injections	of	a	slow-release	form	of	octreotide	(Sandostatin	LAR	depot®)	33	Both	patients	
had	visible	uptake	in	the	lungs	on	SRS.	18F-FDG	PET	scans	before	therapy	and	3–4	months	after	the	
start	of	the	monthly	injections	of	sandostatin	LAR	showed	a	reduction	of	standard	uptake	values	in	
both	patients,	which	suggested	octreotide-induced	reduction	of	metabolic	activity	in	the	tumors.	
However,	no	effect	on	tumor	size	and/or	serum	Tg	levels	was	reported.	Despite	the	absence	of	an	
objective	response,	one	patient	showed	clear	clinical	improvement	whereas	the	other	experienced	no	
change	in	clinical	signs	and	symptoms.	Alternative	explanations	for	the	observed	reduced	metabolic	
activity,	such	as	inhibition	of	inflammatory	cells	and	inhibition	of	revascularization	or	angiogenesis,	
were	suggested.	These	early,	limited	studies	indicate	that	octreotide	is	likely	to	be	of	limited	value	
in	the	management	of	patients	with	DTC,	and	no	further	studies	have	been	published	since	2000.	
Recently,	a	novel	somatostatin	analog,	SOM230,	has	been	introduced	34.	Compared	with	octreotide,	
the	binding	affinity	of	SOM230	for	sstr1,	sstr3	and	sstr5	is	30x,	5x	and	40x	higher,	respectively,	and	
2.5x	lower	for	sstr2	34.	In	addition,	the	favorable	elimination	half-life	of	SOM230	(23	h),	makes	it	
suitable	for	clinical	application.	Therefore,	it	 is	of	interest	to	study	the	anti-tumor	effects	of	this	
somatostatin	analog	with	a	broader	somatostatin	receptor	profile	than	the	somatostatin	analogs	that	
are	currently	available.	
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6.2
177Lu-DOTATATE	 in	patients	with	neuroendocrine	GEP	 tumors	 are	 the	most	
encouraging,	with	24–33%	of	patients	experiencing	either	complete	or	partial	
remission	20.	
In	addition	to	the	use	of	90Y-	and	 177Lu-labeled	somatostatin	analogs	for	treating	
patients	with	neuroendocrine	GEP	 tumors,	 patients	with	non-radioiodine-
avid	DTC	have	 also	 been	 treated.	Recently,	we	have	 reported	 the	 results	 of	
the	first	patients	with	DTC	treated	with	 177Lu-DOTATATE	47	and	reviewed	the	
available	clinical	PRRT	studies	that	report	the	outcome	of	PRRT	in	patients	with	
DTC	14,	19,	29,	35,	44,	48,	49.	Additionally,	Stokkel	et al.	50	reported	their	results	of	high-dose	
(~15–30	GBq)	therapy	with	111In-octreotide	in	patients	with	progressive	radioiodine-
non-responsive	thyroid	cancer.	Table	3	summarizes	the	available	reports	of	PRRT	
on	62	patients	with	DTC.	In	this	group,	five	patients	(8%),	 including	two	with	
HCTC	(Box	2),	had	an	objective	tumor	response	and	26	patients	(42%)	had	stable	
disease.	Time-to-progression	data	were	either	not	available	or	reported	for	<1	year.	
Comparing	these	studies,	some	of	which	include	only	a	few	patients,	is	difficult	
because	of	differences	in	the	radionuclides,	somatostatin	analogs	and	maximum	doses	
administered.	Nevertheless,	it	is	clear	that	the	radiolabeled	analogs	that	have	been	
evaluated,	PRRT	is	less	effective	in	DTC	than	in	neuroendocrine	GEP	tumors.	
THE FUTURE OF PRRT IN DTC 
Most	of	 the	radiolabeled	somatostatin	analogs	that	are	used	for	diagnostic	and	
therapeutic	purposes	bind	with	high	affinity	to	sstr2	and	with	lower	affinity	for	
the	other	receptor	subtypes.	In	DTC,	studies	indicate	that	the	expression	of	the	
different	somatostatin	receptor	subtypes	is	more	variable	than	in	neuroendocrine	
GEP	tumors	in	which	sstr2	is	expressed	predominantly.	The	ongoing	development	
of	somatostatin-based	radioligands	with	a	broader	receptor	subtype	profile	 is,	
therefore,	of	interest	51.	Wild	et al.	28	reported	the	first	preclinical	data	on	the	novel	
radiolabeled	(111In	and	90Y)	somatostatin	analog	DOTANOC	that	has	high	affinity	
for	sstr2,	sstr3	and	sstr5.	They	briefly	mentioned	excellent	image	quality	in	the	first	
scintigraphy	studies	with	 111In-DOTANOC	in	patients	with	thyroid	cancer.	It	 is	
assumed	that	DOTANOC	labeled	with	either	90Y	or	177Lu	will	have	similar	favorable	
binding	properties	and,	therefore,	might	become	available	to	treat	patients	with	DTC.	
Preliminary	results	of	SRS	and	PRRT	with	111In	and	177Lu-DOTANOC,	respectively,	
are	encouraging	52.
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CONCLUDING REMARKS 
In	patients	with	recurrent	and/or	metastatic	non-radioiodine-avid	DTC,	SRS	can	
demonstrate	tumor	sites	in	a	substantial	percentage	of	patients.	Therefore,	SRS	
is	useful	for	 imaging	and	to	localize	tumor	sites	 in	patients	 in	whom	disease	is	
suspected	because	of	elevated	serum	Tg	level	but	who	are	without	apparent	uptake	
during	postradioiodine	therapy	WBS.	Localization	with	SRS	might	be	helpful	in	the	
further	management	of	these	patients.	The	sensitivity	of	SRS	is	likely	to	depend	on	
the	tumor	size,	the	extent	of	disease	and	the	expression	of	the	different	somatostatin	
receptor	subtypes.	
In	patients	with	uptake	on	SRS	who	have	no	alternative	therapeutic	options,	SRS	
can	select	potential	candidates	for	PRRT.	When	conventional	treatment	is	no	longer	
an	option	and	SRS	shows	sufficient	uptake	of	 111In-octreotide,	PRRT	should	be	
considered	as	an	alternative	therapy.	
Research	into	radiolabeled	somatostatin	analogs	that	have	high	binding	affinity	
to	the	different	sstr	subtypes	is	underway.	This	might	introduce	more	receptor	
subtype-specific	SRS	and,	thereby,	more	effective	PRRT	for	patients	with	DTC	in	
the	future.	
Box 2.	PRRT	in	patients	with	HCTC
In	view	of	their	therapeutic	options	patients	with	HCTC	are	of	special	interest.	In	general,	most	pa-
tients	with	HCTC	do	not	accumulate	radioiodine	and,	therefore,	are	unlikely	to	benefit	from	radioio-
dine	therapy.	Consequently,	local	recurrences	and/or	metastases	after	the	initial	therapy	are	difficult	
to	manage,	which	gives	the	diagnosis	of	HCTC	the	worst	prognosis	within	DTC.	New	therapeutic	
options,	such	as	PRRT,	are	of	interest	because	analysis	of	the	reports	summarized	in	Table	1	shows	
that	35	out	of	39	(90%)	HCTC	patients	with	proven	residual	disease	had	detectable	uptake	of	111In-oc-
treotide	during	SRS.	As	suggested	previously	47,	this	is	likely	to	result	from	higher	expression	of	sstr2	
in	HCTC,	which	gives	a	more	favorable	profile	of	the	expression	of	somatostatin	receptor	subtypes	
compared	with	PTC	and	FTC.	However,	a	large	prospective	clinical	trial	of	PRRT	for	HCTC	is	unlikely	
because	of	the	rarity	of	this	condition.	Thus,	substantial	evidence	of	the	effectiveness	of	PRRT	in	
HCTC	is	unlikely	in	the	near	future.	Therefore,	although	the	results	in	HCTC	patients	treated	with	
PRRT,	such	as	excellent	palliation	and	prolonged	stable	disease,	minor	remission	or	partial	remission	
are	anecdotal	14,	19,	47,	PRRT	must	be	considered	as	an	alternative	therapy	when	conventional	treatment	
is	no	longer	an	option	and	SRS	shows	sufficient	uptake	of	111In-octreotide.	
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7 
Summary and general discussion
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The	concept	of	radiolabelled	peptide	analogues	to	target	cell	membrane-bound	
receptors	 is	subject	of	an	 increasing	number	of	research	projects	and	source	of	
inspiration	for	many	researchers	throughout	the	world.	The	first	application	of	
radiolabelled	peptides	in	the	human	was	introduced	by	Krenning	et	al.	 in	19891.	
The	somatostatin	analogue	Tyr3-octreotide	was	labelled	with	123I	and	scintigraphy	
to	localise	somatostatin	receptor	positive	tumours	was	established.	However,	the	
use	of	123I-Tyr3-octreotide	for	scintigraphy	had	several	major	drawbacks	regarding	its	
metabolic	behaviour,	preparation	difficulties	and	the	relatively	short	physical	half-
life	of	the	radionuclide	2.	Therefore,	another	radiolabelled	analogue	of	somatostatin,	
111In-DTPA-D-Phe1-octreotide	was	introduced	which	had	several	advantages	such	
as	easy	preparation,	general	availability,	appropriate	half-life	and	absence	of	major	
interference	in	the	upper	abdominal	region.	In	1994,	111In-DTPA-D-Phe1-octreotide	
(OctreoScan®)	was	approved	by	the	U.S.	Food	and	Drug	Administration	(FDA)	
and	since	then	OctreoScan®	has	become	a	commonly	used	imaging	technique	to	
diagnose	neuroendocrine	tumours,	such	as	carcinoids	and	neuroendocrine	tumours	
of	the	pancreas.	These	tumours	have	a	high	expression	of	somatostatin	receptors,	
especially	the	receptor	subtype	2,	in	common	3.	
The	next	logical	step	in	this	field,	made	by	Krenning	et al.	was	to	use	radiolabelled	
somatostatin	analogues	for	therapy	in	those	patients	with	neuroendocrine	tumours,	
who	had	somatostatin	receptor	positive	tumours	on	scintigraphy	and	inoperable	
disease	4.	This	was	an	important	new	approach	in	these	patients	since	for	most	
of	these	patients	no	effective	systemic	anti-tumour	therapy,	besides	aggressive	
chemotherapy,	was	available.
The	first	radiolabelled	somatostatin	analogue	therapy	in	patients	with	advanced	stage	
neuroendocrine	tumours	was	based	on	the	administration	of	high	dosages	of	the	
therapeutic	Auger	electron	emitting	111Indium-octreotide.	The	total	cumulative	dose	
varied	from	3.1	GBq	up	to	160	GBq.	However,	besides	encouraging	and	promising	
results,	such	as	biochemical	reponses	and	clinical	benefit	in	terms	of	symptomatic	
control,	only	small	numbers	of	patients	with	an	objective	morphological	response	
were	reported	5-7.	Therefore,	several	research	groups,	who	initially	treated	their	
patients	with	111Indium-octreotide,	developed	somatostatin	analogues	that	could	be	
linked	with	a	β-emitting	radionuclide,	such	as	90Yttrium	(90Y)	or	177Lutetium	(177Lu).	
For	these	radionuclides	a	better	efficacy	was	expected	due	to	the	longer	radiation	
path	length	of	the	emitted	β-particles	in	comparison	with	the	relatively	short	range	
of	Auger	electrons	emitted	by	111Indium.	Studies	with	various	somatostatin	analogues	
labelled	with	the	β-emitting	radionuclide	90Y	followed	and	better	efficacy	in	terms	
of	the	percentage	of	patients	with	objective	tumour	responses	was	demonstrated.	
Shortly	after	the	start	of	the	clinical	studies	with	90Y-labelled	somatostatin	analogues,	
peptide	receptor	radionuclide	therapy	(PRRT)	with	the	β-emitting	radionuclide	
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7177Lutetium	coupled	to	the	somatostatin	analogue	octreotate	was	started	in	Rotterdam	
for	the	treatment	of	patients	with	inoperable	and	or	metastasised	neuroendocrine	
gastroenteropancreatic	tumours	(GEP-NETs).	
The	 aim	of	 this	 thesis	was	 to	 evaluate	 the	 efficacy	of	 treatment	with	 [177Lu-
DOTA0,Tyr3]octreotate	(177Lu-DOTATATE)	therapy	in	patients	with	somatostatin	
receptor	positive	GEP-NETs	in	terms	of	toxicity,	effects	on	tumour	size	and	number,	
side-effects	and	quality	of	 life.	Furthermore,	 it	was	questioned	whether	 177Lu-
DOTATATE	or	177Lu-DOTATOC	might	be	the	radiolabelled	analogue	of	choice	in	
this	form	of	PRRT.	All	these	aspects	are	discussed	in	chapter	2-5	of	this	thesis.
Since	177Lu-DOTATATE	therapy	demonstrated	favourable	clinical	efficacy	in	GEP-
NETs,	other	somatostatin	receptor	positive	tumours	were	considered	as	candidates	
for	this	therapy	and	subsequently	patients	with	non-radioiodine	avid	differentiated	
thyroid	carcinoma,	who	had	no	alternative	treatment	option	left,	were	treated.	
Feasibility	of	PRRT	with	177Lu-DOTATATE	therapy	in	these	patients	is	described	in	
chapter	6.	In	addition,	staging	with	radiolabelled	somatostatin	analogue	scintigraphy	
and	the	use	of	 177Lu-DOTATATE	therapy	in	differentiated	thyroid	carcinoma	is	
reviewed.	
An	 overview	 of	 the	management	 of	 patients	 with	 GEP-NETs	 is	 given	 in	
chapter 1.1.	Together	with	a	large	number	of	other	therapeutic	options	currently	
available,	PRRT	with	radiolabelled	somatostatin	analogues	is	put	into	perspective,	
addressing	important	results	and	findings	of	each	therapy	such	as	toxicity,	side-
effects,	outcome	and	survival.	An	extensive	overview	of	PRRT	in	patients	with	
GEP-NETs,	is	given	in	chapter 1.2.	The	aims	and	outline	of	this	thesis	are	presented	
in	chapter	1.3.
In chapter 2.1	the	first	results	of	177Lu-DOTATATE	therapy	studied	in	35	patients	
with	GEP-NETs	 is	presented.	Side-effects	of	and	toxicity	after	 treatment	with	
177Lu-DOTATATE	are	infrequent	and	mostly	transient,	with	mild	bone	marrow	
depression	as	 the	most	common	finding.	Although	 the	main	objective	of	our	
study	was	to	evaluate	the	feasibility	of	the	treatment	in	terms	of	side-effects	and	
toxicity,	the	reported	effects	on	tumour	size	with	complete	and	partial	remission	
in	38%	of	patients	 compared	 favourably	with	 the	earlier	 reported	PRRT	with	
[90Y-DOTA0,Tyr3]octreotide	(90Y-DOTATOC)	and	the	reported	outcome	of	most	
trials	with	chemotherapy.	However,	inclusion	of	more	patients	was	necessary	to	
prove	these	early	preliminary	findings.	The	results	in	a	larger	number	of	patients	are	
presented	in	chapter 2.2,	in	which	the	favourable	objective	responses	as	described	
in	chapter	2.1	were	confirmed	with	minor,	partial	or	complete	response	in	47%	of	
125	evaluable	patients.	Furthermore,	we	were	able	to	delineate	predictive	factors	
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of	tumour	response.	A	high	uptake	on	pretherapy	111In-octreotide	scintigraphy	and	
limited	liver	involvement	were	predictive	for	a	favourable	response,	whereas,	in	
general,	patients	with	a	low	Karnofsky	Performance	Score	and,	to	a	lesser	extent,	
a	high	tumour	load	before	therapy	had	a	higher	risk	of	progressive	disease.	From	
these	results	we	concluded	that	early	treatment,	even	in	patients	without	evidence	
of	progression	or	symptoms,	may	be	better.	Comparison	of	our	results	 in	 177Lu-
DOTATATE	treated	patients	with	studies	in	which	90Y-DOTATOC	was	used,	is	
difficult,	as	besides	differences	in	study	design,	protocol	and	administered	dosages,	
patient	selection	could	have	influenced	the	study	outcome.	Therefore,	until	now,	it	
is	not	proven	which	radiolabelled	somatostatin	analogue	can	be	regarded	as	the	most	
optimal	for	PRRT	in	GEP-NET	patients.	
Another	interesting	finding	described	in	this	chapter	was	the	decrease	of	uptake	
on	the	last	posttherapy	scan	compared	with	the	first	posttherapy	scan,	which	was	
frequently	seen	in	patients	who	eventually	had	objective	tumour	regression	on	
computed	tomography.	Also,	in	patients	who	had	stable	disease	or	a	tumour	size	
reduction,	the	median	time	to	progression	was	more	than	36	months.	A	direct	
comparison	with	chemotherapeutic	regimens	was	not	performed	as	chemotherapy	is	
relatively	ineffective	in	patients	with	inoperable	GEP-NETs.	Therefore,	we	compared	
our	results	with	historical	data	from	earlier	studies	with,	mostly,	chemotherapy	as	
the	first	option	of	cytoreductive	therapy	in	inoperable	GEP-NETs.	High	variation	
in	reported	objective	tumour	responses	made	it	difficult	to	make	that	comparison.	
However,	most	studies	reported	a	response	duration	of	less	than	18	months,	whereas	
the	median	time	to	progression	after	177Lu-DOTATATE	therapy	was	longer	than	36	
months.	Furthermore,	toxicity	of	most	chemotherapeutic	regimens	is	more	severe	
and	more	frequent	than	with	177Lu-DOTATATE	therapy.	However,	since	our	study	
is	ongoing	and	the	median	time	of	follow-up	is	16	months,	evaluation	at	a	later	time	
point	will	provide	more	definite	evidence	of	these	observations.	
As	described	in	chapter 3,	the	quality	of	life	of	patients	treated	with	177Lu-DOTATATE	
therapy	improves,	especially	in	patients	who	have	an	objective	tumour	response	or	
stable	disease.	To	our	surprise,	the	quality	of	life	in	patients	who	had	progressive	
disease	did	also	show	significant	improvement.	Beside	bias	from	a	placebo	effect,	
another	explanation	of	this	unexpected	result	might	be	the	relatively	low	number	of	
patients	in	this	group,	caused	by	the	fact	that	patients	with	highly	aggressive	tumours	
were	not	able	to	fill	out	the	questionnaire	or	even	died	before	the	last	 intended	
therapeutic	cycle	was	given.	Therefore,	the	interpretation	of	the	data	in	this	category	
of	patients	is	difficult	and	has	to	be	looked	at	with	caution.	In	addition	to	the	global	
health-related	quality	of	life,	the	scales	of	role,	emotional,	and	social	function	as	
well	as	the	symptom	scales	fatigue,	pain	and	the	single	item	insomnia	improved	
significantly	after	PRRT.	Finally,	we	concluded	that	the	favourable	objective	tumour	
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7responses	found	in	our	patients	were	accompanied	by	an	improvement	of	their	
health-related	quality	of	life	in	most	patients.	
In	chapter 4,	 the	short-	and	 long-term	effect	of	 177Lu-DOTATATE	therapy	on	
endocrine	function	is	described	and	discussed.	As	PRRT	is	a	systemic	therapy	and	
many	endocrine	organs	are	known	to	possess	somatostatin	receptors,	these	organs	
are	potential	unwanted	targets	of	PRRT.	In	line	with	the	observations	in	men	treated	
with	high	doses	of	 radioiodine	after	 thyreoidectomy	because	of	differentiated	
thyroid	carcinoma	8,	our	male	patients	demonstrated	a	temporarily	decrease	of	
inhibin	B	levels	and	a	mirrored	course	of	FSH	levels.	Although	no	semen	analysis	
was	performed,	this	indicated	a	temporarily	impaired	spermatogenesis.	Increased	
serum	levels	of	gonadotropins	and	subnormal	serum	levels	of	testosterone	were	also	
documented	in	men	with	rectal	carcinoma	treated	with	external	beam	radiation	9.	
Because	no	direct	evidence	of	the	presence	of	somatostatin	receptor	protein	in	the	
testes	is	available	and	because	of	the	similarity	of	these	findings	in	men	treated	with	
high	doses	of	radioiodine	or	external	beam	radiation	in	proximity	of	the	gonads,	this	
observed	radiotoxicity	is	probably	not	somatostatin	receptor	related.	More	obvious	
reasons	are	radiation	from	the	circulation	and	(scattered)	radiation	in	proximity	of	
the	radiosensitive	gonads	such	as	the	bladder	urine	or	faeces	from	the	rectum	after	
PRRT.
Another	 interesting	observation	 is	 the	decrease	of	both	LH	and	FSH	 levels	 in	
postmenopausal	women.	This	decrease	 is	more	 than	could	be	expected	 from	
ageing	alone10.	As	somatostatin	receptors	are	present	in	the	pituitary	and	because	
postmenopausal	women	lack	the	premenopausal	negative	feedback	mechanism,	a	
receptor	dependent	radiation	delivery	mechanism	is	likely.	
Although	remaining	within	the	reference	range,	the	mean	FT4	level	of	the	group	
available	for	thyroid	hormone	analyses	decreased	significantly.	Furthermore,	two	
patients	developed	primary	hypothyroidism	during	and	after	 177Lu-DOTATATE	
therapy.	Whether	the	occurrence	of	the	primary	hypothyroidism	cases	in	our	series	
of	patients	is	caused	by	the	177Lu-DOTATATE,	or	can	be	regarded	as	normal	incidence	
of	the	disease	is	difficult	to	determine.	However,	the	observed	decrease	of	the	mean	
FT4	level	is	suggestive	for	a	somatostatin	receptor-mediated,	but	limited	radiation	
dose	to	the	thyroid	gland	resulting	in	the	subtle	decrease	demonstrated,	which	is	
probably	not	clinically	important.	Furthermore,	we	demonstrated	a	decrease	of	
mean	rT3	levels	directly	after	 177Lu-DOTATATE	therapy,	which	was	elevated	at	
baseline.	This	decrease	is	suggestive	for	a	change	in	disease	status	according	to	the	
observed	changes	of	thyroid	hormone	levels	in	patients	with	chronic	disease	with	
the	non-thyroidal	illness	syndrome	11.	No	adrenal	insufficiency,	as	was	assessed	
by	a	low-dose	ACTH	stimulation	test,	was	observed	in	patients	before	and	after	
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177Lu-DOTATATE	therapy.	Additionally,	five	patients	developed	elevated	levels	of	
HbA1c	without	any	obvious	cause	such	as	pancreatic	surgery.	Because	pancreas	islets	
are	known	to	exhibit	somatostatin	receptors,	a	receptor-mediated	detrimental	effect	
of	177Lu-DOTATATE	therapy	on	the	glucose	homeostasis	cannot	be	excluded.	Also	
the	effect	of	chronic	‘cold’	somatostatin	analogue	therapy	in	these	patients	might	
have	contributed	to	this	observation.	Overall	we	conclude	that	patients	who	are	
treated	with	177Lu-DOTATATE	therapy	may	develop	radiation-induced	hormone	
disturbances,	some	of	which	are	temporary,	but	which	in	general	are	mild.	Although	
the	treating	physician	should	be	aware	of	the	possibility	of	hormonal	changes,	such	
as	in	young	men	planning	to	have	children,	177Lu-DOTATATE	therapy,	in	terms	of	
endocrine	sequelae,	can	be	regarded	as	safe.	
To	date	many	different	somatostatin	analogues	have	been	synthesised,	which	
exhibit	diverse	affinity	profiles	for	the	currently	known	somatostatin	receptor	
subtypes.	To	evaluate	which	analogue	has	the	best	profile	regarding	the	ideal	balance	
between	uptake	in	the	tumour(s)	and	dose-limiting	organs	or	therapeutic	window	
we	compared	the	 two	most	commonly	used	somatostatin	analogues	 in	PRRT,	
DOTATATE	and	DOTATOC,	coupled	to	177Lu.	The	results	of	this	study	are	described	
in	chapter 5.	A	direct	comparison	between	both	analogues	in	a	PRRT	setting	was	
performed.	Residence	times	of	the	radioactivity,	which	are	directly	related	to	absorbed	
tumour	dose,	within	the	spleen,	kidneys	and	tumours	was	longer	with	the	use	of	
177Lu-DOTATATE	than	 177Lu-DOTATOC.	The	ratios	of	mean	residence	time	of	
177Lu-DOTATATE	versus	177Lu-DOTATOC	were	1.5,	1.4	and	2.1,	for	spleen,	kidneys	
and	tumours,	respectively.	Consequently,	higher	absorbed	tumour	doses	are	expected	
to	be	achievable	with	 177Lu-DOTATATE	than	with	177Lu-DOTATOC.	The	higher	
kidney	residence	time	with	the	use	of	177Lu-DOTATATE	can	be	a	problem	in	PRRT,	
as	beside	the	bone	marrow,	the	kidneys	are	one	of	the	dose	limiting	organs.	However,	
in	any	case	of	PRRT	in	which	the	dose	is	 limited	because	of	reached	maximum	
calculated	dose	to	the	kidneys	(23	Gy)	the	absorbed	dose	within	the	tumour(s)	will	
still	be	higher	since	the	mean	tumour	residence	time	ratio	(2.1)	exceeds	the	mean	
kidneys	residence	time	ratio	(1.4)	with	a	factor	of	1.5	in	favour	of	177Lu-DOTATATE.	
Furthermore,	in	most	of	our	patients	the	bone	marrow	(maximum	allowed	dose	of	
2	Gy)	is	the	dose	limiting	factor	instead	of	the	kidneys.
A	similar	 study	was	performed	by	Forrer	 and	colleagues	 in	Basel,	 comparing	
111In-DOTATOC	with	111In-DOTATATE	12.	It	was	assumed	that	for	dosimetry	purposes	
111In	could	be	used	as	a	surrogate	for	90Y,	frequently	used	for	PRRT	at	their	institution.	
Three	out	of	 five	patients	demonstrated	a	better	 tumour-to-kidney	ratio	with	
111In-DOTATOC	compared	to	111In-DOTATATE.	Based	on	these	data,	it	was	decided	
that	they	would	continue	to	use	the	somatostatin	analogue	DOTATOC	labelled	
with	90Y	for	PRRT.	However,	the	assumption	that	111In	is	a	useful	surrogate	for	90Y,	
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7is	questionable.	Different	radionuclides	coupled	to	one	somatostatin	analogue	may	
have	different	affinity	profiles	 13	which	subsequently	may	result	in	differences	in	
radiopharmacon	biodistribution	as	was	shown	in	a	neuroendocrine	tumour	model	in	
rats	14.	Also,	the	diagnostic	quantity	of	peptide	used	in	the	study	by	Forrer	et al.	was	
much	less	than	the	quantities	used	in	PRRT.	Differences	in	amount	of	peptide	can	
introduce	different	biodistribution	patterns	as	was	demonstrated	by	several	authors	
15-17.	Breeman	et al.	reported	that	the	uptake	of	 111In-pentetreotide	in	somatostatine	
receptor	positive	organs	when	presented	as	a	function	of	the	injected	mass	of	the	
radiopharmaceutical	resembles	a	tissue	specific	bell-shaped	curve.	The	same	bell-
shaped	curve	was	demonstrated	in	normal	tissue	as	well	as	in	tumours	by	Bernhardt	
et al.	 in	SSTR	positive	tumour	bearing	nude	mice	 18.	Thus,	 the	biodistribution	
patterns	can	have	a	significant	effect	on	the	absorbed	kidney	dose	as	well	as	tumour	
dose	and,	thus,	on	the	tumour-to-kidney	ratios	which	were	found	by	Forrer	et al.	
12.	Furthermore	and	in	contrast	to	the	diagnostic	setting	amino-acid	co-infusion	is	
currently	used	in	PRRT	at	most	institutions.	Co-infusion	of	the	amino-acids	lysine	
and/or	arginine	in	PRRT	results	in	a	significant	inhibition	of	renal	radioactivity	
and,	thereby,	has	its	effect	on	the	tumour-to-kidney	ratio	19.	Thus,	in	contrast	with	
the	study	from	the	Basel	group,	our	study	resembles	the	therapeutic	setting	better	
on	several	important	points.	Furthermore,	we	compared	the	residence	times	in	the	
tumour	and	kidneys,	reflecting	absolute	absorbed	tumour	dose,	instead	of	the	relative	
uptake	method	of	tumour-to-kidney	ratios.	
Finally,	in	177Lu-DOTATATE	and	90Y-DOTATOC	based	PRRT	the	critical	organs	are	
the	kidneys	and	bone	marrow.	The	corresponding	maximal	tolerated	doses	(MTD)	
for	external	radiation	of	these	tissues	are	23	and	2	Gy,	respectively,	and	are	used	as	
dose	constraints	to	avoid	radiation-induced	nephropathy	and	severe	bone	marrow	
toxicity,	such	as	myelodysplastic	syndrome	or	leukaemia.	In	approximately	30%	of	
the	patients	treated	with	177Lu-DOTATATE	the	MTD	for	the	kidneys	was	reached	
before	the	intended	cumulative	dose	of	29.6	GBq,	which	corresponds	with	the	
accepted	MTD	for	the	bone	marrow	of	2	Gy.	The	remaining	70%	of	patients	received	
the	cumulative	dose	of	29.6	GBq,	which	for	most	patients	resulted	in	a	cumulative	
dose	to	the	kidneys	less	than	23	Gy.	Thus,	only	in	a	minority	of	the	patients	treated	
with	177Lu-DOTATATE	the	tumour-to-kidney	ratio	plays	a	role	in	the	maximum	
cumulative	dose	of	29.6	GBq	given.	
In	contrast,	in	patients	with	90Y-DOTATOC,	the	kidneys	must	be	considered	as	the	
main,	if	not,	the	only	dose-limiting	organ,	since	the	MTD	for	the	kidney	is	reached	
before	the	bone	marrow	MTD	comes	in	view	20.	
Taken	into	consideration	all	of	the	aforementioned	arguments,	we	concluded	that	
DOTATATE	has	a	better	therapeutic	window	than	DOTATOC	and	therefore	is	the	
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preferred	somatostatin	analogue	to	be	coupled	to	177Lu	when	used	in	PRRT.
In	chapter 6.1,	we	describe	the	feasibility	to	treat	patients	with	differentiated	thyroid	
carcinoma,	who	had	proven	non-radioiodine	avid	disease	and	were	inoperable,	with	
177Lu-DOTATATE.	Five	patients	with	metastatic	differentiated	thyroid	carcinoma	
(3	with	Hürthle	cell	carcinoma,	1	with	papillary	thyroid	carcinoma	and	1	with	follicular	
thyroid	carcinoma)	were	treated	with	22.1–30.1	GBq	177Lu-DOTATATE.	After	PRRT,	
two	patients	had	stable	disease,	two	had	tumour	shrinkage	and	one	had	progressive	
disease.	Besides	objective	tumour	response	favourable	time	to	progression	was	
demonstrated.	Since	these	patients	had	no	alternative	treatment	option	left,	 it	
was	concluded	that	treatment	with	177Lu-DOTATATE	can	be	benificial.	Obviously,	
studies	with	a	larger	group	of	patients	are	necessary	to	establish	the	true	potential	
of	this	approach.	In	addition,	other	radiolabelled	somatostatin	analogues,	such	as	
[DOTA-1-Nal3]octreotide	coupled	to	either	90Y	or	 177Lu	which	exhibit	a	different	
affinity	profile	to	the	somatostatin	receptor	21,	are	of	interest.	This	somatostatin	
analogue	has	in	addition	to	the	high	affinity	to	the	somatostatin	receptor	subtype	2,	
favourable	affinity	to	the	subtypes	3	and	5	which	is	potentially	more	effective	in	the	
treatment	of	differentiated	thyroid	carcinoma.	This	is	because	the	expression	profile	
of	somatostatin	receptors	in	differentiated	thyroid	carcinoma	is	likely	to	be	different	
from	GEP-NETs,	with	evidence	of	(co-)	expression	of	subtypes	3	and	5	22.	
In	chapter 6.2	 the	current	use	of	somatostatin	receptor	imaging	and	therapy	in	
non-radioiodine	avid	differentiated	thyroid	carcinoma	is	reviewed.	The	overall	
conclusion	regarding	scintigraphy	is	that	it	can	be	useful	to	localize	tumor	sites	in	
patients	in	whom	disease	is	suspected	because	of	an	elevated	serum	Tg	level	but	
without	apparent	uptake	during	postradioiodine	therapy	whole	body	scintigraphy.	
In	more	than	50%	of	the	cases	somatostatin	receptor	scintigraphy	is	able	to	localize	
disease	and	hence	helpful	in	the	further	management	of	these	patients.	PRRT	in	
differentiated	thyroid	carcinoma	has	been	described	in	only	62	patients	up	until	now.	
Three	different	radionuclides	(111In,	90Y	and	177Lu)	coupled	to	4	different	somatostatin	
analogues	(DOTATOC,	[DTPA0]octreotide,	lanreotide	and	DOTATATE)	were	used	
with	cumulative	dosages	in	the	range	of	0.9	to	30.1	GBq.	The	90Y	and	177Lu	coupled	
somatostatin	analogues	demonstrated	to	be	the	most	promising	in	terms	of	tumour	
response	compared	to	111In,	and	therefore	the	usage	of	the	latter	is	not	recommended	
anymore	for	PRRT	in	differentiated	thyroid	carcinoma	which	is	also	true	for	PRRT	
in	GEP-NET	patients.	
Final conclusions
PRRT	with	177Lu-DOTATATE	is	the	choice	of	therapy	in	patients	with	inoperable,	
metastasised	well-differentiated	somatostatin	receptor	positive	GEP-NETs.	The	
outcome	of	therapy	in	terms	of	objective	response,	quality	of	life,	time	to	progression	
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7and	preliminary	survival	analysis	compares	favourably	with	the	historical	data	of	
alternative	therapeutic	approaches,	including	the	currently	available	chemotherapy.	
Also,	 side-effects	and	 toxicity	profile	are	 in	general	 favourable.	Furthermore,	
177Lu-DOTATATE	therapy	can	be	an	optional	therapy	in	selected	patients	with	non-
radioiodine-avid	differentiated	thyroid	carcinoma.	Especially	in	non-radioiodine-
avid	differentiated	carcinoma,	radiolabelled	somatostatin	analogues	with	a	different,	
more	specific,	somatostatin	receptor	profile	may	be	promising.
To	increase	the	effectiveness	of	PRRT,	administration	of	higher	cumulative	doses	
to	the	individual	patient	could	be	one	of	the	methods.	This	can	only	be	achieved	
via	the	introduction	of	individually	assessed	dosimetry	in	order	to	estimate	the	
exact	dose	to	the	dose-limiting	organs.	However,	since	this	approach	is	difficult,	
time-consuming	and	therefore	costly,	individual	accurate	pre-therapy	dosimetry	
is	currently	not	available	in	any	therapeutic	institution	23.	Further	research	towards	
patient-based	dosimetry,	 including	the	kidneys	and	bone	marrow,	 is	necessary	
to	provide	practical	methods	for	tailored	PRRT	so	that	 it	can	be	part	of	patient	
management	in	the	future.	Furthermore,	besides	individual	dosimetry	to	provide	
optimal	treatment	dose,	the	development	of	kidney	protective	agents	could	widen	
the	therapeutic	window.	With	the	use	of	kidney	protective	agents,	higher	dosages	
can	be	given	which	could	increase	PRRT	efficacy.	
Besides	attempts	to	widen	the	therapeutic	window	of	PRRT,	new	approaches	for	future	
studies	include	the	development	of	new	somatostatin	analogues	with	more	favourable	
affinity	profiles,	combinational	therapy	with	other	radionuclides,	such	as	90Y	or	111In,	
and	the	use	of	radiosensitizing	agents.	A	multi-centre	randomised	controlled	trial	
with	 177Lu-DOTATATE	therapy	in	combination	with	the	radiosensitizing	agent	
capecitabine	versus	monotherapy	with	177Lu-DOTATATE	has	been	started	at	our	
department	in	2007.
Finally,	the	use	of	PRRT	in	patients	with	somatostatin	receptor	positive	tumours	
demonstrates	that	a	therapy	based	on	a	radionuclide	coupled	to	a	peptide	can	be	
succesful	and	holds	great	promise	for	future	treatment	of	various	other	cancers.	
Frequently,	new	tumour-specific	 receptors	are	discovered	 that	might	become	
potential	targets	for	high	affinity	radiolabelled	peptides	and	thus	PRRT.	Therefore,	
it	is	not	unlikely	that	PRRT	will	become	an	important	therapeutic	modality	in	other	
parts	of	the	challenging	field	of	oncology.
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Het	concept	van	radioactief	gelabelde	peptiden	die	zich	kunnen	binden	aan	membraan	
gebonden	receptoren	is	een	inspiratiebron	voor	veel	onderzoekers	en	resulteerde	in	
een	groot	aantal	 interessante	onderzoeksprojecten	op	dit	gebied.	De	allereerste	
humane	toepassing	van	radioactief	gelabelde	peptiden	werd	geïntroduceerd	door	
de	groep	van	Krenning	in	1989	1.	Het	somatostatine	analoog	Tyr3-octreotide	werd	
gelabeld	met	Jodium-123	(123I).	Door	middel	van	scintigrafie	met	dit	radiofarmacon	
konden	neuroendocriene	 tumoren,	die	somatostatinereceptoren	 tot	expressie	
brengen,	worden	aangetoond.	Het	gebruik	van	123I-Tyr3-octreotide	had	echter	een	
aantal	nadelen	zoals	de	hoge	 fysiologische	activiteit	 in	de	buik	na	 toediening,	
de	moeizame	productiemethode	en	de	relatief	korte	halfwaardetijd	 2.	Om	deze	
problemen	 te	voorkomen	werd	een	ander	 radioactief	gelabeld	somatostatine-
analoog	ontwikkeld,	het	111Indium-DTPA-D-Phe1-octreotide	(111In-octreotide).	Het	
111In-octreotide	heeft	een	aantal	voordelen	zoals	de	relatief	gemakkelijke	bereiding,	
de	goede	beschikbaarheid,	de	praktische	halfwaardetijd	en	minimale	fysiologische	
opname	in	de	buik.	In	1994	werd	111In-octreotide	(OctreoScan®)	goedgekeurd	door	
de	Amerikaanse	Food	and	Drug	Administration.	Vanaf	die	tijd	is	scintigrafie	met	
OctreoScan®	de	meest	gebruikte	methode	voor	het	diagnosticeren	van	gastro-
intestinale	neuroendocriene	tumoren,	zoals	het	carcinoid	en	de	neuroendocriene	
tumoren	van	de	pancreas.	Deze	tumoren	hebben	in	het	algemeen	een	hoge	expressie	
van	somatostatinereceptoren,	met	name	van	subtype	2	op	hun	celmembraan	3.
De	volgende	 logische	stap	op	dit	gebied,	 tevens	uitgevoerd	door	de	groep	van	
Krenning,	was	het	gebruik	van	 radioactief	 gelabelde	 somatostatine-analogen	
voor	 therapie	bij	patiënten	met	 inoperabele,	 somatostatinereceptor	positieve	
neuroendocriene	tumoren,	aangetoond	op	de	OctreoScan®	4.	Dit	was	een	belangrijke	
nieuwe	therapeutische	benadering	voor	deze	groep	patiënten,	aangezien	er	op	dat	
moment	geen	effectieve	systemische	therapie	beschikbaar	was.	
De	eerste	therapie	met	een	radioactief	gelabeld	somatostatine-analoog	was	gebaseerd	
op	hoge	doses	van	het	 111In-octreotide.	De	radiotoxiciteit	van	met	name	de	Auger	
electronen	die	door	het	 111Indium	worden	uitgezonden	zijn	van	belang	voor	het	
eventuele	therapeutische	effect.	Vanwege	het	experimentele	karakter	van	deze	therapie	
kwamen	voornamelijk	patiënten	met	uitgebreid	gemetastaseerde	neuroendocriene	
tumoren	in	aanmerking.	De	totaal	gecumuleerde	dosis	die	aan	deze	patiënten	werd	
gegeven,	varieerde	van	3,1	tot	en	met	160	Gigabecquerel	(GBq).	Hoewel	de	resultaten,	
zoals	biochemische	en	klinische	verbeteringen,	bemoedigend	en	veelbelovend	waren	
kon	slechts	in	een	klein	aantal	patiënten	een	objectiveerbare	verkleining	van	de	
tumoren	(tumorrespons)	worden	aangetoond	5-7.	Het	is	dan	ook	niet	verwonderlijk	
dat	verschillende	onderzoeksgroepen,	die	eerst	hun	patiënten	behandelden	met	
111In-octreotide,	somatostatine-analogen	ontwikkelden	die	gekoppeld	konden	worden	
aan	een	radionuclide	dat	bètastraling	uitzendt,	zoals	het	90Yttrium	(90Y)	of	177Lutetium	
Sa
m
en
va
tt
in
g 
en
 a
lg
em
en
e 
di
sc
us
si
e
8(177Lu).	Van	deze	radionucliden	was	een	betere	effectiviteit	te	verwachten,	gezien	
het	langere	emissiepad	van	de	uitgezonden	bètadeeltjes	(2-12	mm)	in	vergelijking	
met	de	relatief	korte	afstand	(≈	10	µm)	die	wordt	afgelegd	door	de	Auger	electronen	
uitgezonden	 door	 het	 111Indium	 (111In).	 Klinische	 studies	met	 verschillende	
somatostatine-analogen	gelabeld	met	90Y	volgden	en	toonden	inderdaad	een	hoger	
percentage	patiënten	met	een	tumorrespons	in	vergelijking	met	111In-octreotide.	Bijna	
gelijktijdig	werd	in	het	Erasmus	MC	in	Rotterdam	gestart	met	de	behandeling	van	
patiënten	met	inoperabele	of	gemetastaseerde	gastro-intestinale	neuroendocriene	
tumoren	met	177Lu	gelabeld	[DOTA0,Tyr3]octreotaat	(177Lu-DOTATAAT)	.
Het	doel	van	dit	proefschrift	was	om	de	effectiviteit	van	177Lu-DOTATAAT	therapie	
bij	patiënten	met	somatostatinereceptor	positieve	gastro-intestinale	tumoren	te	
evalueren.	Hierbij	komen	achtereenvolgens	de	toxiciteit,	bijwerkingen,	het	effect	op	
de	tumorgrootte	en	de	kwaliteit	van	leven	na	177Lu-DOTATAAT	therapie	aan	de	orde.	
Vervolgens	is	onderzocht	welk	somatostatine-analoog	het	meest	geschikt	is	om	te	
gebruiken	bij	peptide	receptor	radionuclide	therapy	(PRRT)	met	177Lu;	DOTATAAT	
of	[DOTA-D-Phe1-Tyr3]octreotide	(DOTATOC).	Deze	onderwerpen	komen	aan	de	
orde	in	het	eerste	gedeelte	van	dit	proefschrift	(hoofdstuk	2	t/m	5).
Aangezien	 177Lu-DOTATAAT	therapie	succesvol	bleek	te	zijn	 in	patiënten	met	
gastro-intestinale	neuroendocriene	tumoren,	werd	deze	therapie	mogelijk	ook	
geschikt	geacht	voor	de	behandeling	van	andere	somatostatinereceptor	positieve	
tumoren.	Mogelijke	kandidaten	voor	177Lu-DOTATAAT	therapie	bleken	patiënten	
met	gedifferentieerd	schildkliercarcinoom,	waarbij	de	tumor	niet	meer	in	staat	
was	om	radioactief	jodium	(131I)	op	te	nemen.	Voor	deze	specifieke	patiëntengroep	
bestaat	er,	naast	het	gebruikelijke	131I,	geen	goede	alternatieve	systemische	therapie.	
Wanneer	er	wel	duidelijke	activiteitsstapeling	werd	gezien	op	de	OctreoScan®	werden	
deze	patiënten	behandeld	met	 177Lu-DOTATAAT.	De	effectiviteit	van	PRRT	met	
177Lu-DOTATAAT	bij	een	aantal	van	deze	patiënten	is	beschreven	in	het	tweede	
gedeelte	van	dit	proefschrift	(hoofdstuk	6.1).	Daarnaast	is	een	uitgebreid	overzicht	
van	de	 stagering	van	gedifferentieerd	schildkliercarcinoom	met	OctreoScan®	
en	het	gebruik	van	PRRT	bij	deze	specifieke	patiëntenpopulatie	weergegeven	
(hoofdstuk	6.2).
Hoofdstuk 1.1	geeft	een	overzicht	van	de	behandelingsmogelijkheden	van	patiënten	
met	gastro-intestinale	tumoren.	Een	groot	aantal	therapeutische	opties,	inclusief	
PRRT	met	radioactief	gelabelde	somatostatine-analogen,	 is	beschreven	waarbij	
uitkomstmaten	en	bevindingen	zoals	toxiciteit,	bijwerkingen,	therapierespons	en	
overlevingsduur	ter	sprake	komen.	Hoofdstuk 1.2	bevat	een	uitgebreid	overzicht	van	
PRRT	bij	patiënten	met	gastro-intestinale	neuroendocriene	tumoren.	In	hoofdstuk 
1.3	zijn	het	doel	en	de	opzet	van	dit	proefschrift	uiteengezet.
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In hoofdstuk 2.1 zijn	de	eerste	resultaten	van	177Lu-DOTATAAT	therapie	bij	35	
patiënten	met	gastro-intestinale	neuroendocriene	tumoren	beschreven.	Het	doel	
van	deze	studie	was	 in	eerste	 instantie	het	evalueren	van	de	mogelijkheid	van	
behandeling	van	patiënten	met	177Lu-DOTATAAT	met	daarbij	de	nadruk	op	evaluatie	
van	de	mogelijke	bijwerkingen	en	de	toxiciteit	van	de	behandeling.	Toxiciteit	en	
bijwerkingen	na	behandeling	met	 177Lu-DOTATAAT	kwamen	niet	frequent	voor	
en	waren	meestal	kortdurend.	Tijdelijke	milde	beenmergdepressie	was	de	meest	
voorkomende	bijwerking.	Naast	deze	resultaten	zijn	ook	de	effecten	op	tumorgrootte	
beschreven.	Complete	en	partiële	remissie	werd	gevonden	in	38%	van	de	onderzochte	
patiënten,	hetgeen	een	beter	resultaat	was	dan	dat	van	de	eerder	beschreven	PRRT	
studies	met	90Y-DOTATOC	en	chemotherapie.	Het	was	echter	noodzakelijk	om	
deze	eerste	veelbelovende	bevindingen	te	bevestigen	in	een	grotere	groep	patiënten.	
Deze	resultaten	bij	een	grotere	groep	patiënten	zijn	beschreven	in	hoofdstuk 2.2, 
waarin	de	goede	therapierespons,	zoals	eerder	beschreven	in	hoofdstuk	2.1,	werd	
bevestigd.	Minimale,	partiële	of	complete	tumorrepons	werd	gevonden	in	47%	van	
de	125	geëvalueerde	patiënten.	Voorspellende	factoren	voor	een	goede	respons	waren	
zowel	een	hoge	opname	van	het	radiofarmacon	in	de	tumoren	op	de	OctreoScan®	
voorafgaande	aan	de	therapie	als	ook	een	minimale	hoeveelheid	metastasen	in	de	
lever.	Daarentegen	hadden	patiënten	met	een	lage	Karnofsky	Performance	Score	of	
een	hoge	tumor	load,	een	hoger	risico	op	progressieve	ziekte	na	therapie.
Uit	de	resultaten	van	dit	onderzoek	concludeerden	wij	dat	vroege	behandeling	
met	177Lu-DOTATAAT	therapie,	zelfs	bij	patiënten	zonder	duidelijk	aantoonbare	
tumorgroei,	waarschijnlijk	tot	betere	therapieresultaten	leidt.	Een	goede	vergelijking	
van	onze	bevindingen	omtrent	de	behandeling	met	 177Lu-DOTATAAT	met	de	
resultaten	van	90Y-DOTATOC	therapie	is	moeilijk	te	geven,	aangezien	naast	de	
verschillen	in	studie-opzet,	protocol	en	de	hoogte	van	de	gegeven	doses,	de	selectie	
van	bepaalde	categoriën	patiënten	de	uitkomsten	van	ons	onderzoek	mogelijk	heeft	
beïnvloed.	Tot	op	de	dag	van	vandaag	is	het	op	basis	van	de	klinische	studies	nog	
niet	goed	mogelijk	om	aan	te	geven	welk	radioactief	gelabeld	somatostatine-analoog	
nu	echt	beschouwd	mag	worden	als	het	ideale	radiofarmacon	om	te	gebruiken	bij	
PRRT	in	patiënten	met	gastro-intestinale	neuroendocriene	tumoren.
Een	andere	interessante	bevinding	beschreven	in	hoofdstuk	2.2	is	de	verminderde	
177Lu-DOTATAAT	opname	op	het	laatste	posttherapie	scintigram	in	vergelijking	
met	het	eerste	posttherapie	scintigram.	Meerdere	malen	bleek	een	vermindering	van	
opname	samen	te	gaan	met	een	objectiveerbare	tumorrespons	op	de	CT	scan.	Ook	
werd	duidelijk	dat	bij	patiënten	met	stabiele	ziekte	of	regressie	als	therapierespons,	
de	mediane	periode	tot	progressie	meer	dan	36	maanden	bedroeg.	Een	direct	vergelijk	
met	chemotherapie	werd	niet	verricht,	aangezien	chemotherapie	relatief	ineffectief	
is	bij	patiënten	met	inoperabele	gastro-intestinale	neuroendocriene	tumoren.	Wel	
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8werden	onze	resultaten	vergeleken	met	historische	data	van	studies	waarbij	meestal	
chemotherapie	werd	gebruikt	als	systemische	cytotoxische	therapie.	Een	grote	
variatie	in	de	beschreven	objectiveerbare	tumorresponsen	maakt	het	echter	nog	
steeds	moeilijk	om	de	studies	goed	met	elkaar	te	kunnen	vergelijken.	Toch	kwam	
naar	voren	dat	in	de	meeste	studies	een	responsduur	van	minder	dan	18	maanden	
werd	beschreven,	hetgeen	duidelijk	minder	is	dan	de	door	ons	gevonden	mediane	
periode	tot	progressie	van	36	maanden.	Verdere	vergelijking	bracht	naar	voren	dat	
de	toxiciteit	van	de	gebruikte	chemotherapie	schema’s	duidelijk	ernstiger	 is	en	
frequenter	werd	geconstateerd	dan	met	177Lu-DOTATAAT	therapie.	Op	dit	moment	
worden	er	nog	steeds	patiënten	in	de	studie	geïncludeerd	en	is	de	mediane	periode	
van	follow-up	16	maanden.	Waarschijnlijk	zal	evaluatie	op	een	later	tijdstip	meer	
definitief	bewijs	voor	onze	huidige	bevindingen	opleveren.	
In hoofdstuk 3	wordt	de	kwaliteit	van	leven	van	50	patiënten	na	177Lu-DOTATAAT	
therapie	beschreven.	De	kwaliteit	van	leven	werd	bepaald	door	middel	van	een	
gestandaardiseerde	en	gestructureerde	vragenlijst	van	de	European	Organisation	
for	Research	and	Treatment	of	Cancer	(EORTC),	de	EORTC	QLQ-C30.	Binnen	de	
gehele	patiëntengroep	verbeterde	de	kwaliteit	van	leven,	met	name	bij	patiënten	
die	later	ook	een	goede	tumorrespons	lieten	zien.	Tot	onze	verrassing	bleek	echter	
ook	de	kwaliteit	van	leven	significant	te	verbeteren	bij	patiënten	die	later	bewezen	
progressieve	ziekte	bleken	te	hebben.	Naast	het	placebo-effect	zal	ook	het	kleine	
aantal	patiënten	in	deze	groep	een	rol	hebben	gespeeld	bij	deze	verrassende	uitkomst.	
Het	kleine	aantal	patiënten	dat	de	gestructureerde	vragenlijst	had	ingevuld	is	te	
verklaren	uit	het	feit	dat	patiënten	met	de	meest	agressieve	tumoren	soms	fysiek	
niet	in	staat	waren	de	vragenlijst	in	te	vullen.	Daarom	zijn	de	resultaten	in	deze	
categorie	patiënten	niet	erg	betrouwbaar	en	moeten	ze	met	enige	terughoudendheid	
worden	geïnterpreteerd.
Naast	de	algemene	kwaliteit	van	 leven	was	er	een	significante	verbetering	van	
een	aantal	zogenaamde	functioneringsschalen	(het	emotioneel,	rol	(gezin,	werk)	
en	sociaal	functioneren),	symptoomschalen	(moeheid	en	pijn)	en	het	single	item	
slapeloosheid.
Tenslotte	concludeerden	we	dat	een	goede	therapierespons	meestal	gepaard	ging	met	
een	verbetering	van	de	algemene	kwaliteit	van	leven	in	de	onderzochte	patiënten.	
In	hoofdstuk 4 	wordt	 ingegaan	 op	 de	 korte-	 en	 langetermijneffecten	 van	
177Lu-DOTATAAT	therapie	op	de	hormonale	functies.	Aangezien	PRRT	een	systemisch	
toegediende	therapie	is	en	omdat	vele	endocriene	organen	somatostatinereceptoren	
tot	 expressie	 brengen,	worden	deze	 organen	mogelijk	 blootgesteld	 aan	 een	
ongewenste	hoeveelheid	stralenbelasting.	We	toonden	aan	dat,	net	zoals	bij	mannen	
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behandeld	met	hoge	doses	131I	na	thyreoidectomie,	er	een	tijdelijke	daling	was	van	
de	concentratie	van	het	hormoon	inhibine	B	van	ongeveer	24	maanden,	terwijl	de	
concentratie	van	het	FSH	een	gelijktijdige	tijdelijke	stijging	liet	zien.	Hoewel	er	geen	
analyse	van	het	sperma	van	deze	mannen	was	verricht,	geven	deze	waarden	aan	dat	
de	spermatogenese	tijdelijk	verminderd	moet	zijn	geweest.	
Verder	werd	duidelijk	dat,	hoewel	de	serumconcentratie	van	zowel	het	 totale	
testosteron	als	van	het	sexhormoonbindend	globuline	een	daling	lieten	zien	na	
177Lu-DOTATAAT	therapie,	de	ongebonden	testosteronconcentratie	niet	veranderde.	
Tegelijkertijd	was	er	sprake	van	een	tijdelijke	toename	van	de	concentratie	van	het	
luteïniserend	hormoon	(LH).	Dit	suggereert	dat	hormonale	feedbackmechanismen	
hebben	gezorgd	voor	het	op	peil	houden	van	de	ongebonden	testosteronconcentratie	
in	het	bloed.
Verhoogde	serumconcentraties	van	de	gonadotrope	hormonen	en	de	subnormale	
testosteronconcentratie	in	het	serum	zijn	recent	ook	gerapporteerd	bij	mannen	met	
rectumcarcinoom	na	behandeling	met	externe	radiotherapie	9.	Omdat	er	geen	goed	
direct	bewijs	is	voor	de	aanwezigheid	van	eiwitexpressie	van	somatostinereceptoren	
in	de	testes	en	vanwege	de	overeenkomsten	met	de	bevindingen	bij	mannen	behandeld	
met	hoge	doses	 131I	en	externe	radiotherapie,	is	de	geconstateerde	radiotoxiciteit	
waarschijnlijk	niet	gerelateerd	aan	de	expressie	van	somatostatinereceptoren.	De	
meest	waarschijnlijke	oorzaak	hiervoor	is	dat	er	bestraling	van	de	radiosensitieve	
testes	vanuit	de	systemische	circulatie	plaatsvindt.	Daarnaast	is	er	ook	een	bijdrage	
van	gescatterde	straling	aanwezig	door	radioactieve	urine	in	de	blaas	of	ontlasting	
in	het	rectum	na	PRRT	te	verwachten.	
Een	andere	opmerkelijke	bevinding	is	de	daling	van	zowel	LH	als	FSH	concentraties	
in	postmenopauzale	vrouwen.	Deze	daling	is	duidelijk	meer	dan	verwacht	kan	
worden	op	basis	van	veroudering	alleen10.	Aangezien	somatostatinereceptoren	tot	
expressie	worden	gebracht	in	de	hypofyse	en	omdat	postmenopauzale	vrouwen	
het	premenopauzale	 feedback	mechanisme	missen,	 is	een	receptorafhankelijk	
mechanisme	een	voor	de	hand	liggende	oorzaak.	
Daarnaast	daalde	de	gemiddelde	serumconcentratie	van	het	schildklierhormoon	
vrij-T4	in	de	groep	patiënten	significant.	De	waarden	bleven	echter	nog	ruim	binnen	
de	referentiewaarden.	Twee	patiënten	ontwikkelden	een	primaire	hypothyreoidie	
tijdens	en	na	177Lu-DOTATAAT	therapie.	Het	is	echter	de	vraag	of	deze	hypothyreoidie	
veroorzaakt	 is	door	de	PRRT	of	dat	het	beschouwd	mag	worden	als	berustend	
op	variatie	binnen	de	normale	populatie.	De	subtiele,	maar	significante	daling	
van	de	gemiddelde	vrij-T4	concentratie	 is	 echter	 suggestief	voor	een	beperkt	
receptorgerelateerde	dosiseffect.	
Sa
m
en
va
tt
in
g 
en
 a
lg
em
en
e 
di
sc
us
si
e
8Van	de	geobserveerde	subtiele	daling	mag	worden	aangenomen	dat	deze	in	het	
algemeen	klinisch	niet	relevant	is.	
Vervolgens	toonden	we	aan	dat	er	een	daling	is	van	de	gemiddelde	serumconcentratie	
van	 het	 schildkierhormoon	 reverse	 T3	 (rT3)	 direct	 na	 behandeling	 met	
177Lu-DOTATAAT	therapie.	De	rT3	concentratie	was	overigens	al	verhoogd	voor	
de	eerste	therapie.	Een	dergelijke	daling	is	ook	beschreven	bij	patiënten	met	een	
chronische	ziekte,	het	zogenaamde	“non-thyroid	illness”	syndroom.	Een	daling	
van	het	rT3	correleert	met	de	ernst	van	de	ziekte	11.	De	daling	van	het	rT3	bij	onze	
patiënten	wijst	daarom	mogelijk	op	een	verandering	in	de	ernst	van	de	ziekte.	
Met	behulp	van	de	 lage	dosis	ACTH-stimulatie	 test	werd	 aangetoond	dat	na	
177Lu-DOTATAAT	therapie	geen	bijnierschorsdeficiëntie	ontstaat	.
Bij	vijf	patiënten	werden	verhoogde	HbA1c	waarden	geconstateerd,	zonder	dat	er	sprake	
was	van	een	aanwijsbare	oorzaak,	zoals	bijvoorbeeld	pancreaschirurgie	in	het	verleden.
Omdat	het	bekend	is	dat	de	eilandjes	van	Langerhans	somatostatinereceptoren	tot	
expressie	brengen	is	een	receptorafhankelijk	stralingseffect	van	177Lu-DOTATAAT	
therapie	op	de	glucose	huishouding	niet	uitgesloten.	Ook	het	effect	van	langdurig	
gebruik	van	een	“koud”	somatostatine-analoog,	hetgeen	niet	ongebruikelijk	is	bij	
deze	groep	patiënten,	kan	eventueel	hebben	bijgedragen	aan	onze	bevindingen.	
In	het	algemeen	concludeerden	we	dat	patiënten,	behandeld	met	177Lu-DOTATAAT,	
stralingsgeïnduceerde	hormonale	veranderingen	kunnen	ontwikkelen.	Vaak	zijn	
dergelijke	veranderingen	tijdelijk	en	klinisch	niet	relevant.	De	behandelend	arts	dient	
echter	rekening	te	houden	met	eventuele	veranderingen	in	de	hormoonhuishouding,	
bij 	 bijvoorbeeld	 jonge	 mannen	 met	 een	 kinderwens . 	 Desondanks	 kan	
177Lu-DOTATAAT	therapie	op	basis	van	door	ons	geobserveerde	endocriene	effecten	
als	veilig	worden	beschouwd.	
In	hoofdstuk 5 worden	de	resultaten	beschreven	van	een	onderzoek	naar	welk	
van	de	twee	meest	gebruikte	somatostatine-analogen,	DOTATAAT	of	DOTATOC,	
het	meest	geschikt	 is	om,	gekoppeld	 aan	 177Lu,	gebruikt	 te	worden	bij	PRRT.	
Beide	somatostatine-analogen	hebben	verschillende	affiniteiten	voor	de	bekende	
somatostatinereceptor	subtypen.	Voor	PRRT	is	de	balans	tussen	opname	in	de	
tumor	en	in	de	dosislimiterende	organen	van	belang,	aangezien	dit	de	therapeutische	
breedte	van	het	radiofarmacon	bepaalt.	Een	directe	vergelijking	van	beide	analogen	
in	een	therapeutische	setting	werd	uitgevoerd.	Verblijftijden	van	radioactiviteit	in	
milt,	nieren	en	aanwezige	tumoren,	die	direct	gerelateerd	zijn	aan	de	geabsorbeerde	
tumordosis,	waren	langer	met	gebruik	van	177Lu-DOTATAAT	in	vergelijking	met	
177Lu-DOTATOC.	Daarbij	waren	de	ratio’s	van	de	gemiddelde	verblijftijden	van	
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17 7Lu-DOTATAAT	 versus	 17 7Lu-DOTATOC	 respectievelijk	 1 ,5 , 	 1 , 4	 en	 2 ,1	
Dientengevolge	is	te	verwachten	dat	hogere	geabsorbeerde	tumordoses	worden	
bereikt	met	177Lu-DOTATAAT	dan	met	177Lu-DOTATOC.	De	langere	verblijftijd	in	
de	nieren	bij	gebruik	van	177Lu-DOTATAAT	kan	echter	een	probleem	vormen	bij	
PRRT.	De	nieren	kunnen	namelijk	naast	het	beenmerg	ook	dosislimiterend	zijn.	
Indien	de	nieren	echter	inderdaad	de	limiterende	factor	zijn,	doordat	bij	eventuele	
voortgang	van	therapie	de	maximale	tolereerbare	dosislimiet	(MTD)	van	23	Gy	
voor	de	nieren	wordt	overschreden,	dan	zal	de	geabsorbeerde	tumordosis	met	
177Lu-DOTATAAT	altijd	hoger	zijn	dan	met	 177Lu-DOTATOC.	De	ratio	van	de	
gemiddelde	verblijftijd	in	de	tumor(en)	(2,1)	is	namelijk	een	factor	1,5	hoger	dan	de	
gemiddelde	verblijftijdratio	van	de	nieren	(1,4),	in	het	voordeel	van	177Lu-DOTATAAT.	
Overigens	bleek	dat	bij	de	meeste	patiënten	niet	de	nieren,	maar	het	beenmerg	(MTD	
van	2	Gy)	het	dosisbeperkende	orgaan	was.	
Een	vergelijkbare	 studie	 is	uitgevoerd	door	Forrer	 en	 zijn	 collega’s	 in	Bazel,	
waarbij	 111In-DOTATOC	werd	vergeleken	met	 111In-DOTATAAT	12.	Aangenomen	
werd	dat	voor	dosimetrie	berekeningen	 111In	gebruikt	kon	worden	als	surrogaat	
for	90Y,	het	radionuclide	dat	in	Bazel	wordt	gebruikt	voor	PRRT.	Drie	van	de	vijf	
patiënten,	van	wie	tweemaal	een	scintigram	werd	vervaardigd,	hadden	een	betere	
tumor/achtergrond	ratio	op	het	scintigram	na	111In-DOTATOC	in	vergelijking	met	
111In-DOTATAAT.	Op	basis	van	deze	gegevens	werd	besloten	om	het	gebruik	van	
het	somatostatine-analoog	DOTATOC	gelabeld	met	90Y	in	PRRT	te	continueren.	De	
aanname	dat	111In	een	bruikbaar	surrogaat	is	voor	90Y,	is	echter	niet	helemaal	valide.	
Verschillende	radionucliden	gebonden	aan	één	somatostatine-analoog	kunnen	
geheel	andere	affiniteitsprofielen	hebben	13.	Dit	zou	kunnen	leiden	tot	een	verschil	
in	biodistributie	van	de	verschillende	radiofarmaca,	hetgeen	is	aangetoond	in	een	
onderzoeksmodel	in	ratten	met	neuroendocriene	tumoren	14.	Ook	de	diagnostische	
hoeveelheid	van	het	peptide	dat	gebruikt	werd	in	de	studie	van	Forrer	et al.	was	veel	
kleiner	dan	de	gebruikelijke	hoeveelheid	bij	PRRT.	Door	verschillende	auteurs	is	
aangetoond	dat	het	verschil	in	de	hoeveelheid	peptide	een	verschil	in	biodistributie	
kan	betekenen	15-17.	Breeman	et al.	beschreven	dat	indien	de	opname	van	111In-octreotide	
in	somatostatinereceptor	positieve	organen	wordt	weergegeven	als	functie	van	de	
hoeveelheid	toegediende	massa	er	een	weefsel-specifieke	klokvormige	curve	ontstaat.	
Vervolgens	werd	het	bestaan	van	dezelfde	klokvormige	curve	aangetoond,	zowel	in	
het	normale	weefsel	als	in	somatostatinereceptor	positieve	tumoren	in	zogenaamde	
naakte	muizen	door	Bernhardt	et al18.	De	biodistributie	kan	dus	zowel	een	effect	
hebben	op	de	geabsorbeerde	dosis	in	de	nieren	als	in	tumoren.	Het	directe	gevolg	
is	een	effect	op	de	tumor/nieren	ratio	zoals	gevonden	door	Forrer	et al.	 12.	Tevens	
is	het	in	de	meeste	instituten	gebruikelijk	om,	gelijktijdig	met	radioactief	gelabelde	
somatostatinereceptoren,	aminozuren	 intraveneus	toe	te	dienen.	Gelijktijdige	
toediening	van	de	aminozuren	lysine	en	arginine	tijdens	PRRT	bewerkstelligt	een	
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8significante	afname	van	renale	radioactiviteit	en	heeft	dus	ook	een	effect	op	de	
tumor/nieren	ratio	19.
Concluderend	is	onze	studie,	in	tegenstelling	tot	de	studie	uit	Bazel,	op	verschillende	
punten	beter	vergelijkbaar	met	de	uiteindelijke	therapeutische	setting.	Daarbij	geven	
de	door	ons	geanalyseerde	verblijftijden	van	radioactiviteit	in	de	tumor	en	nieren	een	
betere	indruk	van	de	absolute	geabsorbeerde	dosis	dan	de	relatieve	uptake	methode	
met	tumor/nieren	ratio’s.	
Tenslotte	 zijn,	 zoals	 eerder	 genoemd,	 bij	 PRRT	met	 17 7Lu-DOTATAAT	 of	
90Y-DOTATOC,	de	nieren	en	het	beenmerg	de	kritische	organen.	De	bijbehorende	
MTD	voor	externe	bestraling	van	deze	organen	zijn	respectievelijk	23	en	2	Gy	en	worden	
gebruikt	als	dosisgrens	om	stralingsgeïnduceerde	nefropathie	en	beenmergtoxiciteit,	
zoals	het	myelodysplastische	syndroom	of	leukemie	te	voorkomen.	
Wanneer	PRRT	met	177Lu-DOTATAAT	of	90Y-DOTATOC	wordt	overwogen,	dan	
is	de	tumor/nieren	ratio	bij	het	gebruik	van	177Lu-DOTATAAT	niet	zo	belangrijk	
als	bij	het	gebruik	van	90Y-DOTATOC,	aangezien	in	ongeveer	30%	van	de	patiënten	
behandeld	met	 177Lu-DOTATAAT	de	MTD	van	de	nieren	(23	Gy)	werd	bereikt	
voordat	de	MTD	van	het	beenmerg	werd	bereikt.	Dientengevolge	ontvingen	deze	
patiënten	minder	dan	de	vooraf	beoogde	29,6	GBq	(4x	7400	MBq)	177Lu-DOTATAAT,	
overeenkomstig	met	de	geaccepteerde	MTD	van	het	beenmerg	van	2	Gy.	Uiteindelijk	
ontving	ongeveer	70%	van	de	patiënten	de	volledige	dosis	van	29,6	GBq.	Bij	PRRT	met	
90Y-DOTATOC	worden	de	nieren	beschouwd	als	het	belangrijkste	dosislimiterend	
orgaan,	aangezien	de	MTD	van	de	nieren	vrijwel	altijd	eerder	bereikt	is	dan	de	MTD	
van	het	beenmerg	20.	
De	eerder	genoemde	argumenten	in	ogenschouw	nemend,	concluderen	we	dat	
het	somatostatine-analoog	DOTATAAT	een	betere	therapeutische	breedte	heeft	
dan	DOTATOC	en	daarom	de	voorkeur	geniet	om,	gekoppeld	aan	177Lu,	te	worden	
gebruikt	bij	PRRT.	
In	hoofdstuk 6.1 worden	de	eerste	patiënten	met	inoperabel	en	Jodium-131	(131I)	
negatief	gedifferentieerd	schildkliercarcinoom	die	behandeling	met	177Lu-DOTATAAT	
hebben	ondergaan,	beschreven.	
Vijf	patiënten	met	gemetastaseerd	gedifferentieerd	schildkliercarcinoom	(3x	Hürthle	
cel	carcinoom;	1x	papillair	schildkliercarcinoom;	1x	folliculair	schildkliercarcinoom)	
werden	behandeld	met	22,1-30,1	GBq	 177Lu-DOTATAAT.	Na	behandeling	met	
177Lu-DOTATAAT	hadden	2	patiënten	stabiele	ziekte,	2	patiënten	hadden	een	
verkleining	van	de	tumor	en	1	patiënt	had	progressieve	ziekte.	Naast	deze	objectieve	
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therapierespons	was	er	een	gunstige	periode	tot	progressie.	Aangezien	deze	patiënten	
geen	alternatieve	therapeutische	opties	meer	hadden,	werd	geconcludeerd	dat	
therapie	met	177Lu-DOTATAAT	bij	deze	patiëntengroep	een	goede	behandelingsoptie	
kan	zijn.	Vanzelfsprekend	is	een	studie	met	inclusie	van	een	grotere	groep	patiënten	
noodzakelijk	om	de	echte	waarde	van	deze	therapeutische	benadering	vast	te	stellen.	
Naast	het	 177Lu-DOTATAAT	zijn	andere	 radioactief	gelabelde	 somatostatine-
analogen,	zoals	het	[DOTA-1-Nal3]octreotide,	gelabeld	met	90Y	of	177Lu,	interessant	
21.	Deze	somatostatine-analogen	verschillen	met	het	 177Lu-DOTATAAT	in	hun	
affiniteitsprofiel	voor	de	somatostatinereceptor,	waarbij	er	naast	een	hoge	affiniteit	
voor	subtype	2,	ook	een	hoge	affiniteit	voor	de	subtypen	3	en	5	bestaat.	Behandeling	
van	schildkliercarcinoom	met	deze	gelabelde	somatostatine-analogen	zou	interessant	
kunnen	 zijn,	 aangezien	 er	 aanwijzingen	 zijn	 dat	 het	 somatostatinereceptor	
expressieprofiel	bij	schildkliercarcinomen	anders	is	dan	bij	de	gastro-intestinale	
neuroendocriene	tumoren,	met	hogere	expressie	van	zowel	subtype	3	als	5,	naast	
subtype	2	22.	
In hoofdstuk 6.2	is	een	overzicht	gegeven	van	het	gebruik	van	somatostatinereceptor	
scintigrafie	en	PRRT	bij	het	 131I	negatief	gedifferentieerd	schildkliercarcinoom.	
De	 conclusie	 die	 getrokken	 kan	worden	 uit	 dit	 literatuuroverzicht	 is	 dat	
somatostatinereceptor	scintigrafie	behulpzaam	kan	zijn	om	de	tumoren	te	localiseren	
indien	er	aanwijzingen	zijn	voor	aanwezigheid	van	ziekte	door	bijvoorbeeld	een	
verhoogde	 thyroglobulineconcentratie	 in	het	 serum,	echter	zonder	duidelijke	
stapeling	van	131I	bij	totale	lichaamsscintigrafie	na	131I	behandeling.	In	meer	dan	50%	
van	de	patiënten	is	somatostatinereceptor	scintigrafie	alsnog	in	staat	om	de	ziekte	
te	localiseren.	Op	deze	wijze	speelt	somatostatinereceptor	scintigrafie	een	rol	bij	de	
stagering	en	het	verder	te	bepalen	behandeltraject.
PRRT	bij	 gedifferentieerd	 schildkliercarcinoom	 is	 beschreven	 in	 slechts	 62	
patiënten.	Drie	verschillende	radionucliden	(111In,	90Y	and	177Lu)	gekoppeld	aan	4	
verschillende	somatostatine-analogen	(DOTATOC,	[DTPA0]octreotide,	lanreotide	
and	DOTATAAT)	zijn	gebruikt	met	cumulatieve	doses	variërend	van	0,9	tot	30,1	
GBq.	De	somatostatine-analogen	gekoppeld	aan	90Y	en	177Lu	waren	veelbelovender	
met	betrekking	tot	tumorrespons	dan	wanneer	gekoppeld	aan	111In.	Het	111In	wordt	
daarom,	net	zoals	bij	de	behandeling	van	gastro-intestinale	neuroendocriene	tumoren,	
niet	meer	aanbevolen	voor	PRRT	bij	gedifferentieerd	schildkliercarcinoom.	
Slotconclusies 
PRRT	met	 17 7Lu-DOTATAAT	 is	 de	 aangewezen	 therapie	 bij	 patiënten	met	
inoperabel,	gemetastaseerde,	goed	gedifferentieerde,	somatostatinereceptor	positieve	
gastro-intestinale	neuroendocriene	tumoren.	De	uitkomsten	op	het	gebied	van	
objectiveerbare	tumorrespons,	kwaliteit	van	leven,	gemiddelde	periode	tot	progressie	
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8en	de	eerste	overlevingsduuranalyse	laten	zien	dat	in	vergelijking	met	de	historische	
data	van	andere	beschikbare	therapeutische	benaderingen,	 inclusief	de	huidige	
chemotherapie,	PRRT	met	177Lu-DOTATAAT	beter	is.	Daarbij	zijn	de	geobserveerde	
bijwerkingen	minder	en	is	het	toxiciteitsprofiel	gunstig.	
Ook	kan	bij	het	ontbreken	van	chirurgische	opties	bij	 131I	negatief	gedifferentieerd	
schildkliercarcinoom	behandeling	met	 177Lu-DOTATAAT	als	 therapeutische	
behandeling	overwogen	worden.	Met	name	in	deze	groep	zijn	de	radioactief	gelabelde	
somatostatine-analogen	met	een	ander	affiniteitsprofiel	veelbelovend.
Een	methode	om	de	effectiviteit	van	PRRT	nog	verder	te	vergroten	is	door	toediening	
van	hogere	cumulatieve	doses	bij	de	individuele	patiënt.	Dit	is	alleen	mogelijk	door	
gebruik	te	maken	van	dosimetrie	bij	iedere	afzonderlijke	patiënt.	Door	de	exacte	
dosis	op	de	dosis-beperkende	organen	per	behandeling	en	per	patiënt	te	berekenen	
kan	worden	bepaald	of	er	nog	(dosis)ruimte	is	voor	verdere	behandeling.	Omdat	
deze	methode	lastig,	zeer	arbeidsintensief	en	dus	kostbaar	is,	wordt	deze	manier	
van	behandelen	nog	niet	in	alle	instituten	toegepast	23.	
Verder	onderzoek	naar	deze	patiëntgebonden	dosimetrie,	met	name	van	de	nieren	en	
het	beenmerg,	is	essentieel	om	tot	praktische	oplossingen	te	komen	voor	zogenaamde	
PRRT	op	maat,	zodat	dit	 in	de	toekomst	toegepast	kan	worden	bij	de	 integrale	
benadering	en	behandeling	van	de	patiënten.	
Ook	de	ontwikkeling	van	zogenaamde	nierbeschermende	middelen	is	van	belang	om	
de	therapeutische	breedte	te	vergroten.	Door	gebruik	te	maken	van	nierbeschermende	
middelen	wordt	het	mogelijk	om	hogere	doses	toe	te	dienen	om	zo	de	effectiviteit	
van	PRRT	te	vergroten.
Naast	het	vergroten	van	de	therapeutische	breedte	bij	de	bestaande	radioactief	
gelabelde	 somatostatine-analogen	zijn	er	verscheidene	nieuwe	benaderingen	
zoals	de	ontwikkeling	van	nieuwe	somatostatine-analogen	met	een	gunstiger	
somatostatinereceptor	 affiniteitsprofiel , 	 combinatietherapie	met	 andere	
radionucliden	zoals	90Y	of	111In	of	combinatie	met	radiosensitizers.	Een	multicentrum	
gerandomiseerde	studie	met	177Lu-DOTATAAT	in	combinatie	met	de	radiosensitizer	
capecitabine	versus	monotherapie	met	 177Lu-DOTATAAT	is	reeds	gestart	op	de	
afdeling	Nucleaire	Geneeskunde	in	het	Erasmus	MC	(Rotterdam).	
Tenslotte	 laat	het	gebruik	van	PRRT	bij	patiënten	met	somatostatinereceptor	
positieve	tumoren	zien	dat	een	therapie	gebaseerd	op	een	radionuclide	gekoppeld	
aan	een	peptide	zeer	succesvol	kan	zijn.	PRRT	is	daarom	veelbelovend	voor	de	
behandeling	van	andere	vormen	van	kanker.	Nieuwe	tumor-specifieke	receptoren	
234
worden	veelvuldig	ontdekt.	Deze	receptoren	zijn	in	principe	allemaal	een	potentiëel	
doelwit	voor	radioactief	gelabelde	peptiden	en	dus	ook	voor	PRRT.	Het	 is	dan	
ook	niet	ondenkbaar	dat	PRRT	in	de	toekomst	ook	in	andere	deelgebieden	van	de	
oncologie	een	belangrijke	therapeutische	optie	zal	zijn.
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5-FU		 	 fluorouracil	
5-HIAA	 5-hydroxyindoleacetic	acid	
ACTH	 	 adrenocorticotropic	hormone
AML	 	 acute	myeloid	leukemia	
ANOVA		 analysis	of	variance	
BMI	 	 body	mass	index
CARC	 	 carcinoid
CCDP		 	 cisplatin
CNS	 	 central	nervous	system
CR	 	 complete	remission
CT	 	 computed	tomography	
DOTA				 1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tetra-acetic	acid	
DOTALAN	 DOTA-lanreotide	
DOTANOC		 [DOTA0-1-naphthyl3]octreotide	
DOTA-OC	 DOTA-octreotide
DOTATOC	 [DOTA0,Tyr3]octreotide
DOX	 	 doxorubicin	(adriamycin	)
DNA		 	 deoxyribonucleic	acid	
DTPA		 		 diethylene	triamine	penta-acetic	acid	
DOTATATE	 [DOTA0,Tyr3]octreotate
DTC	 	 differentiated	thyroid	carcinoma
DTIC		 	 dimethyltriazenoimidazole	carboxamide
E2	 	 oestradiol
EBRT	 	 external	beam	radiation	therapy
EGFR		 	 epidermal	growth	factor	receptor
ENETS		 European	Neuroendocrine	Tumour	Society
EORTC		 European	Organization	for	Research	and	Treatment	of	Cancer	
FDA		 	 Food	and	Drug	Administration	
18F-FDG	 18F-fluorodeoxyglucose
FDG-PET		 fluorodeoxyglucose-positron	emission	tomography
FSH	 	 follicle	stimulating	hormone
FT4	 	 free	thyroxine
FTC	 	 follicular	thyroid	carcinoma	
GBq		 	 Gigabecquerel	(109	Bq)	
GEP	 	 gastroenteropancreatic	
GEP-NET		 gastroenteropancreatic	neuroendocrine	tumour	
GLP-1	 	 glucagon-like	peptide-1	
Gy		 	 Gray
HACE	 	 hepatic	artery	chemoembolisation	
HAE		 	 hepatic	artery	embolisation	
HbA1c		 	 haemoglobin	A1c	or	glycolysated	hemoglobin	
HCTC	 	 hürthle	cell	thyroid	carcinoma
HPA-axis	 hypothalamo-pituitary-adrenal	axis
HPF	 	 high	power	field
HRQoL		 health	related	quality-of-life
HYNIC		 hydrazinonicotinyl
ICC	 	 islet	cell	tumour
IFN	 	 interferon
ITT		 	 insulin	tolerance	test		
IU		 	 international	unit
keV	 	 kiloelectron	volt	
KPS	 	 Karnofsky	Performance	Scale
LAN	 	 lanreotide
LDST		 	 low-dose	ACTH	stimulation	test
LH		 		 luteinizing	hormone	
LITT	 	 laser	induced	thermotherapy	
MBq		 		 Megabecquerel	(106	Bq)	
mCi	 	 millicurie	
MDS	 	 myelodysplastic	syndrome
MMC		 	 mitomycin	C	
MR		 	 minor	remission
MRI	 	 magnetic	resonance	imaging	
mTOR			 mammalian	target	of	rapamycin	
NE	 	 neuroendocrine
NEP	 	 neuroendocrine	pancreatic	tumour
NET	 	 neuroendocrine	tumour	
NOC	 	 Nal3-octreotide
NTI	 	 non-thyroidal	illness
OLT	 	 orthotopic	liver	transplantation
OS	 	 overall	survival
PD	 	 progressive	disease
PDEC	 		 poorly	differentiated	endocrine	carcinoma	
PDGF	 	 platelet	derived	growth	factor
PFS		 	 progression	free	survival
PRRT		 		 peptide	receptor	radionuclide	therapy	
PR		 	 partial	remission
PRS	 	 peptide	receptor	scintigraphy	
PTC	 	 papillary	thyroid	carcinoma
QLQ-C30	 Cancer	30-item	Quality	of	Life	Questionnaire	
QoL	 	 quality	of	life
RECIST	 Response	Evaluation	Criteria	in	Solid	Tumors	
RFA		 	 radiofrequency	ablation	
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rT3	 	 reverse	triiodothyronine	
SD	 	 stable	disease
SEER	 	 Surveillance,	Epidemiology,	and	End	Results	database
SEM		 		 standard	error	of	the	mean	
SHBG	 	 sex	hormone	binding	globulin
SPECT	 	 single-photon	emission	computed	tomography
SRS	 	 somatostatin	receptor	scintigraphy
SS	 	 somatostatin	
SSTR	 	 somatostatin	receptor
STZ	 	 streptozotocin
SWOG		 SouthWest	Oncology	Group
T	 	 testosterone
T3	 	 triiodothyronine
TATE	 	 Tyr3-Thr8-octreotide
Tg	 	 thyroglobulin
TOC	 	 Tyr3-octreotide
TPO	 	 thyroid	peroxidase	
TK	 	 tyrosine	kinase
TSH	 	 thyroid-stimulating	hormone
TT	 	 total	testosterone	
TTP	 	 time	to	progression
Tyr	 	 tyrosine
US	 	 ultrasound
VEGF	 	 vascular	endothelial	growth	factor	
VIP		 	 vasoactive	intestinal	peptide
WBS	 	 whole	body	scan
WHO		 	 World	Health	Organization
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Promoveren	is	te	vergelijken	met	aan	boord	van	een	zeilboot	stappen	zonder	dat	je	
precies	weet	waar	je	naar	toe	zal	gaan,	wie	er	tijdens	de	reis	nog	zullen	aanmonsteren,	
hoe	 lang	de	 reis	 gaat	duren	en	of	 je	wel	 genoeg	zeilervaring	hebt	om	de	vele	
weersveranderingen	te	trotseren.	Gedurende	de	afgelopen	jaren	heb	ik	met	het	
schrijven	van	mijn	proefschrift	elk	weertype	en	iedere	windrichting	mogen	ervaren.	
Gelukkig	is	de	haven	nu	in	zicht	en	is	de	tijd	gekomen	om	met	plezier	terug	te	kijken	
op	een	lange,	maar	mooie	en	leerzame	reis.	
Het	is	onmogelijk	om	iedereen	die	de	afgelopen	jaren	betrokken	is	geweest	bij	alle	
onderzoeken	persoonlijk	te	noemen	in	een	dankwoord.	Toch	wil	 ik	een	aantal	
mensen	in	het	bijzonder	bedanken.
	
Op	de	eerste	plaats	komen	voor	mij	alle	patiënten	die	hebben	meegewerkt	aan	de	
diverse	onderzoeken	beschreven	in	dit	proefschrift.	
Mijn	promotor,	Prof.	dr.	E.P.	Krenning.	Beste	Eric,	mede	dankzij	jouw	enthousiasme,	
optimisme	en	gedrevenheid	is	dit	proefschrift	tot	stand	gekomen.	Dank	voor	de	
mogelijkheden	die	je	me	hebt	gegeven	voor	het	verrichten	van	het	onderzoek	en	de	
kans	om	op	de	diverse	internationale	bijeenkomsten	en	congressen	te	spreken.
Mijn	copromotor,	dr.	D.J.	Kwekkeboom.	Beste	Dik,	bedankt	voor	de	samenwerking	
en	je	begeleiding	de	afgelopen	jaren.	Niet	alleen	ben	ik	je	dankbaar	voor	je	hulp	
bij	het	schrijven	van	de	manuscripten	en	de	discussies	bij	soms	lastige	klinische	
beslissingen,	maar	ook	voor	je	humor	(alleen	niet	vóór	10	uur….)	en	aanmoediging	
(“	..Is	het	al	af?...”).	
Leden	van	de	kleine	commissie:	
Prof.	dr.	ir.	M.	de	Jong.	Beste	Marion,	zonder	de	prekliniek	en	het	CIL	uiteindelijk	
geen	klinische	studies.	Ik	bewonder	je	enthousiasme	en	de	manier	waarop	je	alles	
voor	elkaar	hebt	gekregen,	met	onder	andere	het	huidige	Animal	Imaging	Facility	
als	mooi	resultaat.	
Prof.	dr.	F.H.	de	Jong.	Beste	Frank,	bedankt	dat	 je	 in	de	kleine	commissie	wilde	
plaatsnemen	en	voor	het	uiterst	kritisch	lezen	en	beoordelen	van	het	proefschrift.	
Dr.	W.	W.	de	Herder.	Beste	Wouter,	bedankt	voor	de	samenwerking	in	de	kliniek,	
je	heldere	kijk	op	de	behandeling	van	onze	patienten	vanuit	de	endocrinologische	
hoek	en	je	medewerking	bij	de	beoordeling	van	mijn	manuscripten.	En,	bedankt	
voor	de	zeer	persoonlijke	ringtone!
De	medische	stafleden:	Jan-Paul	Esser,	beste	Jan-Paul,	‘JeePee’,	het	is	al	weer	een	
tijd	geleden,	dat	we	samen	verantwoordelijk	waren	voor	de	Lu-taat	behandelingen.	
Bedankt	voor	de	prima	samenwerking	bij	de	vele	toedieningen.	Boen	Kam,	beste	
Boen,	de	transformatie	van	jou	als	collega	AIOS	naar	baas	was	bijzonder	om	mee	te	
maken.	Gelukkig	geen	transformatie	van	onze	vriendschap.	Lideke	Fröberg,	beste	
Lideke,	dank	voor	je	kritische	blik	en	opmerkingen.	Bart	de	Keizer,	beste	Bart,	samen	
stonden	we	op	congressen	onze	ervaring	met	radionuclide	therapie	te	vertellen	
zonder	dat	we	wisten	dat	we	ooit	samen	zouden	werken.	Helaas	was	dit	van	korte	
duur.	Veel	succes	in	Utrecht.	Roelf	Valkema,	beste	Roelf,	net	als	ik	weet	jij	als	geen	
ander:	Leiden	en	omstreken	is	zo	gek	nog	niet.	Hoewel	anderen	daar	soms	anders	
over	denken…	Bedankt	voor	je	bijdragen	aan	de	diverse	manuscripten	en	nuttige	
discussies.	Jo	Verhaegen,	beste	Jo,	mijn	vroegere	kamergenoot,	nooit	zal	ik	vergeten	
wat	het	betekent	als	ik	bij	de	achteras	van	mijn	auto	iets	hoor	rammelen	en	dat	je	in	
de	tijd	van	mijn	promotie	makkelijk	kan	trouwen	en	vader	van	drie	kinderen	kan	
worden.	Bedankt	voor	al	je	verhalen,	gezelligheid	en	‘jij	ook	nog	een	bakkie	koffie?’.	
Peter	van	Noorden,	beste	Peter,	helaas	werkten	we	alleen	maar	op	de	dinsdag	samen.	
Je	nuchtere	kijk	op	de	lopende	klinische	zaken	waren	erg	leerzaam.
Overige	stafleden:	Peter	Kooij,	beste	Peter,	dankzij	jouw	klinisch	fysische	kennis	
en	inzet	hielden	we	enig	inzicht	in	de	geabsorbeerde	nierdosis	bij	onze	patienten.	
Bedankt	voor	al	die	berekeningen,	je	uitleg	en	vaak	nuchtere	blik.	Willem	Bakker,	
Beste	Willem,	zonder	jouw	leiding	zou	er	geen	‘veilig’	Lutetium-octreotaat’	zijn	
geweest.	Bedankt	voor	alles.	Wout	Breeman,	beste	Wout,	hoewel	je	niet	direct	
betrokken	bent	geweest	bij	de	vooral	klinische	resultaten	van	mijn	proefschrift,	dank	
ik	je	voor	alle	wetenschappelijke	opmerkingen,	handige	tips	en	humor.	
Researchverpleegkundigen:	Beste	 ‘Lu-dames’;	 Jolande,	Daniëlle,	Els	en	Agnes,	
zonder	jullie	zou	het	onderzoek	niet	mogelijk	zijn	geweest.	Van	in	het	begin	‘samen	
met	Jolande’,	zijn	jullie	inmiddels	uitgegroeid	tot	een	soepel	draaiend	topklinisch	
gespecialiseerd	researchverpleegkundig	team,	waar	de	afdeling	trots	op	kan	zijn.
Mijn	opvolgers,	collega	arts-onderzoekers,	Martijn	en	Saima;	het	 is	 fijn	om	te	
weten	dat	het	werk	nu	verdeeld	is	over	twee	artsonderzoekers,	zodat	de	nog	steeds	
groeiende	groep	patiënten	blijvend	goed	wordt	begeleid	en	voldoende	medische	
aandacht	krijgen.	Bedankt	voor	jullie	interesse	in	mijn	proefschrift	en	succes	met	
die	van	jullie!	
Mijn	mede-AIOS	de	afgelopen	jaren,	Albert,	Sergio,	Marc,	Kathleen	en	Hanneke.	
Een	grote	diversiteit	van	boeiende	personen	die	allen	voor	hetzelfde	geweldige	vak	
hebben	gekozen.	Dank	voor	de	gezelligheid	op	cursussen,	niet	alleen	nationaal,	maar	
ook	internationaal	(zeer	leerzame	combi-cursus	botanische	tuinen	en	geologie	van	
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de	Franse	Alpen	door	Marc	in	Nice	en	omstreken..)	en	op	de	pisten	van	de	Franse	
Alpen.	Dat	soort	evenementen	waren	zeer	nuttig	om	zo	af	en	toe	de	stress	van	het	
publiceren	te	doen	vergeten.	
Iedereen	van	de	afdeling	nucleaire	geneeskunde:	zonder	een	goed	functionerend	
team	op	de	afdeling	met	de	verschillende	groepen	zoals	de	‘ADMI’-medewerkers,	
de	MNAA’ers,	MNW’ers	en	de	mannen	van	de	soft-	en	hardware	(Ambroos,	Ron,	
Tuki,	Ronald	en	Paul)	is	het	onmogelijk	om	zoveel	patiënten	goed	en	professioneel	
te	 behandelen,	 te	 scannen	 en	vervolgens	 te	 begeleiden.	Dank	voor	de	 goede	
samenwerking,	professionaliteit	en	met	name	ook	flexibiliteit;	eigenschappen	van	
onze	afdeling	die	hun	nut	al	meerdere	malen	hebben	bewezen.	
Isabel,	speciaal	voor	jou	ook	een	woord	van	dank;	jouw	hulp	was	belangrijk	voor	
mij.	Niet	alleen	qua	secretariële	ondersteuning,	maar	ook	als	 luisterend	oor	en	
geheugensteuntje	richting	Eric.
Naast	onze	afdeling	wil	 ik	ook	de	afdeling	Interne	Geneeskunde	bedanken.	Ten	
eerste	de	medische	specialisten	Wouter	de	Herder,	Richard	Feelders	en	Maarten	van	
Aken.	Alledrie	stonden	jullie	altijd	klaar	voor	overleg	en	opvang	van	onze	patiënten,	
waarvoor	dank.	
Daarnaast	gaat	mijn	dank	uit	naar	iedereen	van	de	klinische	afdeling	endocrinologie	
(voorheen	4	Noord,	maar	waar	ze	nu	weer	zitten	…	?),	zoals	de	verpleegkundigen	
en	de	vele	AIOS,	die	daar	op	de	afdeling	zorg	droegen	voor	onze	patiënten.	Bedankt	
voor	jullie	opvang	van	alle	‘op	te	werken’	patiënten	en	de	soms	‘stralende’,	maar	toch	
wel	zieke	patiënten	na	toediening.
CIL	promovendi:	Monique,	Suzanne,	Astrid	en	Edgar,	met	veel	plezier	kijk	ik	terug	
naar	de	gezelligheid	tijdens	met	name	de	(internationale)	congressen	(Wenen,	Capri,	
Gent,	Londen	etc).	Ook	waren	jullie,	als	voorgangers,	mijn	voorbeelden	‘hoe	te	
promoveren‘	en	een	inspiratiebron	om	vooral	door	te	gaan.
De	andere	CIL	medewerkers:	Magda,	Ria	en	Bert.	Tijdens	de	korte	periodes	dat	ik	
in	het	‘oude	CIL’	ben	geweest,	waren	jullie	altijd	bereid	me	te	helpen,	waarvoor	
mijn	dank.
Karlijn	en	Vincent,	na	de	mooie	 lay-out	en	voorkant	van	het	proefschrift	van	
Maaike,	kon	ik	niet	om	jullie	heen.	Bedankt	voor	jullie	inzet	bij	het	maken	van	een	
professionele	lay-out	en	omslag.	Wederom	ziet	het	er	geweldig	uit!
Alle	vrienden	en	vriendinnen,	vaak	had	ik	geen	tijd	om	iets	af	te	spreken,	te	gaan	
zeilen,	ergens	te	borrelen,	flipperen	of	te	feesten.	Met	name	het	laatste	jaar	heb	ik	
jullie	een	beetje	verwaarloosd.	Dit	gaan	we	de	komende	jaren	zeker	weer	inhalen!	
Paranimfen:	Merijn	en	Michiel,	goede	vrienden	zijn	belangrijk	in	het	leven,	ik	was	
dan	ook	superblij	dat	jullie	bereid	waren	om	mij	bij	te	staan	de	afgelopen	periode	
en	op	de	promotie	zelf.	Dankzij	het	samen	sporten,	gamen	en	korte	vakanties	heb	
ik	me	elke	keer	weer	goed	kunnen	opladen	voor	het	volgende	onderzoeksproject	of	
te	schrijven	manuscript.	
Mijn	schoonfamilie	wil	ik	bedanken	voor	de	ontspannende	vakanties	die	we	samen	
hebben	mogen	beleven,	niet	alleen	in	Dubai,	maar	ook	in	‘Le	Biot’.	Bedankt	voor	
de	mogelijkheid	om	in	de	winter	het	hoofd	goed	leeg	te	maken	op	de	verschillende	
pisten	en	 in	de	zomer	verder	 te	kunnen	schrijven	op	 jullie	eigen	Alpenweide.	
Maarten	en	Ellen,	bedankt	voor	de	vele	gezellige	après-ski	avonden	en	4-wheel	
drive	avonturen.
Broers	en	(schoon)zussen,	bedankt	voor	jullie	begrip	en	steun	de	afgelopen	jaren.	
Door	alle	deadlines	was	het	helaas	niet	mogelijk	om	aanwezig	te	zijn	bij	sommige	
familie	aangelegenheden.	Verder	wil	ik	Petra	bedanken	voor	het	corrigeren	van	de	
nederlandse	documenten	en	samenvatting	van	dit	proefschrift.	
Mijn	ouders,	dankzij	 jullie	heb	ik	qua	studie(s)	alles	kunnen	doen.	Hoewel	het	
voor	jullie	eerst	schrikken	was	na	mijn	‘carrièreswitch’,	hebben	jullie	me	blijvend	
gesteund.	Helaas	is	Pap	op	de	promotiedag	er	niet	bij.	Maar	ik	weet	hoe	trots	hij	op	me	
zou	zijn.	Ik	ben	oneindig	dankbaar	voor	al	jullie	liefde,	steun,	zorg	en	vertrouwen.	
Mijn	 lieve	Maaike,	zoals	 jij	het	al	zo	mooi	aangaf	 in	het	dankwoord	van	 jouw	
proefschrift;	de	afgelopen	jaren	waren	omgedraaid;	 jij	 in	de	kliniek	en	 ik	mijn	
promotie	afmaken.	Gelukkig	had	je	nog	tijd	over	om	me	op	de	cruciale	momenten	
met	raad	en	daad	bij	te	staan.	Bedankt	voor	je	hulp,	steun,	liefde,	aanmoediging	en	
geduld.	Op	naar	de	volgende	uitdaging!
Curriculum Vitae
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Jaap	Teunissen	was	born	on	August	25th,	1972	in	Arnhem,	the	Netherlands.	In	1990	
he	graduated	from	highschool	 (VWO;	Van	Lingen	College)	 in	Arnhem.	 In	the	
same	year	he	started	his	study	Biomedical	Sciences	at	the	University	of	Leiden.	In	
1995	he	started	his	medical	training	at	the	Faculty	of	Medicine	at	the	University	of	
Leiden.	From	September	1997	till	March	1998,	he	participated	in	a	project	called	‘An 
Assessment of Steroid Cover during Pituitary Surgery’	at	the	department	of	Internal	
Medicine,	division	of	Endocrinology,	Radcliffe	Infirmary,	Oxford,	UK	under	the	
supervision	of	Prof.	dr.	J.A.H.	Wass.	In	1999	he	obtained	his	biomedical	degree,	
followed	by	his	medical	degree	in	2000.	He	started	to	work	as	a resident in Internal	 	 	 	
Medicine	at	the	department	of	Internal	Medicine	of	the	Rode	Kruis	Hospital	in	The	
Hague	(head:	Dr.	R.M.	Valentijn).	From	November	2001	till	December	2008	he	
worked	as	a	research	fellow	at	the	department	of	Nuclear	Medicine	of	the	Erasmus	
MC	in	Rotterdam	(supervised	by	Prof.	dr.	E.P.	Krenning	and	Dr.	D.J.	Kwekkeboom)	
on	the	research	presented	in	this	thesis.	In	September	2005	he	started	his	clinical	
nuclear	medicine	residency	in	training	(AIOS)	at	the	Erasmus	MC	in	Rotterdam	
(head:	Prof.	dr.	E.P.	Krenning).	As	part	of	his	 training,	he	worked	as	a	resident	
at	 the	department	of	 Internal	Medicine	of	the	Rijnland	Hospital	 in	Leiderdorp	
(head:	Dr.	F.H.M.	Cluitmans),	at	the	department	of	Radiology	of	the	Erasmus	MC	in	
Rotterdam	(head:	Prof.	dr.	G.P.	Krestin)	and	at	the	department	of	Nuclear	Medicine	
of	the	The	Netherlands	Cancer	Institute/Antoni	van	Leeuwenhoek	Hospital	 in	
Amsterdam	(head:	Dr.	C.	Hoefnagel).	At	the	end	of	February	2009,	he	will	finish	
his	training	period	and	become	a	Nuclear	Medicine	specialist	and	a	staff	member	of	
the	department	of	Nuclear	Medicine,	Erasmus	MC,	Rotterdam.	
Since	2003,	he	is	living	happily	together	with	Maaike	Schaart	in	Leiden.
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